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SUMMARY OF THE WORK
THE EFFECT OF RIMONABANT AND GENDER ON LIPID KINETICS 
IN OBESITY
In this thesis the effects of rimonabant, the CB1 endocannabinoid receptor antagonist, and 
gender on free fatty acid (FFA) and very-low-density lipoprotein (VLDL)-triacylglycerol 
kinetics, insulin sensitivity and circulating adipokines was examined in obese 
postmenopausal women and age- and body mass index (BMI)- matched men.
In the first study, the effect of rimonabant (20 mg/day for 12 weeks, with energy intake 
matched for energy requirements) was compared with the effect of a hypocaloric diet (to 
achieve the same weight loss as on the rimonabant treatment, for 12 weeks). Fourteen obese 
(BMI=33.0±0.5 kg/m2), postmenopausal, aged 57.8±4.7 years Caucasian women were 
randomised to the 2 treatments and the following was measured at the baseline and after 12 
weeks: FFA kinetics, VLDL-triglyceride kinetics; insulin sensitivity; circulating fasting 
glucose, FFA, glycerol, triglycerides, VLDLi and VLDLi-triglycerides, total cholesterol, 
high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol, 
leptin, adiponectin and insulin. In the second study, the same variables were compared 
between 16 obese postmenopausal Caucasian women (57.9±5.4 years, BMI=32.8±1.8 kg/m2) 
and 7 age- and BMI- matched men (60.6±6.6 years, BMI=31.5±1.4 kg/m2).
Results: Weight loss was not different between 2 treatment groups in the first study (2.6±1.4 
kg in the rimonabant group vs. 3.1±2.8 kg in the diet group, p>0.05). Rimonabant treatment
increased palmitate rates of appearance (Ra), metabolic clearance rates (MCR) and oxidation 
rates, while dietary treatment did not influence these variables. The effect of rimonabant on 
palmitate oxidation rates was significantly different from the effect of the hypocaloric diet, as 
well as the effect on VLDLi and VLDL2-triglyceride absolute production rates (APR), 
circulating fasting triglycerides, VLDLi- and VLDL^-triglycerides, glucose, insulin and 
homeostasis model assessment (HOMA)-estimates of insulin sensitivity. Both treatments 
similarly increased adiponectin and decreased leptin. Neither treatment significantly changed 
insulin sensitivity estimated by hyperinsulinaemic-euglycaemic clamp. In the second study, 
women had higher palmitate Ra, MCR, non-oxidative disposal and total plasma fatty acid 
oxidation (TPFAO) rates, VLDLi and VLDL^-triglyceride fractional clearance rates (FCR), 
circulating leptin, glycerol and FFA. The other variables were not significantly different.
In conclusion, the increase in fatty acid turnover and oxidation may be the mechanism by 
which the weight loss was achieved by rimonabant treatment, without caloric restriction. The 
effects of rimonabant on FFA and VLDL-kinetics, insulin sensitivity and metabolic 
parameters, were the opposite from the effects of the hypocaloric diet, although the weight 
loss was similar. Postmenopausal obese women, compared with age- and BMI-matched men, 
have higher rates of fatty acid turnover, accounted by both increased metabolic clearance, 
non-oxidative disposal and increased fatty acid oxidation. However, their metabolic profile 
was not different from the men. This suggests that women are intrinsically “primed” for 
increased lipid turnover, without a significant deterioration of metabolic risk.
KEY WORDS:
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CHAPTER 1. THE USE OF STABLE ISOTOPIC TRACERS IN 
STUDYING LIPID METABOLISM KINETICS IN HUMANS
1.1. Introduction: the kinetic studies and the use of stable isotopes in 
studying metabolism in humans
During the last century many types of studies to investigate metabolism in humans have been 
developed, including both in vitro and in vivo techniques.
In vitro techniques allow a broad range of experiments, research in depth (e.g. studies of gene 
expression), but since they are performed under specific, restricted and controlled conditions, 
the results can not always be applicable to the conditions in vivo. The influence of many 
additional important contributing factors which exist in the body are excluded, or changed, 
and the results can not be directly extrapolated to the in vivo situation. Mostly they provide 
the basis for further research or the explanation of findings of research conducted in vivo.
In vivo techniques refer to real conditions in the body. However, a valid picture of what is 
happening with one metabolite and how it influences metabolism and contributes to health 
and disease is not always possible with single measurements (e.g. using the measured 
concentrations of the metabolite in different tissues). The concentration of a metabolite in a 
tissue is a product of its influx (and local synthesis) or efflux (and local degradation) over 
time. Therefore, a high concentration of a metabolite in a tissue could be a result of its 
increased input or decreased output.
The kinetics of a metabolite in the body is most appropriately studied by introducing a
labelled metabolite (“tracer”) in the body and following its dynamics through different tissues
(e.g. biopsy, blood) through which the tracer (labelled metabolite) passes.
“Labelling” of tracer can be made by introducing a specific quality to the metabolite, by
which it can be easily distinguished from the unlabelled metabolite, but at the same time it
13
must not change its metabolic characteristics, since the tracer needs to behave metabolically 
exactly the same as the metabolite [1] [2].
With the development and commercial availability of radioactivity counters, in most 
metabolic studies during the 1950s and 60s, labelling was done by the introduction of non­
stable (radioactive) isotopes of C, H, O or N (Table 1.1). The specific radioactivity 
measurement of tissues samples during a period of time (enough to determine the metabolite 
kinetics) shows the behaviour of the metabolite in the body. However, the introduction of 
radioactive material in the body is associated with high health risks, ethical issues and 
regulatory limitations (it is not possible to study specific populations, including children and 
pregnant women; repeated studies on the same subject are related to increased risks; there are 
also radioactive disposal environmental issues), which is the main weakness of this approach. 
Furthermore, even though the measurement does not require complicated preparation 
procedures and expensive equipment, there are some methodological weaknesses related to 
the inability to distinguish and eliminate the influence of other labelled molecules generated 
by the tracer on overall measured radioactivity [1] [2].
With increased concerns about potential health and environmental risks associated with the 
use of radioactive tracers and, on the other hand, increased commercial availability of highly- 
sensitive mass-spectrometers (MS) and stable isotope-labelled compounds, in metabolic 
studies labelling by the introduction of stable isotopes has risen markedly during the last 30 
years [3] [4]. Different stable isotopes of atoms forming organic molecules (C, H, O, and N) 
are naturally present (Table 1.1).
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Table 1.1. Different isotopes of H, C, N and O: their isotopic masses and natural abundances
Name Symbol Mass o f  atom (u) Natural abundance (%)
Hydrogen 1.007825 99.989
Deuterium 2H 2.014102 0.012
Tritium 3h 3.016049 *
Carbon 12C 12.000000 98.930
13c 13.003355 1.070
14c 14.003242
Nitrogen 14n 14.003074 99.636
15n 15.000109 0.364
Oxygen 16o 15.994915 99.757
170 16.999132 0.038
18o 17.999160 0.205
(*) indicate short-lived radioactive isotopes, which are not present in nature or a meaningful natural 
abundance cannot be given.
The isotopic mass data is from references [5] and [6]. The percent natural abundance data is from 
reference [7]
Usually in nature 12C, 1H, 160 , and 14N isotopes have the highest abundance (99% and more).
Only very low amounts of other stable isotopes (13C, 2H, 170 , 180  and 15N) are normally
present in molecules of organic compounds (e.g. the natural abundances for 2H and 13C are
0.012% and 1.070%, respectively) [1] [4] [5] [6] [7] [8]. However, they can be introduced in
high amounts during artificial synthesis of an organic compound (in this case the metabolite
whose kinetics is to be examined), and replace one, several or all naturally present isotopes in
a molecule. For example, it is possible to exchange all ^H isotopes of hydrogen atoms in a
glycerol molecule with 2H isotopes. Similarly, only one or all C-atoms in a palmitic acid
molecule can be labelled with 13C (e.g. l - 13Ci palmitic acid or uniformly labelled U-13Ci6
palmitic acid) [3] [4] [9] [10]. Additionally, for different metabolites different stable isotopes
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can be used for labelling, depending on the study method chosen. For example, both 2H and 
13C can be used for labelling a palmitic acid molecule [3] [4] [9] [10] [11]. Labelling more 
atoms in a molecule increases the cost of tracer preparation and could increase significantly 
the weight of a molecule [4] [10] [11]. For example, the molecule of uniformly 2H labelled 
(dgi) palmitic acid has a molecular weight 11.9% higher compared with the molecular weight 
of unlabelled palmitic acid (287.00 g/mol and 256.42 g/mol, respectively) [4] [11]. This can 
possibly cause an “isotopic effect” (which means that isotopomers have different physico­
chemical properties, violating the rule of tracer behaving exactly as the tracee) [3] [9] [10] 
[12]. Nevertheless, labelling more atoms in a molecule increases the precision of the tracer 
tracking (reducing the influence of possible tracer recycling) and the sensitivity of mass- 
spectrometry measurement [3] [4] [9] [10].
Once a stable-isotope-labelled metabolite is introduced in the body, its kinetics are followed
by measuring its concentration in different body compartments (e.g. tissues and bodily fluids)
and dilution with the unlabelled metabolite present in that compartment [1] [2] [13]. The
samples of tissue (e.g. biopsies, blood) or body excretions (e.g. urine, expired breath) are
taken at specific time points after the introduction of the tracer [1] [2] [13]. The ratio of
labelled to unlabelled metabolite concentrations in the tissue gives the rate at which a
metabolite appears and disappears from the tissue. The rate by which the tracer or its
metabolic products appear in the tissues and the rate they disappear from the tissues describe
the substrate’s kinetics (substrate anabolism, transfer or catabolism) and specific turnover
rates can be calculated by use of mathematical models [1] [2] [4] [13] [14] [15].
To measure concentrations and ratio of a labelled to unlabelled metabolite (“tracer to tracee
ratio”) in the tissue sample, firstly the metabolite needs to be isolated [1] [2] [10] [13] [16].
The next step is a purification of the metabolite and transformation into the form by which it
can be introduced into the gas-chromatograph (GC) (or high performance liquid-
chromatograph, HPLC), which can separate different organic compounds before they enter
16
the mass-spectrometer [10] [13] [16] [17] [18]. Mass-spectrometry (MS) can distinguish and 
measure the abundance of different isotope ions made by ionisation of an organic molecule
[1] [2] [3] [16]. The abundance of different isotopic ions acquired from ionisation of the 
metabolite molecules- both labelled and unlabelled (presented as ions “peak area” for the 
different “mass-to charge-ratio” (“m/z”), on the MS signal analyser), and their relative ratios 
are used to calculate the ratio of the labelled and unlabelled metabolite in the sample [1] [2]
[3] [16]. The total concentration of metabolite can be obtained from standard enzymatic 
methods, or from gas-chromatograph/mass-spectrometer (GC/MS) measurements by the use 
of an internal standard added to the sample, which is not naturally present and has similar 
physico-chemical properties but slightly distinguishable chromatographic and spectrometric 
characteristics compared with the metabolite [1] [2] [3] [17].
There are different techniques for ionisation of the molecule, and the choice is made 
depending on the physico-chemical properties of the studied compound. In metabolic research 
most techniques use chemical and electron ionisation [1] [2] [3] [4] [13]. In the ion source of 
the MS, the molecules of the vaporised metabolite sample are transformed into molecular 
ions, by electrons (electron ionisation, El, with a homogeneous beam of electrons typically at 
70 electron volts energy) or charged ionisation reagent gases (chemical ionisation, Cl, with 
e.g. ammonia or methane previously ionised by El1) [1] [2] [3] [16]. The ionised molecule of 
the organic compound fragments to generate a spectrum of molecular ions (there is a 
predilective place in the molecule for breakage of chemical bonds, and each molecule will 
give a typical spectrum of molecular ions generated) [1] [2] [3] [16]. Chemical ionisation is 
considered to be a much “softer” ionisation technique and generates less fragmentation of the
In Cl, in the source reagent gases are in a higher excess compared to the analyte. Electrons entering the 
source will therefore preferentially ionise the reagent gas.
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molecule and a simpler spectrum2 [1] [2] [3] [19] [20]. After molecular ions are made (both 
positive and negatively charged ions can be generated) they are separated in electromagnetic 
or magnetic field according to their “mass to charge”, m/z, ratios and accelerated to the 
detector [1] [2] [3] [19] [20].
Some mass spectrometers can measure directly the abundance and ratio of different stable 
isotope variants in molecules of small molecular weight gases (CO2 , SO2 , N2 and H2) present 
in an air sample or made by combustion of organic compounds [1] [2] [3] [10] [21]. In the 
latter case, after passing through the gas-chromatograph organic compounds are oxidised by 
combustion at an interface, then the oxides are reduced (e.g. NO, NO2 in N2), and analysed on 
isotope-ratio-mass-spectrometers (IRMS) [1] [2] [3] [10] [21]. In the former case, some gases 
present in an air sample (e.g. CO2 or O2 collected from exhaled breath) do not need a 
combustion step before entering the mass-spectrometer [22] [23].
In the mass-spectrometer the abundance ratios of specific isotopes in one molecule can be 
measured. For example, the abundance of different combinations of 12C, 13C, and 160 , 170  
isotopes in CO2 molecule (e.g. 12C16C>2 , 13C160 2, 12C160  170  are the most abundant compared 
with very low abundance of 13C160  170 , 12C1702 or 13C1702) can be measured in a breath 
sample or in CO2 derived from the plasma free fatty acids (FFA) after being combusted in 
gas-chromatograph/combustion/isotope-ratio-mass-spectrometer (GC/C/IRMS) [1] [2] [3] 
[10] [21]. The results are expressed relative to commercially available gas standards 
concomitantly introduced into the mass-spectrometer, in which the isotopic ratio is known 
compared to reference standards. For example the international standard for 13C/12C is 
Vienna-PeeDee belemnite (V-PDB), which has a 13C/12C abundance ratio of 1.1237 x ÎO 2 [1] 
[2] [3] [10].
2 In Cl, ionisation is mostly due to proton transfer and is therefore a much lower energy process. As a 
consequence the protonated molecules posses less residual energy and the fragmentation of the protonated 
molecule is greatly reduced.
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The way of expressing mass-spectrometry measurements differs.
For classic GC/MS where molecular ions of a metabolite are made by an electron impact, 
positive or negative chemical ionisation, the results are often expressed as Tracer/Tracee ratio 
(TTR), or atom percentage (APE) which are calculated from the ratio of the measured peak 
areas of specific ions selected for monitoring referred to as labelled and unlabelled metabolite,
i.e.
TTR= [peak area tracer ion] / [peak area tracee ion], [1]
APE= [peak area tracer ion] /  [peak area tracer ion + peak area tracee ion], [2]
corrected for background enrichment3 [1] [2] [4].
For IRMS where molecular ions of a gas (CO2 , SO2 , N2 or H2) are produced by combustion 
(or taken from an air sample) and electron impact ionisation, the results are expressed as a 
delta value (8), which is calculated from the ratio of the measured peak areas of specific ions 
referred to the sample and compared to the reference gas with the known delta value:
[sample isotope ratio - standard isotope ratio]/[standard isotope ratio]xl000 [%o]. [3] 
From this TTR can be indirectly calculated [1] [2] [3] [10] [21] [22] [23].
Selection of ions with typical m/z (“mass-to charge ratio”) for monitoring is very important.
In IRMS, for measurement of CO2 enrichment, three ions are selected and simultaneously 
measured, with m/z 44, 45 and 46, as representative of (12C1602), (13C1602 + 12C160 170 ) and 
(13C160 170  + 12C170 2 + 12C160 180) isotopomers, respectively, which can be expected to be 
present naturally [3]. The m/z 46 is used to correct the m/z 45 for the contribution of 
12C160 170  in the peak area, which naturally contributes approximately 7% to the abundance 
of m/z 45, therefore allowing the calculation of the true 12C/13C ratio (the natural abundance of 
O and 180  isotopes is 0.037% and 0.204%, respectively, and lower than the natural17
3 In metabolic studies, TTR and APE need to be corrected for background enrichment, e.g.: 
TTR=TTR measured - TTR baseline (before introduction o f  a tracer).
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abundance of 13C). Since the contribution of 12C160 170  is typically low, the m/z 45 correction 
by m/z 46 contributes little to the uncertainty of the measurement [23].
For the conventional GC/MS, electron impact ionisation (El) gives a typical spectrum of 
different ions the peaks of which can be measured (e.g. for palmitate and uniformly labelled 
palmitate methyl esters) [1] [2]. The selection of ions with specific m/z to be measured needs 
to be the best representative of the true ratio of labelled/unlabelled in the tissues sampled [1]
[2]. There are several limitations of the method in this respect, since there can be a non-linear 
correlation between real TTR in the sample and the measured TTR, often depending on the 
concentration of the sample introduced into the GC/MS. This can be related to the “isotopic 
effect” [9] [10] [12], especially with labels which have more labelled atoms introduced, and 
therefore have different physico-chemical properties compared with the unlabelled 
isotopomer. Therefore, not only can they behave differently during laboratory preparation of 
the sample for GC/MS measurement, during GC separation and MS ionisation (especially 
with electron impact ionisation), also they can behave differently in the body and show 
different kinetics (e.g. different permeability and enzymatic properties), therefore violating 
the principle rule of a tracer behaving exactly the same as a tracee [9] [10] [12]. For that 
reason the isotopic effect needs to be minimalised as much as possible. Regarding sensitive 
and precise MS measurements, the isotopic effect can be more pronounced when low 
enrichments and low sample concentrations (low peak areas) are present [21].
1.2. Different tracer kinetic techniques
Tracer techniques can differ in a number of ways, and the choice of a proper technique 
depends on the purpose of the study and the metabolite to be analysed. There is not an ideal 
technique, and each of the techniques has its strengths and weaknesses, therefore the choice 
needs to be made according to the specific study requirements [1] [2] [4].
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For example, several different tracer techniques exist depending on the molecules sampled 
and analysed. It could be the tracer itself (“tracer dilution techniques”, e.g. uniformly labelled 
13C -palmitic acid for whole body or local tissues kinetics), or the metabolic product of the 
tracer, when the tracer can be incorporated into more complex molecules (“tracer 
incorporation techniques”, e.g. glycerol in very-low-density lipoprotein (VLDL)- 
triglycerides), or be metabolised by the body into different molecules (“tracer conversion 
techniques”, e.g. uniformly labelled 13C -palmitic acid oxidised into breath ^COz) [4]. 
Additionally, non-compartmental models and compartmental models can be used to describe 
the metabolite (tracer) kinetics [1] [2] [4]. Non-compartmental models may not account for 
the metabolite (tracer) “recycling” [4]. They assume that a metabolite kinetic through the 
body is simplified and the metabolite enters one homogenous, freely mixing “pool” with one 
constant rate, and after rapidly mixing with other components of that pool, disappears from 
the pool with another constant rate. In the case when the concentration of the metabolite in the 
pool does not change with time (“steady-state”), the rate the metabolite appears in that pool 
must be equal to the rate the metabolite disappears from it [1] [4]. Non-compartmental models 
also assume that once a metabolite disappears from the pool, it does not appear again in that 
pool [1] [4]. As the tracer behaves in the same way as the metabolite, the same rules apply to 
the tracer.
Nevertheless, in reality, metabolite kinetics are more complex and the metabolite often enters 
into one pool (compartment) from several different pools at different rates, and then 
disappears from that pool into several others pools at different rates, distinctive for each pool 
[1] [2] [4] [14]. Additionally, once the metabolite disappears from one pool into the other 
pools, it can appear again from those pools into the primary pool. Therefore, those “multi- 
compartmental” models involve a complex mathematical modelling of the metabolite kinetics 
which allows the metabolite (and tracer) to “recycle” [1] [2] [4] [14] [15].
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There are also different approaches to introduce labelled metabolites into the body [2] [4]. In 
lipid research, labelled lipids (or lipid precursors) could be introduced orally (by labelling 
food nutrients, e.g. fatty acids in dietary lipids, the approach mostly used in studying 
postprandial nutrient metabolism), or by introducing tracers directly into the circulation 
(arterial, venous) [2] [4]. Accessing arteries for administration of tracers in humans is difficult 
and unsafe and requires specific techniques. Therefore the administration of tracer is usually 
into the venous circulation [2] [4].
If the tracer is introduced into the body orally it is usually in the form of one (or more) 
“boluses” - meals containing the tracer (labelled nutrient), administered to the subjects in 
defined time sequences. The tracer kinetic is subsequently followed - the rate the tracer 
appears in the circulation (in the same form or it is incorporated into more complex 
molecules, e.g. chylomicrons) is calculated from the slope of the curve that models its kinetics
[4]. If only one bolus (meal) is given, the curve has an incrementing, maximum and 
decrementing part (Figure 1.1-A). When many small equal “boluses” are given in small 
constant intervals over longer period of time (e.g. each 15 minutes, over 4.5 hours), the curve 
has its incrementing, plateau and decrementing part, similar to a constant infusion (Figure
1.1.-B) [4] [24]).
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Figure 1.1 Atom percentage excess (APE) o f  L’C in linoleic acid in plasm a phospholipids after a single oral bolus 
(A) and after a fractionated oral application (multiple oral boluses) (B) o f ljC-labelled linoleic acid. (Adapted,
with permission, from reference [24])
Introduction of a tracer into the venous circulation can be via continuous infusion (which can 
be primed or not) or bolus injection (Figure 1.2) [2] [4]. The choice depends on the metabolite 
in question [2] [4].
Bolus injection is suitable for those metabolites which do not show rapid turn-over or rapid 
tracer recycling [2] [4]. After introducing the tracer into the body, the rate of its appearance 
into other tissues (or incorporation into different metabolites) or disappearance (clearance) 
from the tissue it was introduced in, is measured [2] [4]. To calculate the clearance rate, a 
slope of the monoexponential curve of tracer decay is used [25] [26].
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Figure 1.2. A. Plasma [2H5] glycerol enrichment (TTR) after a single intravenous bolus o f  [2H5] glycerol.
B. VLDL, and V LDL2 -  triglyceride [2H5] glycerol enrichm ent after a single intravenous bolus o f  [2H5] glycerol. 
C. Plasma [U -I3C] palmitate enrichment in arterialised and deep-venous blood samples after a continuous 
intravenous infusion o f [U-' ’C] sodium palmitate (without priming).
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If the metabolite shows rapid turnover, frequent sampling and large amounts of tracer need to 
be introduced to measure its kinetics. This can be impractical and present a burden to the 
body, possibly perturbing the endogenous kinetic of the metabolite, which is the main 
limitation of this approach [4]. Additionally, some metabolites can have the high rates of 
tracer recycling - once they have been removed (cleared) from one pool (transferred to the 
other tissues where they can be stored or incorporated into some different metabolites), they 
can appear again into the primary pool (released from the storage or the molecules 
incorporated). This can change the curve of the tracer decay and present as slower tracer 
clearance [4].
Instead, when there is a rapid metabolite turnover and recycling (e.g. fatty acids recycle very 
fast between different pools), continuous infusion of a label is more suitable, or the sampling 
should last until tracer begins to recycle from the tissues it has been stored in previously [4]. 
Moreover, when tracer recycling is expected, multicompartmental mathematical models need 
to be applied [1] [2] [4] [14] [25].
The continuous infusion tracer dilution approach (in its simplest mode, a single pool non- 
compartmental model, as shown in Figure 1.3) assumes the rate of appearance of a metabolite 
(Ra) in one pool (e.g. blood) from the secreting (producing, storing) pools (e.g. fat tissue) is 
constant [1] [4]. Since the concentration of metabolite in the sampling pool (e.g. blood, i.e. 
plasma) is proven to be constant over the specified amount of time, the conclusion can be 
made that the rate of transfer of metabolite from that pool to the other pools (tissues that use, 
metabolise or store again that metabolite i.e., muscle, liver, another fat storage tissue) is also 
constant.
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Figure 1.3. A single pool, model for tracer and tracee kinetics.
In that case it follows that the metabolite rate of disappearance (Rd) is equal to its rate of 
appearance (Ra=Rd). This is defined as a “steady-state” condition [1] [4]. For steady-state 
conditions, if the tracer is continuously infused (infusion rate F), with time the tracer 
concentration in sampled tissue (blood) will increase exponentially until steady-state of tracer 
concentration is achieved, when the tracer infusion rate will be equal to the tracer rate of 
disappearance [1] [4]. Since the ratio of tracer and tracee in blood (plasma) is constant, the 
ratio:
[Rd tracer] /  [Rd tracee] [4]
will be the same as the ratio:
[plasma tracer concentration]  /  [plasma tracee concentration] [5]
and at the same time will be equal to the ratio:
[F tracer] /  [Ra tracee]. [6]
Therefore in an isotopic steady state the following equations are valid:
[F tracer] /  [Ra tracee] = [blood TTR] =[Rd tracer] /  [Rd tracee] [7]
and since:
[Ra tracee] = [Rd tracee] [8]
and:
[F tracer] = [Rd tracer], [9]
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the equations could be simplified:
[blood TTR] = [F tracer] /  [Ra tracee]. [10]
Since the tracer infusion rate is much lower than the expected metabolite rate of appearance, 
the contribution of the infused tracer to the metabolite kinetic will not be significant, and the 
metabolite’s homeostasis will not be perturbed (in other words, there will be much higher 
concentration of tracer in the blood compared with the concentration of tracee, and therefore 
concentration of total metabolite (tracer + tracee) will not be significantly higher to involve 
the homeostatic mechanisms) [1]. But in situations where the infusion rate is higher, and the 
metabolite Rd is a rate limiting step (which determines the metabolite Ra), the negative feed­
back homeostatic control mechanisms will be included to keep the concentration of total 
metabolite in blood constant and the rate of the metabolite appearance will be consequently 
reduced for the infusion rate during the infusion period [1]. Therefore the correction of the 
calculated Ra during study needs to take into account the possible influence of homeostatic 
mechanisms during isotopic steady state (actual Ra =Ra measured during study +F) [1].
Nevertheless, since the infusion rate is usually significantly lower than metabolite Ra, the
correction often is not necessary, and does not change the results significantly [1]. (In case the 
metabolite Ra is a rate limiting step, which determines metabolite Rd, then the correction does 
not need to be applied.)
When the metabolite has a slow turnover rate, it takes a long time to achieve isotopic steady 
state [1] [4]. The pool can be primed with a tracer bolus to decrease the duration of study and 
discomfort of the subject [1] [4]. The correct amount of the tracer injected as a bolus over one 
minute relative to body weight (mol/kg) can be calculated as the product of the infusion rate F 
(mol/kg/min) and the metabolite pool size (metabolite concentration in plasma multiplied by 
plasma volume) per kg body weight (mol/kg), divided by the pool Ra (mol/kg/min) [1]. In 
other words:
priming relative to infusion rate = pool size (mol/kg) /R a  (mol/kg/min). [11]
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Samples collected for MS analysis can be breath, blood, body excretions (urine, faeces, saliva,
etc.) or tissue biopsies [1] [2] [4] [13]. The sampling site is very important and depends on the
purpose of the study [2] [4]. If a labelled metabolite is introduced intravenously for analysis
of whole body kinetics, then sampling needs to be done in arterial blood, after mixing and
dilution of the tracer with the unlabelled metabolite released into the circulation from the
whole body, to avoid the additional influence of metabolite kinetics in local tissues [2]. If
blood is sampled from the peripheral vein, that venous sample will reflect not only the whole
body metabolite kinetics, but also the kinetics of the local tissue which that vein is draining
(e.g. muscle, subcutaneous fat, visceral fat, etc) [2]. Therefore, the additional influence of
local tissue factors (including the local tissue metabolite release and uptake, and velocity of
blood flow), can not be excluded [2]. However, obtaining arterial blood is problematical since
direct cannulation of arteries is associated with potential serious complications [27]. For that
reason, “arterialised blood”, resembling arterial blood, can be used as a suitable alternative
[28] [29] [27]. Arterialised blood can be obtained from superficial dorsal veins draining a
heated hand (Figure 1.4) [30] [31] [32]. The hand can be heated by using a heated-air hand
box at 55-60°C [34] (as shown in Figure 1.5, [33]). In that case collateral circulation in the
hand is opened, and velocity of circulation through opened capillary beds is high enough that
blood in the dorsal hand veins has similar characteristics as arterial blood (including high
oxygenation), and can be used as a surrogate for arterial blood [29] [32] [35] [36] [37] [38]
[39] [40] [41]. This approach (intravenous administration of tracer with arterialised blood
sampling) allows estimation of whole body kinetics of a metabolite by dilution techniques
[36]. Additionally, it allows the estimation of the local tissue (e.g. forearm muscle,
subcutaneous abdominal fat, splanchnic hepatic or non-hepatic tissues, etc.) metabolite
kinetics by the use of the arterious-venous (A-V) difference technique [1] [38] [42] [43] [44].
This technique involves the measurement of the difference in enrichment and concentration of
a tracer in arterial (or arterialised) blood and venous blood draining the tissue (e.g. as shown
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in Figure 1.6) in the simultaneously obtained samples, and the local tissue blood flow [1] [37]
[40] [42] [44] [45] [46] [47] [48] [49] [50] [51] (Figure 1.7).
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Figure 1.4. Dorsal venous network used to obtain arterialised blood samples.
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Figure 1.5. The heated hand technique to obtain the arterialised blood samples.
A Heating box with hot air. B rise in the hand skin tem perature when using the heating box. 
C. Oxygen saturation in arterialised blood when using the heated hand technique at 55°C
(from reference [33])
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1.3. The tracer kinetic methods used in lipid research
1.3.1. Adipose tissue lipolysis
Whole body lipolysis reflects mostly adipose tissue lipolysis [1] [2] [4], although 
intravascular lipolysis of plasma lipids and intramyocellular lipids lipolysis can contribute 
significantly [1] [2] [4] [52] [53] [54].
Additionally, there are differences in lipolytic rates between different adipose tissues depots 
(e.g. intraabdominal and visceral fat, abdominal subcutaneous fat, peripheral leg- femoral, 
gluteal, etc), and each adipose tissue depot contributes separately to whole body lipolysis 
depending on the depot specific lipolytic rate, the depot size and local blood flow [55] [56] 
[54].
To study the rate of whole body lipolysis, both labelled glycerol and FF A can be used as 
tracers [1] [2] [4]. In both molecules only one, several or all atoms can be labelled [4]. 
Increasing number of labelled atoms brings several advantages and disadvantages, regarding 
less possible tracer recycling, higher precision of mass-spectrometry measurement, lower 
infusion rates, but may introduce an isotopic effect and increase the cost of the study [4]. The 
rapid plasma turnover of both palmitate and glycerol limits the possibility to use bolus 
injection for the estimation of the tracer kinetics, and therefore the constant infusion approach 
is generally preferred to estimate the tracer Ra [4].
In adipose tissue glycerol is less intracellularly re-utilised compared with FF A (FF A are in a 
substantial proportion re-esterified), and therefore glycerol is considered to be a better choice 
as a tracer for the estimation of adipose tissue lipolysis rate [1] [2] [4]. This is explained by 
the very low level of glycerol kinase activity in adipocytes [1] [2] [57] [58] (almost absent in 
humans) [57] [58] [59], which activates glycerol for synthetic or catabolic pathways [58], and 
therefore all produced glycerol within adipocyte from lipolysis is expected to be released into
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the circulation by a facilitated diffusion process [1] [2] [57] [58]. In muscle and liver, in 
contrast, glycerol can be phosphorylated to glycerol-3 -phosphate and used for oxidation or 
other processes (including re-esterification and gluconeogenesis in the liver), apart from being 
released into the circulation (e.g. from muscle) [48] [57] [58] [60] [61] [62]. Therefore, if the 
assumption is made that lipolysis is a complete process (one molecule triglycerides gives 3 
molecules FFA and one molecule glycerol), and all liberated glycerol is released into the 
circulation from adipose tissue, glycerol can be a good indicator of adipose tissue lipolysis [1] 
[2] [4]. On the contrary, fatty acids are readily re-esterified after lipolysis within adipose 
tissue, before appearing in the circulation (“intracellular re-esterification”) [1] [2] [4] [63] 
[64].
Several assumptions are made when using the systemic glycerol Ra as an index of adipose 
tissue lipolysis, and their validity may be questioned:
1) It is assumed that adipose tissue lipolysis is the only source of glycerol in the blood. 
However glycerol can also be released from muscle triglyceride lipolysis, in significant 
amounts, since the fasting rates of glycerol release per kg tissue from skeletal muscle is 20- 
25% of that from adipose tissue [52], or from intravascular lipolysis of plasma triglycerides 
by lipoprotein lipase (LPL) and hepatic lipase (HL), but this contributes only to a small 
extent, about 4% [1]. However, new data show that LPL action derived glycerol release in 
subcutaneous abdominal adipose tissue contributes about 15-20% to total local glycerol 
release [53]. This assumption in addition implies that glycerol is derived only from 
triglyceride hydrolysis, not from other metabolic pathways (e.g. glycolysis).
2) It is assumed that intracellular glycerol cannot be re-utilised in adipose tissue because of 
low glycerol kinase activity. However, adipose tissue has a very small glycerol kinase 
activity, which could be increased in certain circumstances (e.g. there are data on increased 
activity of glycerol kinase in a subgroup of obese subjects) [65] [66] [67] [68] [69].
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3) It is assumed that triglyceride lipolysis in adipose tissue is complete, that each triglyceride 
molecule is always disintegrated to 3 FFA and 1 glycerol molecule [1]. However, lipolysis is 
a multi-step, gradual process. Each step has its own regulation and rate, and therefore does not 
have to be a complete process [70] [71]. Moreover, there is an intensive intracellular fatty 
acids re-esterification after lipolysis [1] [64]. In weight-stable, non-obese subjects the ratio of 
FF A/glycerol leaving the adipocytes is only 1.4, while with caloric restriction, this ratio 
increases up to 2.7, close to the theoretical maximum of 3 [72]. Additionally, different fatty 
acids composing triglycerides can have different lipolysis rates (lipases have preferences 
towards specific fatty acids [57] [58], in specific positions [57] [58]), what needs to be taken 
into account, especially when specific FFA are used as tracers [71].
4) It is assumed that all glycerol released from triglycerides is secreted in the circulation. 
Glycerol moves across the cell membrane by facilated diffusion, using specific glycerol 
channels which can regulate the release of glycerol into the circulation. In adipocytes, 
aquaporin 7 (AQP7) acts as a glycerol gateway molecule for release of glycerol [73]. 
Regulation of AQP7 expression in fat cells is subject to nutritional and neuroendocrine 
influences [74] [75] [76] [77], indicating that glycerol release in the circulation does not have 
to be in a direct proportion with glycerol release from triglycerides).
5) It is assumed that glycerol release from adipose tissue is continual. Glycerol, as well fatty 
acids, is released from adipose tissue in a 12-15- minute pulsatile manner [78], and that could 
contribute to the observed higher intra-individual inter-day variability.
Assumptions 1 and 2 can lead to the overestimation of adipose tissue lipolysis, while
assumption 3 can lead to an underestimation. Additionally, glycerol released from visceral fat
into portal vein is at least partly cleared by liver, and does not appear in the systemic
circulation, therefore this can lead to an underestimation of whole-body lipolysis rate [53].
The rapid disappearance of glycerol after bolus injection (half life is about 4 minutes), limits
the possibility to use a bolus injection for the estimation of endogenous glycerol Ra, and
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therefore a constant infusion is usually used, which typically lasts about 1-2 hours, at a rate of 
0.05-0.10 pmol/kg/min [4]. The choice of tracer is not essential, because 1,1,2,3,3- 2Hs 
labelled glycerol, 2-13Ci- glycerol and 1,2,3-13C3 glycerol give similar results when estimating 
Ra [4] [79]. Because glycerol has a high volume of distribution, priming can be made (the 
priming dose is usually 15 times of infusion rate [4]), but is not necessary, since glycerol has 
rapid turnover, and isotopic equilibrium is usually achieved within 1 hour [4].
1.3.2. Systemic FFA release, uptake and oxidation
Despite the problems described above, glycerol is considered to be a better indicator of
adipose tissue lipolysis than FFA, because of significant re-esterification of FFA in adipose
tissue before their release in the circulation [1] [2] [4]. However, if FFA metabolism rather
than lipolysis is the subject of study, then labelled fatty acids can be used [1] [2] [4]. Different
fatty acids can have different kinetics (different degree of release from storage, different
uptake and utilization), depending on the physico-chemical properties of the FFA molecule
(number of C- atoms, saturation degree and number of double bonds, omega -3, -6 or -9
position, cis - trans conformation, etc) [57] [58] [80] [81] [82]. The uptake and storage of
different fatty acids in the cells can also differ, e.g. passive diffusion (“flip-flop”) and fatty
acid transporter dependent transport can correlate with the physico-chemical properties of a
FFA molecule [57] [58] [54]. Additionally, adipose tissue lipases have preferences toward
specific fatty acids in specific positions for hydrolysis of triglycerides [57] [58] [83].
Therefore, the kinetics of a specific fatty acid of interest can be followed. However, for the
estimation of the whole body FFA metabolism, usually only one fatty acid, which is estimated
to be the most representative of the total FFA metabolism, is chosen to be followed as a tracer
[4]. In the circulation the six most abundant FF As are oleate, palmitate, linoleate, stearate,
myristate and palmitoleate (representing together more than 97% of all plasma FFA) [4] [58]
[81] [84]. Studies show that stearate, myristate and palmitoleate are not very representative
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for the estimation of total FFA flux [4] [81] [84]. Palmitate is well represented and the most 
often used, because it contributes to about 25% (20%- 30%) of total plasma FFA, its kinetics 
and metabolic pathways are well representative of the total plasma FFA (as close as possible 
to the “average” plasma FFA) in most instances (together with oleic acid) [46], it is cheap, 
stable (as saturated fatty acid (SFA) it is not easily degraded during sample storage and 
sample preparation as monounsaturated (MUFA) or polyunsaturated (PUFA) fatty acids) [4]. 
Once the representative fatty acid is chosen, the results obtained are extrapolated to total 
plasma FFA by dividing by the relative contribution of that fatty acid in plasma [1] [2] [4]. 
Alternatively, mixtures of labelled fatty acids resembling the composition of average plasma 
FFA are commercially available, but this is not a practical approach, because of high cost and 
laborious analysis [4].
Both conventional GC/MS and GC/C/IRMS methods can be used for measurement of fatty 
acid enrichment and concentration (by adding heptadecanoic acid as an internal standard it is 
possible to measure the fatty acid concentrations in plasma by GC/MS and GC/C/IRMS) [1] 
[2] [3] [4] [17] [85]. In a fatty acid molecule both H and C atoms can be labelled (and if fatty 
acid oxidation is to be estimated, the production of or 13C0 2 , respectively, can be 
followed) [4]. If enrichment and concentration are measured by IRMS, higher sensitivity and 
precision is obtained with uniformly labelled fatty acids [85]. Uniformly 13C labelled is better 
to use especially if the oxidation rate is estimated, because more 13C0 2  molecules are 
produced, which increases IRMS sensitivity [85].
The constant infusion approach is usually used since FFA have rapid plasma turnover (about
3.5 minutes half time) [4]. Because of fast turnover and small volume of distribution, priming
is not necessary, and after 20-30 minutes steady state is achieved [4]. The rates of infusion are
usually 0.01- 0.04 pmol/kg/min (lower with IRMS) [4] [85]. Since fatty acids are water
insoluble, there is a requirement for the tracer fatty acid to be in a soluble form, e.g. in the
form of potassium salt, which is related to possible health risks of hyperkalaemia, or bound to
35
albumin, which increases the cost of tracer infiisate preparation and limits the amount of 
tracer that can be infused [1] [2] [3] [4] [54]. At the same time albumin keeps the fatty acid in 
the plasma (intravascular) pool, which is an advantage for non-compartmental kinetic 
modelling [2] [4]. The infusion rate of 0.04 pmol/kg/min requires a large amount of albumin, 
necessary for the solubility of fatty acids, to be infused (e.g. a 2 h infusion study may require 
as much as 17 g of albumin) [85]. When using uniformly labelled palmitate, because of the 
increased sensitivity on IRMS, lower infusion rates can be used (0.05 nmol/kg/min), which is 
beneficial because the infusion requires less albumin [85].
The non-compartmental model is suitable for the constant infusion approach. FFA decay 
kinetics after a bolus injection can be the best described by a two-compartmental model [1] 
[2] [4]. With the non-compartmental model, palmitate Ra and Rd are well representative for 
whole body fatty acid release and uptake, if the infusion is made in venous blood, and the 
sampling is done in arterialised blood [2] [4]. Additionally, whole body plasma fatty acid 
oxidation can be estimated from this approach [1] [2] [4] [86] [87]. Furthermore, the local 
tissue kinetics of FFA (as well as of glycerol) can be estimated by the arterious-venous (A-V) 
difference method, by simultaneous sampling of arterial (arterialised) and venous blood 
draining the tissue [1] [36]. For example, forearm, leg, subcutaneous abdominal fat or 
splanchnic region FFA secretion rates and uptake rates can be calculated from the difference 
between arterial (arterialised) and venous blood concentration and enrichment, multiplied by 
the local plasma flow [46] [88] [89] [90] [91]. This method includes the necessity to obtain 
the well mixed sample of the blood draining the tissue (not contaminated with the blood 
draining the other tissues) and precisely measure the local tissue blood flow (e.g. with venous 
occlusion plethysmography or xenon-133 washout technique) [45] [47] [51] [88] [92]. From 
the measured blood flow and haematocrit values is possible to calculate the plasma flow [2] 
[90] [93].
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When estimating FFA oxidation rates, whole body fatty acid Rd and production of labelled 
CO2 need to be measured [1] [2] [4]. Production of 13C02 can be estimated from the measured 
CO2 enrichment (13C02/12C02) by IRMS in expired breath samples, in combination with 
indirect calorimetry for measurement of CO2 production rate (Figure 1.8) [1] [2] [4] [86] [87]. 
The results are extrapolated to total fatty acid kinetics by dividing by the contribution of that 
fatty acid (e.g. palmitate) in total plasma FFA (measured by internal standard and enzymatic 
methods) [86] [87]. However, caution needs to be taken in this extrapolation, because 
different plasma fatty acids will not have the same tendency for oxidation as palmitate [57] 
[58], and therefore the estimation derived for total plasma acid oxidation may not be accurate. 
Moreover, if  the non-plasma acid oxidation is calculated from this estimation combined with 
total fat oxidation estimated by indirect calorimetry and urinary nitrogen production, the error 
can be significant [3] [94].
Figure 1.8. Indirect calorimetry: ventilated hood used to measure C 0 2 production.
Studies show that there is a significant fixation of the 13C label into the bicarbonate pool [95]
and products of the tricarboxylic acid (TCA) cycle (glutamine, glutamate, aspartate,
phosphoenolpyruvate and its end-products glucose, glycerol, pyruvate and lactate) [86] [96].
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A 13C labelled bicarbonate priming dose is given to prime the bicarbonate pool with 13C and 
reduce the time for 13C02 to achieve steady state [95] [97]. To correct for the fixation of 13C 
label into the products of the TCA cycle, the acetate recovery factor (ART) needs to be 
applied [95]. The underestimation of FFA oxidation rates is about 4 times if the ARF is not 
used [87]. During continuous infusion of C-labelled tracers, 13C02 in the breath sample takes 
time to achieve isotopic steady state because of the label fixation in TCA cycle products and 
because the intracellular FFA pools need to equilibrate with plasma pool before entering to 
beta-oxidation and TCA cycle (therefore 8 hours or more of infusion in resting conditions are 
needed) [87]. If the ARF correction factor is applied for each time point to correct the breath 
sample TTR, the calculated breath 13C02 production reaches plateau within 1 hour, and steady 
state equations can be applied [87].
The ARF is estimated from a [1, 2 -13C] labelled sodium acetate infusion in a separate study, 
which mimics the conditions employed for the determination of substrate oxidation (duration 
of the rest and fasting prior to study, time of the beginning of study and sample timing, the 
diet and physical activity several days prior, bicarbonate priming, etc.) [86] [87]. The [1,2- 
13C] sodium acetate infusion rate (relative to FFA infusion rate) can be calculated by dividing 
the number of C atoms in uniformly C-labelled FFA by 2 (which is the number of C atoms in 
the acetate molecule) [86] [87]. Calculation of the ARF needs to be done for each subject 
(because of the high inter-individual coefficient of variance, about 12%, while intra-individual 
coefficient of variance is only 4%) [87]. The main determinators of ARF are the basal 
metabolic rate (BMR) and energy expenditure adjusted for fat free mass [98]. When energy 
expenditure is higher, more 13C is incorporated into CO2 than into TCA cycle products [98] 
[99]. There is a negative correlation of ARF with %FM in the body (independent of BMR) 
and a positive correlation with respiratory quotient (RQ) (less CO2 is produced when fat is 
oxidised). In resting conditions it was shown that women have a higher ARF compared with 
men, while during exercise the opposite was shown [99].
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Another approach for measuring FFA oxidation in the body is by measuring ^ 0  production 
from a 2H- labelled FFA acid [4]. The tracer (e.g. 2H3 i palmitate) is introduced into the body 
(as a bolus intravenously, or orally), and the production of 2ff^O is measured from the blood, 
urine or saliva samples [4] [100].
FFA kinetics (release, uptake, oxidation rates) can be expressed in several different ways [1] 
[2] [4]. Absolute values in pmol/min reflect the total amount of fatty acid release, uptake and 
oxidation in the body [1] [2] [4]. To explore the influence deriving from differences in body 
composition or energy expenditure, systemic FFA kinetic metabolic parameters can be 
expressed also in relative terms, normalised for body weight (BW), fat free mass (FFM), fat 
mass (FM) and energy expenditure, depending on the main aim of the study [4] [84]. If the 
lipolytic activity and release of FFA per unit of fat tissue is to be explored, systemic Ra can 
be expressed per kg FM [4] [84]. If the systemic load of FFA to the “lean” tissues which 
consume FFA (e.g. for oxidation, intracellular storage or incorporation into lipoproteins and 
secretion into plasma) is to be explored, then results can be expressed per kg FFM (“lean 
mass”, including skeletal muscles, liver, etc.) [4] [84]. In reality, FFA are taken also by fat 
tissue (represented by FM), and re-esterified (e.g. fatty acids released by abdominal 
subcutaneous fat depot could be taken-up and stored in femoral fat depot [101]). This 
“extracellular re-esterification” in adipose tissue, skeletal muscle and liver in the form of 
triglycerides (or other molecules), represents non-oxidative FFA disposal, which can be 
calculated from the difference in total uptake rate (Rd) and oxidation rate [48] [91] [102] 
[103] [104].
For example, it is estimated that at rest, in a young, healthy, non-obese man, about 45% of
FFA Ra (Rd) is oxidised to CO2 [102] [105], therefore about 55% are removed for a non-
oxidative disposal [102]. Women have greater non-oxidative disposal compared with men,
64% of FFA turnover [105] [106]. If it is estimated that in a young, healthy, non-obese man
skeletal muscles contribute 40% to body weight [48], then it is found that muscles contribute
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to 21% and 23% of whole body glycerol uptake and release, respectively [48], and 25%, 18%, 
24% of whole body FFA uptake, release and extracellular re-esterification, respectively [48]. 
More than half (50%- 60%) of intramuscular FFA uptake is directed into re-esterification into 
intra-myocellular lipids [107]. The hepatic storage capacity ranges from 7.5 to 67.5 mmol 
(6.7- 60.7g) in normal adults [108]. Liver has high capacity for FFA re-esterification and 
under certain conditions, the hepatic triglyceride content can increase 6-fold in as little as 2 h 
[109]. About 40% of FFA liver uptake is converted to ketone bodies or oxidised to carbon 
dioxide, the other 60% is re-esterified [110]. The re-esterified fatty acids stored in the liver 
(lipid droplets), can be hydrolysed and re-esterified again, and ultimately incorporated in 
VLDL-triglycerides and released from the liver [111]. In one study, it was found that liver 
contributes only up to 5% to total extracellular FFA re-esterification [104], but this 
contribution can be increased in the case where there is an increased FFA supply to the liver 
[112]. In women and men 7% and 6% of systemic FFA are guided towards VLDL- 
triglyceride, respectively [105]. The contribution of fat tissue into extracellular estérification 
is the highest, estimated to be therefore up to 70% [64]. The rate of intracellular re- 
esterification of fatty acids is generally less than 20% of the total whole body re-esterification 
[64] [72]. It was estimated that about 50% of FFA released from triacylglycerol are re- 
esterified intracellularly, and do not leave the cell [72]. Some pathological conditions could be 
related to changed ratios in the regional re-esterification efficiency. For example, insulin- 
resistant states are associated with a higher FFA release from adipose tissue stores (less 
intracellular re-esterification), and reduced FFA uptake and re-esterification by extrahepatic 
peripheral tissues (less extrahepatic extracellular re-esterification), leading to increased 
intrahepatic FFA re-esterification [113]. In type 2 diabetic subjects the oxidation of plasma 
derived FFA was found to be lower, while non-plasma fatty acid oxidation was increased 
[114].
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There is also another way of expressing FFA kinetics. If the rate of FFA release and the rate 
of uptake are determined by energy expenditure rates, then Ra and Rd can be expressed in 
relative terms per kcal/min [4] [84]. This ratio can be useful to explore the FFA release 
relative to the energy demands [4] [84]. When plasma FFA concentration is not increased this 
ratio indicates a higher compensatory non-oxidative disposal (e.g. re-esterification in fat tissue 
or other depots) [4] [84]. When plasma FFA concentration is increased this ratio indicates the 
resistance of fat tissue to antilipolytic actions (or increased sensitivity to lipolytic stimuli), 
which is not compensated by increased re-esterification [3].
However, there is always an error in the estimations derived from these relative indices, 
because the regression lines exploring the relation between Ra (Rd) and BW, FFM, FM and 
energy expenditure have x- and y- intercepts that are significantly different from zero [4] [84]. 
Furthermore, the differences in tissue plasma flow, FFA uptake, release and oxidation rates 
between different fat and lean tissues (e.g. different fat depots and muscles groups), can also 
confound the results [56] [115]. Therefore, these kinetic measurements normalised for body 
composition will be different for the groups who differ in body composition because of 
mathematical bias, rather than true differences in fatty acid metabolism, and caution needs to 
be exercised in cross-sectional studies [4] [84]. Additionally, in longitudinal studies, e.g. if the 
effect of body weight loss is examined, the recognised differences in FM and FFM need to be 
taken in account when interpreting FFA kinetic results [4].
There is a high intra-individual inter-day variability in FFA turnover rates (estimated to be up
to 20% -  25% [116]), and therefore, caution needs to be taken regarding the design of the
study protocol: the beginning of the study, sample timing, duration of prior rest and fasting,
prior diet and physical activity, etc. With this, the inter-day intra-individual variability in FFA
turnover can be reduced up to 8-13% [116]. Based on a high intra-individual inter-day
variability of both basal plasma FFA turnover (e.g. 21%), to detect physiologically
meaningful differences in the means (about 25% -  30% [116]) of basal FFA Ra, at the 95%
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level of significance, with 80% power for the detection (type I error rate a = 0.05 and type II 
error rate P = 0.20), the calculated sample size will require 6-10 subjects in a paired study 
design, or 12-20 subjects per group in a cross-sectional study design (doubled number) [116]. 
To detect less obvious differences in means (e.g. about 15%), more subjects are needed to be 
involved (in this case the double numbers). Therefore, bearing in mind the cost of tracers and 
the analytical burden involved, careful preparation of the study protocol is essential [84] 
[117].
1.3.3. VLDL-triglyceride production and clearance
Triglycerides are not water-soluble, and therefore in plasma they need to associate with other 
molecules to ensure their solubility and transport [57] [58]. In the fasting state the majority of 
plasma triglycerides circulate incorporated in the core of liver secreted VLDL-particles 
(together with cholesterol esters, surrounded by a phospholipid monolayer, in which 
functional proteins are immersed) [57] [58]. The associated molecules (apolipoproteins, 
phospholipids, transfer proteins, etc.) have specific functions in triglyceride molecule 
transport, intravascular hydrolysis (by LPL and HL), uptake of triglycerides and whole 
particles in the tissues, and therefore, the behaviour of the VLDL-particle is different to the 
triglyceride component [57] [58]. This represents a difficulty in the development of specific 
tracer kinetics methods, since VLDL is produced only in the body and commercially available 
triglyceride labels do not resemble adequately endogenous triglyceride kinetics [4]. Therefore 
specific approaches have been developed to label VLDL-particles and trace their kinetics in 
the body [4].
The most widely used techniques infuse or inject a labelled precursor of either the protein- or
triglyceride- component of the VLDL-particle which then in vivo labels the VLDL-particles.
To study VLDL-triglyceride metabolism, either glycerol or FFA (or both) can be used as a
tracer [3] [4] [25] [118]. To study the whole VLDL-particle metabolism, apolipoprotein B 100
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(apoBlOO) can be labelled by introducing labelled amino acids (e.g. leucine) [4] [15] [25]. If a 
labelled amino acid is simultaneously introduced with a triglyceride precursor tracer, the 
conclusion on some specific features of VLDL-particles (e.g. the newly produced VLDLi- 
triglyceride/apoB ratio) or its kinetics (the whole particle uptake vs. hydrolysis) can be made 
[4] [15] [25] [119]. To study de novo production of fatty acids (lipogenesis), labelled acetate 
or water can be introduced into the body and the incorporation of their labelled atoms in 
triglyceride fatty acids (e.g. palmitate) can be followed by the mass isotopomer distribution 
analysis (MIDA) approach [4] [8].
As a triglyceride precursor, glycerol is a better tracer, compared with labelled fatty acids, 
because it shows less tracer recycling (both systemic and non-systemic) [4] [25]. Once 
released from VLDL-triglyceride, glycerol is taken-up by different tissues (mostly by liver, 
kidney, muscle, but untraceably by adipose tissue) and activated by glycerol kinase to form 
alpha-glycerophosphate (the active form of glycerol) [57] [58] [60], which can be used for 
further triglyceride (and other glycerolipids, e.g. glycerophospholipids, glyceroglycolipids) 
synthesis, for gluconeogenesis (production of glucose and, eventually, glycogen and fatty 
acids), and as an energy substrate (for glycolysis and TCA cycle) [1] [2] [57] [58] [60]. 
Another pathway of alpha-glycerophosphate synthesis is by glycolysis from glucose or by 
glyceroneogenesis from lactate, pyruvate, oxaloacetate, and glucogenic amino acids (e.g. 
alanine) [54] [57] [58] [110]. Glyceroneogenesis is the predominant source of triglyceride 
glycerol in adipose tissue, skeletal muscle and liver [110]. It was estimated that about 30-60% 
of glycerol in triglycerides secreted from liver derives from glyceroneogenesis and about 15% 
derives from glucose [120] [121]. Only 5-6% of VLDL-triglyceride glycerol derives from 
plasma glycerol taken-up by the liver and re-esterified into triglyceride molecules [120]. 
There is also a slow-mobilising hepatic glycerol pool in the form of hepatic stored 
triglycerides which presents the source of the remaining 30% of VLDL-triglyceride glycerol
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Figure 1.9. Triacylglycerol biosynthesis by the alpha-glycerophosphate biosynthetic pathway (with permission
from reference [60]).
Alpha-glycerophosphate can be re-esterified with fatty acids into intracellular triglyceride 
depots (by the successive action of glycerol-3-phosphate acyltransferase (GPAT), 
acylglycerophosphate-acyltransferase (AGPAT), phosphatidic acid phosphohydrolase (PAP) 
and diacylglycerol acyltransferase (DGAT), Figure 1.9.) [57] [58] [60] [122], from which it 
can be again readily released into plasma as free glycerol (e.g. from muscle) or incorporated 
in VLDL-triglycerides [57] [58]. Otherwise from being used for re-esterification, glycerol 
can, to a greater extent, become a precursor for glucose production (gluconeogenesis in liver 
and kidney) or can be oxidised (by glycolysis), though to a small extent [57] [58] [122]. Most 
of liberated glycerol is used for gluconeogenesis -  about of 50% of glycerol turnover is 
guided towards glucose production (90% of hepatic glycerol uptake) [120], and only 2% for 
hepatic triglyceride synthesis [104].
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Within the cells (e.g. hepatocytes), glycerol has a fast dynamic. It can recycle from the 
triglycerides stored, and if it is in the form of alpha-glycerophosphate, it can be involved in 
the fast glycolytic recycling, up to pyruvate and oxaloacetate, and then again can be rapidly 
regenerated to be incorporated into intrahepatic triglycerides and VLDL-triglycerides [57] 
[58] [123]. This represents the rapid pool for intrahepatic glycerol recycling. Interestingly, 
most of labelled plasma glycerol taken-up by liver enters this fast glycolytic recycling before 
being incorporated into VLDL-triglycerides, resulting in the loss of uniformly labelled tracer 
atoms in glycerol from VLDL-triglycerides [15] [123].
It was shown that H- labelled glycerol recycles less than C- labelled glycerol, because of
intensive glycolytic intermediary glycerol metabolism, from which C atoms can be recovered
more easily [3]. Uniformly 2H labelled glycerol (2H5) has better properties as a tracer, since it
recycles to a lesser extent (there is a very low probability that all 5 deuterium atoms will be
recovered in a molecule during recycling from intermediary metabolism) [15].
Fatty acids show a high tracer recycling, both systemic and non systemic [1] [2] [4]. Once
released from triglycerides and taken-up by peripheral tissues, they are rapidly re-esterified
into intracellular triglyceride depots, but can be also very rapidly released from those depots
(e.g. adipose tissue, muscle) into the circulation as a source of systemic tracer recycling, or
they could be oxidised within the cells or used for other processes [1] [2] [4] [57] [58].
Plasma FFA taken-up by the liver can be directed towards intrahepatic oxidation (or
ketogenesis), or re-esterification pathways [57] [58]. Re-esterified fatty acids can be retained
in liver (if used for formation of membrane phospholipids or triglyceride storage droplets) or
they can be secreted in the form of triglyceride rich lipoproteins [57] [58]. Fatty acids which
are directed towards secretion are firstly re-esterified, and then hydrolysed again and re-
esterified to be added to the primordial VLDL-particles (which contain apoB and small
amount of triglycerides) [108] [124]. The molecule of triglyceride can be hydrolysed to the
level of DAG and MAG, or by action of hepatic MAG-lipase, glycerol can be completely
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released from the molecule [108]. These cycles of hepatic re-esterification and lipolysis 
before being incorporated into VLDL-triglyceride and secreted from liver are the source of 
the prominent intrahepatic tracer cycling [109] [124].
Even though fatty acids show higher tracer recycling (discussed above) [1] [2] [4], sometimes 
the primary goal is to study VLDL-triglyceride derived fatty acid metabolism, and therefore i 
they are used as the tracer [4]. The regulation of VLDL-triglyceride secretion has been shown ; 
to be under the control of substrate availability (e.g. fatty acids, glucose), and the nutritional 
and hormonal state of the organism [125]. Total flux of fatty acids into hepatocytes plays an 
important regulatory role in VLDL synthesis [125]. In humans, an acute elevation of plasma 
FF A stimulates intrahepatic re-esterification and VLDL production [126]. Increased 
carbohydrate flux stimulates de novo lipogenesis (DNL), triglyceride formation and secretion 
[127]. However, even though hepatic VLDL production is under the control of substrate 
availability, the nutritional and hormonal state of the organism determine whether 
intracellular fatty acids are directed into oxidative, storage or secretory pathways, thus 
ultimately determining the VLDL production rate [125].
It has been estimated that during the postabsorptive state in “normal” subjects 50-70 % of
VLDL-fatty acids derive from systemic plasma FFA re-esterification in the liver and only
about 5% from de novo lipogenesis (DNL) [127] [128], the remaining 30% probably deriving
from non-systemic-plasma fatty acid sources (e.g. from the intrahepatic slow turning-over
pool of triglycerides and other lipids, from lipoprotein particles taken-up by the liver as whole
particles before intravascular hydrolysis, or from other tissues drained by the portal vein- e.g.
visceral fat, etc.) [128]. Visceral fat FFA delivery to the liver contributes only 5-10 % in
normal-weight subjects, depending on sex and the visceral depot size [55] [129].
However, in some pathologic conditions (e.g. insulin resistance, hyperlipidaemia, visceral
obesity and non-alcoholic fatty liver disease), this relation can be distorted. For example, in
obese subjects, 20-30 % of liver FFA flux can derive from visceral fat depots [55] [129]. In
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patients with non-alcoholic fatty liver disease (NAFLD), the VLDL-fatty acid contribution of 
hepatic de novo lipogenesis is increased to 15-25%, while the contribution of plasma FFA re- 
esterification is decreased to 25% [130]. 10% of VLDL-triglyceride fatty acids can derive 
from de novo lipogenesis in obese, hyperinsulinaemic subjects [131]. Hypertriglyceridemic 
subjects as well have increased de novo lipogenesis and plasma fatty acid re-esterification 
[132]. In insulin resistant states there is an interaction of enhanced flux of FFAs from 
peripheral tissues to liver (e.g. adipose tissue resistance to antilipolytic effect of insulin), 
chronic up-regulation of de novo lipogenesis (driven by hyperinsulinaemia and 
hyperglycaemia) and attenuated insulin signalling in the liver (regarding apoB production, 
degradation, VLDL synthesis and secretion), which leads to the overproduction of large, 
triglyceride reach VLDLi-particles [119] [132] [133]. The habitual diet can also influence the 
VLDL-fatty acid sources. When on a low-fat, high-carbohydrate diet (10% fat, 75% 
carbohydrate), de novo lipogenesis comprises 27% of fasting VLDL-triglycerides, compared 
with only 1% when on a standard (30% fat, 55% carbohydrate) diet [127]. In men with type 2 
diabetes, VLDL-fatty acid oxidation accounts for 17% of energy expenditure, while in 
weight- matched “normal” men it accounts for 10% (50% of VLDL-fatty acids is guided 
towards oxidation) [134]. Obese type 2 diabetic men have lower basal VLDL-triglyceride 
clearance (and higher basal and postprandial VLDL-triglyceride secretion) compared with 
healthy controls [135]. In normal-weight, upper-body obese and lower-body obese women 
VLDL-fatty acid oxidation was similar and averaged 20% of resting energy expenditure 
(REE), while only a small proportion of VLDL-triglycerides (8-16%) was partitioned into 
redeposition (redeposition was in upper-body obese women highest in subcutaneous 
abdominal adipose tissue, while in lower-body obese women was the highest in femoral 
adipose tissue) [136]. There is a significant spill-over of VLDL-fatty acids released by action 
of LPL and HL in fasting state, especially in adipose tissues (less in muscle) [49].
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The choice of the FFA to be representative of VLDL-triglyceride kinetics estimation can also 
be an issue, since different fatty acids are metabolised in a different way by the liver and 
peripheral tissues, regarding triglycerides incorporation, secretion and hydrolysis properties
[57] [58] [137] [138] [139] [140]. For example, some fatty acids are more readily 
incorporated into VLDL-triglycerides, some are preferentially stored [57] [58] [137] [141] 
[142] [140]. Some fatty acids are preferentially re-esterified at outer positions (e.g. saturated), 
some at 2-C position of glycerol back-bone (e.g. unsaturated) [57] [58]. Some fatty acids can 
stimulate VLDL-triglyceride secretion (e.g. oleic acid), the others can inhibit it (e.g. omega-3 
fatty acids) [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153]. Most often 
palmitate is used as a tracer, because it is the primary product of de novo fatty acid synthesis
[58], and it is one of the most abundant and the most representative for FFA metabolic 
processes (hydrolysis, oxidation) [4].
Both bolus techniques (bolus injection, bolus infusion) and constant infusion can be used for
the tracer administration [4]. Bolus injection of FFA is not suitable because of the rapid tracer
recycling, and therefore a constant infusion approach is more often used [4].
When using precursor bolus administration techniques, after tracer incorporation in VLDL-
triglycerides and appearance in circulation (a delay of 20-30 minutes was noted [15]), the
tracer incorporation in VLDL-triglycerides peaks after 1-2 hours, and after decays in a
multiexponential fashion [4] [15] [118]. The slope of the decay curve is estimated and from
this the following parameters are calculated: fractional catabolic rate (FCR, in pools/day or
pools/hour), the mean residence time (MRT, in minutes, MRT= 1/FCR) and plasma clearance
rate (PCR, in ml plasma/min, PCR= FCR / plasma concentration) [4] [15] [25] [118] [154]. In
steady state conditions, when concentration of a metabolite in plasma does not change with
time, the metabolite plasma clearance rate is equal with the rate it appears in plasma
(therefore, VLDL-triglyceride fractional production rate (FPR) = FCR) [4] [15] [118] [155].
From the plasma pool size (plasma volume x plasma VLDL-triglyceride concentration) it is
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possible to calculate absolute production rate (APR, pmol/min, or in mg/day, APR=FCR x 
pool size), which can be expressed in relative terms (e.g. per kg BW) [4] [15] [118]. Plasma 
volume can be estimated from body weight (37 ml/kg BW) [156], fat free mass (55 ml/kg 
FFM) [157], or body surface area (BSA) (for women- 1395 ml/m2 BSA, for men- 1578 ml/m2 
BSA, BSA= height °’425 x weight °'725 x 0.007184) [158] [159]. Because of complex precursor 
kinetics and systemic and non-systemic tracer recycling, it is necessary to use a 
multicompartmental model [4] [15] [25] [154]. There are many models proposed [15] [25] 
[154] and since many assumptions about physiological processes are made during model 
development, the accuracy of the model and relevance of the calculated parameters are open 
to discussion [4]. If subjects are normotriglyceridemic, even monoexponential curve can fit 
the data [154].
Some multicompartmental models can also allow the estimation of different VLDL subclasses 
kinetics (VLDLi, VLDL2) [15] [119] [160], and fractional transfer rates (TFR, e.g. referring 
to rate of transformation of VLDLi to VLDL2) or fractional direct catabolic rates (FDCR, 
referring to a direct removal of whole particles or other delipidation processes, apart from 
transfer) can be calculated [15] [119]. The model could be further extended to other 
lipoprotein fractions, including intermediate-density lipoproteins (IDL), low-density 
lipoproteins (LDL) [15] [161] , or high-density lipoproteins (DDL) [162], and the rate of 
triglyceride transfer to other particles (e.g. LDL and DDL by cholesteryl ester transfer protein 
(CETP)) could be estimated [163] [164].
By a constant infusion of a tracer precursor (FFA or glycerol), the kinetics is followed by in
vivo labelling [4]. The tracer appearance in secreted VLDL-triglycerides, usually after a 30
minutes delay [15], is in a monoexponential rise-to-plateau fashion [154]. Fractional
production rate (FPR) can be estimated by a monoexponential mathematical model analysis of
the rise-to-plateau curve of TTR [154], or alternatively by dividing the initial slope of the
curve with the steady state TTR value [4] [165]. From this FCR and APR can be calculated
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(for steady state FCR = FPR) [4] [15]. However, the continuous infusion approach has many
negative points- the study duration is lengthy, since an extended time (up to 6-8 hours) is
necessary to achieve the isotopic steady state (to equilibrate the slow turning pools) and it is
burdensome to keep the subjects under a steady state condition when fasting for such long
period [4]. Additionally, high tracer recycling can not be resolved by multicompartmental
modelling, and therefore often underestimation of the true FCR values occurs [4].
When using triglyceride precursors as tracers (glycerol, FFA), there are often the unsolved
issues of the complex precursor kinetics, inadequate pool equilibration and high tracer
recycling [4] [166]. To overcome those issues, some other approaches are developed.
One approach is to take the subject’s plasma with the previously endogenously labelled
VLDL-triglycerides by administration of a tracer precursor (e.g. glycerol, FFA administered
orally or intravenously -  e.g. infusion 30 minutes; plasma obtained after 1-2 hours), to do the
plasmapheresis under aseptic conditions to separate VLDL-particles, to measure enrichment,
and to re-infuse labelled VLDL-triglycerides into the same subject (2-3 days or a week after)
-  the autologous administration technique, or to another subject- heterologous administration
technique [4] [167]. The administration of in vivo labelled VLDL-triglycerides can be by a
(primed) constant infusion or by a bolus injection or bolus infusion (e.g. 15 minutes) [4]. The
advantage of this approach is that steady state is achieved much earlier [4] [167]; there are no
problems with tracer-precursor recycling and incorporation in other pools [4]. However, the
procedure has increased health risks (especially with heterologous administration technique -
which is why it is not often used) and a necessity for sterile and apyrogenic conditions [4]
[168]. Because of the short expiration date of the infusate, the problem of proper infusate
storage exists, together with the necessity to be used in a shorter period [4] [168]. From
another point of view, when using the autologous administration technique there is a need to
re-infuse tracer in as much as possible distant time (e.g. at least a week later), because there is
still some tracer already incorporated in the body [4]. However, the main problem with this
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approach is that only small amounts of labelled VLDL-triglycerides are recovered from 
plasma for re-infusion [4].
Another approach is to label VLDL-triglycerides ex vivo [135] [169], by the use of sterile 
commercially labelled triglyceride precursors (e.g. triolein-glycerol, with one or more oleate 
C- or H- atoms labelled) which are incubated at 37°C with subject plasma under gentle 
sonication, to allow incorporation of labelled triglycerides into the plasma VLDL-particles. 
The labelled plasma is then ultracentrifuged (to separate VLDL-particles), the enrichment is 
measured and VLDL-particles administered by bolus infusion or (primed) constant infusion 
technique [135] [169]. It is proposed that the VLDL-particles labelled with external 
triglycerides ex vivo by sonication behave the same as naturally present VLDL-particles [135]
[169]. Administration of labelled triglycerides allows the shorter time to achieve steady state 
and there is negligible tracer recycling [135] [169]. Compared with the above described in 
v/vo-triglycerides labelling method, significantly more tracer is recovered [135] [169]. 
However the burden with the complex infusate preparation, requirements for aseptic and 
apyrogenic conditions, and short expiration date of infusate is still a problem [4] [168]..
To estimate VLDL-triglyceride production it is also possible to use the A-V difference 
method, but this technique is laborious to perform in humans (it requires to cannulate an 
artery, the portal vein and hepatic vein, to obtain well mixed venous samples, and to precisely 
measure the hepatic blood flow) [4] [50]. This presents a high degree of discomfort for 
subjects, and therefore is rarely used [4].
There are thus many techniques developed to estimate the VLDL-triglycerides kinetic in vivo
in humans. However, each approach has its advantages and disadvantages, and the choice of a
proper method depends mainly on the purpose of study and available resources [4] [50].
Likewise as for the FFA kinetics, there is a high intra-individual inter-day variability in
VLDL-triglyceride kinetics (it is estimated to be 15- 25% for the VLDL-triglyceride secretion
rate, fractional catabolic rate and pool size) [116]. The calculated sample size to detect 25% -
51
30% differences in the means for postabsorptive VLDL-triglycerides kinetics (a=0.05, (3 = 
0.20) will require 6-10 subjects (in a paired study design) or 12-20 subjects per group (in a 
cross-sectional study design) [116]. If subtractions of VLDL are studied, the introduction of 
ultracentrifugation and separation procedures can further increase the error and variability of 
kinetics parameters estimated, inflating the intra-individual inter-day variability for VLDLi 
and VLDLi kinetics (20%- 35%, with higher variability related to VLDLi kinetics) [4] [15] 
[119]. If caution is taken during study protocol preparation and the sample processing, a lower 
variability can be achieved [50], thus reducing the required number of subjects to 6-10 per 
group (in a cross-sectional study design) [117] [170] [171].
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CHAPTER 2. THE EFFECT OF RIMONABANT ON FREE FATTY 
ACID AND VLDL-TRIACYLGLYCEROL METABOLISM - 
INTRODUCTION
2.1. Obesity, a modern age issue: aetiology, global epidemic, related 
burdens, prevention and treatment strategies
Obesity is a growing problem, not only in the rich western world, but also in transitional and 
undeveloped countries [172] [173]. The main culprit is the modem lifestyle: low physical 
activity level and high energy density of the modem diet [174] [175].
Obesity is one of the most important risk factors for the majority of illnesses (cardiovascular 
diseases (CVD), diabetes, some forms of cancer), which are leading in terms of incidence, 
death rate, disability and economic costs in the modem world [175] [176]. It is also connected 
with negative psychological and social valuation [174] [175]. Abdominal obesity is a 
particular area of concern as it is associated with more elevated health risks, compared with a 
more peripheral fat distribution [177].
Much research has been conducted with the aim to better understand and target obesity, to 
determine the basic mechanism underlying its development and maintenance. According to 
this, both genetic, early developmental and environmental factors (lifestyle and 
psychological) seem to play a role, leading to a discrepancy between energy intake and energy 
expenditure [178] [179] [180] [181].
There has been a lot of effort to prevent and treat obesity [174] [182] [183] [184], but its 
incidence and prevalence is still increasing, and seems to be resistant to treatment [185]. Up to 
now, many drugs have been tested for obesity treatment, targeting energy intake and/or
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energy expenditure, however most with little or limited success [186] [187] [188] [189] [190]. 
Only a few of them were approved as safe and efficient [185].
Recently, a novel drug for the treatment of obesity was proposed [191] [192]. An 
endocannabinoid CB1-receptor blocker, rimonabant (also known as SR141716, Acomplia, 
Riobant, Slimona, Rimoslim and Zimulti, Figure 2.1), showed an appetite blocking effect 
leading to a decrease in energy intake and weight loss [193]. The drug had been approved as 
efficient and safe, and was available in 56 countries in the world. Animal studies showed that 
weight loss was only partly due to a decrease in energy intake, as a consequence of CB1- 
receptor blockade in appetite regulating areas of the brain, since the weight loss was greater 
than estimated for the decrease in energy intake. Therefore, peripheral metabolic mechanisms 
of action were suggested, since a peripheral distribution of CB1 receptors has been shown, 
especially in metabolic active tissues (adipose tissue, liver, endocrine pancreas, skeletal
muscles, gut) [194] [195] [196] [197] [198] [199] [200].
Cl
Figure 2.1. Rimonabant 
[N-(piperidin-1 -yl)-5 -(4-chlorophenyl)-1 -(2,4-dichlorophenyl)-4-methyl-1 
H-pyrazole-3-carboxamide hydrochloride]
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2.2. The endocannabinoid system in the body
The endocannabinoid system (ECS) in mammals was discovered less than 25 years ago. It 
consists of endocannabinoid receptors, their endogenous ligands (called endocannabinoids) 
and the enzymes involved in their synthesis and hydrolysis [194] [201] [202] [203].
2.2.1. A historical overview on endocannabinoid system research
The psychological and physiological effects of marijuana (euphoria, altered perception, 
sedation, analgesia, impaired memory, anti-emesis, appetite stimulation, effects on motor 
function) have been known and used for thousands of years [204] [205]. The principal 
psychoactive ingredient of marijuana is A9-tertrahydrocannabinol (A9-THC), isolated in 1964 
[206], since when its (and its synthesised pharmacological analogues) physiological effects 
have been examined in animals. In the 1980's, pharmacological data (from 1984 [207] [208]) 
and data on administration of radio-labelled synthetic analogues (from 1988 [209]), indicated 
the action was through the G-protein coupled receptors, inhibiting the adenylate cyclase 
activity, and showed a specific cannabinoid analogue-receptor binding in some brain areas. 
Soon after, in 1990 [210] and 1991 [211], a G-protein coupled receptor without a known 
endogenous ligand, but which bound a cannabinoid analogue, was discovered in the rat brain 
and the human testis. Later (in 1993 [212]) this receptor was named cannabinoid receptor 
CB1, because another similar receptor, with 44% amino acid-sequence identity (and 68% 
identity within the transmembrane domains), called CB2, was isolated from a human 
promyelocytic leukaemic cell line [212], with distribution in macrophages and immune 
tissues, but not in the brain. Subsequently, the first selective antagonists for CB1 and CB2 
receptors, SR141716 (in 1994 [191], later called "rimonabant") and SR144528 (in 1998 
[213]), were synthesised and characterised. Development of CB1- or CB2-knockout mice (in 
which one specific receptor gene was deleted), further distinguished CB1- and CB2-receptors
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effects. Consequently, research on possible pharmacological uses of synthesised agonists and 
antagonists started.
The discovery of cannabinoid receptors led to research for their endogenous ligands. The first 
endogenous ligand, jV-arachidonoylethanolamide (AEA, also known as anandamide), was 
discovered in 1992 [214], followed by discovery of 2-arachidonoylglycerol (2-AG) in 1995 
i  [215]. Since then, a number of related endogenous lipids with endocannabinoid-like activity 
have been reported, but follow-up studies about biosynthesis, cellular transport, metabolism, 
and biological function have focused on AEA and 2-AG, with much less information 
available about the other compounds with endocannabinoid-like properties.
2.2.2. Endocannabinoid receptors - structure, distribution and mechanisms 
of action
Mammalian tissues contain at least two types of cannabinoid receptors, CB1 and CB2. CB1 
receptors (Figure 2.2), cloned in 1990 [210], are predominantly expressed in the central 
nervous system but also in different peripheral tissues including, the gastrointestinal tract, 
muscles, pancreas, liver, fat tissue, endothelium, thyroid and adrenal gland, the reproductive 
system (testis, ovaries), lungs, spleen and immune cells [194] [201] [202] [203]; while CB2 
receptors, cloned in 1993 [212], are most abundant in the immune system, i.e. in tonsils, 
spleen, macrophages and lymphocytes (B-cells and natural killer cells) [194] [201] [202] 
[203]. There are also other, non- CB1- and non- CB2- cannabinoid receptors identified in the 
body (e.g. vanilloid receptor), but their function still remains to be characterised [194] [201]
[202] [203].
Cannabinoid receptors are seven-transmembrane-domain proteins coupled to G-proteins of 
the Gj/o type [203]. CB1 efficiently couples and activates both Gj and G0, whereas CB2 can 
only activate G0 [203].
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Both CB1 and CB2 receptors inhibit adenylate cyclase-mediated cyclic adenosine 
monophosphate (cAMP) formation [203] [216] [217] [218], and stimulate p42/p44 mitogen- 
activated protein kinase (MAPK) activity [219]. CB1, but not CB2, receptors signal also via 
ion channels by inhibiting N- and P/Q-type calcium channels and by activating A-type and 
inwardly rectifying potassium channels [203]. Furthermore, activation of CB1 can also 
stimulate several intracellular kinases, such as focal adhesion kinase (FAK), phosphatidyl 
inositol 3-kinase (PI3-K) and its downstream effector protein kinase B (PKB, also known as 
Akt), extracellular signal-regulated protein kinases (ERKs), c-Jun N-terminal kinase (c-JNK), 
and p38 MAPK (p38) [194] [201] [202] [203]. It is possible that other, still undiscovered 
mechanisms of intracellular signalling exist [203].
Ca
CB1
\  ^ I cyclase
PKC
FAX
PKB/ÀKT JNKRaf.1
ERK
Figure 2.2. CB1 receptor and a model o f its intracellular signalling (with permission from reference [194])
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2.2.3. Endocannabinoids - structure, synthesis, degradation
2.2.3.1. Endocannabinoids
By definition, endocannabinoids are endogenous compounds capable of binding to and 
functionally activating CB1 and CB2 receptors. iV-arachidonoylethanolamide (anandamide, 
AEA), the first endogenous ligand to be reported at the end of 1992 [214], is the amide of 
arachidonic acid and ethanolamine, and it acts as a partial CB1 agonist and only as a weak 
CB2 agonist (Figure 2.3). Three years later, the second endocannabinoid, 2- 
arachidonoylglycerol (2-AG), the arachidonate ester of glycerol, which activates both CB1 
and CB2 receptors, was identified [215] [220]. The other endocannabinoid compounds, all 
derivatives of arachidonic acid, were also identified more recently: 2-arachidonyl-glyceryl 
ether (noladin, 2-AGE), a selective CB1 agonist, O-arachidonoyl-ethanolamine (virhodamine, 
OAE), a partial CB2 agonist and a CB1 antagonist, and N-arachidonoyl-dopamine (NADA), a 
selective CB1 agonist and a potent agonist of vanilloid receptors, were discovered [201] [202] 
[203] [221] (Figure 2.3).
Anandamide 
Partial CB, agonist, weak CB2 agonist
2-Ârachidonoyl-glyceml 
Full CB, and CB2 agonist
.NH,
Noladin 
Selective CB) agonist
Virhodamine 
Partial CB2 agonist and a CB, antagonist
OH
,OH
N-Arachidonoyl-Dopamine 
CB, agonist and potent TRPV1 agonist
Figure 2.3. Endocannabinoids: structure and receptor binding potency (with permission from reference [221])
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While the physiological role of virhodamine, NADA and 2-AGE has not been clarified yet, 
the endocannabinoids AEA and 2-AG, since their finding, have been implicated in a wide 
range of physiological and pathological processes, including: maintaince of homeostatic 
balance, metabolism, stress-recovery, mental disorders (anxiety, depression, schizophrenia), 
reward behaviours, modulation of nociception, control of certain phases of memory, 
regulation of motor functions, neuroprotection, neurodegenerative diseases (multiple 
sclerosis, Parkinson’s disease), anti-neoplastic activity (induction of apoptosis, anti­
proliferative and anti-metastatic effect, cancer prevention and treatment), modulation of 
immune and inflammatory response, cardiovascular system (bradycardia, vasodilatation, anti- 
ischaemic effect), respiratory system (bronchodilatation, inflammation, allergic disorders), 
gastrointestinal tract (inflammation and motility), eye function (intraocular pressure, retinal 
neuroprotection), etc. [201] [202] [203].
2.2.3.2. Endocannabinoid formation and inactivation
All endocannabinoids identified so far are derivatives of long-chain PGP As, specifically 
arachidonic acid. Endocannabinoids are mostly synthesised in the central and peripheral 
nervous tissue and macrophages, but also in a wide range of peripheral organs and tissues 
[221].
Endocannabinoids are predominantly synthesised from membrane phospholipids, but can be
also synthesised from intracellular triglyceride depots (2-AG) [221] [222] [223]. Unlike some
other neurotransmitters, AEA and 2-AG are not stored in resting cells, but they are de novo
synthesised and released only “on demand”, i.e. when and where necessary, in response to
elevations of intracellular Ca2+, following physiological (e.g. neuronal depolarization) or
pathological stimuli [221] [222]. Metabolic synthetic pathways for AEA and 2-AG are
slightly different (Figure 2.4), and they include some specific enzymes: NAPE-PLD
(phospholipase D selective for N-acyl-phosphatidylethanolamines) and DAGL (diacylglycerol
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lipase), respectively [203] [217] [221] [222] [223]. AEA is biosynthesised from NArPE (N- 
arachidonyl-phosphatidylethanolamine), which is in turn produced from membrane 
glycerophospholipids (e.g. phosphatidylcholine) and phosphatidylethanolamine (PE), by a 
Ca2+-dependent trans-acylase [203] [221] [222]. NArPE is subsequently hydrolysed by a 
NAPE-PLD. NAPE-PLD is not selective only for AEA production and is widely distributed 
in various tissues and organs [221]. Additionally, another, NAPE-PLD- independent pathway 
for AEA formation from NAPEs has been reported [203] [221] [222] [223]. According to that 
pathway, NAPEs are first hydrolysed to N-acyl-lyso-PE by a secretory phospholipase A2 
(group IB), and then N-acyl-lyso-PE are hydrolysed to AEA by a lyso-PLD-like enzyme 
[203] [221] [222] [223].
Glycerol 
arachidoic aad
2-AG
inactivation
CB2-AGCB
Anandamide Anandamide
inactivation 2-AG
sn-1 -Acvi-2-arachidonoylPhosphatase
Ethanolamine
+
arachidonic acidphospho-AEA 2-AG
biosynthesisNAPE-PLD
GlycerophospholipidNAPE-PLC Anandamide
biosynthesisNArPE
NAT
Glycerophospholipid
phosphatidylethanolamine
Figure 2.4. Schematic representation o f  endocannabinoid synthesis and degradation in pre- and postsynaptic
neurons (with permission from reference [203])
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In unstimulated tissues and cells the levels of 2-AG are higher than those of AEA, which can 
be a consequence of the fact that this cannabinoid can be a precursor and/or degradation 
product of phospho-, di- and tri- glyceride pathways [203] [217] [221] [222] [223]. In most 
cases, 2-AG is produced from the hydrolysis of DAGs containing arachidonate in the 2 
position, catalysed by a DAGL selective for the sn-l position. DAGs can be produced from 
the hydrolysis either of phosphoinositides (PI), catalysed by a Pi-selective phospholipase C 
(PI-PLC), or of phosphatidic acid (PA), catalysed by a PA phosphohydrolase [203] [221] 
[222] [223]. As for the NAPE-PLD, DAGL is not involved only in 2-AG production, and is 
widely distributed in tissues [221].
In the brain, endocannabinoids are produced by postsynaptic neurons following 
neurotransmitter release, and act as retrograde messengers: they activate CB1 receptors on the 
presynaptic neuron, which induces a blockade of neurotransmitter release [203] [217] [221] 
[222] [223].
Because they are lipophilic compounds, the endocannabinoids can diffuse through the cell 
membrane, and there is evidence that this can be facilitated by a carrier transport mechanism, 
known as the AEA membrane transporter (AMT) [203] [217] [221] [222] [223].
Once inside the cell, the endocannabinoids are rapidly degraded through hydrolytic 
mechanisms involving activity of fatty acid amide hydrolases (FAAH - mostly responsible for 
AEA hydrolysis, but can also hydrolyse 2-AG) and monoacylglycerol lipases (MAGLs - can 
catalyse 2-AG hydrolysis, but not AEA) [203] [217] [221] [222] [223]. The hydrolysis 
products of AEA and 2-AG, ethanolamine, arachidonic acid and glycerol, are recycled into 
membrane phospholipids in order to be used again. 2-AG, unlike AEA, can be re-esterified 
into phospholipids also before being enzymatically hydrolysed [203] [221].
Endocannabinoids are also susceptible to oxidative mechanisms of inactivation catalysed by 
lipoxygenases, cyclooxygenases and cytochrome P450 oxidases, which can produce some 
physiologically active derivatives (e.g. eicosanoids) [221].
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There is evidence for possible chronic overactivation of the endocannabinoid system in 
obesity [194] [224] [225]. In a large cohort of Caucasian and black subjects, overweight and 
obesity have been found to be linked with a missense polymorphism of FAAH, which is 
associated with reduced enzymatic activity, leading to a reduced inactivation of AEA and 
chronic increase of endocannabinoid levels [226].
2.3. The role of the endocannabinoid system in energy balance and 
metabolism
The endocannabinoid system is involved in many different physiologic functions in the body 
[203] [227], and one of them targets the energy balance regulatory system: appetite and 
feeding behaviour regulation and peripheral metabolism [196] [203] [227] [228].
Appetite stimulation after marijuana consumption was known for centuries [204] [205] [229] 
[230], and only recently it was shown that the effect was mediated through the A9- 
tertrahydrocannabinol (A9-THC, a chemical component in the marijuana smoke) stimulation 
of CB1 receptors of the brain [192] [202] [203].
However, more recent studies have shown that the endocannabinoid system can influence 
energy balance and metabolism through both central and peripheral mechanisms of control, 
since CB1 receptors, which are responsible for this function, are widely distributed in 
different organs and tissues [201] [202] [203] [225].
2.3.1. Endocannabinoids and central mechanisms of energy balance
Central regulatory mechanisms of the endocannabinoid system are related to appetite
stimulation, increased feeding motivation (especially for highly palatable and rewarding food)
and hedonistic aspects of feeding (higher emotional and sensory valuation of food) [202]
[203] [231] [232] [233]. CB1 receptors are widely distributed in brain areas regulating
appetite and feeding behaviour. Most of the research has been focused on hypothalamic
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regions related to appetite regulation (ventromedial parts, including nucleus paraventricularis- 
PVN, lateral hypothalamus-LH and nucleus arcuatus-Arc), limbic forebrain regions related to 
motivational and emotional aspects of eating (nucleus accumbens-shell region-AcbSh), as 
well as brainstem (dorsal motor vagal nucleus-DMV and nucleus tractus solitarius-NTS) 
[201] [202] [203] [233]. These areas of the brain contain a high density of CB1 receptors and 
high levels of endocannabinoids, and are highly influenced by other hormones and 
neuropeptides involved in the regulation of feeding, including leptin, glucocorticoids, insulin, 
cocaine- and amphetamine- regulated transcript (CART), pro-opiomelanocortin (POMC), 
opioids, alpha-melanocyte-stimulating hormone (alpha-MSH), corticotropin-releasing 
hormone (CRH), melanin-concentrating hormone (MCH), ghrelin, agouti-related peptide 
(AgRP), orexin A, neuropeptide Y (NPY), peptide YY (PYY), cholecystokinin (CCK) and 
glucagon-like peptide 1 (GLP-1) [234]. A lot of recent research has concentrated on the 
interaction of the cannabinoid system with these orexigenic and anorexic signals [194] [196] 
[228] [235] [236] [237] [238] [239] [240]. In addition, CB1 receptors and AEA are 
synthesised on afferent nerve terminals innervating the intestine, suggesting a role of the 
endocannabinoid system in transducing satiety signals from periphery to the brain [241].
It is well confirmed that systemic or direct brain injections of A9-THC, endocannabinoids or 
their synthetic analogues stimulate appetite and feeding (even in satiety state) in animals, 
while administration of a CB1 receptor blocker (rimonabant) abolishes that effect [242] [243] 
[244] [245] [246]. Central or peripheral administration of CB1 antagonists reduces appetite in 
animals, indicating its possible role in obesity treatment and appetite regulation. The appetite- 
and weight- reducing effects of CB1 antagonists are more pronounced in obese, hyperphagic 
animals than in their lean controls, and in non-obese animals the anorexigenic effect of 
rimonabant is more prominent when tested in animals during refeeding after temporary food 
restraint or deprivation than in animals with free access to food [237].
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In feeding areas of the brain, levels of endocannabinoids increase with fasting, and decrease 
to normal levels after re-feeding [243] [245]. However with prolonged fasting, the increased 
levels of endocannabinoids decrease with time, and it was proposed to be an adaptation 
mechanism to reduce energy expenditure related to food seeking and preserve energy only for 
basic metabolic functions [247] [248]. It has been suggested that the PUFA- content of the 
food consumed can directly influence the levels of the endocannabinoids, possibly by 
influencing the brain amounts of their phospholipid precursors. In particular, as shown in 
animal studies, foods relatively rich in omega-6 PUFAs (such as in many “high-fat diets”) can 
significantly enhance both the levels of AEA [249] and 2-AG [250].
Leptin exerts a suppressive effect over central endocannabinoid levels. In genetically obese 
ob/ob and db/db mice and fa/fa Zucker rats, where, respectively, leptin is absent (ob/ob), 
leptin receptor is absent (db/db) or leptin receptor is inactive (fa/fa), the central levels of 
endocannabinoids were increased, compared with lean, wild-type controls [235] [251]. 
Additionally, administration of leptin reduced the central levels of endocannabinoids in ob/ob 
mice, as well as in the wild-type of mice, but not in db/db mice or fa/fa Zucker rats [235] 
[251]. On the contrary, in wild-type mice with diet induced obesity, it was not shown that 
central, hypothalamic endocannabinoid levels (or CB1 receptor density) were changed, which 
could be explained with the obesity related leptin resistance [252] [253]. In one study, 
exposure of rats to a palatable diet containing sucrose and condensed milk resulted in down- 
regulation of CB1 receptors in limbic structures involved in the hedonic aspects of feeding, 
but not in the hypothalamus [254].
Compared with wild-type controls, transgenic CB1-/- knockout mice, in which CB1 receptors 
are absent, have a lower body weight through all their life and are less prone to develop 
obesity and insulin resistance on a high-fat diet, even when they have similar energy intake
[196] [197] [228] [255]. On a high-fat diet, CB1-/- mice do not develop increased adiposity, 
fatty liver, and do not show increased levels of leptin, insulin, triglycerides, higher activity of
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LPL, and lower levels of adiponectin, as do their wild-type littermates with the same energy 
intake [197] [255].
Administration of rimonabant both to normal-weight and obese animals led to a significant 
transient decrease in food intake soon after administration, but this effect disappeared after 
several days (usually within one week) [256] [257]. In transgenic CB1-/- knockout mice 
rimonabant did not have any effects on food intake and body weight, indicating that 
hypophagic and weight reducing effects of rimonabant are mediated through its action on 
CB1 receptors [237] [255].
2.3.2. Endocannabinoids and peripheral mechanisms of energy balance
The first indirect indication that cannabinoids may affect energy homeostasis through a 
mechanism other than food intake came from a study of marijuana smokers, where the 
marijuana-induced increase in caloric intake stabilised after a few days, whereas weight gain 
continued throughout the rest of the 21-day observation period [258].
Additionally, experiments in animals showed that reduction in food intake after CB1 inverse 
agonist (rimonabant) administration was only transient, while the animals continued to lose 
weight on further treatment [237] [259] [260] [261]. This implies that other, non- food intake 
related mechanisms, could be involved, including peripheral metabolic effects. Indeed, CB1 
receptors also are widely spread in the metabolically active tissues, including fat tissue, 
muscle, liver and pancreas, suggesting a direct role of the endocannabinoid system in 
peripheral metabolism.
2.3.2.1. The endocannabinoid system in the adipose tissue
The endocannabinoids 2-AG and AEA, as well as the enzymes involved in their synthesis and
degradation, have been isolated from preadipocytes and mature adipocytes in both animals
and humans [224] [260] [261] [262] [263] [264] [265] [266] [267]. Additionally, the presence
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of CB1 receptors have been confirmed in white (WAT) and brown (BAT) adipose tissue
[196] [260]. In WAT, the higher endocannabinoid levels have been detected in visceral 
(VAT) relative to subcutaneous (SAT) adipose tissue, in both in humans and mice [262] [268]
[269], and the mRNA levels of CB1 receptors were higher in VAT compared with SAT 
depots in humans [267].
The expression of the CB1 receptor is more prominent in mature adipocytes than in 
preadipocytes [224] [260] [262] [264] [265] [270] [271]. CB1 receptors are involved in 
adipocyte proliferation and differentiation [224] [260] [262] [264] [270] [271], and their 
stimulation leads to advanced proliferation and differentiation [271], increased peroxisome 
proliferator-activated receptor (PPAR)-gamma expression [272], increased adipocytes size 
and lipid droplet accumulation [196] [262], as well as inhibition of adiponectin expression 
[262]. Studies in vitro and in vivo, in animal models, have shown that rimonabant reverses 
these effects [240] [273]: rimonabant inhibits preadipocyte proliferation [274] [273], and 
increases the expression of molecular markers of late adipose differentiation (including 
adiponectin), without inducing triglyceride accumulation [274] [273], and reduces adipocyte 
size [273], as well the cell surface CB1 receptor protein expression [273]. In preadipocytes of 
mice, rimonabant down-regulates PPAR-gamma gene expression, and stimulates the gene 
expression of thermogenic uncoupling proteins -1 and -2 (UCP-1 and UCP-2) [270] [275].
As it was previously mentioned, in isolated adipocytes CB1 stimulation increases adipocyte 
size and lipid droplet accumulation [196] [262]. Stimulation of CB1 receptors can affect lipid 
metabolism in adipocytes and increase lipid droplet accumulation by increasing PPAR- 
gamma expression [262], by increasing the expression of lipid droplet proteins [273], by 
increasing the expression of transcription factors and enzymes engaged in lipogenesis and 
triglyceride deposition [196] [262] [273], by increasing LPL activity [176] [177] [196], 
glucose uptake [265], and by decreasing cAMP formation [240], lipolysis [273], adiponectin
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production [260] [273], the AMP-activated protein kinase (AMPK) activity [276] and lipid 
oxidation [273].
Regarding the effect of CB1 stimulation on increased lipogenesis [196] [262] [273], the sterol 
regulatory element-binding proteins-1 (SREBP-la and SREBP-lc) play an important role in 
regulation of lipogenesis in adipose tissue through the control of the gene expression of 
lipogenic enzymes and transcription factors, including acetyl CoA carboxylase 1 (ACC1), 
fatty acid synthase (FAS), stearoyl-CoA desaturase-1 (SCD-1), GPAT and PPAR-gamma 
[277] [278] [279] [280] [281] [282]. A study in humans showed that CB1 mRNA levels in 
VAT were in a positive correlation with SREBP-lc mRNA levels in VAT, suggesting a direct 
effect of cannabinoids on VAT lipogenesis [273]. In a recent study [283], using an anti-sense 
oligonucleotide treatment against peripheral CB1 receptors, a reduction in SREBP-1 mRNA 
together with 81% reduction of CB1 mRNA was noted in VAT of the treated animals [283]. 
In line with the effects on SREBP-1, in preadipocytes and mature adipocytes, in vitro, CB1 
agonists up-regulated the expression of lipogenic genes which are under the control of 
SREBP-1, including: ACC1 (involved in fatty acid biosynthesis and inhibition of fatty acid 
oxidation), FAS (involved in fatty acid biosynthesis), SCD-1 (involved in fatty acid 
desaturation) and DGAT-2 (involved in triglyceride biosynthesis) [275]. At the same time, 
rimonabant exerted the opposite effects, decreasing the expression of these lipogenic enzymes 
(ACC1, FAS, SCD-1 and DGAT-2), both in vitro and in vivo in animals [270] [275] [284] 
[285]. Additionally, in CBl-/-mice adipocyte LPL activity was lower [196], and in adipocytes 
of wild-type mice CB1 agonists increased [196] [275], while rimonabant decreased LPL 
mRNA and activity [196] [270] [275].
PPAR-gamma is also under the control of CB1 receptors [262], possibly through the control 
of SREBP-lc [286]. PPAR-gamma as well enhances adipogenesis and lipid accumulation, by 
inducing the adipocyte fatty acid-binding protein (FABP) aP2 and other adipocyte specific 
genes, including phosphoenolpyruvate carboxykinase (PEPCK) and perilipin gene expression,
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thereby stimulating the generation of lipid droplets, which accumulate triglycerides, and 
preventing them from the hormone-sensitive lipase (HSL)-induced lipolysis [286] [287] 
[288]. In agreement, in mice with diet-induced obesity rimonabant in vivo decreased the 
expression of perilipin-2 in SAT [273], and increased the expression of HSL in SAT [284], 
while decreased the expression of HSL in VAT [284]. On the other hand, in another study, a 
trend toward an increased total triacylglycerol hydrolase activity was shown after rimonabant 
treatment also in VAT from long-term treated animals [289], but only when an HSL inhibitor 
was not present [289]. Additionally, rimonabant administration, in vivo, in diet-obese mice, 
induced in SAT adipocytes the lipolytic beta-3 adrenergic and growth hormone (GH) 
receptors expression [273], and decreased the expression of catechol-O-methyltransferase 
(COMT) [273], which is involved in the local degradation of catecholamines [273], therefore 
favouring adrenergic and GH stimulated lipolysis in SAT [273].
Some of the effects of CB1 receptors on lipid metabolism in adipocytes (e.g. lipogenesis, 
lipolysis and fatty acid oxidation) can also be mediated by the inhibition of AMPK [276] 
[290]. Administration of A9-THC in rats decreased the AMPK activity, both in SAT and in 
VAT [276]. In contrast, CB1 receptor blockade by rimonabant (in vitro, in cultured mice 
cells) or by CB1-receptor depletion (in vivo, in CB1-/- mice fed a high-fat diet) increased the 
AMPK activity and phosphorylation in VAT [290]. The effects could be mediated through the 
effects of CB1 receptors on adiponectin synthesis, since it is known that adiponectin activates 
AMPK [276], and/or through the effects of CB1 receptors on the intracellular adenosine 
triphosphate/adenosine monophosphate (ATP/AMP) ratio, thus decreasing the activation of 
the liver kinase B-l (LKB-1), which is an upstream activating kinase of AMPK [282]. 
Reduced phosphorylation (activation) of AMPK in adipocytes is related to the increased 
lipogenesis and decreased fatty acid oxidation, by a disinhibition of ACC1, the rate-limiting 
enzyme in fatty acid synthesis, or by a decrease in activity of carnitine palmitoyl transferase-1 
(CPT-1), the rate-limiting enzyme in fatty acid oxidation [203]. In accord with this,
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rimonabant in vivo in animals, decreased the expression of ACC1 [284] and increased the 
expression of CPT-1 [273] [285], thus favouring lipid oxidation and diminishing lipogenesis. 
Finally, the study of Jbilo and colleagues [273] revealed that rimonabant treatment in vivo in 
mice with a fat-diet induced obesity can directly target enzymes in WAT involved in lipolysis, 
beta-oxidation and the TCA cycle. In WAT adipocytes, it increased mRNA expression of: 
carnitine acetyltransferase (CAT) and carnitine palmitoyltransferase-2 (CPT-2); the enoyl 
CoA hydratase; fumarase, aconitase and oxoglutarate dehydrogenase (the enzymes of the 
TCA cycle) and cytochrome c oxidase (the enzyme in the respiratory chain), as well as 
antioxidant enzymes glutathione peroxidase 3 (GPX3) and flavin-containing monooxygenase 
1 (FMOl) [273]. Furthermore, in WAT adipocytes rimonabant induced both glycogen 
synthase and glycogen phosphorylase, the enzymes involved in glycogen synthesis and 
breakdown, which could generate “futile cycles” [273]. Rimonabant also increased the 
expression of three enzymes involved in amino acid degradation and four of eight glycolytic 
enzymes (including phosphofmctokinase (PFK), glyceraldehyde 3 phosphate dehydrogenase 
(GAPDH), phosphoglycerate mutase (PGM), and beta enolase), thus stimulating glucose 
metabolism, and PEPCK, which catalyses the limiting step in glyceroneogenesis [273]. 
Moreover, the insulin-responsive glucose transporter-4 (GLUT-4) was induced in vivo [265] 
[273], which can explain the effect of rimonabant to reduce insulin resistance.
In adipocytes, CB1 agonists decreased adiponectin expression [262], while CB1 blockade 
increased adiponectin levels, and stimulation of expression of adiponectin mRNA occurred 
within 30 min of rimonabant treatment [260] [273]. The plasma level of adiponectin and its 
mRNA expression in adipose tissue are decreased in both animal and human obesity, as well 
as in subjects with type 2 diabetes [291]. The positive effect of CB1 blockade on adiponectin 
levels could explain some of its positive metabolic outcomes: weight reduction (even with 
normal energy intake, due to increased beta- fatty acid oxidation), and reduction of 
components of metabolic syndrome (insulin resistance, hyperinsulinaemia,
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hypertriglyceridaemia, low HDL-cholesterol and high mean arterial pressure). However, not 
all studies have found increased adiponectin mRNA and protein in adipose tissue, or serum 
adiponectin concentrations after rimonabant treatment [265] [292] [293].
Apart from adiponectin, rimonabant also modulated the expression of some other adipokines 
and chemokines in adipose tissue, including down-regulation of leptin [273] [294], tumour 
necrosis factor-alpha (TNF-alpha) [295] [296], interleukin-6 (IL-6) [270] [275] [296], visfatin
[270] [275] [295], apelin [270] [275], plasminogen activator inhibitor-1 (PAI-1) [273], 
monocyte chemotatic protein-1 (MCP-1) [270] [296], retinol binding protein-4 (RBP-4) 
[295], C-reactive protein (CRP) [297] [298] [299], lipocortin-1 [273], lipopolysaccharide 
(LPS) binding protein (LBP) [273], and lysozyme M, macrophage inflammatory protein 1 
gamma (MIP-1 gamma), serum amyloid A3, and mac-2 antigen [273], and up-regulation of 
adipsin [273], resistin [273] and spot 14 [273].
Additionally, in vivo in animals rimonabant increased enzymes and proteins involved in
thermogenesis in BAT [273], including: enzymes involved in formation of fatty acyl-CoA for
beta-oxidation (fatty acid CoA ligase), enzymes involved in mitochondrial oxidative
phosphorylation pathway (nicotinamide adenine dinucleotide + hydrogen (NADH),
ubiquinone oxidoreductase, ubiquinol cytochrome c reductase and F1F0-ATP synthase), the
antioxidant function (metallothionein-1, carbonic anhydrase 3, FMOl and GPX3),
mitochondrial biogenesis (chaperonine 10), enzymes involved in production of 3,3',5-
triiodothyronine (T3) (type II deiodinase), and production of intracellular cAMP (adenylate
cyclase type III), which is involved in activation of protein kinase A (PKA) and subsequent
stimulation of lipolysis by HSL [273]. Also, the expression of the thermogenic UCP-1 in BAT
was down-regulated by CB1 activation in animals [300], and the treatment of a high-fat diet
induced obesity in mice with the CB1 receptor antagonist AM251 increased UCP-1 and UCP-
3 mRNA expression level in BAT [301]. All this findings suggest that CB1 receptor blockade
may contribute to increased thermogenesis in BAT, and it was shown that CB1 agonists
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decrease mRNA expression of UCP-1 in BAT, which is a widely used marker of thermogenic 
capacity [300].
Furthermore, it was shown that rimonabant stimulated the UCP-1 and UCP-2 mRNA 
expression in preadipocytes [270] [275] and increased mitochondrial biogenesis in WAT 
[302], thereby stimulating conversion of WAT towards BAT phenotype [302]. This effect is 
probably mediated by the induction of endothelial nitric oxide synthase (eNOS) expression, 
and AMPK might be involved in the effect of CB1 receptor blockade on eNOS-mediated 
mitochondrial biogenesis [280] [302], since the AMPK cascade has been described to activate 
eNOS and nitric oxide (NO) production [290], and it was shown that CB1 receptor blockade 
stimulates AMPK phosphorylation and activity [290]. In turn, it was demonstrated that 
induction of increased mitochondrial biogenesis in cultured adipocytes enhanced adiponectin 
synthesis [303].
In summary, extensive research on endocannabinoid system in adipose tissue, both in vitro 
and in vivo (mostly in animals), indicates that activation of CB1 receptors in adipose tissue 
has a pro-adipogenic and pro-obesogenic effect, increasing the adipocyte number and size, by 
stimulating adipocyte proliferation, differentiation, lipid uptake, de novo lipogenesis, 
triglyceride deposition and lipid droplets accumulation, and by inhibiting lipolysis and fatty 
acid oxidation. In contrast, blockade of the CB1 receptors exerts the opposite effect- it inhibits 
lipid accumulation and stimulates lipolysis and lipid oxidation in adipocytes, as well glucose 
metabolism and insulin signalling. Both in WAT and in BAT these effects were observed, and 
multiple pathways and complex systems are involved. However, data from animal studies 
cannot be directly extrapolated to humans, thus more studies in human adipocytes are 
desirable to confirm those findings.
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2.3.2.1.1. The overactivation of endocannabinoid system in the adipose 
tissue in obesity
Overactivation of the endocannabinoid system in adipose tissue with a high-fat diet induced 
obesity has been reported both in humans and animals [224] [260] [262] [265] [267] [268] 
[304] [305] [306].
In genetically obese hyperphagic fa/fa Zucker rats, with a defective leptin receptor, levels of 
CB1 receptor in adipose tissue were increased [260]. Surprisingly, human studies showed 
decreased CB1 receptor mRNA expression in SAT and VAT in obesity, especially in the 
centripetal type [224] [262] [267]. However, CB1 receptor expression has been also reported 
unchanged in SAT of obese subjects [263] [268], or down-regulated or up-regulated, 
depending on the fat depots [263]. Additionally, some studies [224] [262] [267] showed 
decreased mRNA of FAAH in SAT and VAT in obesity, but a more recent study found a 
down-regulation of FAAH, MAGL and DAGL only in gluteal SAT, while the opposite was 
found in VAT and abdominal SAT [265]. The reduced levels of FAAH in SAT and VAT with 
obesity can increase the local endocannabinoid levels, primarily of AEA, since this enzyme is 
preferentially involved in AEA degradation, while the reduced levels of MAGL lead to the 
increased 2-AG levels. Both 2-AG and AEA were increased in VAT of obese subjects, but 
only 2-AG, not AEA levels were increased in VAT with diet induced obesity in animals 
[262]. Down-regulation of CB1 and FAAH gene expression in SAT and increased circulating 
levels of endocannabinoids were also described in obese postmenopausal women [224]. 
Additionally, both 2-AG and AEA were also increased in blood of obese patients with type 2 
diabetes, compared with overweight healthy controls [262]. However, in one study [267], 
while circulating 2-AG levels were in positive correlation with total body FM, visceral FM, 
fasting insulin levels and insulin resistance, circulating AEA levels were the highest in lean 
subjects. On the contrary, another study showed the higher plasma levels of AEA, but not 2- 
AG, in overweight/obese women with a binge eating disorder [306].
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In conclusion, even though the substantial amount of data indicates an increased 
endocannabinoid tone in obesity in humans, particularly in the visceral-type obesity, there is 
still a lot of confusion about the mode of this overactivation.
2.S.2.2. The endocannabinoid system in the liver
Similarly to adipose tissue, the endocannabinoids 2-AG and AEA, as well as CB1 receptors, 
have been identified in the liver [197] [307], and their levels have been showed to be 
increased in diet-induced obesity and liver steatosis [197] [307] [308] [309]. In mice on a 
high-fat diet, hepatic levels of AEA (but not 2-AG), as well as CB1 receptors mRNA 
expression, were increased at early stages of high fat feeding [197]. Furthermore, the 
expression of CB1 receptors was up-regulated in the liver of patients with NAFLD [307] 
[308] [309].
The resistance of CB1- deficient mice to diet-induced obesity, liver steatosis and metabolic
changes, in spite of similar caloric intake as their wild-type littermates [196], suggests a role
for CB1 in the increased hepatic lipogenesis [307] [309]. In the wild-type mice, hepatic de
novo fatty acid synthesis and lipid droplets accumulation increased soon after the initiation of
the high-fat feeding, even before any significant effects on body weight have been detected
[197]. Pre-treatment of mice with rimonabant significantly reduced the rate of fatty acid
synthesis and lipid droplets accumulation [197]. In contrast, in CB1-/- mice, a high-fat diet
did not change the basal rate of fatty acid synthesis and lipid accumulation at an early stage of
high fat feeding [197]. Also transgenic mice with liver-specific deletion of CB1 (LCB1-/-)
were partially protected from diet-induced hepatic steatosis, insulin resistance and glucose
intolerance [310]. Interestingly, transgenic mice overexpressing CB1 receptors in hepatocytes
on a global CB1 knockout background (htgCBl-/-) [256], had just slightly increased their
hepatic triglyceride content when exposed to a high-fat diet, compared with global CB1-/-
mice. This suggests an important role for CB1 receptors in extrahepatic tissues (e.g. adipose,
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which provides FFA for hepatic triglyceride synthesis) in the development of diet-induced 
hepatic steatosis [256].
The liver is the main source of de novo synthesised fatty acids [311]. The enzymes that are
involved in that process: ATP citrate lyase (ACL, which produces acetyl-CoA from citrate),
acetyl-CoA synthetase (ACAS, which produces acetyl-CoA from acetate), liver-type pyruvate
kinase (LPK, which catalyses conversion of phosphoenolpyruvate to pyruvate, used for
acetyl-CoA synthesis in TCA cycle), ACC1 (which produces malonyl-CoA, a substrate of
fatty acid synthesis and an allosteric inhibitor of CPT-1 activity), FAS (which produces
palmitate from malonyl- and acetyl- CoA), fatty acid-CoA elongase (FACE, which converts
palmitate to stearate), SCD-1 (which converts stearate to oleate), and GPAT (the first enzyme
in triglyceride and phospholipid synthesis), have been shown to be positively regulated by the
hepatic lipogenic transcription factor SREBP-lc [312] [313]. Furthermore, SREBP-lc
activates genes required to generate NADPH, which is necessary for the lipid biosynthetic
pathways [312], and up-regulates ATP-binding cassette (ABC) transporter A l (ABCA1),
which mediates the transport of lipids between Golgi complex and cell membrane, as well the
efflux of cholesterol and phospholipids to apoAI and the HDL formation [314].
Existing data indicate that CB1 receptor stimulation or inhibition affects the hepatic SREBP-
lc activity and expression, while data on other SREBP isoforms (SREBP-la and SREBP-2)
are still lacking [315]. The activation and expression of hepatic SREBP-lc is also under
positive regulation by liver X receptor (LXR) receptors, phosphatidylinositide 3-kinase
(PI3K), insulin and glucose, and negative regulation by glucagon and AMPK [313]. In
transgenic CB1-/- mice, compared with the wild type, liver and adipose tissue SREBP-lc
mRNA levels were lower [197]. In wild type mice, CB1 receptor agonists increased the
hepatic mRNA levels of SREBP-lc and its target lipogenic enzymes (FAS, ACC1, SCD-1
and ABCA1), leading to an increased de novo lipogenesis and lipid secretion, and decreased
expression and activity of CPT-1, both in vivo and in vitro [197] [316]. The effect was
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attenuated in the presence of rimonabant and was absent in globally deficient CBW- mice
[197], while it was partially decreased in LCB1-/- mice, which lack CB1 receptors only in 
hepatocytes, but have normal levels of CB1 receptors elsewhere in the body [310]. Treatment 
of wild-type mice with CB1 agonist increased hepatic de novo lipogenesis, measured by 
incorporation of into hepatic fatty acids, and this effect was prevented by pre-treatment 
with rimonabant and was absent in globally deficient CB1-/- mice [197], and reduced in 
LCB1-/- mice [310]. Interestingly, in comparison with CB1-/- mice, LCB1-/- mice had higher 
HDL-cholesterol levels and lower triglyceride serum levels, even though they developed 
higher degree of obesity when on a high-fat diet [310].
While CB1 antagonism decreased hepatic de novo lipogenesis, it also increased substrate 
oxidation [317] [318], and mitochondrial activity in hepatocytes [318]. In diet-obese rats 
treated with rimonabant, the increase of hepatic mitochondrial respiration and enhanced entry 
of fatty acids into mitochondria via CPT-1 activity (i.e. increased palmitoyl-CoA) were 
observed [318]. CB1-/- mice had higher hepatic CPT-1 expression and activity, compared 
with both wild-type and LCB1-/- mice [310]. In parallel with increased CPT-1 mRNA and 
decreased malonyl-CoA content, beta-oxidation of ( l-14C)-palmitic acid, as measured by 
production of labelled CO2 and acetyl-CoA and ketone bodies, was increased in cultured 
hepatic explants treated with CB1 antagonists [317]. In addition, rimonabant treatment led to 
a reduction in the hepatic enzymatic activity of ATP synthase, whereas the quantity of 
mitochondrial DNA and the activity of citrate synthase remained unchanged, indicating an 
increased proton leak and mitochondrial uncoupling [302]. Besides, the increased 
carbohydrate oxidation was also noted in vitro in cultured liver explants treated with 
rimonabant [317].
The mechanisms by which endocannabinoids and CB1 receptors regulate hepatic metabolic 
processes include multiple pathways [315].
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CB1 is negatively coupled to adenylate cyclase via G i /G 0 proteins, and SREBP-lc, ACC and 
FAS gene expression are negatively regulated by cAMP. This suggests that CB1 may regulate 
lipogenic gene expression via inhibition of adenylate cyclase [197]. Reduction of cAMP leads 
to decreased PKA phosphorylation and inhibition of LXR-alpha, which is the main activator 
of SREBP-lc [316]. In agreement, rimonabant decreased the LXR-alpha mRNA content in 
the liver [316]. i
The hepatic lipogenic pathway may be also activated through a cannabinoid-induced decrease 
in AMPK phosphorylation and activity in the liver [276]. It was confirmed that CB1 
activation via a decrease in cAMP could lead to decreased PKA activation of 
phosphoinositide-dependent kinase (PDK)-1, which is one of the 2 main kinases that activate 
AMPK [316]. AMPK, in turn, downregulates SREBP-lc (reduces its transcription and 
activity, by serine-372 phosphorylation) and its targets (FAS, ACC), and upregulates CPT-1 
and malonyl-CoA decarboxylase (MCD, which catalyses conversion of malonyl CoA into 
acetyl-CoA) [315]. Moreover, AMPK activates and stimulates the expression of PPAR-alpha 
[319] [320], while PPAR-alpha, in turn, controls transcription of CPT-1, long chain acyl-CoA 
synthetase (ACSL, which activates fatty acids for the transport into mitochondria by CPT-1 
[321] [322] [323]), and mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase 2 
(HMGCS2, which is involved in ketogenesis [324] [325]). In line with that, treatment with 
CB1 antagonists increased the hepatic PPAR-alpha mRNA content in diet-obese animals 
[315].
It was proposed that adiponectin could contribute to the increased AMPK activation by CB1 
antagonists. In one study, rimonabant increased the hepatic AMPK activity and expression of 
CPT-1 in both ob/ob mice and Ad(-/-) ob/ob mice (which are both adiponectin- and leptin- 
deficient), but the outcome was less pronounced in the latter group, suggesting that effect of 
rimonabant on AMPK activation was partly adiponectin dependent [326].
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Additionally, CB1 activation, by a combination of increased lipogenesis and reduced fatty 
acid oxidation, depletes ATP, which decreases the cellular ATP/AMP ratio. In a healthy cell, 
the low ATP/AMP ratio would activate AMPK, through action of PDK-1, but in liver 
steatosis, obesity and diabetes AMPK is less sensitive to stimulation by AMP [315].
MAPK and ERKs could also be involved [315]. In CBl-/-mice and rimonabant treated wild 
type animals, in hepatic myofibroblasts a decreased phosphorylation of ERKs and PKB(Akt) i 
was described [315]. Activation of ERK1 and ERK2 was related to SREBP-lc serine-111 
phosphorylation and activation [315]. In contrast, CB1 agonists activate PI3K/PKB(Akt) 
pathway, leading to activation of mTORCl (mammalian target of rapamycin complex 1), 
which in turn can activate SREBP-lc [315].
Apart from being involved in increased de novo fatty acid synthesis and decreased fatty acid 
oxidation (through SCD-1), therefore contributing to increased VLDL-triglyceride secretion, 
the SREBP-lc pathway also downregulates LDL/apoB 100-receptor in the liver, thus reducing 
triglyceride-containing lipoprotein catabolism and plasma clearance [327]. Therefore, 
rimonabant through its action on SREBP-lc pathway in liver could influence both VLDL- 
triglyceride secretion and clearance. Indeed, it was shown that rimonabant increased VLDL 
clearance in one study [328]. Interestingly, peripheral CB1 antagonist AM6545 increased 
VLDL-triglyceride secretion, and at the same time reduced hepatic triglyceride content and 
expression and function of lipogenic genes and de novo hepatic fatty acid synthesis [256]. The 
effect was present both in wild type mice with diet induced obesity and leptin deficient ob/ob 
mice, suggesting that this effect was leptin independent [256].
The effect of rimonabant on hepatic cholesterol metabolism and 3-hydroxy-3-methylglutaryl- 
Co A (HMG-CoA) reductase (HMGCR) activity has been explored as well [317]. In cultured 
hepatic explants, rimonabant alone induced HMGCR and increased liver cholesterol content. 
In parallel, HDL-cholesterol uptake was increased, while scavenger receptor class B type 1 
(SR-B1) and HL mRNA levels were reduced [317].
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Interestingly, even though plenty of data suggest the role of CB1 activation in hepatic 
steatosis development [256] [315] [329] [330] [331] [332], not all experimental data 
confirmed reduction of liver lipids after rimonabant treatment [317] [318] [333] [334] [335]. 
In one study with cultured liver explants [317], rimonabant alone increased hepatic 
triacylglycerol content and caused slight overexpression of SREBP-1, without changing the 
expression of ACC1 and ACC2 and FAS. Apart from this, rimonabant increased expression 
of fatty acid translocase (also known as cluster of differentiation 36, FAT/CD36), which could 
be related to increased fatty acid uptake in the liver [317]. However, in the same study, 
rimonabant in combination with AEA had a different effect. CB1 activation by AEA induced 
an increase in SREBP-1 and related genes (ACC, FAS, GLCK) expression, and rimonabant 
prevented that increase. That study also confirmed that local tissue conditions (e.g. presence 
of different substrates, hormones, stimulators, inhibitors) could significantly influence the 
effect of rimonabant in the liver [317]. In agreement with this, the anti-sense oligonucleotide 
treatment against peripheral CB1 receptors in obese mice caused a reduction in liver fat 
content and liver mRNA content of SREBP-1 and FAT/CD36 [283].
In addition to the effects on hepatic lipid metabolism, the effects of CB1 activation on hepatic 
glucose metabolism have been also examined [308] [317] [336] [337] [338].
CB1 activation stimulates hepatic glucose output by increasing glycogenolysis [308], and 
gluconeogenesis [337]. In h tgC B l-/- mice, which overexpressed hepatic CB1 on the global 
CB1-/- background, glycogen phosphorylase activity was increased by 70%, indicating that 
glycogenolysis was increased [308]. In another study in vitro, in primary rat and human 
hepatocytes, CB1 agonist (2-AG) increased the expression of glucose-6-phosphatase (G-6-P) 
and PEPCK, the key enzymes involved in hepatic glucose releases and gluconeogenesis 
[337]. The addition of a peripheral CB1 blocker (AM251) prevented these effects [337]. In 
addition, the anti-sense oligonucleotide treatment against peripheral CB1 receptors in obese 
mice in vivo reduced the hepatic G-6-P mRNA content [283].
78
CB1 receptor activation by 2-AG increased gluconeogenesis by enhancing cAMP response 
element-binding protein H (CREBH) gene expression, a liver-specific endoplasmic reticulum 
stress-associated transcription factor involved in activation of PEPCK and G-6-P promoters 
[337]. In turn, CREBH gene expression was induced by CB1 stimulation [337].
Rimonabant alone in hepatic explants stimulated carbohydrate oxidation, and increased the 
level of glucokinase mRNA, indicating a higher glucose uptake, phosphorylation and usage 
(for oxidation or for glycogen and triglyceride synthetic purposes) [317]. Rimonabant 
treatment in obese animals, concomitantly with a reduction in body weight, led to a 
significant decrease in hepatic glycogen content, which is most probably related to the 
negative energy balance [338].
Therefore, CB1 activation through the effects on hepatic- and whole body- lipid and 
carbohydrate metabolism can reduce hepatic insulin sensitivity. Indeed, there is evidence that 
CB1 activation negatively influence hepatic insulin signalling [308] [315] [326] [336] [339]. 
Hepatic CB1 receptor overexpression has been linked to insulin resistance in several studies, 
both in humans and animals [315]. Hepatic insulin resistance was induced by a high-fat diet in 
wild-type mice, but not in global CB1-/- mice or in mice with hepatocyte-specific deletion of 
CB1 (LCB1-/-). Moreover, it was shown that hepatic CB1 activation was sufficient to cause 
whole body insulin resistance and glucose intolerance in htgCBl-/- mice [308].
Additionally, CB1 activation was related to a decreased hepatic insulin clearance and 
degradation, due to down-regulation of the insulin-degrading enzyme [308].
Over-expression of hepatic CB1 receptors was related to the impairment of hepatic insulin 
signalling by mechanisms which involved endoplasmatic reticulum stress [315], ERK induced 
insulin receptor substrate-1 (IRS-1) serine-phosphorylation and inhibition of PI3K/ PDK-1/ 
PKB(Akt)/ mTORCl pathway [308] [315], as well as ceramide synthesis [339].
CB1 activation in human or mouse hepatocytes caused endoplasmic reticulum stress- 
dependent suppression of insulin-induced phosphorylation of PKB(Akt)-2 via
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phosphorylation of IRS-1 at serine-307 and by inducing the expression of the serine and 
threonine phosphatase Phlppl [308]. In mice which express CB1 in hepatocytes, both high-fat 
diet and CB1-activation induced the endoplasmic reticulum stress response, while the effect 
was absent in mice with global- or liver specific- deletion of CB1 [308]. Additionally, CB1 
receptor activation, via CREBH, induced the phosphatidic acid phosphatase (Lipinl) gene 
expression, increased the hepatic DAG level and phosphorylation of protein; kinase C (PKC)- 
epsilon, thereby inhibiting hepatic insulin receptor signalling [336]. Moreover, CB1 receptor 
activation increased the ceramide formation, via two different pathways: sphingomyelin 
hydrolysis and de novo ceramide synthesis. Increased ceramide signalling could further 
modulate the ERK and PKB(Akt) cascade. Interestingly, rimonabant treatment increased the 
hepatic insulin-stimulated PKB(Akt) phosphorylation in ob/ob mice, while the effect was 
impaired in the rimonabant-treated Ad(-/-) ob/ob mice, indicating the involvement of 
adiponectin in that process [326].
In summary, evidence exist (in vitro and in vivo) that activation of CB1 receptors in the liver 
may directly influence lipid and carbohydrate metabolism in hepatocytes, by increasing de 
novo lipogenesis, lipid accumulation and hepatic glucose output, and by decreasing lipid and 
carbohydrate oxidation. The involved mechanisms are complex, include multiple cascade 
pathways, as well as the impaired hepatic insulin signalling and reduced hepatic insulin 
sensitivity. Both global and local CB1 receptor blockade can prevent those effects, thus 
reducing hepatic lipid accumulation and increasing hepatic insulin sensitivity. However, most 
of the evidence derives from animal models, while data in humans on direct hepatic CB1 
effects are still scarce, and therefore additional studies are needed to explore the significance 
of hepatic CB1 receptors activation in humans.
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2.3.2 3. The endocannabinoid system in the skeletal muscle
It is well known that skeletal muscle plays a predominant role in glucose homeostasis [340]. 
In non-diabetic subjects, approximately one third of the glucose taken-up by the muscle is 
oxidised, and two thirds are converted to glycogen [341]. In diabetic subjects, the ability of 
insulin to increase glucose oxidation and glycogen synthesis is reduced [341].
The expression of the CB1 receptors have been also detected in skeletal muscle [342] [343], 
in addition to the CB2 receptors and FAAH [198]. The expression of the CB1 receptor in the 
muscle has been shown to be increased in obesity [194] [342]. CB1 receptors activation in 
skeletal muscle has been linked with alterations in insulin signalling [344], glucose uptake 
[342] [344], and adiponectin-1 receptor gene expression in muscle [345].
In ob/ob mice, which exhibit hyperglycaemia, hyperinsulinaemia and insulin resistance, CB1 
receptor blockade in vivo by rimonabant resulted in a significant (68%) increase in the rate of 
glucose uptake and phosphorylation in isolated soleus muscle, in the presence of a 
physiological concentration of insulin [342]. In another study, a 24-hour incubation of skeletal 
muscle with CB1 agonists impaired insulin stimulated serine-473 phosphorylation of 
PKB(Akt), while stimulated serine-307 phosphorylation of IRS-1, activated ERK1/2 and p38 
MAPK, and impaired insulin stimulated glucose uptake in the muscle, and those effects were 
prevented by rimonabant [344]. In another in vitro study [343], a CB1 receptor antagonist 
AM251 increased the expression of AMPK in primary cultures of human myotubes, and AEA 
blocked that effect. AMPK is known to be involved in muscle lipolysis, glycogenolysis and 
fatty acid and glucose oxidation, as well as in insulin-sensitizing effects, and adiponectin is 
known as an AMPK activator [346]. In the same study [343], CB1 receptor antagonist 
AM251 also decreased the expression of the pyruvate dehydrogenase kinase 4 (PDK4). PDK4 
is known to be involved in inhibition of the pyruvate dehydrogenase complex, which links 
glycolysis to the Krebs cycle and ATP production and its inhibition might stimulate glucose 
flux into the mitochondria and increase glucose oxidation in the muscle [343]. However, there
are also studies showing that rimonabant treatment had no effect on the muscle AMPK 
activity [326] and on glucose uptake in skeletal muscle in vivo [334].
Chronic treatment of ob/ob mice with rimonabant increased energy expenditure, as shown by 
increased oxygen consumption using indirect calorimetry [342]. Higher oxygen consumption 
is related to increased fat oxidation, since carbohydrates for their oxidation require less 
oxygen consumption compared with fatty acids [317]. It is well known that muscles make a 
significant contribution to basal energy metabolism (e.g. 22%, [347]), and it is possible that 
insulin sensitivity, beta-oxidation of fatty acids and oxygen consumption in muscles is 
directly stimulated by rimonabant activation of enzymes involved in fat, glucose and protein 
metabolism in skeletal muscle, or indirectly, by increased production of adiponectin from fat 
tissue [197]. In animals, adiponectin improves insulin sensitivity, decreases plasma glucose 
and FFA levels [348] [349] [350] [351], while increasing fatty acid utilization in the muscle 
[352] [353]. Adiponectin insulin-sensitizing effects, predominantly in muscle and liver, 
involve molecular mechanisms of AMPK and PPAR-alpha activity stimulation [346]. Recent 
data show that some of the effects of rimonabant related to insulin sensitivity and glucose 
intolerance are adiponectin mediated, since its effects (decreased hepatic glucose production 
and increased glucose utilization in visceral and SAT, but not in skeletal muscle) are absent in 
adiponectin deficient Ad(-/-) and Ad(-/-)ob/ob mice [326] [334].
Additionally, the increased glucose tolerance after rimonabant treatment may be secondary to 
an effect of rimonabant on CB1 receptors in the liver, since it has been proposed that 
increased lipid synthesis in the liver may produce insulin resistance in other tissues such as 
muscle [354] [355]. Novel studies confirmed a direct enrolment of hepatic CB1 receptors in 
impaired insulin signalling [256]. Selective deletion of CB1 receptors in hepatocytes has been 
shown to protect animals from a high-fat diet-induced glucose intolerance and insulin 
resistance and hepatic steatosis, emphasising the importance of hepatic CB1 receptors in these 
processes [256]. A recent study with genetically modified mice with overexpressed CB1
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receptors only in the liver on the whole body CB1-/- background (htgCB-A mice) [308], 
showed that rimonabant in those mice have increased GLUT-4 transporters expression in 
muscle and increased whole body insulin stimulated glucose disposal.
Furthermore, oral administration of rimonabant in animals was associated with the CB1 
receptor-dependent inhibition of TNF-alpha levels [356], and others cytokines (see above) 
possibly involved in the regulation of glucose transport and insulin sensitivity [357].
In conclusion, existing data suggest that CB1 activation in skeletal muscle may be related to 
impaired insulin signalling, decreased glucose uptake and decreased carbohydrate and fat 
oxidation in skeletal muscle, while the local CB1 blockade by rimonabant may have the 
opposite effects. The role of AMPK and adiponectin in mediating those effects has been 
proposed. However, it is still unclear if the effects are only related to the local CB1 
activation/blockade in skeletal muscle, or are also the consequences of CB1 
activation/blockade in other tissues (e.g. nervous system, liver, adipose tissue). Further studies 
are required to clarify this.
2.3 .2A  The endocannabinoid system in the endocrine pancreas
Similarly to adipose tissue, liver and skeletal muscle, the endocannabinoid system in the 
endocrine pancreas has been also under investigation [199] [234] [262] [268] [358] [359] 
[360] [361]. However, according to the published data, the role of endocannabinoid system in 
endocrine pancreas function still remains unclear.
All components of the endocannabinoid system have been found expressed in pancreatic islets 
[199] [234] [262] [268] [358] [359] [360] [361], but their expression profile in alpha-cells, 
beta-cells and delta-cells, as well as their function in these cells, is still not definitely 
determined since studies revealed contradictory findings [234].
Both AEA and 2-AG were identified in the islets, and it has been shown that in animal model
of obesity their concentrations could increase [262]. Also the enzymes for their synthesis and
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catabolism have been identified, but their expression in different cell types is still not clear 
[234]. In addition, there are many discrepancies related to the expression of CB1 and CB2 
receptors in different cell types. The recent analysis of published data [234] indicates that both 
CB1 and CB2 receptors, as well the other components of the endocannabinoid system, are 
present in pancreatic beta-cells. Their function there as well remains unresolved, since both 
stimulation and inhibition of Ca2+ and insulin release by stimulation of both receptors have 
been described by the studies [262]. According to the same recent analysis of data [234], 
stimulation of both CB1 and CB2 receptors most probably increases insulin release [262], by 
mechanisms which involve elevations in intracellular Ca2+ [262] and reductions in cAMP 
[362]. In vitro and in vivo studies demonstrated that rimonabant inhibits basal insulin 
secretion in islets isolated from obese animals [363] [364], and one study showed that in islets 
isolated from lean mice rimonabant reduced insulin stimulated, but not basal, insulin secretion 
[364]. The effects of rimonabant on pancreatic islets seem to be independent of its effects on 
leptin signalling [365].
Secretion of glucagon and somatostatin was also examined following cannabinoid receptor 
stimulation and inhibition in isolated human islets [366]. CB1 activation stimulated both 
glucagon and somatostatin secretion, and those effects were blocked in the presence of a CB1 
receptor antagonist. In contrast, CB2 receptor activation did not show any effects on glucagon 
or somatostatin secretion [358], suggesting that only CB1 receptors are involved in the 
regulation of hormone secretion from alpha- and delta-cells in human islets [358].
In conclusion, even though the components of ECS have been identified in the endocrine 
pancreas, their function in the pancreatic islets cells still remains unclear. Data suggest that 
stimulation of CB1 receptors can increase insulin, glucagon and somatostatin secretion, while 
CB1 blockade by rimonabant can have the oppostite effect. Additional studies are needed to 
further explore the role of ECS in endocrine pancreas.
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2.4. Rimonabant- the first cannabinoid antagonist used to treat obesity
Rimonabant was the first highly selective and orally active CB1 receptors blocker which was 
registered as an anti-obesity drug [191] [192]. It acts as an inverse agonist for the cannabinoid 
receptor CB1, which means that it binds to the same CB1 receptor binding-site as CB1 
agonists, but exerts the opposite pharmacological effects. Inverse agonists are effective 
against the receptors which have an intrinsic activity without a ligand binding, also referred to 
as “constitutive activity” [219] [367].
Rimonabant was developed by Sanofi Aventis in 1994, and originally used to better 
characterise the function of endocannabinoid system and CB1 receptors in laboratory animals. 
However, since the treatment resulted in significant weight-loss in animals, along with other 
positive effects on obesity- and metabolic syndrome- related issues, and no significant side 
effects were observed in animals, its application for the treatment of human obesity was 
proposed. Consequent human trials confirmed drug safety and efficacy, and in June 2006, the 
European Commission approved the use of rimonabant in the EU. Prescriptions of rimonabant 
began in July 2006 in the U.K., and in only one year more than 41,000 U.K. patients were 
treated. The drug had shown promising effects not only in the treatment of obesity and related 
comorbidities, including metabolic syndrome, diabetes mellitus and NAFLD, but also in some 
other disorders, related to its pleiotropic effects, including nicotine-, drug- and alcohol- 
dependence, neurodegenerative disorders, chronic inflammation, hyperproliferative states, 
cancer, infertility and sexual dysfunction [368] [369]. However, because of fears over the 
drug’s association with psychiatric adverse effects, including depression and anxiety, the drug 
was withdrawn from the worldwide market in October 2008 [370]. It was estimated that at 
that point approximately 700,000 patients had been treated world wide.
85
2.4.1. The rationale for the rimonabant use in the treatment of obesity and 
related comorbidities: data from animal studies
First administrations in genetically obese or wild type animals showed significant weight loss 
and improvement in metabolic parameters [237] [259] [260] [371] [372]. Weight loss was 
proposed to be a result, in part, from the rapid and strong decrease of food intake during the 
first days of treatment [235] [237] [259] [371] [372] [373] [374] [375]. Some animal studies 
showed that rimonabant selectively reduced the consumption of certain types of food, e.g. 
sweet, highly palatable food [376] [377] [378], but not all [373] [379] [380]. However, in 
animals a tolerance to the hypophagic effect of rimonabant developed within several days 
[237] [259] [371] [372] [374] [375], which occurred more rapidly in lean than in obese 
animals [372]. Withdrawal of the drug resulted in rebound hyperphagia and a significant 
weight gain [372].
Interestingly, with the treatment prolongation, even when the food intake increased to the 
baseline levels, animals still showed continuous weight loss [237] [259] [371] [374] [375]. 
This suggested possible effects of drug on REE, apart from its appetite reducing effects. 
Indeed, Liu and associates [342] for the first time demonstrated that rimonabant in obese 
ob/ob mice has a direct effect on energy expenditure, causing a 37% increase in basal oxygen 
consumption and suggesting that its antiobesity property is owing to activation of 
thermogenesis in addition to the initial hypophagia [342]. However, in the study of Cota et al. 
[196], no significant differences were observed between CB1-/- and CB1+/+ mice genotypes 
in energy expenditure, body temperature and locomotor activity. Further studies also revealed 
contradictory findings [237] [256] [273] [310] [335] [338] [381] [382] [383] [384] [385] 
[386] [387].
In parallel, rimonabant treatment in obese animals reduced leptin [237] [256] [273] [334]
[388] [389] [390] [391], insulin [196] [255] [256] [284] [334], FFA [237] [334] [338] [388],
and glucose [256] [284] [389], and increased adiponectin [196] [256] [260] [273] [326] [334]
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[389] levels in circulation. It significantly reduced serum triglycerides [256] [259] [284] [318] 
[333] [334] [338] [388] [389], VLDL-triglyceride and VLDL-cholesterol levels [328] [333] 
and total cholesterol levels [327] [328], and increased HDL-cholesterol levels and the 
HDL/LDL-cholesterol ratio [259] [371]. In obese animals rimonabant improved glucose 
. intolerance and insulin resistance estimated by the homeostasis model assessment for insulin 
j resistance (HOMA-IR) [256] [389], increased glucose disposal rate [317] [334] [342], and 
decreased hepatic glucose production during a hyperinsulinaemic-euglycaemic clamp. It also 
showed preservation of pancreatic beta-cell mass and reduced plasma levels of TNF-alpha 
[294] [295], PAI-1 [273], IL-6 [270] [275] [296], resistin [296], visfatin [270] [275] [296], 
and some other cytokines which were shown to be possibly involved in insulin resistance 
development [392]. Rimonabant reduced both basal levels of fatty acid synthesis and 
development of hepatic steatosis caused by a high-fat diet in mice [197], and increased the fat 
tissue mRNA levels of enzymes involved in lipid, carbohydrate and amino acid catabolism 
and thermogenesis [260] [273].
However, (as discussed later, in Discussion chapter), not all animal studies confirmed that 
rimonabant treatment in obese animals improved plasma glucose, insulin and lipids profiles 
(decreased plasma FFA, insulin, glucose, triglycerides, LDL- and HDL-cholesterol levels), 
and that improved glucose intolerance and insulin resistance (estimated by HOMA model or 
clamp), or modulated plasma adipokine levels. Some of them showed similar changes in pair- 
fed animals, or that effects were stronger with both central and peripheral CB1 blockade than 
with only peripheral blockade, indicating that some effects of rimonabant were mediated 
through its central effects and/or were weight loss-dependent.
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2.4.2. The use of rimonabant in the treatment of human obesity and related 
comorbities: data from human trials
Up to now, several large multicentre human trials, belonging to the clinical phase 3 and 4 of
drug administration, have been conducted or were prematurely terminated, because of the
drug discontinuation [297] [298] [299] [393] [394] [395] [396] [397] [398] [399] [400].
Before the drug approval, four large scale phase 3 clinical trials have been completed and
published, involving more than 6600 patients: RIO-Europe [393] [394], RIO-North America
[395], RIO-Lipids [297], RIO-Diabetes [396]. The trials involved obese subjects, with or
without dyslipidaemia or diabetes. In total 5,580 subjects without diabetes and 1,047 subjects
with diabetes were treated with 5 mg/day or 20 mg/day rimonabant (or placebo), in
combination with a -600 kcal/day caloric reduction and advice to increase physical activity
(the hypocaloric diet was given on individual basis, according to estimated energetic needs,
and every 4 weeks the subjects have seen dietitian). In total 3,165 subjects without diabetes
and 692 subjects with diabetes completed the trials. The effects of drug were dose dependent,
and the main outcomes in the group of patients treated with 20 mg/day rimonabant over 1
year (in the pooled data analysis [401]) were: a mean weight loss of 6.5 kg, a decrease in
waist circumference of 6.4 cm, an increase in HDL-cholesterol by 16.4%, decrease
triglycerides by 6.9%, a decrease fasting insulin of 0.6 pU/ml, and a decrease in HOMA-IR of
0.2 [401]. The effects were highly significantly different compared with placebo (all
pO.OOl). In subjects with diabetes, 20 mg/day rimonabant reduced HbAic levels by 0.6%
(pO.OOl vs. placebo) [396] [401]. A regression analysis [401] of changes in HDL-cholesterol
(in all RIO trials), triglycerides (in all RIO trials), insulin (RIO-Diabetes excluded),
adiponectin (in RIO-Lipids), and HbAic (in RIO-Diabetes) versus changes in body weight at
1 year suggested that: 45%, 46%, 49%, 57% and 55%, respectively, of the effect of
rimonabant on HDL-cholesterol, triglycerides, insulin, adiponectin and HbAic, could not be
explained by the observed weight loss [401]. For comparison, in subjects treated with placebo
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and the hypocaloric diet, the mean weight loss was 1.6 kg, the mean decrease in waist 
circumference was 2.5 cm, HDL-cholesterol increased by 8.5%, triglycerides increased by 
6.9%, insulin increased by 0.6 pU/ml, HOMA-IR increased by 0.6, and HbAic increased by
0.1% [401]. The weight loss in subjects treated with placebo began to stabilise after 24 weeks, 
while in subjects treated with rimonabant in the first 36 weeks weight loss was much faster, 
and only after that period begun to stabilise [401].
In RIO-North America [395], after 1 year, half of the subjects on rimonabant treatment were 
re-randomised to placebo and were followed for the second year. One year following 
cessation of the drug administration, subjects regained most of their lost body weight and the 
positive effects on HDL and triglyceride levels continuously diminished, and by the end of 
second year were similar to the subjects on placebo [395] [402].
After the drug approval, there were additional phase 4 trials involving obese subjects with 
specific features, using the recommended dose of 20 mg/day, many of them prematurely 
terminated with the drug withdrawal from the market. The results from several trials have 
been published up to now: from the SERENADE trial [398] [403], which included drug naive 
obese diabetic subjects; from the APRREGGIO trial [398], which included obese diabetic 
subjects treated with insulin; from the STRADIVARIUS trial [298], which included 
abdominally obese subjects with coronary artery disease; from the ADD AGIO trial [299], 
which included abdominally obese subjects with dyslipidaemia; from the VICTORIA trial 
[293], which included abdominally obese subjects with metabolic syndrome; from the 
AUDITOR trial [399], which also included subjects with abdominal obesity and metabolic 
syndrome; from the CARDIO-REDUCE trial [404], which included subjects with abdominal 
obesity and hyperglycaemia or diabetes; and from the trial in subjects with binge eating 
disorder [400]. The trials followed different metabolic effects of the drug and most of them 
included also a hypocaloric diet. Even though all of them confirmed the higher efficacy of 
rimonabant in weight reduction, the superior effects of the drug over placebo on some other
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metabolic parameters, including lipid status and insulin sensitivity, were not uniformly 
confirmed, as well as the weight loss-independent effects [293] [399] [404].
In all rimonabant trials the most commonly reported adverse reactions were nausea, dizziness, 
diarrhoea, anxiety, insomnia and depression. The drug has not shown any significant 
interactions with other drugs commonly prescribed to patients for conditions associated with 
obesity. |
2.5. The present study rationale
CB1-/- mice are lean and resistant to diet-induced obesity. However, the lean phenotype is 
associated with decreased food intake only in young animals [237]. The wild-type mice are 
heavier than the CB1 gene-deleted animals, even if they have the similar energy intake, thus 
suggesting an additional, most likely peripheral, mechanism on energy expenditure in animals 
[196].
Additionally, rimonabant-induced weight loss in animals was associated only with a 
temporary reduction in food intake and, with the treatment prolongation, the food intake 
increased to the levels equivalent to that in the control group. However, the animals still 
showed continuous weight loss. These data also suggest a prolonged effect of rimonabant on 
the metabolic rate [237] [259] [260] [371] [374] [375].
Rimonabant-induced weight loss in animals was accompanied by correction of abnormal 
plasma profiles related to diet induced obesity [237] [259] [371], but the group of mice which 
switched to a standard diet also showed normalization of these metabolic parameters [259]. In 
this context, it is difficult to establish whether the changes associated with rimonabant 
treatment are primary or indirect in nature, as the consequence of weight loss. For example, it 
is well established that leptin levels fall as a consequence of reduction in FM, and weight loss 
per se can improve insulin sensitivity and increase adiponectin levels [405] [406] [407] [408].
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Also, the human trials of rimonabant showed significant reduction in body weight in obese 
patients, but the parameters followed in the trials could not distinguish if this body weight loss 
was a consequence of reduced energy intake or increased basal metabolic rate [401]. 
Additionally, rimonabant in obese humans reversed the signs of the metabolic syndrome, i.e. 
high waist circumference (abdominal obesity), high triglyceridaemia, low HDL-cholesterol, 
high mean arterial pressure, high fasting glycaemia and hyperinsulinaemia, low adiponectin 
levels [401]. Yet, it is not known whether these additional beneficial effects are merely the 
consequence of weight loss per se, or the direct results of the peripheral actions of CB1 
blockade.
Up to now, there have not been published animal or human studies that tried to distinguish the 
direct peripheral metabolic effects of rimonabant from the effects of the accompanied weight 
loss per se, therefore this study was designed to try to clarify this.
2.6. The aim of the study
The aim of this study was to investigate in obese subjects the direct (food intake- and weight 
loss- independent) effects of the endocannabinoid CB1-receptor blocker rimonabant on fatty 
acid, triglyceride and glucose metabolism and circulating levels of insulin, adiponectin and 
leptin.4
To investigate the food intake- and weight loss- independent effects of rimonabant, the effects 
of rimonabant treatment (while food intake is maintained) were compared with the effects of a 
hypocaloric diet designed to achieve the same weight loss. In other words, the peripheral 
metabolic effects of two treatments were compared:
4 This is a joint project with another PhD student, dietitian, Miss Katherine Backhouse, who investigated the 
effect of Rimonabant on: resting energy expenditure, fat, carbohydrate and protein oxidation rate; the whole 
body fat distribution, intrahepatocellular lipid (IHCL) and intramyocellular (IMCL) lipid content, and 
abdominal sc. adipose tissue and thigh muscle mRNA levels of key regulators of fatty acid metabolism [583].
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1. RIMONABANT treatment: 12 weeks Rimonabant (Acomplia, Sanofi-Aventis, 20
mg/day) and isocaloric diet (diet that meets individual energy requirements to maintain body
weight)5
2. DIET treatment: 12 weeks hypocaloric diet to achieve the same weight loss as in 
the rimonabant treatment group.2
i
2.7. Specific aims and objectives
Specific aims and objectives of the study are to compare the effect of rimonabant with the 
effect of hypocaloric diet on the following:
1. The rate of whole body fatty acid production, oxidation and uptake;
2. Forearm muscle FFA rate of uptake;
3. Whole body VLDLr and VLDLz-triglyceride APRs and FCRs;
4. Insulin sensitivity (assessed by HOMA2 model and hyperinsulinaemic-euglycaemic 
clamp);
5. Fasting plasma levels of total FFA, glycerol, triglycerides, HDL-, LDL- and total 
cholesterol, glucose;
6. Fasting serum levels of insulin, adiponectin, leptin;
The specific tests to investigate parameters mentioned above were performed before and after 
each treatment.
2.8. The study hypotheses
In the present study it was hypothesised that rimonabant could have a stimulating effect on 
REE, therefore the whole body rate of metabolic fuels uptake and oxidation could be
5 All parts related to dietetics in this project were performed by Katherine Backhouse and were presented in
her PhD thesis [583].
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increased. Furthermore, since the published data particularly suggest a possible overactivity of 
the endocannabinoid system in the centripetal obesity, it is likely that the features of the 
metabolic syndrome (abdominal obesity, insulin resistance, dyslipidaemia, etc.) could be 
principally improved.
This means that compared with the hypocaloric diet, the Rimonabant treatment could result 
in: !
1. Increased REE and fuel oxidation rates6 (as calculated per kg FFM), while with the 
hypocaloric diet REE could remain the same or be slightly decreased (depending on the 
amount of body weight loss) [409] [410] [411].
2. An increase in the whole body and regional (forearm muscle) plasma FFA uptake and 
oxidation rate, due to the increased requirements for metabolic fuels, while with the 
hypocaloric diet it would be opposite (depending on the amount of body weight loss) 
[409] [410] [411].
3. An increase in FFA production (lipolysis) rate, due to the increased requirements for 
metabolic fuels; while with the hypocaloric diet the effect is expected to be the opposite 
(depending on the amount of body weight loss), because of the increased antilipolytic 
insulin sensitivity of fat tissue [412] [413], and diminished energy demands [414].
4. A variable effect on plasma FFA levels, depending on the balance between their usage 
(oxidation and re-esterification) and their supply (i.e. if their usage exceeds their 
supply, the levels could be reduced) [415].
5. A larger decrease in VLDLi-triglyceride production rate and circulating levels than in 
the dietary intervention group, as a consequence of the decreased de novo lipogenesis 
and decreased availability of fatty acids for the synthesis of triglycerides in the liver 
(since fatty acids could be guided towards oxidation) and increased hepatic insulin
6 This part belongs to Katherine Backhouse PhD thesis [583].
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sensitivity (increased suppression of insulin on hepatic VLDL-triglyceride secretion) 
[119].
6. A larger decrease in plasma total triglycerides, and VLDLi- and VLDLi-triglycerides, 
because of both decreased hepatic VLDL-triglyceride secretion and increased clearance 
in the periphery due to increased energy demands [416] [417].
7. A higher increase in HDL-cholesterol levels, because of a higher decrease in the 
circulating triglyceride-rich particles and diminished triglyceride to cholesterol esters 
exchange between triglyceride-rich particles and HDL (catalysed by CETP), leading to 
lower catabolism of HDL [119] [162] [417].
8. A higher increase in adiponectin circulating levels than in the dietary intervention 
group (leading to increased beta-oxidation and insulin sensitivity) [297] [299], while 
leptin would decrease to the same degree as in the dietary intervention group [293] 
[297], since its levels are predominately determined by total FM [293].
9. A higher decrease in baseline insulin levels and a higher improvement in insulin 
sensitivity (in fat tissue, muscle and liver), as assessed by a hyperinsulinaemic- 
euglycaemic clamp (which predominately measures insulin stimulated peripheral 
glucose disposal) and HOMA2 model (which predominately measures insulin 
sensitivity of hepatic glucose production and insulin secretion) [418].
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CHAPTER 3. THE EFFECT OF RIMONABANT ON FREE FATTY 
ACID AND VLDL-TRIACYLGLYCEROL METABOLISM - 
CLINICAL METHODOLOGY
3.1. Ethical issues
The whole study design and methods of recruitment were approved by the East Kent Research 
Ethics Committee and the University of Surrey Ethics Committee. All subjects were provided 
with oral and written information about the study goals and design, and asked to sign the 
written consent forms for participating in the study. The study was registered with 
ClinicalTrials.gov (NCT00584389) and had MHRA approval (Eudract 2006-006424-18).
3.2. Experimental study type and design
The study was designed as an exploratory, parallel, open label trial with the randomised block 
design [419].
3.3. Study subjects
147 obese (BMI 30-35 kg/m2) Caucasian post-menopausal females, aged 50-70 were recruited 
from the local Surrey population utilising:
1. University of Surrey (staff) circular e-mails
2. local newspaper advertisements
3. poster advertisements placed at local NHS-establishments
Exclusion criteria: Subjects were not included in the study if they fulfilled any of the 
exclusion criteria: body weight instability (body weight variation more than 2.5 kg in last 3
It was originally planned to recruit 32 subjects, according to our study power calculations. However, as 
Rimonabant was withdrawn from EU market in October 2008, the trial had to be stopped. At that time only 
14 subjects had completed the trial.
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months); diabetes and other endocrine diseases; CVD (angina, stroke), hepatic and renal 
disorders; severe food, drug allergies; eating disorders and restraint eating (Dutch eating 
questionnaire [420]; drug or alcohol abuse; medical history of depression or score more than 
14 on Beck Depression Inventory - 2nd Edition, BDI-II (Beck, Steer & Brown, 1996, [421]; 
other substantial psychological or neurological illness; prescribed use of any medications 
known to alter body weight or appetite, beta-blockers, statins, fibrates, metformin; previous 
surgical procedures for weight loss; severe under-reporting of food intake based on a 4 day 
food diary [422]. Diet diaries were analysed using the nutritional analysis programme 
WinDiets Professional 2005 (The Robert Gordon University, Aberdeen, Scotland).
3.4. General study schedule
After the decision to be included in the study and randomisation procedure all study subjects 
had a 3-week run-in period to ensure body weight was stable, immediately after which the 
pre-treatment test were performed within one week, followed by a 12-week treatment period 
and then one week of post-treatment tests, which were identical to the pre-treatment tests.
Therefore each subject was enrolled into the study for 17 weeks:
• Run In Period: 3 weeks
• Pre-Treatment Tests: 1 week
• Intervention Period: 12 weeks
• Post-Intervention Tests: 1 week
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3.5. Detailed study design and schedule (Figure 3.1, Figure 3.2 and Figure 
3.3)
(Visit 1): SCREENING VISIT
RANDOMISATION
RUN IN PERIOD (3 weeks):
(Visit 2 and 3): REE & AEE (1 week)
(Visit 3 and 4): Diet prescription and control (2 weeks)
INTERVENTION PERIOD (Rimonabant or hypocaloric diet)
(12 weeks):
(Visits 8-12): Every 2 weeks visit to dietician, every second week a 
phone call
PRE-TREATMENT TESTS (1 week):
(Visit 5): Test 1: REE measurement, ARE, insulin sensitivity 
measurement
(Visit 6): Test 2: Fat distribution, IHCL, IMCL measurements
(Visit 7): Test 3: VLDLi, VLDL2 and FFA kinetics measurements
POST-TREATMENT TESTS (1 week):
(Visit 13): Test 1: REE measurement, ARE, insulin sensitivity 
measurement
(Visit 14): Test 2: Fat distribution, IHCL, IMCL measurements
(Visit 15): Test 3: VLDLi, VLDL2 and FFA kinetics measurements
Figure 3.1. Detailed study design and schedule (schematic diagram)
(Abbreviations: REE-resting energy expenditure; AEE-activity energy expenditure; IHCL-intra-hepatocellular 
lipid content, IMCL-intra-myocellular lipid content, VLDL-very low density lipoproteins; FFA-free fatty acids)
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Figure 3.2. Graphic presentation o f study visits: A. Visits schedule; B. Visit 5 and Visit 13 (Test 1); C. V isit 7
and Visit 15 (Test 3)
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1. Screening visit:
Subjects were asked to fill in a diet diary for 4 days prior the screening visit. At the screening 
visit the following was performed and recorded: Dutch eating questionnaire, medical history, 
current medication, physical examination, diastolic and systolic blood pressure, weight, 
height, age, smoker/non smoker status, fasting triglyceride, total cholesterol, glucose and 
insulin levels, haematology (haemoglobin, red and white blood cells count, platelet count), 
clinical chemistry (sodium, potassium, creatinine, total protein, albumin, ALT, alkaline 
phosphatase). The subjects were accepted into the study if all of the inclusion criteria and 
none of the exclusion criteria were fulfilled.
2. Randomisation:
After the screening visit, the subjects were randomised to 2 intervention groups
1. Rimonabant Group (N=7): Rimonabant intervention (Acomplia, Sanofi-Aventis, dose 
20 mg/day, 12 weeks) with energy intake matched for the energy expenditure 
individually determined in the run-in period;
2. Diet Group (N=7): Hypocaloric dietary intervention (12 weeks) with the aim of 
achieving the same weight loss as in the Rimonabant group. The energy prescription 
was based on energy deficit estimated from weight loss in the Rimonabant Group.
In the randomisation procedure the sealed envelope method [423] was used. The 
randomisation was done by a third (independent, “blind”) party, to avoid any selection bias 
and secure “blindness” of the randomisation procedure. However, as the study design 
required, the study was of the open trial type: after the randomisation both researchers and 
subjects were fully aware of the treatment assigned.
Since the study had the randomised block design, the permuted block randomization was used 
[419] [424] [425]. It was originally planned that 32 subjects (16 in each group) would be
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studied in blocks of 8. In the first block of 8 subjects, 4 subjects randomised to Rimonabant 
treatment would have been studied first, and then the next 4 subjects randomised to the Diet 
treatment would have been studied. Everything was supposed to be repeated in the following 
blocks. This schedule would have enabled the monitoring of weight loss in the Rimonabant 
group (which would have set the target weight loss for the consecutive Diet group) and the 
monitoring of drop-out rate. It was originally intended that a minimum of 15 subjects in each 
group complete the study, and 1 drop-out per treatment group was allowed. If the dropout rate 
had been greater, the number of subjects involved in the following blocks would have been 
increased accordingly. However, since the trial was stopped, only 2 blocks of subjects 
completed the trial- the first one of 8 subjects (4R + 4D) and the second one of 6 subjects 
(3R+3D) (Figure 3.3).
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Block 2 (R09-R14)
RANDOMISATION (R09-R14)
SUBJECTS: R01-R14
RANDOMISATION (R01-R08)
Block 1 (R01-R08)
SCREENING VISIT
Rimonabant group (subjects R09-R11)
Diet group (subjects R12-R14)
Rimonabant group (subjects R01-R04)
Diet group (subjects R05-R08)
SUBJECTS’ RECRUITMENT
Figure 3.3. Subjects’ involvement in the study
3. Run In Period8 (3 weeks) :
Subjects were asked to keep a continual diet diary and to minimise the alcohol consumption 
from the start of the study till the end of week 17 (including the run-in period).
At baseline, during the 1st week of the run-in period, physical activity energy expenditure 
(AEE) was recorded for 5 days with an Actiheart monitor (a method which measures 
simultaneously vertical acceleration and heart rate [426] (Actiheart®, CamNtech Ltd.,
The data from the run in period form part of Katherine Backhouse PhD project [583].
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Cambridge, U.K.) and REE was measured by indirect calorimetry (Europa GEM (Gas 
Exchange Monitor), Europa Scientific Ltd, U.K.) [427]. The estimated average daily energy 
expenditure (DEE) was calculated DEE=REE+AEE+DIT (where DIT is diet induced 
thermogenesis, estimated as 10% of total DEE [428]). According to the above calculations 
and 4-day diet diaries [429] [430], obtained, an isocaloric diet was prescribed individually, to 
maintain their body weight. During the 2nd and 3rd week the caloric adequacy of the isocaloric 
diet was tested (no more than 1 kg variation from the baseline was allowed), and if this was 
satisfactory, the subjects started with the pre-intervention tests.
4. Pre-Treatment Tests (1 week):
Visit 5 (TEST 1): This visit took place immediately after the last (3rd) week of the run in 
period at the CEDAR clinical research unit. Royal Surrey County Hospital, Guildford. REE9 
was measured by indirect calorimetry, followed by a [1,2-13C] acetate infusion with 
measurements of 13C02 production rate to estimate the ARE. Lastly a hyperinsulinaemic- 
euglycaemic clamp [431] was performed to measure insulin sensitivity.
Visit 6 (TEST 2): This visit was performed at the MRC Clinical Sciences Centre, 
Hammersmith Hospital, London. Whole body fat distribution was be measured by MRI, while 
intra-hepatocellular lipid content (IHCL) and intra-myocellular lipid content (IMCL) was 
measured by ^-magnetic resonance spectroscopy.12
Visit 7 (TEST 3): This visit took place approximately 6 days after Test 1 at the CEDAR 
clinical research unit. VLDLi- and VLDL^-triglyeeride APRs and FCRs, fatty acid production 
rate (Ra) and oxidation rate were measured using stable isotope methodology and rate of 
uptake by muscle using the A-V difference method [43] combined with stable isotopes. At the 
end of visit 7 subjects started their assigned treatment.
9 This forms part of Katherine Backhouse PhD project [583].
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5. Intervention period (12 weeks) 10:
During this period each subject was seen every 2 weeks by a dietitian at the CEDAR clinical 
research unit (with a telephone call between visits), when body weight was measured (only at 
visits) and dietary compliance and targets were reviewed -  this allowed for changes to be 
made to the diets and to ensure consistency of the interventions. All the subjects kept a 
continual diet diary throughout the study (including the run-in period) which was analysed by 
a dietitian using the nutritional analysis programme WinDiets Professional 2005 (The Robert 
Gordon University).
Rimonabant intervention: Rimonabant, 20 mg/d, with energy intake and diet composition kept 
the same as in the run in period and matched with the determined energy requirements (the 
diet compliance was controlled every week). Additionally, at each visit medication 
compliance was assessed by tablet counting and the Beck Depression Inventory score was 
assessed. If during the intervention the scores increased by more than 3 points, or subjects 
reported the side effects of the drug, they would have been carefully monitored and excluded 
from the study if necessary.
Dietary intervention: A hypocaloric diet was prescribed on an individual basis by a dietitian. 
The energy reduction was estimated from the average weight loss of the same block 
Rimonabant Group. The aim was to achieve the same weight loss over 12 weeks as in the 
Rimonabant group by the controlled reductions in carbohydrate and fat intake. Weight and 
dietary compliance and targets were reviewed were reviewed each week by a dietitian.
10 This forms part of Katherine Backhouse PhD project [583].
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6. Post-Treatment Tests (1 week) :
Visit 13 (TEST 1): This visit took place at the beginning of week 17 and was identical to visit
5.
Visit 14 (TEST 2): This visit took place during week 17 and was identical to visit 6.
Visit 15 (TEST 3): This was took place during week 17 and was identical to visit 7.
3.6. Clinical protocols -  TEST 1 and TEST 3
Test 1
Subjects were asked not to undertake any vigorous exercise or drink any alcohol 48 hours 
before the test day. The evening before the test day the subjects were provided with a 
standardised low fat, low fibre meal at 8 p.m. Next morning subjects attended the CEDAR 
clinical research unit at 8 a.m., after an overnight 12 hour fast, and after resting for 1 hour in a 
quiet room the production of CO2 and consumption of O2 in basal conditions (REE)11 was 
measured by the indirect calorimeter Europa GEM (Europa Scientific Ltd, U.K.) [2] [427] 
[432] [433] [434].
L Acetate Recovery Factor (ARF)
This study was performed immediately after measuring REE. An intravenous cannula was 
inserted into the antecubital fossa of one arm for the administration of isotopes. At 0 minutes 
a priming dose of [13C] sodium bicarbonate (0.085 mg/kg) was given over 1 minute followed 
by a 2 hour infusion of [1,2 -13C] sodium acetate (0.08 pmol.kg^.min'1) with measurements of 
13C 02 production rate to estimate the ARF, which was needed to correct the palmitate 
oxidation rate for the loss of label in the TCA cycle [86] [87]. Breath samples were taken at 
baseline and then every 10 minutes from 90 to 120 minutes for the measurement of 13C02
11 This forms part of Katherine Backhouse PhD project [583].
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enrichment (2 breath samples per each time point) by forced expiration into a 12 ml exetainer 
glass tubes (Labco Limited, High Wycombe, U.K.). CO2 production rate was measured 
between 60- 90 minutes using indirect calorimetry (Europa GEM (Gas Exchange Monitor), 
Europa Scientific Ltd, U.K.) [427].
2. Insulin sensitivity
Immediately after the ARF study a hyperinsulinaemic-euglycaemic clamp [431] was 
performed. Subjects remained fasted. A constant insulin infusion of 40 mU/m2 BSA/min was 
infused for 3 hours into the antecubital fossa of one arm (cannulated previously for acetate 
isotope infusion) with a simultaneous variable infusion of dextrose in the same arm to 
maintain blood glucose at the fasting level [435] [436] [437]. The contra-lateral arm was used 
for frequent blood sampling (every 5-10 minutes) to measure blood glucose concentrations at 
the bedside using a glucose analyser (Glucose analyser YSI 2300 Stat Plus, Analytical 
Technologies, Hampshire, U.K.), and then the infusion of 20% dextrose was adjusted 
accordingly to maintain the blood glucose concentration at the fasting level. Blood samples 
were also collected at the beginning of the clamp study (the baseline sample) and every 10 
minutes in the steady state for the determination of serum insulin concentrations. The steady 
state period of the clamp was defined as a 150-180 minutes period after the beginning of the 
insulin infusion (the last half an hour of the 3 hours constant infusion [437] [438]. The main 
measures of insulin sensitivity used were: the average glucose infusion rate between 150 and 
180 minutes G IRqso-isom in) (mg/min/kgBW) and the insulin sensitivity index ISdamp [431] 
[437] [439].
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TEST 3
1. Fatty acid, VLDLj and VLDL2 triacylglycerol metabolism
Subjects were studied after an overnight fast. For 2 days prior to the study subjects were 
asked not to undertake vigorous exercise and not to consume alcohol and were provided with 
the same standardised low fat, low fibre diet as prior to Test 1. An intravenous cannula was 
inserted into the antecubital fossa of one arm for the administration of isotopes ([1,1,2,3,3- 
2H5] glycerol, [U-13C] sodium palmitate and [13C] sodium bicarbonate). In the same arm a 
retrograde cannula was inserted into a vein draining the hand, which was pre-warmed in a 
hot-box at 50-60°C, to provide arterialised blood samples [29]. To enable measurement of 
peripheral skeletal muscle uptake of palmitate using the A-V difference technique [90] [93], 
in the opposing arm antecubital fossa, a deep vein draining the forearm muscles (the median 
cubital vein) was cannulated to obtain the blood draining forearm muscles. Artérialisation of 
the hand-vein and the position of the deep vein cannula were checked at the beginning and 
during the palmitate infusion steady state period using blood gas measurements (GEM OPL 
CO-Oximeter, GEM® OPL™ Oxygenation Portable Laboratory, Instrumentation Laboratory 
Ltd, U.K.). Acceptable oxygen saturation was defined as higher than 90-95% for arterialised 
blood samples and lower than 60% for the deep venous samples [90]. Samples from the deep 
forearm vein were taken after exclusion of hand circulation for 3 minutes by inflating a wrist 
sphygmomanometer cuff to 60-100 mmHg above arterial pressure (around 200-220 mmHg). 
Forearm blood flow was measured immediately after obtaining deep venous blood samples, 
by mercury strain-gauge plethysmography (Hokanson EC6 Plethysmograph, D.E. Hokanson, 
Incorporated, Washington, USA), with wrist cuff inflation up to 200-220 mmHg and upper 
arm cuff inflation up to 50 mmHg.
At 8.30 a.m. a baseline blood sample was taken to measure the baseline VLDLi- and VLDL2- 
triglyceride enrichment, baseline enrichment and concentration of plasma palmitate, and 
baseline concentrations of total plasma triglycerides, total cholesterol, LDL-cholesterol, HDL-
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cholesterol, FFA, glucose, insulin, adiponectin, leptin, as well as VLDLi- and VLDL2- 
cholesterol and triglyceride concentration. Additionally breath samples were taken to measure 
the baseline enrichment of 13C02 in the breath. Immediately after the collection of baseline 
blood and breath samples stable isotopes were administrated. To measure the synthesis rate of 
VLDLi-and VLDL2-triglyceride at 0 minutes an i.v. bolus of [1,1,2,3,3-2H5] glycerol (75 
pmol/kg) was administered over one minute, and then blood samples were taken at 5, 15, 30, 
45, 60, 90 and 120 minutes, and then hourly for 7 hours. To measure the rate of fatty 
oxidation [2] [86] [87], at -1 minute a priming dose of [13C] sodium bicarbonate (0.085 
mg/kg) was administered over 1 minute, followed by a constant intravenous infusion of [U- 
13C] sodium palmitate bound to human albumin (5%) (0.01 pmol.kg^.min'1) for 2 hours. 
Arterialised and venous blood samples were taken every 10 minutes from 90 to 120 minutes 
to measure plasma palmitate enrichment. To measure breath 13C02 enrichment, breath 
samples were taken every 10 minutes from 90 to 120 minutes. CO2 production rate and O2 
consumption rate were measured between 60- 90 minutes with the Europa GEM [432] [433].
3.7. Sample collection and storage
Blood samples were taken with sterile syringes and were immediately transferred to precooled 
tubes containing EDTA (for plasma lipids), lithium-heparin (for plasma glycerol) or fluoride- 
oxalate (for plasma glucose) and kept on ice, except for blood samples for serum (which were 
placed in plain tubes at room temperature for 30 minutes to allow coagulation). Blood 
samples were then centrifuged within 30 minutes of the sample being drawn at 4°C at 2,500 
rpm (1013 x g RCF12) for, 15 minutes (Heraeus Primo R Centrifuge, Thermo Scientific, 
Fisher Scientific, U.K., rotor type: Swinging Bucket Rotor). Separated plasma samples were 
then stored immediately at -80°C in 2ml plastic screw capped microtubes (Alpha 
Laboratories, Eastleigh, U.K.), except for the plasma for VLDLi and VLDL2 fractions, which
12 RCF (relative centrifugal force) was calculated from the formula:
RCF (xg)  =  1.118 x max. rotor radius (mm)/(rotor speed  (rpm)/WOO)2.
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were stored in 7 ml glass tubes with foil lined caps (VWR, Lutterworth, U.K.) at -4°C until 
ultracentrifugation the next day.
Breath samples were collected in 12ml exetainer glass tubes (Labco Limited, High Wycombe, 
U.K.), by forced expiration through a straw (the very last breath from the chest was collected 
and glass tubes were capped immediately). For every sampling point, 2 breath samples were 
taken. Breath samples were kept securely capped at room temperature until the day when the 
analyses were performed (within several weeks).
All plasma, breath and infusate samples were given anonymous coding and the identity of the 
codes kept in a secure cabinet.
3.8. Preparation of tracer solutions and infusâtes
[13C] sodium bicarbonate (MW=85; 99% purity, Cilbatch PR-15602, U.K.), [1,2-13C] sodium 
acetate (MW=84; 99% purity, Cambridge Isotopes Laboratories, U.K.), [U-13C] sodium 
palmitate tracer (MW=294.3, 98% purity, Cambridge Isotopes Laboratories, U.K.) and 
[1,1,2,3,3-2H5] glycerol (MW=97.1, 99% purity, Cambridge Isotopes Laboratories, U.K.) 
were purchased and sterile water solutions were prepared by Pharmacy Department of Guy’s 
and St Thomas’ Hospital, London, NHS Trust Pharmacy. Accurately weighed amounts of 
sodium bicarbonate, sodium acetate, sodium palmitate or glycerol were dissolved in known 
amount of sterile, pyrogen-free double distilled water under sterile conditions to give 
concentrations of 5 mg/ml, 10 mg/ml, 10 mg/ml and 30 mg/ml respectively. These solutions 
were filtered through a 0.22 pm filter into sterile ampoules (containing 5 ml, 2.5 ml, 2.5 ml 
and 2.5 ml of solutions, respectively), which were then aseptically sealed. After the 
preparation a random sample of ampoules was checked for chemical purity, concentration, 
sterility and pyrogenity at Pharmacy Department of Guy’s and St Thomas’ Hospital. The 
ampoules were kept at room temperature until the day of their usage.
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The amounts needed to be injected as a bolus of prepared solutions of [1,1,2,3,3-2H5] glycerol 
and [13C] sodium bicarbonate were calculated on the day of study based on subject’s 
measured body weight (75 pmol/kgBW and 0.085 mg/kgBW, respectively).
On the day of the study [1,2-13C] sodium acetate infusate was prepared by diluting the content 
of the ampoule by 0.9% saline to achieve a concentration which would give an [1,2-13C] 
sodium acetate infusion of 0.08 pmol/kg/min (6.72 pg/kg/min) by a constant infusion (10 
ml/h, IVAC PCAM PCA Syringe Pump, Alaris products, Cardinal Health U.K. 305 Ltd).
On the day before the study day the infusate of [U-13C] sodium palmitate bound to human 
albumin (concentration 1.5 pmol [U-13C] sodium palmitate/ml) was prepared at Guy’s and St 
Thomas Hospital, NHS Trust Pharmacy by dissolving 4.6 ml of the prepared uniformly 
labelled [U-13C] sodium palmitate solution (concentration lOmg/ml) into 100 ml 5% human 
albumin. [U-13C] sodium palmitate water solution was pre-heated to 60°C to dissolve 
completely and then 4.6 ml were injected through a 0.45pm filter under aseptic conditions 
into 100 ml sterile 5% human albumin bottles (Grifols U.K. Ltd, Cambridge, U.K.), pre­
heated at 60°C and mixed well, to achieve a concentration of palmitate of 1.5 pmol/ml. The 
infusate was kept at room temperature until the study on the following day. [U-13C]-sodium 
palmitate was infused at a constant infusion rate of 0.01 pmol/kgBW/min using an I VAC 
Variable Pressure Volumetric Pump, Model 560 (IVAC, San Diego, USA) and i.v. 
administration set with a low-protein binding 0.2 pm filter attached (Pall Neo Posidyne i.v. 
filter 0.2pm, NE096E, Pall Medical, Portsmouth, U.K.).
On the day of the study the insulin infusate was prepared by diluting the individually 
calculated amount of insulin Actrapid 100 lU/ml (Novo Nordisk Ltd, Crawley U.K.) 
(according to the subject’s BSA, calculated using the Mosteller formula [440]), in a solution 
containing 2 ml of the subject’s blood and 38 ml of 0.9% saline to achieve a concentration 
which would give an infusion rate of 40 mU insulin/m2BSA/min with a constant infusion rate 
(10 ml/h, IVAC PCAM PCA Syringe Pump, Alaris products, Cardinal Health U.K. 305 Ltd).
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All infusion pumps were checked and serviced every 6 months at Royal Surrey Hospital, 
Guildford.
3.9. Clinical measurements
3.9.1. Measurement of body weight, fat mass, fat free mass and waist and 
hip circumference
BW, FM and FFM were measured on a Tanita BC-418 Segmental Body Composition 
Analyser (Tanita U.K. Ltd., Middlesex, U.K.) by bioelectrical impedance analysis (BIA). 
Subjects were weighted fasted at 8 a.m., after empting their bladder and bowels, wearing only 
underwear. The precision of measurements was as follows (results expressed as coefficient of 
variance, CV)13:
• BW measurements: intra-day CV=0.3% and inter-day CV=0.9%;
• FM measurements: intra-day CV=1.0% and inter-day CV=2.8%;
• FFM measurements: intra-day CV=1.0% and inter-day CV=3.4%.
Waist and hip circumferences were measured with a tape measure at the level of the umbilicus 
and as a maximum circumference over the buttocks. The mean of 3 measurements taken to 
the nearest 0.5 cm by the same operator (to avoid inter-operator variability) were taken as the 
result. The precision of measurements14 was:
• waist circumference measurements: intra-day CV=1.2% and inter-day CV=2.8%
• hip circumference measurements: intra-day CV=0.8% and inter-day CV=1.2%.
13 Based on 3 measurements during one day for intra-day CV, repeated on 3 consecutive days for inter­
day CV
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3.9.2. Measurement of carbon-dioxide production
Carbon dioxide production rate was measured by indirect calorimetry with a Europa GEM 
(Gas Exchange Monitor) (Europa Scientific Ltd, U.K.) [427]. The instrument was calibrated 
every time before measurement.
The subject laid in bed in the supine position for 1 hour. A ventilation hood was placed over 
the head. Subjects were asked not to move during the measurement and to breathe normally. 
Measurements were taken over a 20 minute period (65-85 minutes from the beginning of the 
infusion of sodium acetate or sodium palmitate). The precision of the measurement was: the 
intra-day CV=3.8%, the inter-day CV=5.1%. (For details see Appendix, the Study 
methodology validation chapter)
3.9.3. Measurement of blood flow
Mean blood flow was measured by a Hokanson plethysmograph (D.E. Hokanson, 
Incorporated, Washington, USA), 10 minutes after obtaining the last A-V difference blood 
samples, by a standardised procedure [51] [89] [441] [442]. A strain gauge was placed on the 
arm used for deep venous blood sampling 8 cm from the elbow. The wrist cuff was inflated 
up to 220mm Hg for 3 minutes prior to the measurement to occlude the hand. The upper arm 
cuff was inflated to a pressure of 50 mm Hg (to allow affluence of arterial blood, but to block 
venous drainage). Subjects were asked not to make any movements during the measurements. 
The mean of 10 measurements was calculated and used for calculation of forearm plasma 
flow. The precision of the measurements was: intra-day CV=27.7%, inter-day CV=35.9%. 
(For details see Appendix, the Study methodology validation chapter)
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CHAPTER 4. THE EFFECT OF RIMONABANT ON FREE FATTY 
ACID AND VLDL-TRIACYLGLYCEROL METABOLISM - 
ANALYTICAL METHODS
4.1. Laboratory methods
All laboratory methods were based on standardised laboratory protocols and procedures 
developed at Diabetes and Metabolic Medicine of the Postgraduate Medical School, 
University of Surrey. All laboratory techniques were previously validated. Regular check-up 
and service of all instruments, conditions and standards was performed. There was strict 
adherence to the principles of Good Laboratory Practice to minimise error during laboratory 
analyses of the samples.
4.1.1. Materials
All laboratory chemicals and regents were purchased from Sigma-Aldrich Ltd. (Dorset, U.K.) 
and Fisher Scientific U.K. Ltd. (Leicestershire, U.K.), unless stated otherwise.
4.1.2. Method for the measurement of glycerol enrichment in plasma VLDLi 
and VLDL2- triglycerides by mass-spectrometry
The method [161] used in this study for the estimation of VLDLi- and VLDL2-triglycerides
kinetics involved the following laboratory procedures: 1) separation of plasma lipoprotein
VLDLi and VLDL2 subtractions by ultracentrifugation [161]; 2) lipid extraction from
lipoproteins fractions by the Folch method [443]; 3) isolation of triglycerides by thin layer
chromatography (TLC) [444]; 4) separation of glycerol from triglycerides: hydrolysis and
glycerol extraction [444]; 5) purification of the liberated glycerol by ion exchange
chromatography [18]; 6) derivatisation of purified glycerol to form the volatile tri-acetate
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derivative) [18]; 7) measurement of glycerol-tri-acetate derivative enrichment by positive 
chemical ionisation - gas chromatography/mass spectrometry (PCI-GC/MS) [18].
The mathematical multicompartmental model [15] for metabolic calculation of VLDLi- and 
VLDLi-triglyceride FCRs and APRs also required measurement of plasma glycerol 
enrichment [18], as well as the measurement of plasma VLDLi- and VLDLi-triglyceride 
concentration (the method is described later in the section on enzymatic measurements).
4.1.2.1. VLDLi and VLDL2 fractions separation by ultracentrifugation
The day after obtaining plasma samples, VLDLi (Sf 60-400) and VLDL2 (Sf 20-60) 
subtractions were separated by sequential ultracentrifugation [161] using a Beckman Coulter 
Optima LE80K ultracentrifuge (Beckman Coulter, High Wycombe, U.K.; rotor type: 50.4 Ti 
Rotor). Three ml of plasma was transferred into ultracentrifuge tubes (Quick-Seal 
Polyallomer Tubes, 4.7 ml, Beckman Coulter, High Wycombe, U.K.) and carefully overlaid 
with the 1.006 mg/ml density NaCl solution (0.9% saline with 0.1% EDTA) using a syringe. 
Ultracentrifugation was performed at 4°C at 45,000 rpm (252,000 x g), for 66 minutes to 
separate VLDLi. The top layer containing VLDLi (1 ml) was then separated by slicing the top 
1 ml of the ultracentrifuge tube (Tube Slicer kit, Beckman Coulter, High Wycombe, U.K.) 
and transferred into 3.5 ml glass tubes with foil lined caps (VWR, Lutterworth, U.K.). The 
bottom layer of the sliced ultracentrifuge tube was then immediately transferred into a new 
ultracentrifuge tube, the volume was made up using the 1.006 mg/ml density NaCl solution 
and the whole procedure was repeated (the ultracentrifugation this time at 4°C at 37,000 rpm 
(171,000 x g) for a minimum of 16 hours) to separate VLDL2. The VLDLi (Sf 60-400) and 
VLDL2 (Sf 20-60) fractions were diluted with 0.9% saline with 0.1% EDTA up to 2 ml, 
vortexed and stored at -2O°C in 3.5 ml glass tubes with foil lined caps until further analysis 
was performed.
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4.1.2.2. VLDLi and VLDL2 lipid extraction
After pre- and post-treatment tests were completed, the lipid extraction step was performed. 
VLDLi and VLDL2 lipoprotein fractions were defrosted, vortexed and 0.5 ml was aliquoted 
into 7 ml glass tubes with foil lined caps (VWR, Lutterworth, U.K.). Two ml of the mixed 
solvent Chloroform: Methanol 2:1 (v/v) was added, the samples were vortexed and left 
overnight in the fridge at 4°C. The next day, after centrifugation at 4°C for 30 minutes at 
2,500 rpm (1342 x g) (Sorvall Legend RT Centrifuge, Thermo Scientific, Fisher Scientific, 
U.K., rotor type: TTH-750 High-Capacity Swing-Out Rotor), the bottom layer (containing 
lipid extracts in chloroform) was removed to a new labelled 7 ml glass tubes by a Pasteur 
glass pipette and kept in the fridge at 4°C (first wash). To the rest of the sample, 1 ml of the 
mixed solvent Chloroform: Methanol 2:1 (v/v) was added. The samples were vortexed, kept 
in the fridge for 1 h and than centrifuged at 4°C for 30 minutes at 2,500 rpm. The bottom 
layer was removed by a glass pipette (second wash) and combined with the bottom layer from 
the first wash. After adding 0.75 ml of 0.88% KC1, the samples were vortexed, spun at 4°C 
for 30 minutes at 2,500 rpm, and the top layer was removed completely (to eliminate non­
lipid contaminants). To the bottom layer 100 pi ethanol was added and the samples were dried 
( - 3 0  minutes) under nitrogen (nitrogen generator Techne sample concentrator, Parker 
Filtration UK Ltd, U.K.), after which 100 pi of chloroform was added.
4.1.2.3. Thin-Layer Chromatography (TLC)
The samples were gently vortexed and transferred by a TLC syringe onto TLC plates (Silica-
gel 60 on aluminium sheets, 20x20 cm, MERCK, Germany), which were then placed into a
TLC developing tank containing a solution of hexane (140 ml): diethyl ether (60 ml): acetic
acid (4 ml) prepared the previous day. The plates were left in the tank until the solvent
reached the upper line on the plate ( -  20-30 minutes), when the plates were taken out of the
tank to dry in the fume-hood. After placing the dried plates into an iodine tank for about 5
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minutes (till the bands became visible by iodine binding to double bonds of FF As of the 
VLDL lipids) (Figure 4.1), the bands were marked and, after leaving the plates in the fume- 
hood (to evaporate the iodine completely), the bands were scraped off and placed into new 7 
ml glass tubes for the next step - triglyceride hydrolysis.
Cholesterol esters
Triacylglycerol
Diacylglycerols
M onoacylglycerol
Sample 
application (only 
polar m olecules 
rem ained, e.g. 
phospholipids)
Figure 4.1. TLC chromatogram o f VLDLi lipids (plates: silica-gel on alum inium  sheets; 
solvent mixture: hexane/diethyl ether/acetic acid: 70/30/2 v/v/v)
4.1.2.4. Hydrolysis of triglycerides and glycerol extraction
1 ml of toluene and 2 ml of 3% HC1 in methanol was added and the glass tubes were left in a 
heating block (50°C) overnight to allow the hydrolysis process to take place.
The next day 1 ml of 5% NaCl and 2 ml of hexane was added, the samples were vortexed, left 
in the fridge at 4°C for at least 30 minutes and then centrifuged for 30 minutes at 2,500 rpm at 
4°C to separate glycerol from FFA. The top layer (FFA with hexane) was removed (first 
wash) and to the rest of sample 2 ml of hexane was added (second wash). After the samples
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were centrifuged for 30 minutes at 2,500 rpm at 4°C, the top layer (FFA with hexane) was 
removed and the infranatant (glycerol) dried under nitrogen for 1 hour to eliminate methanol 
and hexane (or tubes were left overnight open in the fume-hood).
4.1.2.5. Glycerol purification -ion exchange columns
The resins: cation resin AG50W-X8 (hydrogen form, BioRad Laboratories Ltd, Hemel 
Hempstead, U.K.) and anion resin AG1-X8 (formate form, BioRad Laboratories Ltd, Hemel 
Hempstead, U.K.) were washed 3 times with deionised (d.i.) H2O before being placed into the 
columns. The ion-exchange columns (5" polypropylene chromatography gravity columns 15- 
45 pm, Evergreen Scientific, BioConnections, Leeds, U.K.) were positioned into the tank, 
washed with 0.5 ml d.i. H2O and then 1 ml (2 cm) of cation resin AG1-X8 was added and the 
columns were carefully washed with 1 ml d.i. H2O. Then 1 ml (2 cm) of anion resin was 
carefully overlaid and the washing procedure with 1 ml d.i. H2O was repeated. After draining 
all water, the columns were capped to prevent the resins from drying and new 7 ml glass tubes 
were placed underneath. Before adding the samples 0.5 ml of d.i. H2O was added and the 
columns were un-capped. The samples infranatant (glycerol) was added to the columns and 
eluate was collected into 7 ml glass tubes. The columns were eluted with the further 3 ml d.i. 
H2O and the glass tubes containing eluate were covered with parafilm (pierced with small 
holes) and placed into the freezer (at -80°C) overnight to freeze. The frozen samples were 
placed in a freeze-dryer (Modulyo D, Thermo Electron Corporation, Thermo Fisher Scientific 
Inc., U.K.) to lyophilise at -50°C until completely dried (overnight, at least 15 hours).
4.1.2.6. Glycerol derivatisation
A freshly made solution of acetic anhydride: pyridine 1:1 (v/v) was prepared and added to 
freeze-dried samples (100 pi per sample). The samples were gently vortexed, left at room
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temperature for at least 30 minutes (to allow the derivatisation process to take place to form 
the volatile glycerol-triacetate derivative) and then dried under nitrogen (~ 25 minutes). After 
adding 100 pi of ethyl acetate, the samples were vortexed and transferred into autosampler 
gas-chromatography vials (300 pi, clear glass, Chromacol, U.K.) and the vials were capped.
4.1.2.7. Plasma glycerol extraction, purification and derivatisation
Plasma samples for plasma glycerol analysis stored at -80°C were defrosted, gently vortexed 
and aliquoted (0.5 ml of sample) into a 3 ml plastic sample tube containing 1 ml of 3.5% 
sulphosalicylic acid (SSA) was added. The tubes were capped, mixed and left at 4°C for 30 
minutes to precipitate proteins. Samples were vortexed and centrifuged for 20 minutes at 
2,000 rpm (859 x g) at 4°C. The resins and ion-exchange columns were prepared as described 
above and the glycerol supernatant was added. The further procedure for glycerol purification 
and derivatisation was identical to that described for glycerol derived from VLDL 
subfractions.
4.1.2.8. Mass spectrometry- measurement of VLDLi and VLDL2 triglyceride 
glycerol and plasma glycerol enrichment
All GC/MS analysis of glycerol isotopic enrichment (both for VLDL-subfractions and plasma 
glycerol) were performed by positive chemical ionisation (with methane as the reagent gas) 
on an 5975 inert XL Mass Selective Detector (MSD) coupled with a 6890 Series gas 
chromatograph (Agilent Technologies, U.K.) [18]. Chromatographic separations were 
performed on a Thames Restek Rtx-5 capillary column (95% dimethylpolysiloxane and 5% 
diphenyl, length 30 m x internal diameter 0.25 mm x film thickness 0.25 pm) using helium as 
the carrier gas (constant flow rate, initial flow: 1 ml/min). Samples (1 pi) were injected by the 
autosampler injector syringe in the splitless mode (or alternatively- split ratio varied from
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1:10 to 1:20, depending on previously measured VLDLi- and VLDL^-triglyeerides 
concentrations by an enzymatic method on an automated analyser; the method is described 
later in the section on enzymatic measurements). The sample injector temperature was held at 
250°C. The column oven temperature was 70°C at injection and programmed to increase to 
250°C after 2 min at a rate of 20°C/min. Interface temperature was held at 240°C; the ion 
source temperature was held at 176°C. Selected ion monitoring (SIM), data acquisition, and 
quantitative calculations were performed using the Agilent Technologies ChemStation. The 
position of ion peaks (the retention time) was determined by comparison with peaks of 
glycerol standards. The total run time was 12 minutes. Ions at mass-to-charge ratios (m/z) of 
159 (representing ion fragments of triacetyl-glycerol, m+0, tracee) and 164 (representing ion 
fragments of triacetyl-^Hg-glycerol, m+5, tracer) were selectively monitored. The ratio 
between peak areas of ions with m/z 164 (tracer) and m/z 159 (tracee) was calculated at each 
time point as tracer to tracee (Tr/Te) enrichment. TTR (tracer to tracee ratio) was calculated at 
the each time point as Tr/Te enrichment (Tr/Tet) relative to baseline enrichment (Tr/Teo) [2]:
TTRt=(Tr/Te)r (Tr/Te)0 [12]
4.1.2.9. Preparation of glycerol standards and standard curves
Stock solutions 42 pg/ml= 0.457 pmol/1 of unlabelled glycerol (representing plasma glycerol- 
tracee) and 6.6 pg/ml= 0.068 pmol/1 of 2H5-glycerol (Cambridge Isotopes Laboratories, U.K., 
representing tracer) were prepared in d.i. water. Calibration curves of standards were prepared 
by adding different amounts of standards, to achieve different ratios of tracer/tracee, similar to 
that expected in plasma during the clinical studies. The standards were aliquoted and frozen at 
-80°C. The frozen aliquots of glycerol standards were freeze-dried, derivatised to form tri­
acetyl derivatives in ethyl acetate as described above. The standard curves were made to 
confirm a linear slope for glycerol enrichment measurement on GC/MS (Figure 4.2).
Additionally, before and after each sample run the same calibration curves were run, to
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measure repeatability and to ensure the validity of the data, both for plasma glycerol and 
VLDL-triglycerides glycerol. Overall the CV% for glycerol standards emichment was 13.5% 
(ranging from 19.3% for small enrichments to 6.9% for high enrichments). (For details see 
Appendix, the Study methodology validation chapter)
y = 0.9499x + 0.001
0.000 0.050 0.100 0.150 0.200
Theoretical umol ratio labeled / unlabeled glycerol
Error bars: ±SD
Figure 4.2. Repeatability of GC/MS measurements - standard curves for GC/MS measurement ofVLDL-
triglyceride glycerol enrichment (N=28)
4.1.3. Method for the measurement of plasma FFA enrichment and 
concentration by mass-spectrometry
FFA were extracted from plasma and derivatised to their methyl esters (which were then 
purified) by the method of Patterson et al. [17].
4.1.3.1. Plasma FFA extraction
Plasma samples for plasma FFA analysis stored at -80°C were defrosted, gently vortexed and 
250 pi of plasma aliquoted into 7 ml glass tubes. To aliquots of plasma samples 250 pi of
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internal standard (heptadecanoic acid (C l7:0) in heptane, concentration =31 (ig/ml =113.64 
pmol/1) was added and samples were shaken gently on a platform vortexer for 3 minutes. 
Three ml of ice-cold acetone was added, samples were vortexed for 10 seconds, left at -20°C 
for 15 minutes to precipitate plasma proteins, and then centrifuged at 4°C for 10 minutes at
2.500 rpm. The supernatant was transferred into new 7 ml glass tubes using a glass Pasteur 
pipette. Three ml of hexane and 3 ml of water were added, the vials were securely capped 
with foil-lined caps and shaken gently in a horizontal platform shaker for 15 minutes. The 
samples were centrifuged at 4°C for 10 minutes at 2,500 rpm to separate the solvent and 
aqueous phase. Using a glass Pasteur pipette the upper phase (hexane) was transferred into 
new uncapped 7 ml glass tubes, which were dried under nitrogen to evaporate all solvent 
carefully.
4.1.3.2. Plasma FFA derivatisation (méthylation)
To form volatile fatty acid methyl esters (FAME), 250 pi of buffer (0.2 M dibasic potassium 
phosphate and 0.05 M tetrabutylammonium hydrogen sulphate, pH adjusted to 9.0 with 
tribasic potassium phosphate) and 250 pi of iodomethane in dichloromethane solution (1:10 
v/v) were added and samples were vortexed for 10 minutes. To extract FAME, 3 ml of hexane 
was added, samples were vortexed for 15 minutes and centrifuged at 4°C for 10 minutes at
2.500 rpm to separate solvent phases. Using a glass Pasteur pipette the upper layer (hexane) 
was transferred into new uncapped 7 ml glass tubes, which were dried under nitrogen to 
evaporate all solvent. To each sample 1.5 ml of hexane was added, vials were capped and 
vortexed for 2 min.
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4.1.3.3. Purification of FAME
The solid phase extraction (SPE) cartridges (LC-Si, 3 mL size; Supelco, Bellefonte, PA) were 
placed on an SPE vacuum manifold and attached to taps, washed twice with 1.5 ml of hexane 
and the hexane eluate was collected into waste tubes. When all solvent had run through the 
cartridges (without allowing them to dry), the samples (1.5 ml) were transferred slowly using 
a glass Pasteur pipette onto the top of the SPE cartridges. The vials were rinsed with 1.5 ml 
hexane and transferred again on the top of the SPE cartridges. When all hexane had run 
through the cartridges, the waste tubes were replaced with uncapped collection tubes (10.5 ml 
glass tubes, VWR, Lutterworth, U.K.) and FAME were eluted with two washes of 1.5 ml 2% 
ethyl acetate in hexane.
When all solvent had evaporated from the collection tubes under nitrogen, 50 pi of hexane 
was added and the samples were transferred into autosampler gas-chromatography vials (300 
pi, clear glass, Chromacol, U.K.).
4.1.3.4. Mass spectrometry- measurement of plasma palmitic acid 
enrichment and concentration
The isotopic enrichment and concentration of the plasma palmitic acid methyl ester was 
measured by GC/MS (5975 inert XL MSD coupled with the 6890 series GC, Agilent 
Technologies, U.K.)
Chromatographic separations were performed on an SGE BP1 capillary column (100%
dimethylpolysiloxane, length 30 m x internal diameter 0.25 mm x film thickness 0.25 pm)
using helium as the carrier gas (constant flow rate, initial flow: 1 ml/min). Samples (2 pi)
were injected by the autosampler injector syringe in the splitless mode. The sample injector
temperature was held at 250°C. The column oven temperature was 150°C at injection and
programmed to increase to 195°C after 3 min at a rate of 4°C/min. Interface temperature was
held at 280°C; the ion source temperature was held at 230°C. The mass spectrometer was
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operated in electronic impact ionisation (El) mode (70 eV). The El mass spectra were 
obtained by scanning at 1.0 scan/s from m/z 50 to 650. The position of ions peaks (retention 
time) was determined by comparison with peaks of palmitic and heptadecanoic acid 
standards. The total run time was 29.25 minutes. Ions at mass-to-charge ratios (m/z) of 270.3 
(representing ion fragments of plasma methyl-palmitate, the tracee), 284.3 (representing ion 
fragments of methyl-heptadecanoate, derivative of the heptadecanoic acid added to plasma 
samples as the internal standard to measure plasma palmitic acid concentration), and 286.3 
(representing ion fragments of uniformly labelled methyl-palmitate, the tracer) were 
selectively monitored.
The ratio between peak areas of ions with m/z 286.3 (tracer) and m/z 270.3 (tracee) was used 
to calculate the tracer to tracee (Tr/Te) enrichment and the tracer to tracee ratio (TTR) 
according to the equation/72y.
Plasma palmitate concentration was measured by using an internal standard (heptadecanoic 
acid) [17]. Peak area of ion with m/z 270.3 (plasma palmitate-methyl ester) relative to peak 
area of ion with m/z 284.3 (internal standard- heptadecanoic acid methyl ester) was used to 
calculate plasma palmitate concentration at steady state [17].
4.1.3.5. Preparation of palmitic acid and heptadecanoic acid standards 
and standard curves
13C uniformly labelled sodium palmitate was purchased from Cambridge Isotopes
Laboratories, U.K. Stock solutions of palmitic acid (in heptane, 117.13 pmol/1), heptadecanoic
acid (in heptane, 124.79 pmol/1) and uniformly labelled sodium palmitate (in 2% HC1
methanol, 0.49 pmol/1) were prepared. Calibration curves of standards were prepared by
adding different amounts of standards in 7 ml glass tubes to achieve a ratio of tracer/tracee
and concentration similar to that expected in plasma during the studies (Figure 4.3 and Figure
4.4). The standards were dried under nitrogen, then 1 ml of 2% HC1 methanol solution was
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added, standards were vortexed and left overnight at 50°C (to derivatise to their methyl 
esters). After adding 1 ml of 5% NaCL and 3 ml of hexane, the standards were vortexed, 
centrifuged at 4°C for 10 minutes at 2,500 rpm and the supernatant (FFA in hexane) was 
removed to new 7 ml glass tubes (first wash). Three ml of hexane was added again to the 
remaining infranatant, the samples were vortexed, centrifuged and the supernatant (second 
wash) was combined with the first wash. The standards were dried under nitrogen and 0.1 ml 
hexane was added. The standards were vortexed and transferred to GC vials and their mass 
spectra were recorded.
As a first stage in the validation of the palmitate assay, methyl derivatives of palmitic acid and 
heptadecanoic acid standards were prepared and their El mass spectra was recorded on 
GC/MS (MS was run in the “SCAN” mode). This allowed GC conditions to be established, 
the m/z of palmitic and heptadecanoic acid ions fragments to be detected and their retention 
time to be determined. Then the standards were run in SIM mode, to confirm that m/z ion 
monitoring was correct. From those standards the calibration curves were made to confirm a 
linear slope for palmitate enrichment and concentration measurement on GC/MS, which was 
in the range of that expected in plasma during the clinical studies. Additionally, before and 
after each sample run, the same calibration curves were run, to measure repeatability and 
ensure validity of the data. Overall, on GC/MS the average CV% for the plasma palmitate 
enrichment and concentration measurements were 10.3% (varying from 15.4% for small 
enrichments, to 7.3% for higher enrichments) and 2.2% (varying from 1.3% to 3.1%), 
respectively. (For details see Appendix, the Study methodology validation chapter)
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Figure 4.3. Repeatability of GC/MS measurements - standard curves for GC/MS measurement of plasma
palmitate enrichment (N=20)
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Figure 4.4. Repeatability of GC/MS measurements - standard curves for GC/MS measurement of plasma
palmitate concentration (N=20)
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4.1.4. Mass spectrometry- measurement of C02 isotopic enrichment in 
breath samples
CO2 enrichment in breath samples was measured by CF-IRMS Deltaplus XP with GasBench II 
(Thermo Electron, Bremen, Germany). Twelve ml of expired air was collected in an exetainer 
(Labco Limited, High Wycombe, U.K.). The sample was flushed into the system by a 
continuous flow of helium at 0.5 ml/min. The CO2 in the gas samples was separated using a 
Pora Plot Q column (25-m length, 0.32-mm internal diameter, and 10-pm film thickness) with 
helium (2.0 ml/min) as the carrier gas. The isotope reference gas was CO2 . The isotopic 
enrichment of breath CO2 samples was expressed as the delta difference between 13C/12C of 
the sample and a known laboratory reference standard related to PDB (the equation [3]). The 
equations [1] and [12] were used to calculate TTR. The precision of measurement was 
CV=10.3% (varying from 0.6% to 1.9%) (For details see Appendix, the Study methodology 
validation chapter).
4.1.5. Enzymatic and radioimmunoassay (RIA) measurements
Plasma FFA, glycerol, HDL-cholesterol, total cholesterol, triglyceride, VLDLi- and VLDL2- 
triglyceride and cholesterol concentration was measured enzymatically using a Gobas MIRA 
(Roche, Welwyn Garden City, U.K.) and commercially available kits (Wako NEFA C test, 
Wako Chemicals GmbH, Neussn, Germany; Glycerol, Randox laboratories Ltd., Crumlin, 
U.K.; Triglycerides CP and Cholesterol CP, ABX Pentra, Horiba, Chicksands, Shefford, 
Bedfordshire, U.K.; HDL-cholesterol, Horiba ABX Pentra Hdl, Direct Cp, Horiba, 
Chicksands, Shefford, Bedfordshire, U.K.). Precision of measurements was: plasma FFA 
CV=5.9%; plasma glycerol CV=5.1%; plasma triglyceride CV=5.5%; VLDLi- and VLDL2- 
triglyceride CV=1.6%; total cholesterol CV=5.0%; VLDLi- and VLDL2-cholesterol 
CV=1.9%; HDL-cholesterol CV=6.9%. LDL-cholesterol was estimated from plasma total
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cholesterol, HDL-cholesterol and triglyceride concentrations using the Friedewald equation 
[445]: Total cholesterol= (LDL-cholesterol) + (HDL-cholesterol) + (triglyceride/5) (mmol/1). 
Insulin, adiponectin and leptin were measured by radioimmunoassay (RIA) using 
commercially available kits (Human Insulin RIA kit, Human leptin RIA kit, Human 
adiponectin RIA kit, by Linco Research, Inc, Missouri USA). Precision of measurements was: 
CV= 5.7%, 5.1%, and 5.6%, respectively. Plasma glucose concentrations were measured ; 
using a glucose analyser (Glucose-Lactate analyser YSI 2300 Stat Plus, Analytical 
Technologies, Hampshire, U.K.). Precision of measurements was: CV= 2.5%.
4.2. Mathematical models for metabolic calculations
4.2.1. Mathematical model and calculation of VLDLi and VLDL2 absolute 
production rates and fractional catabolic rates
VLDLi- and VLDL2-triglyceride APR (g/day) and FCR (pools/day) were calculated using a 
model of VLDLi- and VLDL2-triglyceride kinetics (SAAM II program, SAAM Institute, 
Seattle, WA). The model used the GC/MS measured TTR for plasma glycerol and glycerol 
derived from VLDLi- and VLDL2-triglycerides, the MIRA measured VLDLi- and VLDL2- 
triglyceride concentrations and included a compartment for tracer recycling as previously 
described [25].
In short, the model represents the kinetics of the TTR profiles which change as labelled 
glycerol is removed from plasma and incorporated into the triglyceride fractions. The model 
assumes a steady state of native (unlabelled) glycerol throughout the experimental period, i.e. 
a constant appearance, disappearance, and incorporation of native glycerol into the 
triglyceride fractions. The incorporation of glycerol into VLDL by the liver is subject to a 
delay (Figure 4.5) [25]. The delay shown in the Figure 4.5 included two delay chains. The 
model included a compartment for VLDLi-triglyceride and a compartment for VLDL2-
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triglyceride with an input into both compartments from the glycerol precursor pool, a loss 
from each compartment and a transfer from the VLDL i -triglyceride compartment to the 
VLDL^-triglyceride compartment. In Figure 4.6, the sample of kinetics of 2H5-glycerol 
enrichment (TTR) in plasma VLDLj- and VLDL^-triglycerides after bolus injection was 
presented (data presented here derive from a subject included in the study).
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Figure 4.5. The multicom partmental model o f  2H5-glycerol kinetics in plasm a VLDLi 
and VLDL2- triglycerides after bolus injection, used in the SAAM  II program
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Figure 4.6. A sample o f  the SAAM II program kinetics o f2H5-glycerol enrichm ent (TTR) 
in plasma VLDL, and VLDL?- triglycerides after bolus injection
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VLDL-triglyceride kinetics was estimated according to SAAM II program derived indices 
VLDLi- and VLDLa-triglyceride FCRs (in pools/day).
VLDLi- and VLDL^-trigIyceride APRs (in mg/day), were calculated as the product of the 
VLDLi- and VLDL^-triglyceride FCRs and VLDLi- and VLDL^-triglyceride pool size:
APR (mg/day) =FCR (pools/day) x pool size (mg) [13]
and were expressed in relative terms (e.g. per kg BW, FFM, FM, REE).
Pool size was calculated as the product of the estimated total plasma volume and average 
plasma VLDLi- and VLDL^-triglyceride concentrations:
Pool size (mg)=plasma volume (ml) x VLDL-triglyceride concentrations (mg/dl)/l 0 [14]
Total plasma volume was calculated from BSA, according to Pearson’s equations [158]:
for women: plasma volume (ml) = BSA (ml/m2) xl395 [15]
for men: plasma volume (ml) -  BSA (ml/m2) xl578 [16]
BSA was estimated according to Du Bois' formula [159]:
WgM (cm) % wezgAf (%) " ™ x 0.0077^ /77/
Average VLDLi- and VLDL^-triglyceride concentrations (in mg/dl), were calculated as the 
mean of the values at 0 minute, 360 minute and 720 minute after bolus injection of glycerol, 
using the conversion factor 0.011 for transforming mmol/1 in mg/dl (where triglyceride 
concentrations (mg/dl) = triglyceride concentrations (mmol/l)/0.011 [114]).
VLDLi- and VLDL^-triglyceride absolute secretion rates (ASRs, in mg/ml plasma/day) were 
calculated as the product of the VLDLi- and VLDL^-triglyceride FCRs and VLDLi- and 
VLDLa-triglyceride plasma concentrations:
ASR(mg/ml plasma/day) =FCR (pools/day)x VLDL-triglyceride concentrations (mg/dl/10) [18]
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4.2.2. Calculation of fatty acid release and oxidation rates
During 90- 120 minutes of the 13C-palmitate infusion, a physiological and isotopic steady 
state was present and therefore, to calculate the palmitate Ra or Rd the Steele’s equation for 
steady state [2] was used:
Ra=Rd= F/TTR [19]
where F was the infusion rate of palmitate in pmol/min, and TTR was the increase in the ratio 
of U13C/U12C plasma palmitate during infusion, compared with background (the equations [1] 
and [12]).
The total plasma FFA Ra (a measure of lipolysis) was calculated by dividing palmitate Ra by 
the fractional contribution of palmitate to total FFA concentration. 13CC>2 production rate 
(^COiRa) from the infused palmitate tracer was calculated as:
/20/
where CO2 TTR is the breath 13C02/12C02 ratio at a given time point, VCO2 is carbon dioxide 
production (1/min), k is the volume of 1 mol of CO2 (24.466 1/mol at 25 °C and 101.325 kPa -  
the standard laboratory conditions [446]. The ARF was calculated as:
where F was the infusion rate of [l,2-13C]acetate (pmol/min) [87].
The fraction of infused [U-13C] palmitate oxidised was calculated as:
Fraction o f infused [U-13C] palmitate oxidised =(TTRC02*VC02)/(k*l 6F*ARF) [22] 
where F was the infusion rate of [U-13C] palmitate (pmol/min).
Total plasma FFA oxidation rate (TPFAO) was calculated as:
Total plasma FFA oxidation rate (pmol/min)=
= Rd FFA *(% o f infused palmitate tracer oxidised) [23]
Nonoxidative FFA disposal rate (pmol/min) was defined as the Rd FFA minus TPFAO.
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REE (kcal) was calculated from the rates of O2 consumption and CO2 production during 
steady state (measured by indirect calorimetry), according to the modified Weir equation [2] 
[434]:
ÆEE =7.44 *(7.77EC02(Z/^W+^ ^ ^ 2 ( 7 / /» ^  /24/
RQ was calculated by dividing steady state CO2 production rates by O2 consumption rates:
7^ 6 =EC02(Z/7»W /  EOjfZ/mW
4.2.3. Calculation of forearm FFA uptake and release
The exchange of metabolites across forearm was calculated by multiplying the arterio-venous 
concentration difference of metabolites (pmol/1) by forearm plasma flow (ml/100 ml forearm 
tissue/min). Forearm plasma flow was calculated as:
Forearm plasma flow (ml/100 ml forearm tissue/min) =
=forearm bloodflow (ml/100 ml forearm tissue/min) * (1 -haematocrit) [26]
Net forearm flux rate (pmol/100ml tissue/min) of plasma lipids (FFA, glycerol, total
triglycerides and total cholesterol) was calculated as the product of the venous (V) and 
arterialised (A) concentration differences (pmol/1) and plasma flow:
Net flux (VA difference) =(Cv-Cj) * plasma flow [27]
where Cy and Q  present a metabolite concentrations in venous and arterialised blood,
respectively.
(A positive net flux indicates release, a negative uptake).
The forearm fractional extraction (%FE) of palmitate was calculated by dividing the arterio­
venous concentration differences of [U-13C] palmitate by the arterial [U-13C] palmitate 
concentration (pmol/1):
= (Q  *77% x-Cr*2T7^/Cj *77%,
(A positive exchange indicates uptake, a negative release.)
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Palmitate uptake in muscle (pmol/100ml tissue/min) was calculated as the product of forearm 
plasma flow, arterial palmitate concentration and the fractional extraction of U-13C palmitate 
across the forearm:
Palmitate forearm uptake rate (pmol/100ml tissue/min) =
= %FE * C a( pmol/l) * plasma Flow [29]
Palmitate forearm release rate was than calculated as:
Palmitate forearm release rate (pmol/100ml tissue/min)=
^u p take  -  (Ca-C v)  * p la sm a  f lo w  [30]
4.2.4. Calculation of insulin sensitivity indices
Insulin sensitivity was estimated according to euglycaemic-hyperinsulinaemic clamp derived 
indices:
GIRSS : steady state Glucose Infusion Rate corrected for body weight (mg/kg/min) (between
150-180 min after the start of clamp infusion) [431]:
GIRSS (mg/kg/min) = Glucose Infusion Ratess(mg/kg/min) /  body weight (kg) [31]
MCRSS : steady state glucose MCR (ml/kg/min,) defined as steady state (150-180 min) glucose
infusion rate corrected for body weight (mg/kg/min) relative to the steady state blood glucose 
concentrations (mg/ml) [431]:
MCRSS (ml/kg/min) = GIRSS (mg/kg/min) /  blood glucose concentrationsss(mg/ml) [32]
and blood glucose (mg/ml)= blood glucose (mmol/l)*0.18
IS Ihec  : insulin sensitivity index derived from a hyperinsulinaemic-euglycaemic clamp 
(ml/kg/min per pU/ml), defined as steady state glucose MCR relative to the steady state 
increase in serum insulin concentrations (pU/ml) [431]:
IS Ihec  (ml/kg/minper pU/ml) =MCRSS (ml/kg/min)/ Aserum Insulinss (pU/ml)] [33]
where AI is the difference between basal and steady state plasma insulin concentrations 
(pU/ml) [431]:
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Aserum Insulin(pU/mL) = steady state Insulin (juU/mL)-fasting Insulin (pU/mL) [34] 
Additionally, based on fasting insulin (pU/ml) and fasting glucose (mmol/1), HOMA2 model 
indices of insulin sensitivity were estimated (HOMA2-IR, HOMA2-%S, HOMA2-%B [447] 
using the HOMA2 Calculator v2.2 (available at website: http://www.dtu.ox.ac.uk/homa), as 
well as hepatic insulin sensitivity index ISI-HOMA [448], which was calculated as:
ISI-HOMA = 22.5/(insulin(pU/ml) x glucose (pU/ml)) [35]
4.3. Study power calculations
In the study power calculation the hypothetical increase in REE on Rimonabant treatment was 
set up as a primary outcome of the study. That study power calculation was based on 
predicted weight loss after 12 weeks of Rimonabant treatment with unchanged dietary intake 
(about 2.5 kg, according to data from literature [393]. It was hypothesised that the change in 
weight loss would be due to changes in REE. Over 12 weeks REE would need to increase 
approximately 178 kcal/day to cause a weight loss of 2.5 kg [428]. Using the literature data on 
standard deviation (SD) of REE measurements [84], it was calculated that with 30 subjects 
recruited the study would have the 80 % probability at a two-sided 5 % level of significance 
of detecting those changes in energy expenditure. It was planned to recruit an extra 2 subjects 
in case of drop outs.
However, as Rimonabant was withdrawn from the EU market in October 2008, the trial had to 
be stopped. At that time only 14 subjects had completed the trial.
4.4. Statistics
Data analysis was performed using SPSS 16.0 (SPSS Inc., USA). Differences between the 
Rimonabant and Diet group in the baseline values of all examined parameters were analysed 
with Student’s two independent samples T test. Differences before and after different
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treatment were analysed with Student’s paired T test, while differences between different 
treatments’ results were analysed with Student’s two independent samples T test. Non- 
parametric data were logarithmically transformed before analysis. Associations between 
variable of interest were tested using the Pearson’s Rho coefficient of correlation. Values 
were reported as the mean ± SD, P-value as a number rounded up to 3 decimal places; 
statistical significance was assumed at a two-tailed P-value <0.050.
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CHAPTER 5. THE EFFECT OF RIMONABANT ON FREE FATTY 
ACID AND VLDL-TRIACYLGLYCEROL METABOLISM - 
RESULTS
All of the 14 recruited women completed the study. There were no serious adverse events. In 
the Rimonabant group there was a non-significant (NS) change in the Beck Depression Score 
after 12 weeks of treatment (1.86±0.46 vs. 3.43±1.02), but none of the subjects fulfilled the 
criteria for the study discontinuation (a score of 0-13 is categorised as minimal depression).
5.1. Anthropometric indexes and energy balance (Table 5.1)
The baseline anthropometric characteristics of the study participants and the changes after 12 
weeks of the different treatments are given in Table 5.1.
There was no significant difference between the Rimonabant and Diet group in the baseline 
values of all examined parameters (p>0.05 for all). Mean age in the Rimonabant group was 
58.1 years (range: 51-66) and 57.4 years in the Diet group (range: 52-64) (p=0.790). Mean 
BMI in the Rimonabant group was 32.9 kg/m2 (range: 29.9 -  34.9) and 33.0 kg/m2 in the Diet 
group (range: 29.8 -  34.0) (p=O.9O8) (Table 5.1).
As was planned, in the Rimonabant group the mean daily energy intake and daily AEE 
(expressed per kg BW) remained the same during the study: respectively, 22.4±3.0 and 
4.1±1.8 kcal/day/kg during the Run-In period, and 22.4±2.5 and 4.3±1.6 kcal/day/kg during 
the 12-week treatment period (p=0.919 and p=0.782, respectively).14 In the Diet group there
Only 2 subjects on Rimonabant treatment decreased their average energy intake, one by 100 kcal/day 
(subject R09) and one by 250 kcal/day (subject R10), while one subject increased average energy intake 
during the treatment by 250 kcal/day (subject R03). In the other subjects energy intake during Rimonabant 
treatment was the same as in the Run-In period (p=0.128), in average lower by 25±26 kcal/day (ranging from
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was a significant decrease in the mean daily energy intake during the intervention period 
compared with the Run-In period (22.8±2.7 vs. 19.Ü2.9 kcal/day/kg, p=0.001), while the 
AEE stayed the same during the study (6.5±3.5 vs. 6.0±3.0 kcal/day/kg, p=0.407). The 
average energy reduction in the Diet group was -341.6±144.2 kcal/day. Dietary intervention 
was based on a significant reduction in the intake of fats (-25.6%), mostly SEA (-25.0%) and 
MUFA (-20.8%), (p<0.02), while the intakes of PUFA, carbohydrates and proteins were 
reduced (by -20.0%, -14.0% and -6.4%, respectively), but not significantly.15 
In the Rimonabant group the average weight loss was 2.6±1.4 kg (-2.9=1= 1.6% of their initial 
BW and BMI, p=0.002), while in the Diet group the average weight loss was 3.1±2.8 kg (- 
3.7±3.3% of the initial body weight and BMI, p=O.O26), with no statistical difference between 
the 2 treatments (Table 5.1).
In 6 subjects in both groups data on body composition were obtained by BIA. There was no 
statistical difference in the effect of the 2 treatments on body composition. Subjects on both 
treatments lost more FM (in the Rimonabant group -1.8±0.6 kg, p=0.001, in the Diet group - 
2.7=62.5 kg, p=0.042) than FFM (in both Rimonabant and Diet group a non-significant change 
in FFM). This lead to a decrease in %FM in both groups (by -0.9=61.0 %FM, p=O.O6O, and - 
2.1=61.9 %FM, p=0.040) (Table 5.1).
In the Rimonabant group waist circumference decreased by -3.7=63.6 cm (p=0.036) and hip 
circumference by -1.5=64.6 cm (NS), while on the dietary treatment waist and hip 
circumference decreased by -5.9=64.7% (p=0.016) and -3.0=62.7% (p=0.027), respectively. 
WHR ratio did not change significantly in either group. There was no significant difference 
between the 2 treatments in the effects on anthropometries (Table 5.1).
-53 to +5 kcal/day), which would in 12-13 weeks period lead to average caloric deficit o f  2100-2275 kcal, 
leading to loss o f  0.27-0.29 kg FM (or 13% o f  the average FM loss o f  2.1±0.6 kg in those subjects).
(All data in this paragraph were presented in Katherine Backhouse’s PhD thesis [583])
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Table 5.1. Anthropom etric characteristics o f  the study participants (baseline values vs. values after 12
weeks o f  the treatments and the differences in the effects o f  the 2 different treatments: Rimonabant vs. Diet)
R IM O NABANT GROUP DIET GROUP
A treatment 
effect:
A RIMO. vs. 
A DIETn=7 n -7
0 weeks 12 weeks
P
value § 0 weeks 12 weeks
P
value § P  value *
Age (years) 58.1±4.9 - 57.464.9 - -
Body height (cm) 164.5±3.2 - 159.666.9 - -
BW  (kg) 89.065.9 86.465.6 0.003 84.267.8 81.168.1 0.027 NS
BMI (kg/m2) 32.961.9 31.961.9 0.003 33.062.0 31.861.9 0.027 NS
%FM (% )f 45.562.1 45.263.0 0.060 44.262.7 42.064.3 0.040 NS
FM (kg)t 40.263.7 39.164.2 0.001 36.965.4 34.2 66.8 0.042 NS
FFM (kg)f 48.263.4 47.363.0 NS 46.463.6 46.563.3 NS NS
Waist (cm) 108.567.2 104.865.3 0.036 107.2612.2 102.0611.5 0.016 NS
Hip (cm) 115.965.7 114.464.3 NS 112.467.0 109.468.1 0.026 NS
WHR 0.9460.09 0.9260.06 NS 0.9660.11 0.9360.11 N S N S
Data are presented as mean ±SD. BW: body weight; BMI: body mass index; FM: fat mass; FFM: fat free mass; 
WHR: waist to hip ratio.§- statistical significance o f  differences between baseline values and the values after 12 
weeks o f  the treatm en t;sta tistica l significance o f  the differences between the effects o f  2 different treatments; N S- 
non significant difference (p>0.05); f -  data obtained from 6 subjects in both groups (n=6)
5.2. Serum adipokines (Table 5.2)
In both groups serum leptin levels decreased and adiponectin levels increased significantly, by
-13.4±11.4% (p=0.028) and 16.2±13.8% (p=0.034) in the Rimonabant group, and -14.7±9.9%
(p=0.028) and 6.1±7.5% (p=0.043) in the Diet group, respectively, with no difference
between 2 treatments. The ratio between serum adiponectin and leptin levels [449] increased
136
significantly in both groups, by 35.9±22.7% (p=0.018) in the Rimonabant group and 
25.7±16.5% (p=0.018) in the Diet group (Table 5.2).
Table 5.2. Fasting levels o f serum  adipokines (baseline values vs. values after 12 weeks o f  the treatments and 
the d ifferen ces in the effects of the 2 different treatments: Rimonabant v s .  Diet)_____________
R IM O NABANT GROUP DIET GROUP
A treatm ent 
effect:
A RIM O . 
vs. A DIETn=7 n=7
0 weeks 12 weeks
P
value §
0 weeks 12 weeks
P
value §
P  value $
leptin
(ng/ml)
23.5±7.7 20.6*7.8 0.028 19.5*3.9 16.8*4.5 0.028 NS
adiponectin
(pg/ml)
10.4*4.2 11.8*4.1 0.034 10.8*4.7 11.3*4.7 0.043 NS
adiponectin /leptin 
ratio
0.48±0.22 0.67*0.39 0.018 0.59*0.31 0.75*0.40 0.018 NS
Data are presented as mean ±SD.
§- statistical significance o f  differences between baseline values and the values after 12 weeks o f  the treatm ent;$- 
statistical significance o f  the differences between the effects o f  2 different treatments; NS-non significant difference 
(p>0.05)
5.3. Fasting glucose, insulin and derived insulin sensitivity indices (Table 
5.3)
Fasting (8 a.m.) plasma glucose levels did not change in either group. In the Rimonabant 
group fasting insulin levels increased by 17.0±25.3% (NS), while in the Diet group fasting 
insulin decreased by -11.9±16.0% (p=0.081). The effect on fasting insulin was significantly 
different between the 2 treatments (p=0.026) (Table 5.3).
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Table 5.3 Fasting levels of plasma glucose, insulin and derived insulin sensitivity indices (baseline values vs.
values after 12 weeks of the treatments and the differences in the effects of the 2 different treatments:
Rimonabant vs. Diet) ________________________________ ________________________________ _________
R IM O N A B A N T  G R O U P D IE T  G R O U P
A treatm ent 
effect:
A RIM O . 
vs. A DIETn=7 n=7
0 w eek s 12 w eek s P
value 5
0 w eek s 12 w eek s P
value ®
P  value *
fasting plasma glucose 
(mmol/1)
5.56±0.53 5.43±0.27 NS 5.36=1=0.40 5.38=60.43 NS NS
fasting insulin (pU/ml) 19.6±13.1 21.5±13.2 NS 17.6±4.3 15.6=60.4 0.081 0.026
HOMA2- %S 62.6±46.2 51.5±29.5 NS 50.0±15.1 58.1=620.3 0.096 0.029
HOMA2- %B 135.0±59.0 149.3±55.1 NS 139.0±25.4 125.2=623.3 0.011 0.030
ISI-HOMA 5.7±4.3 7.4±2.8 NS 4.7=6!.6 5.4=62.2 0.028 0.048
Data are presented as mean ±SD. HOMA2: homeostasis model assessment-2; ISI-HOMA- hepatic insulin sensitivity 
index derived from homeostasis model assessment;
§- statistical significance o f  differences between baseline values and the values after 12 weeks o f  the treatment; *- 
statistical significance o f  the differences between the effects o f  2 different treatments; NS-non significant difference 
(p>0.05)
Insulin sensitivity indices derived from fasting glucose and insulin values and homeostasis 
model assessment-2, HOMA2-%S (an index of insulin sensitivity) and HOMA2-%B (an 
index of insulin secretion), in the Rimonabant group non-significantly decreased by - 
10.2±20.2% and increased by 17.2±29.1%, respectively, while in the Diet group those indices 
moved in the opposite directions: HOMA2-%S increased by 16.1±16.5% (p=0.096) and 
HOMA2-%B decreased by -9.7±6.9% (p=0.011). The difference between the 2 treatments in 
the effects on HOMA2 model derived indices was significant (p=0.029 and p=0.030, 
respectively for HOMA2-%S and HOMA-%B). Index of hepatic insulin sensitivity (ISI- 
HOMA) in the Rimonabant group decreased by -9.0±20.8%, while in the Diet group
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increased by 16.6±23.4% (NS in both groups). The difference between the 2 treatments in the 
effects on hepatic insulin sensitivity ISI-HOMA was significant (p=0.048).16
5.4. Hyperinsulinaemic-euglycaemic clamp (Table 5.4)
On the day when the hyperinsulinaemic-euglycaemic clamp (HEC) was performed (Test 1), 
baseline17 values of blood glucose showed changes in the opposite directions: in the 
Rimonabant group baseline glucose increased by 10.0±7.8% (p=0.017), while in the Diet 
group values of blood glucose decreased by -4.1±4.7% (p=0.057). Those effects were 
significantly different (p=0.002). Baseline insulin values in the Diet group decreased by - 
16.2±18.2% (p=0.047), while in the Rimonabant group the effect on insulin was variable and 
not significant. HOMA2-%S and ISI-HOMA in the Rimonabant group did not change 
significantly, while in the Diet group there was a significant improvement by -24.4±24.5% 
(p=0.040) and -29.4=1=28.1% (p=0.027). In the Diet group, HOMA2-%B did not change 
significantly, while in the Rimonabant group there was a significant decrease by -19.8±21.3% 
(p=0.046) (Table 5.4).
In the Rimonabant group, when the 2 subjects who reduced their energy intake were excluded from the 
analysis, HOMA2-%S and ISI-HOMA decreased significantly by -16.8±11.8%  (p=0.027) and -18.6±8.4%  
(p=0.012), respectively.
17 Clamp started about 3.5h later after fasting (8 a.m.) samples were obtained, thus subjects were fasting 
longer. Baseline insulin levels during the clamp were lower by 20% comparing with 8 a.m. samples obtained 
on test 3 (p=0.012).
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Table 5.4. Insulin sensitivity indices derived from hyperinsulinaemic-euglycaemic clamp (baseline
values vs. values after 12 weeks of the treatments and the differences in the effects o f the 2
different treatments: Rimonabant vs. Diet)_____________________________________ _______ _
R IM O NABANT GROUP DIET GROUP
A treatm ent 
effect:
A RIM O . 
vs. A DIETn=7 n=7
0 weeks 12 weeks P
value §
0 weeks 12 weeks P
value §
P  value *
HEC baseline blood 
glucose (mmol/1)
4.49±0.23 4.93±0.26 0.017 4.66=60.30 4.46=60.14 0.057 0.002
HEC baseline insulin 
(pU/ml)
17.0±8.4 14.9±6.4 NS 16.1=66.1 13.3=65.4 0.047 NS
HOMA2- %S 61.6±30.6 62.7=1=19.1.5 NS 60.0=622.3 73.9=630.1 0.040 NS
HOMA2- %B 187.2±52.2 146.5=b52.8 0.046 173.7=659.7 165.4=655.9 NS NS
ISI-HOMA 6.5±3.3 6.2=bl.9 NS 6.1=62.6 7.8=63.1 0.027 NS
Steady state GIR 
(mg/kg/min)
4.1±1.3 4.4± l .9 NS 4.1=62.01 4.7=62.31 NS NS
Glucose MCR 
(ml/kg/min)
4.7±3.0 4.8=63.4 NS 5.3=62.7 6.1=63.1 NS NS
IS Ih ec  (ml//kg/min) 
(pU/ml)-1
4.7±3.9 4.6=63.4 NS 6.2=63.1 6.6=63.5 NS NS
Data are presented as mean ±SD. HOMA2: homeostasis model assessment-2; ISI-HOMA- hepatic insulin sensitivity 
index derived from homeostasis model assessment; GIR: glucose infusion rate; MCR: metabolic clearance rate; ISIHec- 
insulin sensitivity index derived from hyperinsulinaemic-euglycaemic clamp; HEC: hyperinsulinaemic-euglycaemic 
clamp;
§- statistical significance o f  differences between baseline values and the values after 12 weeks o f  the treatment; *- 
statistical significance o f  the differences between the effects o f  2 different treatments; NS-non significant difference 
(p>0.05)
During the hyperinsulinaemic-euglycaemic clamp steady state glucose infusion rates (GIR) 
and glucose MCR (expressed per kg BW), as well as calculated insulin sensitivity index 
(ISIhec) did not change significantly (Table 5.4). In both groups the changes were highly 
variable between the subjects (e.g. for ISIhec varying from a decrease of -20.9% to an 
increase of 53.4% in the Rimonabant group, and a decrease of -40.8% to an increase of 81.4% 
in the Diet group)18.
During clamp in some subjects “steady state” (defined as a 30 minutes period 2.5-3 hours after initiation 
o f  insulin infusion, during which the coefficient o f  variation for blood glucose, plasma insulin, and GIR is 
less than 5%) was not achieved, contributing to the observed high variability.
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5.5. Fasting plasma lipids (Table 5.5)
In the Rimonabant group there was a significant decrease in venous fasting (8 a.m.) plasma 
FFA levels of -22.0±13.2% (p=0.028), while in the Diet group plasma FFA levels did not 
change significantly. The effect of Rimonabant of plasma FFA levels was on the border of 
statistical significance compared with the effect of the hypocaloric diet (p=0.073) (Table 5.5). 
Fasting plasma glycerol levels decreased by -15.3±16.2% in the Rimonabant group (p=0.091), 
while in Diet group increased by 13.7±40.4% (NS). The effects were not statistically different 
(Table 5.5).
Fasting plasma triglyceride levels in the Diet group significantly decreased by -22.3.6± 18.7% 
(p=0.022), while there was a non-significant increase in the plasma triglyceride levels of 
21.4±69.1% in the Rimonabant group (the medians before and after the treatment were 1.04 
and 1.40 mmol/1, respectively). The effects of the 2 treatments were not significantly 
different19 (Table 5.5).
Plasma total cholesterol and LDL-cholesterol values did not change significantly in either 
group. Plasma HDL-cholesterol levels in the Rimonabant group increased by 7.84=7.3% 
(p=0.031) and in the Diet group by 14.94=9.8% (p=O.OO5). The difference between the 2 
treatments in the effects on HDL-cholesterol did not reach statistical significance (p=O.O85) 
(Table 5.5).
When the 2 subjects in the Rimonabant group who reduced their energy intake were excluded from the 
analysis, the effects were significantly different (p=0.025).
141
Table 5.5. Fasting plasma lipids levels (baseline values vs. values after 12 weeks of the treatments
R IM O NA BANT GROUP DIET GROUP
A treatm ent 
effect:
A RIM O . vs. 
A DIETn=7 n=7
0 weeks 12 weeks P
value §
0 weeks 12 weeks Pvalue §
P  value *
Fasting FFA 
(mmol/1)
0.60=1=0.23 0.46=1=0.18 0.028 0.65=1=0.23 0.66=1=0.21 NS 0.073
Glycerol
(pmol/1)
146.9±40.9 124.1=1=44.3 0.091 131.5=1=35.2 141.5=1=31.6 NS NS
Triglycerides
(mmol/1)
1.6±1.5 1.7=1= 1.2 NS 1.2±0.2 0.9±0.3 0.022 NS
Cholesterol
(mmol/1) 5.6±1.2
5.4±2.0 NS 5.5±0.9 5.2±1.3 NS NS
LDL-cholesterol
(mmol/1)
4.23±1.32 3.86=1=1.98 NS 4.14±0.80 3.69^=1.20 NS NS
HDL-cholesterol
(mmol/1)
1.39=1=0.35 1.49±0.34 0.031 1.35=1=0.14 1.55±0.21 0.005 0.085
Data are presented as mean ±SD. FFA: free fatty acid; HDL: high-density lipoprotein; LDL: low-density 
lipoprotein;
§- statistical significance o f  differences between baseline values and the values after 12 weeks o f  the treatment; * -  
statistical significance o f  the differences between the effects o f  2 different treatments; NS-non significant difference 
(p>0.05)
5.6. VLDL- subfractions (VLDLi and VLDL2) lipid content (Table 5.6)
The concentrations of plasma VLDLi- and VLDLi-triglyceride in the Rimonabant group 
increased by 40.6±83.7% and 40.6±70.5%, respectively, but the effects did not reach 
statistical significance20. In the Diet group VLDLi- and VLDL^-triglyeeride levels decreased 
by -31.7±39.9% and -28.8.1±25.3% (p=0.097 and p=0.031, respectively). There was 
significant difference between the 2 treatments in the effects on plasma VLDLi- and VLDL2- 
triglyceride concentrations (p=0.037 and p=0.014, respectively) (Table 5.6).
In the Rimonabant group, when the 2 subjects who reduced their energy intake were excluded from the 
analysis, fasting VLDLi- and VLDL2- triglyceride concentrations increased significantly by 79.3±110.5%  
(p=0.034) and49.0=1=85.4% (p=0.019).
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Table 5.6. Fasting plasma VLDL-subfractions triglyceride and cholesterol content (baseline values vs.
values after 12 weeks of the treatments and the differences in the effects of the 2 different treatments:
Rimonabant vs. Diet)_______________________________ ________________________________ _______
R IM O NABANT GROUP DIET GROUP
A treatm ent 
effect:
A RIM O . vs. 
A DIETn=7 n=7
0 weeks 12 weeks
P
value §
0 weeks 12 weeks
P
value § P  value *
VLDLi-triglyceride
(mmol/1)
1.00±1.04 1.06±0.77 NS 0.65±0.12 0.42±0.23 0.097 0.037
VLDL2-triglyceride
(mmol/1)
0.22±0.16 0.27±0.06 NS 0.23±0.08 0.16±0.07 0.031 0.014
VLDLi-cholesterol
(mmol/1)
0.34±0.55 . 0.34±0.33 NS 0.15±0.03 0.11±0.05 0.097 0.025
VLDL2-cholesterol
(mmol/1)
0.23±0.22 0.22±0.19 NS 0.11±0.04 0.08±0.05 NS NS
Data are presented as mean ±SD. VLDL: very low-density lipoprotein;
§- statistical significance o f  differences between baseline values and the values after 12 weeks o f  the treatment; *- 
statistical significance o f  the differences between the effects o f  2 different treatments; NS-non significant difference 
(p>0.05)
The concentrations of plasma VLDLi- and VLDL^-cholesterol in the Rimonabant group 
increased by 90.1±167.5% and 65.4±155.3%, but this did not reach statistical significance21, 
while in the Diet group plasma VLDLi- and VLDL^-cholesterol concentrations decreased by - 
26.8±32.1% and -18.3±28.3% (p=0.097 and p=0.110, respectively). The effects of the 2 
treatments on VLDLi-cholesterol were significantly different (p=0.025) (Table 5.6).
5.7. VLDLi- and VLDL2 - triglyceride kinetics (Table 5.7)
In the Rimonabant group the APRs of VLDLi- and VLDL^-triglycerides increased by 
43.9=1=43.5% (p=0.045) and 42.6=1=58.7% (p=0.107), respectively. In the Diet group the APRs 
of VLDLi- and VLDL^-triglycerides decreased by -26.5=642.9% (p=0.141) and -20.7=636.3% 
(p=0.173), respectively. There was a significant difference between the 2 treatments in the 
effects on VLDLi- and VLDL^-triglyceride APRs (p=0.027 and p=0.033, respectively). The 
effects of treatment on VLDLi- and VLDL^-triglyceride FCRs were not significant in either 
group (there was heterogeneity in the responses of subjects to both treatments) (Table 5.7).
21 In the Rimonabant group, when the 2 subjects who reduced their energy intake were excluded from the 
analysis, there was a significant increase in fasting VLDLi- cholesterol by 134.7±182.7% (p=0.030)
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Table 5.7. VLDLi and VLDL2 -tr ig lyceride kinetics (baseline values vs. values after 12 weeks o f  the 
treatments and the differences in the effects o f  the 2 different treatments: Rimonabant vs. Diet)________
R IM O NA BANT GROUP DIET GROUP
A treatm ent 
effect:
A RIM O . vs. 
A DIETn=7 n=7
0 weeks 12 weeks
P
value §
0 weeks 12 weeks
P
value § P  value *
VLDLr TG APR  
(mg/kg/d)
281.9±137.7 375.9±190.1 0.045 229.9±59.5 154.6±78.0 NS 0.027
VLDL2-TG APR  
(mg/kg/d)
78.9±44.0 99.4±48.4 NS 94.5±48.2 67.2±41.4 NS 0.033
VLDLr TG FCR 
(pools/d)
14.6±6.2 16.2±8.4 NS 12.8±3.7 14.0±6.0 NS NS
VLDL2-TG FCR 
(pools/d)
13.4±3.7 13.5±2.7 NS 14.8±5.0 15.1±3.0 NS NS
Data are presented as mean ±SD. VLDL: very low-density lipoprotein; FCR: fractional catabolic rate, APR: 
absolute production rate;
§- statistical significance o f  differences between baseline values and the values after 12 weeks o f  the treatment; *- 
statistical significance o f  the differences between the effects o f  2 different treatments; NS-non significant difference 
(p>0.05)_____________________________________________________________________________________________________
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5.8. FFA kinetics
5.8.1. Steady state FFA and palmitate concentrations and TTR (Table 5.8.1)
There was a problem with obtaining arterialised and deep venous blood samples for some 
subjects both in pre- and post-treatment tests, and therefore A-V data could not be obtained 
for all subjects (arterialised blood was collected in 10 subjects and venous blood was 
collected in 13 subjects both pre- and post-treatment).
In both the Rimonabant and Diet group there was no difference before and after treatment in 
steady state plasma FFA and palmitate concentrations for arterialised and venous blood, or in 
the contribution of palmitate to total plasma FFA (Table 5.8.1).
5.8.2. Forearm palmitate kinetics (Table 5.8.2)
In 5 subjects in both groups forearm palmitate kinetics was examined. The values of oxygen 
saturation in the obtained arterialised and venous blood samples are given in Table 5.8.2. The 
values were in acceptable range (for arterialised blood HbO >90%, and deep venous blood 
HbO<60%) [90].
Blood flow and plasma flow did not change significantly in either group (Table 5.8.2). In the 
Rimonabant group there was an increase of 39.1% and 43.8% in forearm palmitate uptake and 
release rates, respectively. In the Diet group there was a decrease of -25.7% and -28.2% in 
forearm palmitate uptake and release rates. However, statistical significance in these effects 
was not achieved (Table 5.8.2).
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Table 5.8.1. Steady state FFA and palmitate concentrations (baseline values vs. values after 12 weeks of the
treatments and the differences in the effects of the 2 different treatments: Rimonabant vs. Diet) ___________
RIM O NABANT GROUP DIET GROUP
A treatm ent 
effect:
A RIM O . vs. 
A DIETarterialised n=5, venous n=6 arterialised n=5, venous n=7
0 weeks 12 weeks
P
value §
0 weeks 12 weeks
P
value § P  value *
arterialised. plasma 
SS FFA (pmol/1)
803.6±338.0 833.5±204.9 NS 670.7Ü10.5 692.8±195.0 NS NS
!
arterialised plasma 
SS palmitate (pmol/1)
139.3±36.7 143.0±41.3 NS 127.4±16.7 131.0±39.8 NS NS
arterialised plasma 
ratio [palmitate/total 
plasma FFA] (%)
18.2±3.2 17.1±2.7 NS 19.Ü1.4 18.9±2.3 NS NS
venous plasma SS 
FFA(pmol/l)
836.3±216.2 814.0±143.0 NS 800.7±245.1 807.5±221.4 NS NS
venous plasma SS 
palmitate (pm ol/l)
151.7±30.5 156.6±30.7 NS 138.6±24.6 144.3±40.0 NS NS
venous plasma 
ratio [palmitate/total 
plasma FFA] (%)
18.5±3.1 19.6±4.8 NS 18.0±3.4 18.1±3.6 NS NS
Data are presented as mean ±SD. SS: steady state; FFA: free fatty acids;
§- statistical significance o f  differences between baseline values and the values after 12 weeks o f  the treatment; *- 
statistical significance o f  the differences between the effects o f  2 different treatments; NS-non significant difference 
(p>0.05)
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Table 5.8.2. Forearm palmitate kinetics (baseline values vs. values after 12 weeks of the treatments and the
differences in the effects o f  the 2 different treatments: Rimonabant vs. Diet)
R IM O NA BANT GROUP DIET GROUP
A treatm ent 
effect:
A RIM O . vs. 
A DIETn=5 n=5
0 weeks 12 weeks
P
value § 0 weeks
12 weeks
P
value §
P  value *
arterialised blood 
oxygen saturation 
(%HbO)
9 3 .Ü 2 .8 91.4±3.7 NS 9 1 .9 Ü .9 92.662.7 NS NS
deep venous blood  
oxygen saturation 
(%HbO)
52.2±4.6 56.5±9.7 NS 49.6±9.5 56.5613.0 NS NS
forearm blood flow  
(ml/min/100 ml 
forearm tissue)
3.1±0.6 3.6±0.9 NS 3.5±0.9 3.461.2 NS NS
haematocrit (%) 39.3±1.7 39.5±1.8 NS 39.1±2.4 38.162.2 NS NS
forearm plasma flow  
(ml/min/100 ml 
forearm tissue)
1.9±0.4 2.2±0.5 NS 2.1±0.7 2.160.8 NS NS
palmitate forearm 
fractional extraction 
rate (%)
25.2±16.0 26.4±15.6 NS 37.3±11.8 31.7616.4 NS NS
palmitate forearm 
uptake rate 
(pmol/min/100 ml 
forearm tissue)
67.7±40.7 94.2±74.9 NS 92.7±16.8 68.8630.4 NS NS
palmitate forearm 
release rate 
(pmol/min/100 ml 
forearm tissue)
73.8±48.8 106.1±52.1 N S 120.8644.0 90.7654.3 NS NS
Data are presented as mean ±SD.
§- statistical significance o f  differences between baseline values and the values after 12 weeks o f  the treatment;$- 
statistical significance o f  the differences between the effects o f  2 different treatments; NS-non significant difference 
(p>0.05)
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5.8.3. Whole body plasma FFA kinetics- rates of appearance and oxidation 
rates (Table 5.8.3)
Using arterialised blood samples for studying whole body plasma FFA kinetics, paired pre- 
and post-treatment results were obtained in 5 subjects on Rimonabant treatment and in 5 
subjects on Diet treatment.
In the Rimonabant group the whole body palmitate Ra expressed in absolute terms, per kg 
FFM and kg FM increased significantly by 12.9±12.1% (p=0.039), 12.5±11.0% (p=0.030) 
and 20.9±17.5% (p=0.029), respectively. When palmitate Ra was expressed per kcal/min 
steady state REE, it increased non-significantly by 8.8±13.9% (p=0.133). In the Diet group 
there was no significant change in any of these measurements. There was no significant 
difference between the 2 treatments in the effects on palmitate Ra (Table 5.8.3).
Palmitate MCR expressed per kg BW, per kg FFA and per kcal/min increased by 16.5±13.4% 
(p=0.038), 13.1±13.3% (p=0.074) and 8.8±8.6% (p=0.038), respectively in the Rimonabant 
group, while in the Diet group there was no significant change. Non-oxidative disposal did 
not change in either group (data not shown).
In the Rimonabant group palmitate oxidation rates expressed in absolute terms and per kg 
FFM and kcal/min increased by 31.6=1=16.4% (p=0.103), 30.5=1=7.5% (p=0.052) and 
26.3=1=13.2% (p=0.041), respectively. There was no significant change in TPFAO in either 
group, even though a trend toward increase was noted in the Rimonabant group (Table 5.8.3). 
There was a significant difference in the effects on palmitate and total plasma FFA oxidation 
rates between 2 treatments. Statistical significance was achieved for palmitate oxidation rates 
expressed in absolute terms, per kg FFM and kcal/min steady state REE (p=0.040, p=0.020 
and p=0.039, respectively), and TPFAO expressed per kg FFM (p=0.034). For TPFAO 
expressed in absolute terms and kcal/min steady state REE there was a borderline statistical 
significance (p=0.058 and p=0.051, respectively) (Table 5.8.3).
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5.9. Steady state C02 production, 0 2 consumption, RQ, REE and ARF 
(Table 5.9)
Steady state measured CO2 production, O2 consumption, RQ and REE (estimated according to 
the Weir’s equation) did not change significantly in either group. CO2 production non- 
significantly increased in Rimonabant group22 by 3.2±5.3% (p=0.153) and decreased in the 
Diet group by -3.3±7.3% (p=0.267). The difference in the effect between the treatments did 
not achieve statistical significance (p=0.097), even when expressed per kg FFM (p=0.099). 
ARF in the Diet group increased by 6.9=1=12.2% (p=0.135), while in the Rimonabant group it 
decreased by -6.0±9.2% (p=0.172). The effect on ARF was different between the 2 treatments 
on the borderline of statistical significance (p=0.053) (Table 5.9).
In the Rimonabant group, C 0 2 production expressed per kg FFM decreased only in one subject who 
reduced its energy intake. When the 3 subjects who changed their energy intake during Rimonabnat treatment 
were excluded from the analysis, C 0 2 production expressed per kg FFM increased significantly by 6.4±2.9%  
(p=0.019).
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Table 5.8.3. Whole body palmitate and plasma FFA kinetics (baseline values vs. values after 12
weeks of the treatments and the differences in the effects o f the 2 different treatments:
Rimonabant vs. D ie t)_______________________ ____________________________ ___________
RIM O NABANT GROUP DIET GROUP
A t r e a tm e n t  
e f fe c t:
A RIM O. 
v s . A DIETn=5 n=5
0 weeks 12 weeks
P
value §
0 weeks 12 weeks
P
value §
P  value *
palmitate Ra 
(pmol/min) 143.6±41.9
159.63=36.2 0.039 124.83=30.6 131.23=53.0 NS NS
palmitate Ra 
(pmol/kgFFM/min)
3.01±0.80 3.383:0.76 0.030 2.753=0.93 2.833=1.20 NS NS
palmitate Ra 
(pmol/kgFM/min)
3.60±1.26 4.253=1.23 0.029 3.603=1.35 4.103=1.74 NS NS
palmitate Ra 
(pmol/kcal/min)
152.9±46.6 167.53=29.1 0.133 131.53=26.9 144.43=57.0 NS NS
palmitate MCR  
(pmol/min)
1062.5±365.3 1219.0±593.7 0.110 977.2±176.2 1000.5±352.0 NS NS
palmitate MCR  
(pmol/kgBW/min)
12 .U 4 .6 14.4±7.4 0.038 12.13=3.2 12.63=3.6 NS NS
palmitate MCR  
(pmol/kgFFM/min)
22.3±7.6 25.53=11.5 0.074 21.43=5.2 21.33=6.3 NS NS
palmitate MCR  
(pmol/kcal/min)
1128.9±396.9 1263.7±520.7 0.047 1028.0±109.7 1093.2±300.8 NS NS
palmitate oxidation 
rate (pmol/min)
43.5±7.5 53.33=13.8 0.103 43.93=3.5 39.13=10.7 NS 0.040
palmitate oxidation 
rate
(pmol/kgFFM/min)
0.91±0.12 1.123=0.27 0.052 0.963=0.14 0.843=0.25 NS 0.020
palmitate oxidation 
rate (pmol/kcal/min)
46.23=8.4 55.73=10.9 0.041 46.53=3.1 43.13=10.9 NS 0.039
TPFAO
(pmol/min)
249.53=81.6 326.63=135 0.143 2 3 1.53=34.8 208.6±60.6 NS 0.058
TPFAO
(pmol /kgFFM/min) 5.213:1.51
6.883=2.68 0.082 5.063=1.04 4.493=1.35 NS 0.034
TPFAO
(pmol /kcal/min)
265.6±90.1 338.4±117.6 0.089 244.3±20.5 22.8.73=52.9 NS 0.051
Data are presented as mean ±SD. Ra: rate o f  appearance; MCR: metabolic clearance rate; TPFAO: total plasma free 
fatty acid oxidation rate; FM: fat mass; FFM: fat free mass;
§- statistical significance o f  differences between baseline values and the values after 12 weeks o f  the treatment; - 
statistical significance o f  the differences between the effects o f  2 different treatments; NS-non significant difference 
(p>0.05)
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Table 5.9. Steady state COz production, 0 2 consumption, RQ, REE and ARF (baseline values VS.
values after 12 weeks of the treatments and the differences in the effects of the 2 different
treatments: Rimonabant vs. Diet)_____________ ______________________________________ _
R IM O NABANT GROUP D IET GROUP
A treatm ent 
effect:
A RIM O . 
vs. A DIETn=7 n=7
0 weeks 12 weeks
P
value § 0 weeks 12 weeks
P
value §
P  value *
C 0 2 production 
(ml/min) 160.6±18.6
165.3±17.1 NS 168.6±17.7 163.1±22.3 NS 0.097
C 0 2 production 
(ml/min/kgFFM)
3.4±0.4 3.5±0.3 NS 3.7±0.3 3.5±0.5 NS 0.099
0 2 consumption 
(ml/min)
204.0±16.4 205.0±24.6 NS 202.4±23.8 201.0±30.6 NS NS
0 2 consumption 
(ml/min/kgFFM)
4.3±0.3 4.3±0.4 NS 4.4±0.6 4.4±0.7 NS NS
RQ 0.79±0.06 0.81±0.05 NS 0.84±0.09 0.82±0.07 NS NS
steady state REE 
(kcal/min)
0.98±0.08 0.99±0.11 NS 0.98±0.11 0.97±0.14 NS NS
steady state REE 
(kcal/day/kgFFM)
30.6±2.9 31.1±3.9 NS 30.9±4.0 30.5±4.9 NS N S
Acetate recovery 
factor
0.18±0.01 0.17±0.02 NS 0.19±0.02 0.20±0.02 NS 0.053
Data are presented as mean ±SD. RQ: respiratory quotient; REE: resting energy expenditure;
§- statistical significance o f  differences between baseline values and the values after 12 weeks o f  the treatment; - 
statistical significance o f  the differences between the effects o f  2 different treatments; NS-non significant difference 
(p>0.05)
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CHAPTER 6. THE EFFECT OF RIMONABANT ON FREE FATTY 
ACID AND VLDL-TRIACYLGLYCEROL METABOLISM - 
DISCUSSION
6.1. The effects of the rimonabant treatment
The results of this study confirm that rimonabant has direct effects on peripheral metabolism, 
which are independent from its central effects on reduction in caloric intake, as stated in the 
hypotheses.
More importantly, this is the first study in humans that shows, by the use of stable isotopes, 
that rimonabant in obese subjects has food -  intake independent effects on whole body 
lipolysis, plasma FFA uptake and oxidation rates. Additionally, rimonabant influences 
glucose metabolism and VLDLi- and VLDLz-triglyceride production; it increases plasma 
HDL-cholesterol and serum adiponectin, and reduces plasma leptin levels. These effects were 
independent from the known central effects of rimonabant related to food intake, and some of 
these effects were also weight loss independent.
It is well known that rimonabant decreases appetite and food intake via central CB1 receptor 
blockade [374] [450]. In addition, there are gut CB1 receptors which also play an important 
role in food intake and satiety regulation [234] [332] [451] [452]. However, rimonabant
induces weight loss not only via its anorexigenic effects [285] [400] [453] [454] [455]. This
was shown previously by some studies in animals [196] [237] [259] [260] [273] [289] [338]
[372] [374] [375] [389] [456] [457] [458], and humans [298] [299] [393] [394] [395] [396]
[397] [398] [399], which have indicated that the metabolic effects of rimonabant are somehow 
greater than expected from the reduction in caloric intake [257] [293] [401] [402] [459] [460]. 
However, this study is the first study in humans that directly confirmed that weight loss is
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much higher than expected for the reduction in calorie intake52. For example, the average 
caloric reduction in this study was about 25 kcal/day in subjects on the rimonabant treatment 
who kept their energy intake similar as in the Run-In period, and this could explain only 13% 
of the average FM loss in these subjects (e.g. 0.28-0.29 kg of 2.1 kg FM loss). The remaining 
87% of FM loss had to be attributed to the direct effects of rimonabant on basal metabolism. 
Notwithstanding that there could be insecurities related to the food diary methodology used 
[422] [461] and the validity of self-reported food consumption data and a possibility of 
underreporting24 [298] [422] [462] [463] [464], the other findings from this study support the 
conclusion that rimonabant has a direct effect on peripheral metabolism [401], which can lead 
to a reduction in body weight and FM.
One of the most important findings of this study is that rimonabant in humans has direct 
effects on plasma FFA release, uptake and oxidation rates, examined in vivo by use of stable 
isotopes kinetic approach, and these effects were independent from negative energy balance 
and weight loss.
The direct effect of rimonabant was a significant increase in whole body palmitate release 
rates (expressed in absolute terms and per kg FM), indicating higher lipolysis rates from fat 
tissue. This higher palmitate lipolysis was followed by a higher palmitate uptake rate 
(expressed per kg FFM), and higher palmitate MCR (expressed per kg BW and per kcal/min 
REE). Additionally, the forearm palmitate release and uptake rates tended to be increased, 
indicating a possible higher fatty acid turnover rate in the forearm skeletal muscle [107]. Even 
though in the diet group a significant reduction in whole body palmitate release was not 
shown, there was a trend towards decreased palmitate turnover in the forearm region caused 
by the hypocaloric diet, which was opposite to the effect of rimonabant.
This part of the study belongs to the Katherine Backhouse’s PhD thesis work [583].
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Although there were no significant changes in REE and RQ measured during the steady state, 
palmitate oxidation rate expressed per kcal/min REE significantly increased on the 
rimonabant treatment (while when expressed per kg FFM tended to be statistically 
significant). Moreover, the effect of rimonabant on palmitate oxidation rate (expressed in 
absolute terms, per kg FFM and kcal/min REE) was significantly different from the effect of 
the hypocaloric diet. The same was shown for TPFAO (expressed per kg FFM, while the 
difference for TPFAO expressed in absolute terms and kcal/min REE approached statistical 
significance). On the hypocaloric diet there was a trend towards a decrease in palmitate and 
total plasma FFA oxidation rates, but this was not statistically significant.
These results univocally indicate that the effects of rimonabant on palmitate and plasma fatty 
acid release, uptake and oxidation rates are direct (food intake independent), and at least some 
of them (e.g. oxidation rates) are also opposite from the effects of the hypocaloric diet.
To the author's knowledge, there are no other published data on the effect of rimonabant 
treatment on palmitate oxidation rates in humans. However, the results here are in accordance 
with previously published findings in animals [273], which showed the changes in liver, 
muscle, WAT and BAT indicative for increased fatty acid oxidation.
Only one recently published study in humans with abdominal obesity and metabolic 
syndrome, the VICTORIA trial [293], directly examined the effect of rimonabant on insulin 
suppression of FFA flux, as representative for insulin sensitivity of adipose tissue. This Phase 
4 randomised trial included 48 subjects on a hypocaloric (-600 kcal/day) diet combined with 
rimonabant (20 mg/day, N=21) or placebo (N=27), treated for 1 year. Similar improvements 
in the effect of insulin to suppress lipolysis were observed after diet alone and diet plus 
rimonabant treatment, even though the weight loss was greater with rimonabant (-11.03=4.4 vs. 
-7.43=9.4 kg). The post hoc regression analysis revealed that the improvements in the adipose 
tissue insulin suppression of lipolysis after rimonabant treatment was directly correlated with 
changes BMI and was independent from the type of treatment [293].
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In this study we did not observed changes in RQ, REE, CO2 production and O2 consumption, 
which is in contrast with previous studies in animals, which showed increased REE [237] 
[260] [273] [310] [338] [342] [381] [382], and some of them either decreased RQ (indicative 
of increased fat oxidation) [335] [338], or increased RQ (indicative of increased carbohydrate 
oxidation) [256] [317], but in agreement with others which did not observe those changes 
[196]. To the authors' knowledge, only 2 studies in humans examined the effect of rimonabant 
on energy expenditure. In a Phase 2 clinical trial with rimonabant (PDY3796) [385], 
involving 45 obese subjects, energy expenditure was measured in a calorimetric chamber at 
baseline and after a 4-week treatment with rimonabant 40 mg/day (without control of caloric 
intake) or placebo. Differences in energy expenditure were not shown between the 2 
treatments, while the average weight loss in the rimonabant group after 6 weeks was -4.33=1.8 
kg (and in the placebo group was -1.73=1.7 kg). In the VICTORIA trial, where the average 
weight loss was -11.03=4.4 kg after 12 months of rimonabant treatment combined with a 
caloric reduction (-600 kcal/day), the REE decreased, while RQ did not change [293]. The 
effect was not different compared with the effect of the diet (on diet alone the average weight 
loss was -7.43=9.4 kg). In one recent study in humans with a new CB1 receptor inverse agonist 
taranabant, the acute administration of the drug significantly increased REE and decreased 
RQ, indicating increased fat oxidation [383].
Rimonabant had also effects on VLDLi- and VLDL2-triglyceride production rates, which was 
independent from its central effects on food intake. In this study VLDLi-triglyceride 
production rate was increased by rimonabant (while VLDL2-  triglyceride production rate 
tended to be increased), and these effects were opposite from the effects of the hypocaloric 
diet. In regard to VLDLi- and VLDL2-triglyceride FCRs, there was heterogeneity in the 
responses of subjects after both treatments. The results presented here are in agreement with 
previous results from the study in animals examining VLDL-triglyceride production and 
showing an increased VLDL secretion [256], but do not confirm the results from a study
183
examining VLDL plasma clearance in animals, which showed an increased VLDL plasma 
clearance [328]. To the author's knowledge, no results from human studies on VLDLi- and 
VLDLa-triglyceride kinetics have been reported previously. One registered clinical trial [465], 
enrolling 64 abdominally obese patients with additional cardiometabolic risk factors 
(increased triglycerides and/or decreased HDL-cholesterol) was prematurely terminated, and 
the results have not been published.
Surprisingly, fasting triglyceride, VLDLi- and VLDL^-triglyceride levels, as well as VLDLi- 
and VLDLz-cholesterol levels, were not decreased by the rimonabant treatment in this study. 
Instead, they tended to be increased, which was significantly different from the effect of the 
hypocaloric diet. Since VLDLi- and VLDL^-triglyceride FCRs were not significantly 
changed, this indicates that augmented fasting triglyceride and VLDLi- and VLDL2- 
triglyceride levels were related to the increased VLDLi- and VLDL2-triglyceride production 
rates, without comparably increased clearance rates. This is in contrast with some previous 
findings in humans, where fasting triglycerides were significantly decreased, and that 
decrease could not be fully accounted by the weight loss [298] [299] [393] [394] [395] [396] 
[401] [466]. However, there are also results in humans which are in line with the findings 
presented here [293] [404]. In one recently published human Phase 4 trial (CARDIO- 
REDUCE) [404], involving 222 subjects with abdominal obesity and hyperglycaemia (or type 
2 diabetes), randomised to placebo or rimonabant for 1 year, without a strict hypocaloric diet 
(only a lifestyle counselling was offered at baseline, at 3-month and 6-month visits), in which 
the average weight loss (-4.0 ±5.9 kg) was significantly greater than in placebo group (- 
0.2±3.3 kg), the effect of rimonabant to lower plasma triglycerides was small and 
significantly less than in subjects on placebo [404]. In the VICTORIA trial [293], where the 
reduction in body weight after the rimonabant treatment was significantly greater compared 
with the reduction after the diet alone, the reduction in plasma triglycerides was not different 
between the 2 treatments, and the effect of rimonabant on triglycerides was fully accounted by
the weight loss. In most of the previous animal studies, plasma triglycerides levels were 
decreased after rimonabant treatment [256] [259] [284] [318] [333] [334] [338] [388] [389], 
as were VLDL-triglyceride and VLDL-cholesterol levels [328] [333], although in some 
studies plasma triglycerides did not change [338] [386], and in some they even increased 
[256], as a consequence of increased VLDL secretion [256].
It was previously shown that plasma VLDLi- and VLDL^-cholesterol levels are correlated 
with plasma VLDLi- and VLDL^-triglyceride levels and their production and clearance rates 
[297] [299] [467], as well as with LDL-cholesterol concentrations and metabolism [297] 
[299] [467], indicating that their metabolism is closely inter-related, and this was also 
confirmed by the correlation results presented in this thesis (data presented in Appendix, the 
section on correlations).
Total cholesterol and LDL-cholesterol in plasma were not significantly changed in this study. 
This is in accordance with the previous studies in humans, which did not show the changed 
plasma levels of LDL-cholesterol [297] [299], but showed increased size of LDL-particles, 
indicating the reduction in contribution of small dense atherogenic LDL-particles when 
rimonabant administration was combined with the reduction in caloric intake [297] [299]. 
However, in some trials in humans also reduction in total cholesterol was noted [293].
Previous studies in humans showed a significant increase in plasma HDL-cholesterol 
concentrations, which was higher than the amount of weight loss would have predicted [299] 
[393] [394] [395] [396] [466]. In this study, HDL concentrations were significantly increased 
by the rimonabant treatment, despite maintaince of energy intake. However, this study did not 
manage to confirm that rimonabant itself has a direct effect on HDL-cholesterol which is 
more beneficial compared with the effect of a hypocaloric diet, since the increase in HDL- 
cholesterol concentration following the hypocaloric diet was no different compared to the 
increase after the rimonabant treatment. In the VICTORIA trial, a non significant decrease in 
HDL-cholesterol was noted [293].
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In the present study, fasting 8 a.m. FFA and glycerol levels were decreased, but 3.5 hours 
later, the steady state measured FFA levels were unchanged. It is possible that the prolonged 
fasting and resting in subjects influenced the difference [415] [468]. Therefore, the effect of 
rimonabant on decreased plasma FFA levels was not continually observed, which is in 
agreement with the studies in animals, which showed a decrease [237] [334] [338] [388], no 
change [289], or even increase [335] [338] [389] in plasma FFA levels. In animal studies also 
plasma glycerol levels were significantly lower or unchanged [289].
Rimonabant without caloric reduction increased adiponectin levels, but this effect was not 
different compared with the effect of the hypocaloric diet. This contrasts the previous studies 
in vitro and in vivo, in animals [196] [256] [260] [273] [326] [334] [389] and humans [297] 
[299] [397], which have indicated that the increase in adiponectin levels following rimonabant 
treatment was not fully accounted by the weight loss [260] [297] [299] [397]. However, there 
are some studies in cultured adipocytes [265], animals [292], and humans [293], in which the 
effect on adiponectin production was not observed [265], or was fully accounted by changes 
in food intake and body weight [292] [293]. Additionally, in this study rimonabant also 
reduced plasma leptin levels, and this effect was most probably due to the reduction in body 
weight and FM, since the effect was not different from the effect of the hypocaloric diet. This 
is in agreement with other studies on rimonabant in animals [237] [256] [273] [334] [388] 
[389] [390] [391] and humans [293] [297] [396], or other studies which indicate that total 
body FM is the most important predictor of circulating leptin levels in sex matched subjects 
[469] [470]. In addition, in one study in vitro, rimonabant was not shown to directly influence 
the production of leptin in cultured adipocytes [265]. In this study, the ratio of adiponectin to 
leptin in serum increased consequently with no difference in the effect between the 2 
treatments. In a previous study, this ratio has been shown to correlate well with measures of 
insulin resistance and components of metabolic syndrome, but was shown to have an only
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marginally better predictive significance in estimating the presence of insulin resistance or 
metabolic syndrome, compared with its components alone [449].
The effect of rimonabant on glucose metabolism was intriguing. Fasting (8 a.m.) plasma 
glucose level were not changed, and fasting serum insulin levels did not decrease, which is a 
contrast to what could be expected according to some previously published data on the effect 
of rimonabant on glucose (in animals [256] [284] [389] and humans [299] [393] [394] [396]) 
and insulin (in animals [196] [255] [256] [284] [334] and humans [298] [299] [393] [394]
[395]), which showed reductions. However, in some animal and human studies glucose levels 
were unchanged [388] [395], or even increased [386], and the same increases were also 
described for insulin [386]. Similarly, in this study insulin level tended to increase, which led 
to a non-significant increase in HOMA2-%B and decrease in ISI-HOMA and HOMA2-%S, 
the effects which were completely opposite to the effects of the hypocaloric diet. When the 2 
subjects who had decreased their caloric intake in the rimonabant group were excluded from 
the statistical analysis, the ISI-HOMA and HOMA2-%S decreased significantly, indicating 
that insulin suppression of hepatic glucose output was diminished with rimonabant treatment 
without caloric restriction. This contrasts with most findings in humans [393] [394] [395]
[396] and animals [256] [389] on HOMA-IR, but not all, since in some studies no additional 
improvements apart from those related to body weight loss were observed [293].
The insulin sensitivity indices derived from hyperinsulinaemic-euglycaemic clamp, which is 
predominantly a measure of insulin stimulated glucose disposal [471] (75-80% of which is in 
muscle [341]), were not significantly changed, which was different from the expectations 
based on the other studies results, although not on all [256] [326]. In some previous studies in 
vitro and in vivo in animals, glucose uptake into the cells (in muscle, adipocytes, hepatocytes) 
and whole body glucose disposal rates were increased [317] [334] [342], and in some were 
decreased by rimonabant [256] [265]. In the VICTORIA trial, the improvements in glucose
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disposal were not significantly different between the 2 treatments even without accounting for 
the differences in weight loss [293].
Interestingly, although no changes were found in the fasting 8 a.m. plasma glucose levels, 
when the hyperinsulinaemic-euglycaemic clamp was performed (3.5 h later), the baseline 
blood glucose levels were increased by the rimonabant treatment, and this was significantly 
different from the effect of the hypocaloric diet (which tended to decrease the levels of 
baseline blood glucose). This was in contrast with previous studies in humans and animals, 
which have shown a decrease in fasting glucose levels [256] [284] [389], and a decrease in 
hepatic glucose production [472]. In the VICTORIA study, the insulin sensitivity in regard to 
hepatic glucose production did not change significantly, since there was a significant 
heterogeneity in the responses, and the changes in hepatic insulin resistance were in a positive 
correlation with changes in BMI [293]. In this study the pancreatic beta-cell function and 
insulin secretion, estimated from HOMA2-%B model, was significantly decreased by 
rimonabant treatment, which is in accordance with some [262] [363] [364], but not all [234], 
in vitro and animal in vivo data. Insulin sensitivity estimated from ISI-HOMA and HOMA2- 
%S models was not changed significantly. The HOMA derived insulin sensitivity indices 
reflect the degree of hepatic insulin sensitivity, since fasting insulin and glucose values are 
mostly determined by the hepatic glucose output and compensatory beta-cell secretion.
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6.1.1. The underlying mechanisms
The main finding of this study is that rimonabant increased whole body palmitate release, 
uptake and oxidation rates, and there are several possible underlying mechanisms: 1) the 
higher oxidation rates and increased demands for the supply of fatty acids determined the 
increased lipolysis rates in this study; or 2) the higher lipolysis increased palmitate uptake and 
oxidation in muscle and liver, the main fatty acid consumers during postabsorptive conditions 
[473]; or 3) both processes were independently stimulated by rimonabant.
The results from the previous studies in vitro and in vivo in animals point toward 
simultaneous stimulation of lipolysis and fatty acid oxidation. Moreover, the rate of plasma 
palmitate (and other FFA) uptake in the cells is determined mostly by the palmitate 
concentration gradient between plasma and intracellular tissue. Therefore palmitate release 
and oxidation rate are the major determinants of the palmitate uptake, explaining the 
increased uptake and metabolic clearance with the rimonabant treatment. However, a possible 
direct influence of rimonabant on fatty acid transporters (as it was shown FAT/CD36 in 
hepatocytes [317]), acylation stimulating protein (ASP) [474] and lipid droplet proteins [273] 
[289] [475] [476], and/or some other factors which control the plasma fatty acid uptake and 
intracellular storage [88] [114], can not be excluded .
The underlying mechanism explaining the increased palmitate oxidation and release rates 
could involve multiple pathways.
The effect on rimonabant on peripheral metabolism could be related both to its central effects 
(including the central modulation of some humoral and neural factors included in peripheral 
metabolic control, which are unrelated to the modulation of food intake) and its peripheral 
effects, by acting on peripheral tissue CB1 receptors.
In regard to the latter, rimonabant can act: 1) directly on the CB1 receptors expressed in the
effector cells; 2) on the CB1 receptors expressed in the other structures in the tissue which are
important for the metabolic control of the effector cells (e.g. sympathetic and parasympathetic
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afférents and efferents); 3) it can act on some “remote” peripheral tissues, which then by 
humoral and neural factors communicate with the effector cells (the inter-tissue “cross-talk”).
It is well known that rimonabant can have some central effects [450] which are food intake 
independent, which could affect peripheral metabolism [477] through brain -  other tissues 
(adipose tissue, liver, pancreas, muscle) “cross talk”. This could be conducted through both 
hormonal influences and innervation. For example, CB1 receptors have been found expressed 
in hypothalamus, pituitary, thyroid gland, and possibly in the adrenal gland [194]. CB1 
blockade stimulates the hypothalamic-pituitary-adrenal axis (HPA) [389], by increasing 
hypothalamic CRH, but also by directly stimulating ACTH production at the level of pituitary 
[194] [389] [478]. Apart from this stimulatory effect on the HPA axis (and therefore cortisol 
release), rimonabant can also have stimulatory effects on the hypothalamic-pituitary-thyroid 
(HPTh), hypothalamic-pituitary-gonadal (HPG), hypothalamic-growth hormone (HGH) and 
hypothalamic-prolactin axes (HPr) [194], and all of them are involved in the regulation of 
energy balance.
Additionally, rimonabant can influence metabolism in the periphery (in WAT, BAT, pancreas 
liver, muscle) by neural activation, via its central CB1 receptors, involving both autonomic 
sympathetic and parasympathetic nervous system (SNS and PNS) modulation [194], as well 
as the effect on increased locomotor activity [256] [386]. For example, it is know that 
sympathetic innervation of WAT can modulate lipolysis and lipogenesis, the expression of 
adipokines and chemokines, local insulin sensitivity, glucose and fatty acid uptake, while 
parasympathetic innervation of WAT has an anabolic effect and stimulates fat growth [479].
It is possible that effects of rimonabant on energy expenditure and peripheral metabolism are 
mediated in a large part via its sympathetic activation through the action on CB1 receptors in 
the CNS [456] [480]. It has been shown that rimonabant, through its modulation of several 
hypothalamic active peptides which are involved in energy balance and metabolism, by 
mechanisms other than regulation of food intake (e.g. via increased sympathetic tone or other
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humoral influences), can increase energy expenditure, increase fat oxidation (in liver and 
muscle), thermogenesis (in BAT), increase glucose uptake (in muscle), increase lipolysis (in 
WAT and BAT), decrease lipogenesis (in liver and WAT), and decrease lipid accumulation in 
liver, WAT and muscle [194] [195] [273] [274] [382] [477] [480]. These neuropeptides 
(including CRH, leptin, POMC, opioids, alpha-MSH and melanocortin system, CART, MCH, 
NPY, AgRP, orexins, ghrelin, CCK and GLP-1), through their food intake independent 
effects, mediated via sympathetic activation, can in WAT, BAT, liver and muscle change the 
levels of ACC, FAS, SCD-1, LPL, CPT-1, UCP-1 and UCP-2 [234] [389]. This would then 
influence glucose and fatty acid uptake, oxidation and storage in the form of glycogen and 
triglycerides.
Additionally, rimonabant has been shown to cause an anxiogenic response in animals [256] 
and humans, and to increase ambulatory activity in animals [256] [386], although the latter 
was not uniformly confirmed [196]. These effects can also contribute to the increased energy 
dissipation and contribute to the weight loss. Additionally, in animals rimonabant was shown 
to increase gut motility [256], thereby reducing the time of food passage and decreasing the 
food assimilation, which can also contribute to its weight-reducing effect.
The direct effects of rimonabant on the effector cells in metabolically active tissues have 
already been described. CB1 receptors, as well endocannabinoids and enzymes involved in 
their synthesis and degradation, have been shown expressed in adipocytes, hepatocytes, 
myocytes, and pancreatic beta-, alpha- and delta- cells [194] [195] [196] [197] [198] [200] 
[241] [262] [342] [481], and some of the rimonabant effects demonstrated in this study could 
be meditated through the direct blockade of those receptors.
For example, by blockade of CB1 receptors in adipocytes, rimonabant could increase WAT 
and BAT lipolysis, beta-oxidation, glycolysis, thermogenesis, decrease lipogenesis, reduces 
adipocytes size and lipid accumulation, enhance adipocyte differentiation and inhibit 
proliferation [273] [274]. By blockade of CB1 receptors in hepatocytes, rimonabant could
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increase hepatic beta-oxidation and ketogenesis, decrease lipogenesis, hepatic lipid 
accumulation, endoplasmatic reticulum stress and intracellular damage, VLDL-triglyceride 
production and secretion, increase glycolysis, and decrease gluconeogenesis and glucose 
secretion [315] [329] [330] [331] [332].
Those effects could be mediated via adenylate cyclase dependent stimulation of cAMP 
formation [262], stimulation of adiponectin production and secretion [262], activation of 
AMPK by adiponectin and PDK-1 [316] and LKB-1 [315], down-regulation of PPAR-gamma 
expression [270] [275], up-regulation of PPAR-alpha expression [315], down-regulation of 
SREBP-lc and its targets [315], and mechanisms which involve a complex intracellular 
signalling cascade, including activation of MAPK, ERK1 and ERK2 [315], PI3K/PKB(Akt), 
LXR-alpha, mTORCl, and possibly some other mechanisms [315].
The anti-lipogenic effect of rimonabant in adipose tissue could be mediated by the inhibition 
of PPAR-gamma expression [262], inhibition of LPL activity and expression [482], inhibition 
of lipid deposition (by down-regulation of triglyceride forming enzyme DGAT-2) and 
inhibition of de novo lipogenesis (by down-regulation of the lipogenic enzymes SREBP-lc, 
ACC1, FAS, SCD-1) [196] [270] [275]. In the liver rimonabant also decreases the expression 
of the lipogenic enzymes SREBP-lc, ACC1, FAS, SCD-1 [316], and ABCA1, the key protein 
included in cholesterol efflux, HDL formation and VLDL-triglyceride secretion [316]. 
Additionally, rimonabant through its action on the SREBP-lc pathway could up-regulate the 
LDL/apoB 100-receptor in the liver and thus enhance VLDL and LDL catabolism and plasma 
clearance [327] [328].
In adipose tissue, by activating adenylate cyclase type III and production of intracellular 
cAMP [262], and subsequent activation of PKA, rimonabant can stimulate lipolysis directly, 
causing the phosphorylation and activation of HSL and inhibition of perilipin-1 [289]. 
Additionally, it was shown that rimonabant can also increase the expression of HSL and 
decrease the expression of perilipin-2 in SAT, indicating possible long-term adaptation [273]
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[284] [289]. It can also augment lipolysis by induction of beta-3 adrenergic and GH receptors 
in adipose tissue, and by decreasing degradation of catecholamines by decreasing the 
expression of COMT [273]. Additionally it can stimulate noradrenaline release from the 
sympathetic neurons in adipose tissue, by acting on presynaptic CB1 receptors [256].
The studies in vitro and in vivo in animals have shown that rimonabant can increase beta- 
oxidation in WAT, BAT, liver and muscle. Muscle and liver are the main fatty acid 
consumers during postabsorptive conditions [473] [483], while the contribution of BAT and 
WAT in total body fat oxidation in humans is much lower. However, rimonabant could also, 
through its action in WAT and BAT, contribute to the increased fatty acid (and glucose) 
oxidation rates, the increased oxidative phosphorylation, the increased uncoupling of 
oxidative phosphorylation and thermogenesis [387] [484] [485] [486], leading to weight loss.
It was already described that rimonabant can increase the liver, muscle, WAT and BAT beta- 
oxidation by increasing expression of enzymes involved in fatty acid activation and 
mitochondrial transport (ACSL, CAT and CPT-1 and CPT-2) [316] [318]. It can also 
increase liver ketogenesis by induction of HMGCS2 [315]. It can stimulate energy 
consumption and basal metabolism also through the induction of enzymes involved TCA 
cycle, mitochondrial biogenesis [302], mitochondrial oxidative phosphorylation and the 
respiratory chain 1 [290] [302] [317] [318] [475]. It can as well, by inducing UCP-1, UCP-2 
and UCP-3 mRNA expression in WAT, BAT, liver and muscle [270] [275] [300], stimulate 
the uncoupling of oxidative phosphorylation and proton leak [302] [318] [475], therefore 
increasing thermogenesis and energy dissipation [387] [484] [485] [486]. Furthermore, it can 
also increase energy dissipation and contribute to weight loss by induction of the substrate 
(calcium and glycogen) “futile cycles”.
Additionally, it can increase the effect of thyroxine (T4) on thermogenesis and lipolysis by the 
induction of the type II deiodinase, the enzyme involved in conversion and thus activation of 
T4 to T3 in BAT.
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Rimonabant can also stimulate glucose metabolism in muscle and adipose tissue, by 
increasing glucose uptake (through stimulation of GLUT-4) and induction of the enzymes 
involved in glucose trapping (glucokinase), glycolysis, glucose flux into the mitochondria and 
synthesis and breakdown of glycogen [265] [317] [343]. Additionally, it can decrease hepatic 
glucose production, by modulating enzymes involved in glycogenolysis [308] and 
gluconeogenesis [337]. Furthermore; rimonabant can increase liver insulin clearance and 
degradation, by increasing expression of the insulin degrading enzyme [308], while in 
pancreas it can decrease insulin secretion [234].
Rimonabant may also act through the increased FFA release (caused by increased lipolysis) 
and the modulation of the expression of adipokines and chemokines in adipose tissue. This 
way it can influence the activity of other (“remote”) tissues (e.g. liver, skeletal muscle, 
pancreas), as well exert local autocrine and paracrine effects in adipose tissue. Its effects on 
beta-oxidation stimulation in liver and muscle could be in part mediated through its 
modulation of the expression and activity of adiponectin (increasing the production of high 
molecular weight (HMW) adiponectin) [326], and its effects on AMPK and PPAR-alpha 
[487]. It can also modulate directly leptin production and secretion from adipocytes [273], as 
well increase the leptin sensitivity (not only CNS, but also in peripheral tissues, including 
WAT, BAT, liver and muscle), consequently augmenting the leptin mediated anti-lipogenic 
and lipolytic effects, and its effects on increased beta-oxidation in muscle and liver. It was 
shown that leptin can directly activate AMPK in muscle and liver, and AMPK activation in 
turn inhibits fatty acid synthesis and stimulates fatty acid oxidation and glucose uptake [488] 
through the effects on ACC1, ACC2 and PPAR-alpha [488].
Apart from its effects on leptin and adiponectin, rimonabant can modulate the secretion of 
TNF-alpha [294] [295], IL-6 [270] [275] [296], visfatin [270] [275] [296], resistin [296], PAI- 
1 [273], CRP [273], fibrinogen [297], MPC-1 [293], RBP-4 [296], ghrelin [295], adipsin
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[273], apelin [270] [273], spotl4 [273], and some other factors, and this way can influence 
insulin sensitivity and other processes through the inter-tissues “cross-talk” [392].
6.1.2. The possible explanations for the observed discrepancies with some 
previous studies in humans and animals findings.
Several findings of this study were in accordance with previous published findings on the 
effects of CB1 blockade (rimonabant) in humans and animals, including the effect on weight 
reduction independent of caloric intake, the effect on fatty acid release and oxidation, 
adiponectin and leptin levels, and in part for HDL-cholesterol levels [401] [489] [490]. 
However there are discrepancies between this study and some other human studies regarding 
findings for glucose metabolism (fasting glucose and insulin levels [298] [299] [393] [394] 
[395] [396], HOMA-IR [393] [394] [395] [396]) and metabolism of lipids (fasting plasma
triglycerides [297] [298] [299] [393] [394] [395] [396] [466], and partly for HDL-cholesterol
levels - the effect tended to be lesser compared with the hypocaloric diet effect [297] [299] 
[393] [394] [395] [396] [466] [491]). Additionally, the majority of data in animals on these 
metabolic variables, including fasting glucose [256] [284] [389], insulin [196] [255] [256] 
[284] [334], HOMA-IR [256] [389], triglycerides [256] [259] [284] [318] [333] [334] [338]
[388] [389], HDL-cholesterol [164] [371], as well as VLDLi- and VLDL^-triglyceride and
VLDLi- and VLDL^-cholesterol levels [328] [333] and insulin sensitivity estimated by a 
hyperinsulinaemic-euglycaemic clamp [317] [334] [342], are also in a conflict with this study 
findings.
The possible explanation for this discrepancies relies on the fact that subjects in this study did
not change their caloric intake, while in other human and animal studies they did, and weight
loss in all human studies with rimonabant [297] [298] [299] [393] [394] [395] [396] was
much greater than in this study. It is well confirmed [392] [412] [415] [492] [493] [494] that
in obesity the increased fat reserves and resistance to antilipolytic action of insulin in fat
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tissue are related to the increased FFA supply to the metabolically active tissues (e.g. liver, 
muscle), which stimulates fat oxidation (as well as accumulation of fat) in these tissues at the 
expense of carbohydrate oxidation, therefore limiting the use of carbohydrates [107] [355] 
[494] [495] [496]. This concept was firstly proposed by Randle 1961, and nowadays is 
established and extended by numerous studies [107] [412] [493] [494], and the correlation 
data in this study (data are presented in Appendix, the section on correlations) also support it. 
Therefore, the increased fatty acid release and oxidation rates are related to increased hepatic 
fatty acid supply, increased VLDLi- and VLDL^-triglyceride production [125] [472] [497] 
[498] [499], and increased gluconeogenesis and hepatic glucose output [355] [412] [494] 
[500] [501] [502], indicating increased hepatic insulin resistance [355] [494] [500] [503], and 
can be related to increased oxidative damage, accumulation of the reactive oxygen species 
and other by-products of fat metabolism which have been confirmed to negatively influence 
function and insulin sensitivity in hepatocytes [355] [415]. In muscle, the increased FFA 
supply interferes with glucose uptake (e.g. decrease GLUT-4 translocation), oxidation 
(glycolysis and mitochondrial oxidation) and glycogen formation [83] [355] [412] [494] 
[504]. In pancreas, acute FFA elevation stimulates insulin secretion, while chronic FFA 
elevation impairs and diminishes insulin release [412] [494]. Elevated FFA supply and 
accumulation of fat in other stores apart from adipose tissue (e.g. in liver, pancreas, skeletal 
muscle) is most often (but not necessarily [505]) related to dysfunction of these tissues (also 
known as “lipotoxicity”) [494] [495] [496] [506]. On the contrary, after a higher loss of FM 
and weight stabilisation, the reduced fat reserves would be more sensitive to antilipolytic 
actions of insulin, and the fatty acid supply would be reduced, therefore the insulin sensitivity 
would improve [412] [413] [493] [507] [508] [509]. If body fat reserves are not diminished 
(because e.g. food intake and AEE are not changed), and lipolysis, FFA supply and oxidation 
are stimulated (e.g. during the rimonabant treatment in this study), the increased endogenous 
fatty acid supply to liver could overcome the positive effects of the drug in the liver to reduce
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fatty acid synthesis and decrease glucose output, which are mediated via its direct actions on 
hepatic CB1 receptors [49] [329] [510] [511] [512]. If food supply (especially of dietary fat) 
is diminished, and body fat reserves are reduced, then the fatty acid supply will be lower and 
would not overcome the direct positive effects of the drug in the liver. The results of the 
subjects in this study who decreased their energy intake while they were on the rimonabant 
treatment, also confirm this explanation.
In line with this study findings, there are some studies in animals [256] [338] [388] [386] and 
humans [293] [404], which did not show that rimonabant improved the metabolic profile. 
Additionally, there is a possibility that some people in the population could be higher 
responders to CB1 blockade, which is probably regulated by genetic polymorphisms in the 
CB1 receptor [513] [514] [515] [516], but also by the level of obesity (especially abdominal 
obesity) [270] [329] [513] [514] [515] [516]. It was shown that intracellular localisation of the 
CB1 receptor and endocannabinoids, which highly influences the receptor function, can be 
directly determined by the degree of obesity [329].
Furthermore, in the current study significant changes in RQ, REE, CO2 production and O2 
consumption, which is in contrast with previous studies in animals, which showed increased 
REE [237] [260] [273] [310] [338] [342] [381] [382], and some of them showed decreased 
RQ [335] [338], or increased RQ [256] [317]. One of the possible explanations for these 
discrepancies in the results could be that the accuracy and precision of the method for 
measurement of CO2 production and O2 consumption in this study did not allow such changes 
to be observed. However, there is a possibility that species differences in the metabolic effects 
could exist [293]. For example, adrenergic beta-3 receptors have more important functions in 
rodents than in humans [517], and rimonabant mediates at least some of its effects trough 
increased activation of beta-3 receptors [289]. Similarly, the role of BAT in thermogenesis 
and energy balance is more important in animals than in humans [518] [519] [520], and this 
could be one of the possible explanations why rimonabant in animals could have more
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beneficial effects, through its stimulatory effects on beta-oxidation and thermogenesis in BAT 
[273] [300] [301]. Moreover, animals treated with rimonabant had anxiogenic effects, which 
could increase locomotor activity, as shown by some studies where rimonabant increased 
ambulatory activity [256] [386], although not all [196], while in humans this was not shown, 
and increased anxiety would lead to the drug discontinuation [293]. Furthermore, in treated 
animals the measured tissue concentrations of rimonabant were much higher than in humans 
(indicating several times higher doses for animals [293] [329].
The possible explanation for the discrepancies with the findings from the VICTORIA trial 
[293], is that the decrease in FFM was much higher in that trial (-4.0 kg), and it was probably 
related to the observed significant reduction in REE. The changes in FFM in the rimonabant 
group in this study were much smaller (-0.3 kg in average), and were in a direct correlation 
with the changes in observed REE (data not shown).
6.2. The effects of the hypocaloric diet
Evidence exist that a hypocaloric diet, depending on FFM reduction, can lead to a decrease in 
REE and fat oxidation, as well some additional metabolic adaptations to conserve energy and 
reduce energy dissipation [293] [409] [410] [411] [521]. While the effect of the hypocaloric 
diet on the improvement in cardiometabolic risk is well documented [522] [523] [524], a 
decreased REE and reduced fat oxidation after a weight-loss programme, could increase the 
risk of weight regain when an individual returns to a regular diet [525]. Nevertheless, in some 
studies REE and fat oxidation rates expressed by kg FFM were not changed after the caloric 
restriction. In the present study, there was an average caloric deficit of -342 Kcal/day in 
subjects on the hypocaloric diet53. This did not reduce significantly the steady state CO2 
production, O2 consumption, RQ, or REE expressed in absolute terms or per kg FFM. When 
in this study REE was measured on another day by indirect calorimetry and results were
53 Details on caloric reduction are presented in Katherine Backhouse thesis [583].
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corrected by data on urinary nitrogen excretion (to account for protein oxidation), REE 
significantly decreased in the diet group when expressed in absolute terms, but when 
expressed per kg BW or kg FFM, this difference was not anymore significant.54 This is in 
agreement with some previous studies [409] [414], but contrasts the others [409] [410] [411] 
[414] [521] [526] [527] [528] [529]. It is possible that weight loss induced by caloric 
restriction in this study was too small to lead to the notable changes in REE, or our 
methodology was not sensitive enough to detect those changes. The reduction of -342 
Kcal/day in 12-13 week period would lead to loss 3.7 kg body weight, what is indeed 
observed in this study. In the other studies weight loss was significantly greater, as well was 
the loss in FFM [88] [414] [530], for example in the VICTORIA trial it was -3.0 kg FFM 
[293], and in the present study it was only 0.2 kg, and this can explain the discrepancies in the 
findings, since FFM is one of the main predictors of REE [531] [532].
Some studies indicated that dietary treatment, because of reduced total and visceral fat 
amount, could lead to a decrease in the plasma FFA Ra and circulating FFA levels [533] 
[534] [535]. However, this was not shown in this study.
After the diet, plasma FFA and palmitate concentration in this study did not change both in 
deep venous and arterialised blood, contrasting some [414], but not all [409] [411] [528], 
previous findings. The plasma concentrations of FFA are highly variable, influenced by many 
other factors [78] [415] [468], not only by the body fat reserves, and therefore do not always 
correlate with the amount of total fat and visceral fat tissue stores. In this study, the changes 
in FFA concentrations were inversely correlated with changes in body weight and FM loss, 
indicating that a higher FM loss was related to a higher FFA supply (data not shown). 
However, resting FFA concentrations measured at only one time point are not very 
representative of the FFA availability [528]. Additionally, in some other studies weight loss
54 Details are presented in Katherine Backhouse thesis [583].
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and FM reduction were significantly higher [411] [414] [528], leading to more overt loss of 
FM [528]. In the current study subjects on the diet on average lost 2.7 kg of FM.
In line with this discrepancy with other studies regarding FFA concentrations [530], in the 
present study the palmitate Ra did not change, which contrasts with findings in other studies 
[293] [530] [536] [537]. Following a weight loss after a hypocaloric diet, a significant 
improvement in the anti-lipolytic action of insulin has been shown, which was in a direct 
correlation with the decrease in BMI and FM [293]. The reduction in lipolysis rates with 
caloric reduction was attributable to the reduced HSL expression and activity, and the effect 
was independent from the fat depots characteristics [535]. However, the weight loss in the 
mentioned studies was significantly higher [528] compared with the present study (e.g. in the 
VICTORIA trial the average FM loss in the diet group was -4.6 kg [293]), and the subjects in 
other studies were weight stabilised at least for 2 weeks [414] [528], while in the present 
study subjects were continuously on the diet, and it is known that negative energy balance can 
increase lipolysis rates [538].
The present study also did not show that palmitate oxidation rate was significantly decreased 
with the hypocaloric treatment, although a trend was noted, which is in agreement with some 
[530], but in contrast with other findings on fat oxidation [528]. A reduction in palmitate 
oxidation rate could be a consequence of changed local tissue neural and humoral (i.e. 
hormonal and substrate) milieu after the negative energy balance and significant weight loss 
(e.g. lower sympathetic activity [539] [540] [541], decreased plasma T3 [542], or decreased 
fatty acid availability due to decreased lipolysis rates and body fat stores [409] [483] [528]), 
which can decrease the expression and activity of enzymes involved in beta-oxidation. In a 
study of subjects with type 2 diabetes [530] [543], after a weight loss of 15.3 kg with a very 
low calorie diet, a trend towards a decrease in plasma FFA oxidation was noted, but the 
amount of muscle oxidative enzymes (hydroxyacyl-CoA dehydrogenase (HADH) and citrate 
synthase) did not significantly change.
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According to some studies, whole body and (forearm) muscle plasma fatty acid uptake would 
be expected to decrease after a hypocaloric diet [536]. This could be a consequence of both 
reduced FFA supply [530] and reduced beta-oxidation rate [536]. Forearm muscle FFA 
release could be slightly decreased also as a result of reduced intramuscular triglyceride 
content. However, this study did not show that the forearm muscle uptake and release, as well 
as the whole body palmitate uptake and metabolic clearance, were changed after the diet, 
although a trend towards a decrease in the former was noted. As it was previously mentioned, 
the FFA uptake in peripheral tissue is mostly determined by the palmitate concentration 
gradient between plasma and the intracellular matrix, and the concentration gradient is 
determined by the rate of FFA oxidation and intracellular re-esterification and incorporation 
in intracellular lipids, as well by the rate of the lipolysis of these intracellular lipid depots. 
Additionally, there could be influence of other factors, such as fatty acid transporters, ASP, 
proteins involved in lipid droplet formation, etc. [88] [530]. Since in the current study neither 
FFA release nor FFA oxidation significantly changed, the finding that FFA metabolic 
clearance did not change is not surprising. A decreased fatty acid uptake per kg FFM in 
diabetic subjects was described by Blaak and co-workers [530] [543], after a weight loss of 
15.3 kg with a very low calorie diet, while the skeletal muscle cytosolic FABPc, which is 
involved in control of the skeletal muscle FFA uptake, was non-significantly increased [114]. 
This could mean that FABPc protein increased as a compensatory mechanism for decreased 
FFA supply, indicating the metabolic adaptations.
The ARF did not change significantly after the dietary treatment, which is in agreement with 
the previous finding by Blaak and co-workers [530]. ARF is mostly determined by the %FM 
(negatively), REE (in absolute terms and expressed by kg FFM) and RQ (positively) [42], and 
neither of those variables was changed in a greater degree after the dietary treatment in this 
study. The small decrease in %FM could lead to a non-significant increase in ARF, as it was 
observed.
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It is well confirmed that reduced energy intake reduces the intrahepatocellular and 
intramyocellular lipid content55. The reductions could lead to beneficial metabolic changes 
observed after the hypocaloric diets [507] [544], including the improvements in insulin 
sensitivity of peripheral glucose uptake and suppression of hepatic glucose output, and the 
decrease in fasting glucose and insulin levels and HOMA2-IR [409] [411] [530] [545]. 
Nevertheless, in the present study a significant increase in the insulin sensitivity of glucose 
disposal, estimated by the hyperinsulinaemic-euglycaemic clamp, could not be demonstrated, 
which is an agreement with some studies, in which the non-oxidative glucose disposal was 
not significantly changed [411]. In the present study the weight loss was modest, which can 
explain why significant changes in the insulin sensitivity of glucose disposal could not be 
demonstrated. The improvements in glucose disposal, estimated by ISI-clamp and GIR, were 
directly correlated with the improvements in plasma triglycerides, VLDLi- and VLDL2- 
triglyceride concentration, and reductions in their secretion and clearance rate (data not 
shown). In the VICTORIA trial [293], the improvement in glucose disposal rate did not 
correlate with the degree of body weight and FM loss in the diet group (indicating that the FM 
loss was not the main determinant of the increased insulin stimulated glucose uptake).
The current study confirmed that even a small body weight (-3.7 kg) and FM (-2.7 kg) loss, 
after a hypocaloric diet could cause a significant improvements in metabolic risk factors, 
including fasting insulin, glucose, triglycerides and HDL-cholesterol, which are all important 
components of the metabolic syndrome. Additionally, the significant improvements in insulin 
secretion, hepatic insulin sensitivity and hepatic glucose output were achieved (as estimated 
by fasting insulin levels and ISI-HOMA). Moreover, the changes in FM caused by the dietary 
restriction were in direct correlation with the improvements in fasting glucose, insulin and 
HOMA2-IR (data not shown), which is in agreement with some previous studies [536] [545]
55 In this study the amount o f  intramyocellular and intrahepatocellular lipid content was not significantly 
reduced after the hypocaloric diet. This is mostly because the weight loss in this study was quite modest, and 
the small number o f  the participant involved in MRI analysis probably did not allow the eventual changes to 
be observed. Details on IHCL and IMCL are presented in Katherine Backhouse thesis [583].
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[546]. On the contrary, in the VICTORIA trial [293], the improvement in insulin suppression 
of hepatic glucose production was not significant after a more pronounced body weight- and 
FM loss (-7.4 kg and -4.6 kg, respectively), and the effects only tended to correlate with the 
changes in BMI, while the changes in regional fat depots were not associated at all [293].
After the dietary restriction VLDLi- and VLDLi-triglyceride secretion rate could be expected 
to decrease [168], even though no change or even an increase have been also described [536],: 
while VLDLi- and VLDL^-triglyceride metabolic clearance rate could remain the same, 
although a decrease [171] [467] and an increase [467] have been described as well. The 
decreased VLDLi- and VLDL^-triglyceride production, together with unchanged (or 
increased) clearance, would lead to decreased fasting circulating triglycerides, VLDLi-and 
VLDL^-triglyceride and VLDLi- and VLDL^-cholesterol levels [547]. HDL-cholesterol levels 
would change in the opposite direction (even though there are some contradictory findings 
[544]), while LDL-cholesterol could remain the same, or could decrease, depending on the 
contribution of certain fatty acids and other factors in the diet [547] [548] [549] [550] [551] 
[552] [553]. Eventually the proportion of small dense LDL-particles could be expected to 
decrease [467] [554] [555] [556] [557]. The results of this study were in agreement with the 
above mentioned findings, indicating that even small dietary changes could lead to significant 
health improvements. The underlying mechanisms are related both to the decrease in FM (and 
thus endogenous fatty acid supply) and to the reductions in dietary (exogenous) fatty acids 
supply [558], and improvements in insulin sensitivity. In this study, the improvements in 
fasting triglycerides, HDL-cholesterol, VLDLi- and VLDL^-triglycerides and cholesterol, as 
well as VLDLi- and VLDL^-triglyceride APRs and FRCs, were in a direct correlations with 
the reduction in FM and leptin, the improvements in fatty acid release and oxidation rates, and 
with the improvements in fasting glucose, insulin and insulin sensitivity, estimated by clamp 
and HOMA2 model (data not shown). In another study [536], only a third of the decrease in 
VLDLi- and VLDL^-triglyceride APR after weight loss (one year after gastric surgery) was
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related to decreased systemic FFA Ra, while two thirds were related to decreased non- 
systemic sources, and the latter was inversely related to the changes in leptin levels.
According to the published data [559] [560] [561], after the dietary treatment the circulating 
levels of leptin were expected to decrease, in parallel with the decrease in FM, while the 
levels of adiponectin were expected to increase, or to remain the same. Indeed, in the present 
study, both a decrease in leptin and an increase in adiponectin were found. The changes in 
leptin were in a positive correlation with the changes in FM and %FM, as well with the 
changes in insulin and HOMA2 model insulin sensitivity indices, while in negative 
correlation with plasma FFA levels, TPFAO and VLDLi-triglyceride FCRs (data not shown), 
indicating that decreased leptin levels could be related to increased FFA and VLDLi- 
triglyceride clearance. Indeed, it was shown that leptin decreases lipid accumulation and LPL 
activity in adipose tissue [562], but not all studies confirmed the latter finding [563], and 
some findings also showed that leptin could also stimulate LPL activity in muscle in 
postprandial conditions [564], as well as in macrophages [562]. Additionally, leptin can 
augment the hepatic clearance of triglyceride rich lipoproteins by stimulating hepatic 
expression of lipid transporter lipolysis-stimulated lipoprotein receptor (LSR) [565]. 
Therefore, the role of leptin in VLDLi-triglyceride clearance is still an uncertain issue. In one 
study [536], changes in leptin were in a negative correlation with VLDL-triglyceride ASR (in 
pmol per liter plasma per min, which represents the amount of VLDL-triglyceride secreted by 
the liver per unit of plasma). Leptin influences beta-oxidation and lipogenesis in liver by 
inhibiting SCD-1, the main controlling enzyme which shifts metabolism towards lipogenesis 
and re-esterification, and blocks beta-oxidation [566] [567] [568] [569] [570] [571]. With 
body weight loss, leptin decreases, and leptin resistance improves not only in CNS, but also 
on periphery, including its actions in liver, muscle and fat tissue [536]. Therefore, after a 
weight loss in obese individuals leptin could be more efficient in its insulin sensitizing, anti- 
lipogenic and weight reducing effects [566] [567] [568] [569] [570] [571].
The effect of diet on adiponectin was inversely related with the decrease in FM and %FM, 
and positively with changes in plasma FFA (data not shown), which is in agreement with 
previous studies [545] [546] [559] [572] [573] [574] [575]. Adiponectin was shown to be 
correlated inversely with the insulin resistance and the presence of metabolic syndrome [575], 
and was shown to be more intensely secreted from small, insulin sensitive adipocytes, than 
from large, hypertrophic cells [576]. The effect on control of adiponectin secretion could be 
mediated through decreased production of TNF-alpha and IL-6 after weight loss, since those 
adipokines were shown to directly influence its expression, translational modification and 
secretion [576]. Additionally a decrease in endoplasmatic reticulum stress could through 
specific intracellular pathways, which involve different signalling kinases, increase the 
production of adiponectin in adipocytes [576]. Adiponectin was shown to have insulin 
sensitizing properties, and was related to AMPK and PPAR-alpha activation, thus stimulating 
glucose uptake, oxidation and fat oxidation, and decreasing hepatic glucose production [576]. 
However, in this study no correlations were found between the increase in adiponectin levels 
and improvements in insulin sensitivity or lipid metabolism parameters (data not shown). 
Therefore the importance of adiponectin involvement in those processes remains unclear.
6.3. Study limitations
Lastly, it is important to have a critical view on the methodology used in this study and
possible study limitations. The number of participants involved meant the study was
underpowered, and therefore questions can be raised regarding the validity of the study
conclusions. The methods used for palmitate kinetics and VLDL-triglyceride kinetics require
at least 6-10 subjects in a paired study design, and to compare differences between the groups
at least 12-20 subjects per group [116]. It was originally planned to recruit 16 subjects in each
group, but because of the suspension of the EU marketing authorisation for rimonabant,
recommended by the European Medicines Agency (EMEA) in October 2008 [483], the study
205
was prematurely terminated, without recruiting the number of the subjects in the original 
study design. There is a high intra-individual intra- and inter-day variability in plasma FFA, 
glycerol, triglycerides, insulin and derived HOMA2 model indices [468] [577] [578], and 
therefore a much higher number of study participants is required to make more reliable 
conclusions regarding these measurements [468]. This high intra-individual variability is 
likely because of the pulsatile and circadian mode of appearance of these variables in 
circulation. It is well confirmed that some of these biochemical variables, e.g. insulin, 
glycerol, FFA, show plasma oscillations in 10-20 minutes intervals, related to their pulsatile 
secretion [78] [468], and their close relation to the level of physical activity, food intake and 
fasting duration [415] [468]. This could lead to misinterpretation of data, and therefore more 
samples and precisely defined conditions of sampling are required [468]. Additionally, the 
data on validation of this study methods (data presented in Appendix), demonstrated that a 
higher intra-individual variability could be also related to some other clinical measurements 
(e.g. blood flow and CO2 production). However, the validation of the laboratory methods in 
the pilot studies (data presented in Appendix) revealed an acceptable reproducibility. 
Additionally, the study was designed to reduce the possible confounding effects of inter-day 
and inter-assay variability. The detailed study protocol tried to ensure that the fasting 
duration, the previous evening’s last meal caloric value and nutrient composition, as well the 
physical activity 3 days prior the study, were not significantly changed between the pre- and 
post-treatment tests. Furthermore, the samples storage conditions were precisely defined, pre- 
and post-treatment samples were analysed in one laboratory assay, and the quality control 
standards were run each time when the samples were run on GC/MS, in enzymatic and in RIA 
assays.
Even though all these preventive measures were undertaken, the results from the present study 
still need to be interpreted with a caution, having in mind the limited participants’ number and 
a high intra-individual variability of the measured variables. In addition, recent data have
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suggested that polymorphism of CB1 receptor gene (CNR1) could predispose some subjects 
for metabolic syndrome [513] [514] [515] [516], indicating that some people could have more 
pronounced and beneficial effects of rimonabant (or other CB1 blockers) administration. 
Also, the findings from some studies indicate that there is an overactivity of endocannabinoid 
system in visceral obesity [260] [262] [267] [270] [299] [304] [305] [329] [335] [383], and 
therefore the subjects with metabolic syndrome and visceral (“android type”) could be better 
responders for CB1 blockade treatment. Since all this suggests that there could be a high 
variability in the response to the CB1 blockade treatment, additional studies, including more 
subjects and comparing the effects of CB1 blockade in different obesity phenotypes, are 
recommended.
6.4. Conclusion
In conclusion, this study confirmed that rimonabant administration in humans increased fatty 
acid oxidation and release, and this may be the mechanism for the weight loss achieved 
during rimonabant treatment, when there was no change in food intake. The study was 
underpowered to make concrete conclusions for the other examined parameters, but the 
results imply that rimonabant per se does not improve the cardio-metabolic profile, 
independently from the weight-loss effect. Additional studies, possibly with new peripheral 
CB1 receptors antagonists in development for humans [329] [335] [579] [580] [581] [582], 
and with larger numbers of participants involved, are needed to confirm the peripheral effects 
of CB1 blockade in humans, which are independent of the reduction in food intake.
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CHAPTER 7. THE EFFECT OF GENDER ON FREE FATTY ACID 
AND VLDL-TRIACYLGLYCEROL METABOLISM -  
INTRODUCTION
7.1. Introduction
Multiple epidemiological data have showed that women of premenopausal age are at a lower 
risk for cardiovascular morbidity and mortality, particularly of coronary heart disease (CHD), 
than men of the same age [1] [2] [3] [4] [5]. However, after menopausal transition in women, 
the risk for developing metabolic abnormalities and the risk for negative outcomes of 
cardiovascular diseases increases, and women could be at a greater risk than men [6] [7] [8] 
[9] [10] [11] [12] [13]. Mortality data show that up to the age of 45-50 years women are at 
relatively lower risk of coronary death, compared with men [14]. Data have shown that 
women of reproductive age have a 3-5 times lower rate of myocardial infarction mortality 
than men, but this difference in the risk reduces after age of 65 [14], and there is on average a 
10-year difference between men and women in terms of when coronary manifestations first 
occur [4] [14]. The prevalence of the metabolic syndrome components, including 
dyslipidaemia (hypertriglyceridaemia, low HDL, increased small dense LDL-particle number, 
low apoAI and high apoB), insulin resistance, glucose intolerance and diabetes mellitus type 2 
and hypertension, which all contribute to the risk for atherosclerosis and myocardial 
infarction, is lower in premenopausal women, compared with men of the same age and degree 
of obesity [15] [16] [17] [18] [19] [20], even though the epidemiologic data showed that the 
prevalence of obesity, which represents a risk itself, is equal or even higher in the same age 
premenopausal women than men [12] [21]. Therefore, for the same degree of obesity (defined 
as BMI), women have lower risk for developing metabolic complications (including 
dyslipidaemia, insulin resistance, diabetes mellitus and myocardial infarction) [17] [22]. For
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example, women of black ethnicity have increased risk for type 2 diabetes (impaired glucose 
tolerance) if their BMI exceeds 30 kg/m2, while in men of black ethnicity, that risk increases 
if their BMI exceeds 25 kg/m2 [23] [24]. In general, premenopausal women, compared with 
BMI- and age-matched men, have been reported to have higher levels of HDL, and lower 
levels of triglycerides and small dense LDL [25] [26] [27], and to have higher (or at least 
equal) whole-body (including hepatic, adipose tissue and muscle) insulin sensitivity [13], 
even though they have higher FM, lower muscular mass and higher level of intramyocellular 
lipid content [28] [29]. These differences are more pronounced in obesity. For the same 
degree of obesity (defined by BMI), women have higher adiposity (defined as an absolute or 
relative amount of FM or %FM) [22]. Normal-weight (BMI 18-25 kg/m2) women have 20- 
30% body weight as FM, while normal-weight men have 10-20% body mass as FM [21] [30]. 
Obese (BMI 30-37 kg/m2) men have about 30% FM, similar as lean women, while obese 
women have about 50% FM [30]. This almost double the amount of fat (adipose tissue) in 
women is related to the same (or lower) metabolic and health risk compared with men, 
indicating that women are predicted to bear higher metabolic reserves (as FM) in the body, 
compared with men, and these increased metabolic reserves are not related to the increased 
metabolic risk [21]. Epidemiological data on mortality rates, using the National Health and 
Nutrition Examination Survey (NHANES) data from 1970 to 1994, indicate that the threshold 
for increased mortality in men and women is different, and that white men have the threshold 
set at BMI> 26 kg/m2 and white women at BMI> 28 kg/m2, while in black men and women 
the difference is even more pronounced: black men have the threshold set at BMI> 32 kg/m2 
and black women at BMI> 38 kg/m2 [23].
In addition to the aforementioned, women have a different distribution of body fat compared 
with men [21]. Both in women and men, most of body fat reserves are stored in subcutaneous 
tissue fat depots, nevertheless in women a higher proportion of fat is stored in subcutaneous 
depots and a lower proportion of fat is stored in visceral fat depots [31]. For the same degree
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of BMI, men have higher amounts of visceral fat compared with women [21]. While men in 
the category of normal-weight have 10-11% of body fat in their visceral fat depots, normal- 
weight women have only 5-8% [30]. Obese men have higher proportion of visceral fat (in 
average 25%), while obese women with upper-body and lower-body obesity have about 16% 
and 11% visceral fat, respectively [30]. At every waist circumference level, men have more 
visceral fat than women [23], and it was estimated that for a given waist circumference 
women have 1.8 kg more subcutaneous abdominal fat, compared with men, independent of 
age [32]. Additionally, in women in reproductive age fat reserves are typically stored in the 
lower-body, in the gluteo-femoral subcutaneous fat depots, the knee region, in the 
subcutaneous abdominal fat area under umbilicus and in the lower back, and in breasts, while 
in men most of the body fat is distributed in the upper-body abdominal subcutaneous and 
intra-abdominal (visceral) fat depots, giving the typical “gynoid” and “android” body shape 
[19] [25] [31] [33].
This different distribution of visceral and subcutaneous fat is present even after birth and in 
early developmental age and prepubertal years, but becomes most apparent after puberty 
when gonads become active [34]. However, with menopause and loss of ovarian function in 
women, the typical “gynoid” pattern of body fat distribution becomes less apparent, and 
women deposit more body fat in visceral depots [8] [21] [25] [35] [36] [31].
In line with this, the sex difference in the risk for metabolic abnormalities development is 
revealed at puberty and after menopause the difference diminishes [28] [34] [37] [38] [39]
[40]. During puberty boys become more insulin resistant compared with girls, even though 
they increase more their lean body mass and decrease their FM. At the same time they 
develop a more atherogenic lipid profile, with increased triglycerides and LDL and decreased 
HDL levels [38]. In parallel with this, the difference in body composition and body fat 
distribution appears [34] [37] [39] [40]. On the contrary, after menopausal transition, women 
lose more subcutaneous fat (especially from femoral region) and increase more their visceral
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fat and ectopic fat deposition (in the liver, skeletal muscle, pancreas) [28] [41] [42] [43] [44], 
which parallels the increase in the risk for development of obesity, insulin resistance, 
dyslipidaemia (high LDL, low HDL, high triglycerides), type 2 diabetes, NAFLD and CHD) 
[13] [45]. However, not all studies have confirmed increased risks for the development of 
obesity, visceral obesity, insulin resistance and dyslipidaemia directly related to menopause, 
which was independent of the influence of age, except for total and LDL-cholesterol [16] [40]
[41] [46] [47] [48].
All these data suggest the role of gonadal sex hormones in metabolic regulation, directing 
metabolic risk and body composition pattern. In women, the abrupt changes in hormonal 
milieu with cessation of ovarian function with menopausal transition may lead to similar 
abrupt changes in metabolic profile, body composition and increase in the metabolic risk [13] 
[17] [43] [42] [49] [50], while in men, the risk gradually increases with years, without a 
dramatic change, since there is a slower, gradual decline in their gonadal function [50] [51] 
[52]. With age, not only gonadal function declines in both sexes, but also involution and loss 
of function of some other endocrine glands appear, therefore not only menopause and 
andropause appear, but also somatopause and adrenopause develop, which can influence 
metabolic changes and increase metabolic risk themselves in both sexes [52] [53] [54] [55] 
[56].
Also in men, a reduction in the level of androgens (testosterone), increases the risk for 
metabolic syndrome (visceral obesity, hypertriglyceridaemia, insulin resistance) and 
development of diabetes mellitus and cardiovascular diseases (hypertension, coronary heart 
disease, stroke) [57] [58] [59] [60]. In men with genetic dysfunction of the androgen receptor 
(AR) the same metabolic abnormalities develop [61] [62]. Levels of total testosterone in men 
are in inverse correlation with the risk for glucose intolerance, type 2 diabetes and CVD [50] 
[63] [64]. Oestrogen function is also important in men. In men with a deficiency in the 
enzyme which convert testosterone to oestradiol (aromatase) or with a genetic dysfunction of
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oestrogen receptor, who have normal or increased androgen levels, the prevalence of 
metabolic syndrome and risk for diabetes type 2 are also increased [60] [64] [65] [66] [67] 
[68].
Similarly, in women androgen levels can affect metabolic risk. In women with high levels of 
endogenous and exogenous androgens (e.g. women with polycystic ovarian syndrome 
(PCOS) and female-to-male transsexuals treated with androgens), visceral obesity occurs, 
together with an increase in insulin resistance, a decrease in HDL and an increase in plasma 
triglyceride levels [63] [64] [68]. Increased levels of testosterone, especially free testosterone, 
is an independent risk factor for type 2 diabetes in women [63].
Data on hypogonadal and postmenopausal women using hormonal replacement therapy 
(HRT), show that HRT may have some beneficial effects on lipoprotein levels (increasing 
HDL, decreasing LDL), increasing insulin sensitivity and decreasing visceral fat 
accumulation [12] [16] [19] [69] [70] [71] [72] [73] [74] [75]. The effects can be different, 
depending on which hormones are used (type of oestrogens, type of progestins), the dosage 
and the route of administration [12] [16] [19] [70] [74] [76] [77] [78]. For example, the rise 
in plasma triglyceride levels, which is considered to be an independent risk factor for 
cardiovascular diseases [19], especially in women [19] [79] [80], have been often reported 
after usage of oral oestrogens, but not after usage of transdermal oestrogens [16] [19].
All these data suggest that women in their reproductive age may be metabolically protected 
by ovarian hormones, and most studies indicate the protective effect of oestrogens, but the 
possible role of progesterone and other hormones derived from ovaries (including androgens) 
can not be excluded, since all of them fall after menopause [11].
As previously mentioned, both increased and decreased androgens, oestrogens and/or 
progestins are related to increased cardio-metabolic risk in both genders, indicating the 
importance of sex hormones in metabolic regulation [7] [16] [36] [81] [82]. The reduction in 
gender specific hormones is related to an increased cardio-metabolic risk, and substitution
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with physiological doses of gender specific hormones reverses that risk, while substitution 
with physiological doses of sex hormones of the opposite gender again increases the risk [24] 
[83] [84] [85] [86]. This suggests the demonstrated gender differences in metabolism cannot 
be attributed solely to the influence of sex hormones [16]. It is possible that some “intrinsic” 
factors additionally contribute to the gender dimorphism in metabolic processes, which could 
include both genetic and early developmental (intrauterine and early postnatal) factors [68].
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Menopause and menopausal transition in women serve as a good model for studying 
metabolic differences between genders and to distinguish which effects are mediated by the 
“intrinsic” sexual determination and differentiation, and which are contributed to by the 
differences in gonadal steroids production and secretion. With menopause the circulating 
levels of oestrogens (oestradiol, oestrone), progesterone and testosterone decrease, because of 
cessation of their ovarian production [88] [89]. At the same time, there are increases in the 
ratio of oestrone: oestradiol, the ratio of androstendione: testosterone, and the ratio of
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androgens: oestrogens. After menopause the adrenal glands continue to secrete androgens (the 
main androgen is androstendione), and there is a conversion of adrenal androgens to 
oestrogens in peripheral tissues, particularly in adipose tissue [60] [65] [84] [90] [91]. By 
activity of aromatase, androstendione is converted to oestrone, and testosterone is converted 
to oestradiol, and by activity of 17-beta-hydroxysteroid dehydrogenase (17-beta HSD) 
androstendione is converted to the more potent testosterone, and oestrone is converted to 
more potent oestradiol [60] [87] [90] (Figure 7.1). The degree of obesity can influence the 
steroid hormone inter-conversion process [84].
Nevertheless, although some gender differences in the level of sex hormones levels diminish 
with menopause (e.g. in levels of oestradiol and progesterone), there are still gender 
differences, and for some hormones (e.g. levels of testosterone) differences become even 
more apparent (e.g. men have 20 times higher testosterone levels compared with 
premenopausal women, and 40 times higher compared with postmenopausal women) [92] 
[93]. Therefore, after menopause the gender differences in levels of gonadal hormones are 
still present, although in a different mode [93]. Taking into account the increasing life 
expectancy [94] and that many women spend almost one third of their lives in 
postmenopausal age [95], studying characteristics of metabolism in postmenopausal age 
women emerges as an important issue.
To date, many studies have been performed in order to study gender differences in plasma 
FFA and VLDL-triglycerides kinetics in premenopausal women and age-matched men, trying 
to explain the female/male differences in cardiometabolic risk. These studies were performed 
in postabsorptive (fasting) and postprandial conditions, during and after exercise, and 
included normal-weight and obese subjects [96] [97] [98] [99] [100] [101] [102] [103] [104] 
[105] [106] [107] [108] [109] [110]. However, a relatively small number of studies have 
compared the gender differences in lipid kinetics in a population of postmenopausal women 
and men (and in those studies subjects were not matched for age) [97] [110], or compared
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lipid kinetics between premenopausal and postmenopausal women [97] [111]. To the best of 
the author’s knowledge, there are no studies which have compared plasma FFA and VLDL- 
triglyceride kinetics in a population of obese, BMI and age matched men and postmenopausal 
women, and related them with measures of insulin sensitivity and serum adipokine levels.
7.2. The aim of the study
The aim of this study was to investigate the gender differences in population obese, BMI- and 
age-matched postmenopausal women and men (BMI: 30-35 kg/m2, aged 50-65 years) in 
plasma FFA, VLDL-triglyceride and glucose metabolism and circulating levels of insulin, 
adiponectin and leptin.
7.3. Specific aims and objectives
The following was compared between BMI- and age-matched obese men and postmenopausal 
women:
• The rate of whole body FFA release, uptake, oxidation and non-oxidative disposal.
• Forearm FFA rate of uptake and release.
• Whole body VLDLi- and VLDL^-triglyceride APRs and FCRs.
• Insulin sensitivity (assessed by HOMA2 model and hyperinsulinaemic-euglycaemic 
clamp).
• Fasting plasma levels of FFA, glycerol, triglyceride, HDL-, LDL- and total cholesterol, 
glucose.
• Fasting serum levels of insulin, adiponectin, leptin.
7.4. The study hypotheses
Compared with men, premenopausal women have a higher plasma FFA supply per kg FFM,
which is overcome by the increased non-oxidative FFA disposal in adipose and lean tissues,
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without deteriorating insulin sensitivity, liver triglyceride synthesis, disposal and secretion in 
the form of VLDL particles, or circulating lipid levels (women also have a higher plasma 
triglyceride clearance) [16] [96] [97] [99] [100] [112]. After menopause, a decreased (in a 
certain extent) FFA storage in SAT [28] [41] [42] [43] [44] would influence FFA disposal, 
guiding it from peripheral fat depots (in a certain extent) more towards lean tissues and VAT, 
therefore a higher supply to skeletal muscle and liver would occur. This would influence the 
function of these organs, increasing intracellular lipid accumulation, decreasing insulin 
sensitivity and stimulating fatty acid oxidation and/or liver lipid secretion. The increased 
VAT accumulation would additionally influence insulin sensitivity in liver and muscle.
This means that, compared with BMI- and age-matched men, obese postmenopausal women 
could have:
10. An increased plasma FFA release and supply per kg FFM [97], followed by an 
increased FFA non-oxidative disposal in adipose and lean tissues [96] [97] [99].
11. Similar or increased plasma FFA oxidation rates [96] [99], because in women with 
menopause the FFA disposal in SAT is partially reduced, and, in compensation, the 
proportion of FFA disposal in lean tissues is partially increased [28] [41] [42] [43] 
[44]. The increased plasma FFA supply to oxidative tissues stimulates their use for 
oxidative processes at the expense of the use of other oxidative substrates available in 
those tissues (e.g. carbohydrates or intracellular lipids) [41] [46] [47] [48] [113], 
therefore plasma FFA oxidation rates could be increased.
12. An increased forearm FFA release and uptake.
13. Similar VLDL-triglyceride secretion rates, while VLDL-triglyceride clearance rates 
would be increased in women [16] [97].
14. Similar levels of plasma triglyceride, VLDLi- and VLDL^-triglyceride, LDL- 
cholesterol and HDL-cholesterol [16].
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15. Similar levels of circulating insulin levels and similar insulin sensitivity [13] [17] [40] 
[47] [48] [49] [50].
16. A higher levels of circulating leptin [114] [115] [116] [117], and a higher or similar 
levels of circulating adiponectin [118] [119] [120] [121] [122] [123].
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CHAPTER 8. THE EFFECT OF GENDER ON FREE FATTY ACID 
AND VLDL-TRIACYLGLYCEROL METABOLISM -  CLINICAL 
AND ANALYTICAL METHODOLOGY
8.1. Ethical issues
The study design and methods of recruitment were approved by the East Kent Research 
Ethics Committee. All subjects were provided with oral and written information about the 
study goals and design, and asked to fulfil written consent forms for participating in the study.
8.2. Experimental study type and design
The study was designed as a cross-sectional study.
8.3. Study subjects
1656 obese Caucasian post-menopausal females (BMI 29.7-35.5 kg/m2), aged 51-67 and 7 
obese Caucasian males (BMI 30.5-34.6 kg/m2), aged 50-69 were recruited from the local 
Surrey population utilising:
■ University of Surrey (staff) circular e-mails
■ local newspaper advertisements
■ poster advertisements placed at local NHS-establishments
■ letters written to subjects in data bases of previous research recruitments
Exclusion criteria: Subjects were not included in the study if they fulfilled any of the 
exclusion criteria: body weight instability (body weight variation more than 2.5 kg in last 3 
months); diabetes and other endocrine diseases; cardiovascular diseases (angina, stroke), 
hepatic and renal disorders; severe food, drug allergies; eating disorders and restraint eating
56 14 females in this study were subjects already studied in the Rimonabant study, which signed a written
consent allowing us to use their data and results for the purpose o f  this study. Two female and 7 male 
subjects were additionally recruited and tests were performed on them for the purpose o f  this study only.
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(Dutch eating questionnaire); drug or alcohol abuse; substantial psychological or neurological 
illness; prescribed use of any medications known to alter body weight or appetite, ^-blockers, 
statins, fibrates, metformin; previous surgical procedures for weight loss; severe under­
reporting of food intake based on a 4 day food diary.
8.4. Detailed study design and schedule (Figure 8.1 and Figure 8.2)
( V i s i t  1 ) :  SCREENING  VISIT
( V i s i t  2 ) :  REE & AEE (resting & physical activity energy expenditure)
(1 week):
TESTS (1 week):
{ V i s i t  3 ) :  Test 1: REE, ARF, insulin sensitivity
( V i s i t  4 ) :  Test 2: Fat distribution, IHCL, IMCL
( V i s i t  5 ) :  Test 3: VLDLi, VLDL2 and FFA kinetics
Figure 8.1. Detailed study design and schedule (schematic diagram)
(Abbreviations: REE-resting energy expenditure; AEE-activity energy expenditure; ARF-acetate recovery factor; 
IHCL-intra-hepatocellular lipid content, IMCL-intra-myocellular lipid content, VLDL-very low  density
lipoproteins; FFA-free fatty acids
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A1-rjC Bicarbon ate Dextrose
infusion
S  ........
1,2 130 acetate infusion Insulin (40 mU/nf/mn)
R est
  ,  =
- 9 0  -6 0  0_________________________ 120 _______________________ 3 0 0  min
5 min blood sam pling
Q  Breath s a m p le s  
gssss Indirect calorimetry
B
2H5Glvcerol 1-rjC B icarbonate
& Ü
U130 palmitate infusion
0 0 1 2 0  4 2 0  min
i___________  ......-------------------------------------------------------------------------------- 1------------------------------------------------------------------1
blood sam pling blood & breath sam pling blood sam pling
V  Blood s a m p le s
Q  Breath & blood s a m p le s
Indirect calorimetry
Figure 8.2. Graphic presentation o f  study visits: A. Visit 3 (Test 1); B. V isit 5 (Test 3)
All visits, tests, clinical and laboratory methods and procedures were completely the same as 
in the Rimonabant study and can be found described in details in Chapter 3, 4, 5 and 
Appendix of the thesis. For the purpose of this chapter only short description of the visits will 
be given.
Visit 1 - Screening visit57: Subjects were asked to fill in a diet diary for 4 days prior the 
screening visit. At the screening visit the following was performed and recorded: medical 
history, current medication, physical examination, diastolic and systolic blood pressure, 
weight, height, age, smoker/non smoker status, fasting triglyceride, total cholesterol, glucose
57 Visit 1, Visit 2 and Visit 4 form part of Katherine Backhouse PhD project [714].
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and insulin levels, haematology (haemoglobin, red and white blood cells count, platelet 
count), clinical chemistry (sodium, potassium, creatinine, total protein, albumin, ALT, 
alkaline phosphatase). The subjects were accepted into the study if all of the inclusion criteria 
and none of the exclusion criteria were fulfilled.
After signing the written consent each subject was enrolled into study for 2 weeks:
Visit 2: REE was measured by indirect calorimetry (indirect calorimeter the Europa GEM 
(Europa Scientific Ltd, U.K.). Each participant was fitted an Actiheart monitor, which they 
wore for 5 days, to estimate AEE. The estimated average DEE was calculated as: 
DEE=REE+AEE+DIT (DIT was estimated to be 10% of total DEE).
Visit 3 (TEST 1): This visit was at the CEDAR clinical research unit, Royal Surrey County 
Hospital, Guildford. REE58 was measured by indirect calorimetry, followed by a [1,2-13C] 
acetate infusion with measurements of 13C02 production rate to estimate the ARF. Lastly a 
hyperinsulinaemic euglycaemic clamp was performed to measure insulin sensitivity.
Visit 4 (TEST 2): This visit was performed at the MRC Clinical Sciences Centre, 
Hammersmith Hospital, London. Whole body fat distribution was be measured by MRI, while 
IHCL and IMCL was measured by ^-magnetic resonance spectroscopy.
Visit 5 (TEST 3): This visit took place approximately 6 days after Test 1. Visit was 
preformed at the CEDAR clinical research unit. VLDLi- and VLDL^-triglyceride APR and 
FCR, fatty acid Ra and oxidation rate were measured using a stable isotope methodology and 
rate of uptake by muscle using the A-V difference method combined with stable isotopes.
8.5. Detailed clinical protocols and laboratory methods
Detailed description of all clinical procedures, laboratory methods used for sample analyses, 
calculations used for data analyses in this study are already given in the Chapters 3 and 4 and 
Appendix the of thesis.
58 Forms part of Katherine Backhouse PhD project [714].
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8.6. Statistics
Data analysis was performed using SPSS 16.0 (SPSS Inc., USA). Differences in variables 
between genders were analysed with treatment results were analysed with the Student’s two 
independent samples T test. Non-parametric data were logarithmically transformed before 
analysis. Associations between variable of interest were tested using the Pearson’s Rho 
coefficient of correlation. Values were reported as the mean ± SD, P-value as a number 
rounded up to 3 decimal places; statistical significance was assumed at a two-tailed P-value 
<0.050.
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CHAPTER 9. THE EFFECT OF GENDER ON FREE FATTY ACID 
AND VLDL-TRIACYLGLYCEROL METABOLISM - RESULTS
In total 16 women and 7 men were recruited. There were no serious adverse events and all 
subjects completed the study.
There was no statistical difference between the 2 gender groups in age and BMI. Mean age in 
the female group was 57.9 years (range: 50-67 years) and 60.6 years in the male group (range: 
53-69 years) (p=0.315). Mean BMI in the female group was 32.8 kg/m2 (range: 29.9-35.5 
kg/m2) and 31.5 kg/m2 in the male group (range: 29.7-34.6 kg/m2) (p=0.125) (Table 9.1).
9.1. Anthropometric indices (Table 9.1).
Compared with the male group, in the female group the average body weight and FFM were - 
11.3% and -29.3% lower (p=O.OO2 and pO.OOl, respectively), while the FM and % FM were 
36.6% and 50.4% higher (pO.OOl both) (Table 9.1). While waist circumference was not 
different between the 2 groups, hip circumference was 5.5% higher (p=0.039) and WHR ratio 
-7.8% lower (p=O.O4O) in the female group compared with the male group (Table 9.1).
9.2. Serum adipokines (Table 9.2)
Serum leptin levels were 144.9% higher in the female group then in the male group 
(pO.OOl), even when corrected for FM. Adiponectin levels did not differ significantly 
between the gender groups. The ratio adiponectin/leptin was 55.3%, higher in the male group 
(p=0.013) (Table 9.2).
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Table 9.1. Anthropometric characteristics of the study participants*
FEMALE GROUP MALE GROUP P  v a l u e  
female vs. 
malen=16 n=7
A ge (years) 57.9=1=5.4 60.6=66.6 NS
Body height (cm) 162.8±5.8 176.5=66.2 <0.001
BW  (kg) 87.0±6.7 98.0=67.2 0.002
BMI (kg/m2) 32.8=1=1.8 31.5=61.4 0.087
%FM (%) 44.4±2.9 29.5=63.0 <0.001
FM (kg) 38.7=64.5 29.0=63.9 <0.001
FFM (kg) 48.3=63.8 68.3=66.3 <0.001
Waist (cm)§ 107.1=69.2 110.4=66.6 NS
Hip (cm )§ 113.5±6.3 107.6=64.8 0.039
WHR§ 0.95=60.09 1.03=60.03 0.040
Data are presented as mean ±SD. BW: body weight; BMI: body mass index; FM: fat mass; FFM: fat free mass; 
WHR: waist to hip ratio; NS-non significant difference (p>0.05);
* data refer to Test 3 ; § data refer to Test 1;
Table 9.2. Fasting levels of serum adipokines
FEMALE GROUP MALE GROUP P  v a l u e  
female vs. 
malen=16 n=7
leptin
(ng/ml)
21.1=66.0 8.6=63.3 <0.001
leptin/kg FM  
(ng/ml/kg)
0.55=60.13 0.29=60.06 <0.001
adiponectin
(Fg/ml)
11.0=64.2 10.0±5.8 N S
adiponectin /leptin 
ratio
0.57=60.27 1.27=60.79 0.013
Data are presented as mean ±SD. NS-non significant difference (p>0.05)
224
9.3. Fasting glucose, insulin and derived insulin sensitivity indices (Table 
9.3)
Fasting (8 a.m.) plasma glucose and insulin, as well as insulin sensitivity and beta-cell 
function indices derived from them, HOMA2-%S, HOMA2-%B and ISI-HOMA, were not 
significantly different between the 2 gender groups (Table 9.3.)
Table 9.3. Fasting levels of plasma glucose, insulin and derived insulin sensitivity and p- 
cell function indices* _________
FEMALE GROUP MALE GROUP P  v a l u e  
female vs. 
malen=T6 n=7
fasting plasma glucose (mmol/1) 5.50±0.47 5.56±0.23 NS
fasting insulin (pU/ml) 18.0±9.0 15.742.7 NS
HOMA2- %S 56.5±31.3 45.4±8.6 NS
HOMA2- %B 133.0±42.7 134.8423.2 NS
ISI-HOMA 0.29±0.16 0.26±0.05 NS
Data are presented as mean ±SD. HOMA2: homeostasis model assessment-2; ISI-HOMA- hepatic insulin 
sensitivity index derived from homeostasis model assessment; NS-non significant difference (p>0.05)
*data obtained from Test 3
9.4. Hyperinsulinaemic-euglycaemic clamp (Table 9.4)
On the day when the hyperinsulinaemic-euglycaemic clamp was performed (Testl), no 
significant difference was found in the baseline blood glucose and serum insulin values, or the 
insulin sensitivity indices. Only the ISI-clamp tended to be higher in the female group, but 
this was not significant (p=0.087) (Table 9.4).
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Table 9.4. Insulin sensitivity indices derived from the hyperinsulinaemic-euglycaemic 
clamp*
FEMALE GROUP MALE GROUP P  v a l u e  
female vs. 
malen=16 n=7
HEC baseline blood glucose (mmol/1) 4.57±0.26 4.60±0.17 NS
HEC baseline insulin (pU/ml) 16.1±6.7 15.7±2.7 NS
HOMA2- %S 61.4±24.0 55.6±10.1 NS
HOMA2- %B 177.5±0.26 173.9=622.3 NS
ISI-HOMA 0.36±0.14 0.32±0.06 NS
Steady state GIR (mg/kg/min) 4.45±2.11 4.34=6!.ÎO NS
Glucose MCR  
(ml/kg/min) 5.96±3.09 5.52=61.70
NS
IS Irec (ml//kg/min) (pU/ml)'1 6.31^=3.34 3.94=61.34 0.087
Data are presented as mean ±SD. HOMA2: homeostasis model assessment-2; ISI-HOMA- hepatic insulin 
sensitivity index derived from homeostasis model assessment; GIR: glucose infusion rate; MCR: metabolic 
clearance rate; ISIheo insulin sensitivity index derived from hyperinsulinaemic-euglycaemic clamp;. NS-non  
significant difference (p>0.05)
*data obtained from Test 1
9.5. Fasting plasma lipids (Table 9.5)
Fasting plasma glycerol levels were significantly higher in the female group by 108.9% 
(pO.OOl). Fasting plasma triglyceride, total cholesterol, LDL-cholesterol and HDL- 
cholesterol levels were not significantly different (Table 9.5).
9.6. VLDL- subtractions (VLDLi and VLDL2) lipid content (Table 9.6)
The concentrations of plasma VLDL 1-triglyceride in the female group tended to be lower 
compared with males (p=0.083). The concentrations of plasma VLDL 1-cholesterol in female 
group were -58.7% lower (p=0.016) (Table 9.6).
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Table 9.5. Fasting plasma lipids levels
FEMALE GROUP MALE GROUP P  v a l u e  
female vs. 
malen=16 n=7
Glycerol (pmol/l) 140.9±37.8 67.5=1=18.2 <0.001
Triglycerides mmol/1) 1.37±0.96 1.62=1=0.82 NS
Cholesterol (mmol/1) 5.53±1.02 5.09=1=0.80 NS
LDL-cholesterol
(mmol/1)
4 .17Ü .03 3.76=1=0.71 NS
HDL-cholesterol
(mmol/1)
1.37±0.27 1.33=1=0.26 NS
Data are presented as mean ±SD. HDL: high-density lipoprotein; LDL: low-density lipoprotein; NS-non  
significant difference (p>0.05)
Table 9.6. Fasting plasma VLDL-subfractions triglyceride and cholesterol content
FEMALE GROUP MALE GROUP P  v a l u e  
female vs. 
malen=16 n=7
VLDLi-triglyceride (mmol/1) 0.79±0.69 1.44=1=1.16 0.083
VLDL2-triglyceride (mmol/1) 0.21=1=0.13 0.17±0.07 NS
VLDLi-cholesterol (mmol/1) 0.21=1=0.25 0.51±0.43 0.016
VLDL2-cholesterol (mmol/1) 0.13=1:0.14 0.13=1=0.07 NS
Data are presented as mean ±SD. VLDL: very low-density lipoprotein; NS-non significant difference (p>0.05)
9.7. VLDLr and VLDL2 - triglyceride kinetics (Table 9.7.1 and 9.7.2)
The APR of VLDLi -triglycerides expressed in absolute terms and per kg BW tended to be 
lower by -44.7% (p=0.059) and -38.9% (p=0.090) in females, while VLDLi- triglyceride ASR 
expressed per ml plasma (plasma secretion rates), per kg FFM and kcal REE were not 
different significantly between 2 genders. When accounted for the total body adiposity, men 
had more than 2-fold higher VLDLi-triglyceride APR/kg FM (p=0.006) (Table 9.7.1).
VLDLi -  triglyceride APRs tended to be higher in the female group, but this did not achieve 
statistical significance (Table 9.7.1).
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Table 9.7.1. VLDLi and VLDL2 -triglyceride APRs
FEMALE GROUP MALE GROUP P  v a l u e  
female vs. 
malen=16 n=6"
VLDLi-TG APR  
(g/d)
22.0=1=9.8 39.8=633.0 0.059
VLDLr TG ASR  
(mg/ml plasma/d) i
8.9±3.7 13.6=610.8 NS
VLDLi-TG APR  
(mg/kgBW/d)
249.6±99.7 408.6=6330.0 0.090
VLDLrTG APR  
(mg/kgFFM/d)
462 .7Ü 97 .6 592.8=6491.7 NS
VLDLi-TG APR  
(mg/kgFM/d)
546.4±202.7 1330.6=61006.8 0.006
VLDLi-TG APR  
(mg/kcal/d)
15.6=1=6.5 21.5=616.7 NS
VLDLRTG APR  
(g/d)
6.7=63.8 5.6=62.6 NS
VLDLz-TG ASR  
(mg/ml plasma/d)
2.8=61.6 1.9±0.9 NS
VLDLz-TG APR  
(mg/kgBW/d)
77.3±44.7 58.3=626.7 NS
VLDL2-TG APR  
(mg/kgFFM/d)
142.8=682.2 82.9=638.4 NS
VLDLz-TG APR  
(mg/kgFM/d)
170.2=6101.0 199.5=689.8 NS
VLDLz-TG APR  
(mg/kcal/d)
4.8=62.7 3.0=61.1 NS
Data are presented as mean ±SD. VLDL: very low-density lipoprotein; APR: absolute production rate; ASR: 
absolute secretion rate; NS-non significant difference (p>0.05)______________________________________________ ___
In the female group, the VLDLi- and VLDLi-triglyceride FCRs expressed in absolute terms 
(pools/day) were significantly higher, by 49.9% (p=0.031) and 32.1% (p=0.003), respectively. 
The difference remained significant even after adjustment for the diversity in BW, FFM and 
REE, and was lost only after adjustment for total body adiposity. Additionally, in both 
genders, FCRs were quite alike for VLDLi- and VLDLi-triglycerides (Table 9.7.2).
59 The quality o f  data from one male subject was not satisfactory to be included in the analysis.
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Table 9.7.2. VLDLi and VLDLi -tri glyceride FCRs
FEMALE GROUP MALE GROUP P  v a l u e  
female vs. 
malen=16 n=6W
VLDLr TG FCR 
(pools/d)
13.6±4.7 9.1±2.6 0.031
VLDLi-TG FCR 
(pools/d/kgBW)
0.16±0.05 0.09±0.02 0.007
VLDLr TG FCR 
(pools/d/kgFFM)
0.29±0.10 0.13±0.03 <0.001
VLDLi-TG FCR 
(pools/d/kgFM)
0.35±0.11 0.32±0.11 NS
VLDLrTG FCR 
(pools/kcal)
0.010±0.004 0.005±0.001 0.002
VLDLRTG FCR 
(pools/d)
13.6±3.9 10.342.2 0.003
VLDLrTG FCR 
(pools/d/kgBW)
0.16±0.05 0.114=0.02 0.015
VLDLrTG FCR 
(pools/d/kgFFM)
0.29±0.09 0.154=0.03 <0.001
VLDLrTG FCR 
(pools/d/kgFM)
0.35±0.13 0.374=0.10 NS
VLDLrTG FCR 
(pools/kcal)
0.010±0.003 0.0054=0.001 0.002
Data are presented as mean ±SD. VLDL: very low-density lipoprotein; FCR: fractional catabolic rate, NS-non  
significant difference (p>0.05)____________________________________________________________________________
9.8. FFA kinetics
9.8.1. Steady state FFA and palmitate concentrations and TTR (Table 9.8.1)
Arterialised blood and venous blood was collected in 15 female and 7 male subjects. The 
values of oxygen saturation in the obtained arterialised and venous blood samples were in 
acceptable range (for arterialised blood HbO >90%, and deep venous blood HbO<60%) 
(Table 9.8.1).
In Table 9.8.1 are given FFA and palmitate plasma concentrations for steady state arterialised 
and deep venous blood. Female subjects tended to have higher plasma FFA and palmitate
60 The quality o f  data from one male subject was not satisfactory to be included in the analysis.
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concentrations compared with males, but significance was shown only for arterialised plasma 
FFA concentrations (p=0.046).
Table 9.8.1. Steady state FFA and palmitate concentrations
FEMALE GROUP MALE GROUP P  v a l u e  
female vs. 
malen=15 n=7
arterialised blood oxygen saturation 
(%HbO)
92.5±2.5 93.74=2.3 NS
arterialised plasma SS FFA concentration 
(pmol/1)
755.3±207.4 601.34=204.9 0.046
arterialised plasma SS palmitate 
concentration (pmol/1)
138.4±32.2 126.94=26.3 NS
arterialised plasma ratio [palmitate/total 
plasma FFA] (%)
18.7±3.4 21.04=1.6 NS
venous blood oxygen saturation 
(%HbO)
54.3±9.0 57.54=9.2 NS
venous plasma SS FFA concentration 
(pmol/1)
845.14=220.4 744.34=143.3 NS
venous plasma SS palmitate concentration 
(pmol/1)
146.2±26.5 130.54=30.5 NS
venous plasma ratio [palmitate/total plasma 
FFA] (%)
17.84=3.2 17.74=3.7 NS
Data are presented as mean ±SD. SS: steady state; FFA: free fatty acids; NS-non significant difference (p>0.05)
9.8.2. Forearm palmitate kinetics (Table 9.8.2)
In 13 female and 7 male subjects forearm kinetics were examined. Blood flow and plasma 
flow were significantly lower in the female group compared with the male group, by -27.9% 
and -23.6% (p=0.015 and p=0.046), respectively. Nevertheless, forearm palmitate uptake and 
release rates were not different between the 2 groups (Table 9.8.2).
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Table 9.8.2. Forearm palmitate kinetics
FEMALE GROUP MALE GROUP P  v a l u e  
female vs. 
malen=15 n=7
forearm blood flow  
(mFmin/100 ml forearm tissue)
3.46±0.83 4.80±1.43 0.015
haematocrit ( % ) 39.7±2.5 43.3=63.4 0.013
forearm plasma flow  
(ml/min/100 ml forearm tissue)
2.09±0.50 2.73=60.87 0.046
palmitate forearm fractional extraction rate 
(%)
26.8±15.1 22.0=66.4 NS
palmitate forearm uptake rate 
(fimol/min/100 ml forearm tissue)
79.0=1=31.2 76.7=639.5 NS
palmitate forearm release rate 
(pmol/min/100 ml forearm tissue)
98.1=1=45.8 88.9=670.7 NS
Data are presented as mean ±SD. NS-non significant difference (p>0.05)
9.8.3. Whole body plasma FFA kinetics- rates of appearance and oxidation 
rates (Table 9.8.3)
The whole body palmitate Ra, palmitate MCR and non-oxidative disposal rate expressed per 
kg FFM were significantly higher in the female group, by 42.9% (p=0.014), 34.6% (p=0.047) 
and 57.1% (p=0.010), respectively. When palmitate Ra and MCR were expressed per kg FM, 
the rates were significantly lower by -27.4% (p=0.028) and -31.7% (p=0.009), respectively. 
When expressed per kcal/min steady state REE, in the female group palmitate Ra rates were 
higher (by 26.4%), which approached statistical significance (p=0.051), and non-oxidative 
disposal was significantly higher by 37.9% (p=0.032). Palmitate oxidation rates expressed per 
kcal/min were also tended to be higher in the female group (p=0.085). TPFAO expressed per 
kg FFM and kcal/min were significantly higher in the female group, by 44.1% (p=0.034) and 
33.3% (p=0.048), respectively (Table 9.8.3).
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Table 9.8.3. Whole body palmitate and plasma FFA kinetics
FEMALE GROUP MALE GROUP P  v a l u e  
female vs.
n=15 n=7 male
palmitate Ra 
(pmol/min) 151.4±45.6
152.7±31.2 NS
palmitate Ra 
(pmol/kgFFM/min)
3.18±0.92 2.23±0.48 0.014
palmitate Ra 
(pmol/kgFM/min)
3 .9 2 Ü .2 7 5.40±1.56 0.028
palmitate Ra 
(pmol/kcal/min)
154.2±37.2 122.0±28.7 0.051
palmitate MCR  
(pmol/min)
1128.4±402.2 1219.6±207.4 NS
palmitate MCR  
(pmol/kgFFM/min)
23.8±8.5 17.742.3 0.047
palmitate MCR 
(pmol/kgFM/min)
29.3±10.8 42.94=10.5 0.009
palmitate MCR  
(pmol/kcal/min)
1151.9±358.8 960.84=113.0 NS
palmitate non-oxidative disposal 
(pmol/min)
100.2±34.7 92.5427.8 NS
palmitate non-oxidative disposal 
(pmol/kgFFM/min) 2.11±0.72
1.344=0.41 0.010
palmitate non-oxidative disposal 
(pmol/kgFM/min)
2.60±1.00 3.284=1.29 NS
palmitate non-oxidative disposal 
(pmol/kcal/min)
102.0±30.4 73.94=24.4 0.032
palmitate oxidation rate 
(pmol/min)
51.2±13.6 60.24=10.4 NS
palmitate oxidation rate 
(pmol/kgFFM/min) 1.07±0.26 0.884=0.20
0.085
palmitate oxidation rate 
(pmol/kcal/min)
52.2±10.2 48.04=9.9 NS
TPFAO
(pmol/min)
287.6±120.8 286.54=44.8 NS
TPFAO
(pmol /kgFFM/min)
6.05±2.55 4.204=0.88 0.034
TPFAO
(pmol /kcal/min)
75.6±23.6 56.74=16.0 0.048
Data are presented as mean ±SD. Ra: rate o f  appearance; MCR: metabolic clearance rate; TPFAO: total plasma 
free fatty acid oxidation rate; FM: fat mass; FFM: fat free mass; NS-non significant difference (p>0.05)__________
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9.9. Steady state CO2 production, 0 2 consumption, RQ, REE and ARF 
(Table 9.9)
Steady state CO2 production, O2 consumption and REE estimated according to the Weir’s 
equation and expressed in absolute terms were significantly lower in the female group, by - 
23.2%, -22.4% and -22.6%, respectively (pO.OOl). However, when expressed per kg FFM, 
these measurements were higher in the female group, by 11.8% (p=0.056), 13.2% (p=0.027) 
and 12.9% (p=0.025). RQ and ARF were not different between males and females (Table 
9.10).
Table 9.9. Steady state CO2 production, 0 2 consumption, RQ, REE and ARF
FEMALE GROUP MALE GROUP P  v a l u e  
female vs. 
malen=15 n=7
Acetate recovery factor 0.19±0.02 0.19±0.02 NS
RQ 0 .8Ü 0 .07 0.82±0.06 NS
C 0 2 production (ml/min) 164 .5Ü 9.4 214.29±24.12 <0.001
C 0 2 production (ml/min/kgFFM) 3.5±0.4 3.11±0.36 0.056
0 2 consumption (ml/min) 202.8±22.0 261.43±21.94 <0.001
0 2 consumption (ml/min/kgFFM) 4.3±0.5 3.8±0.3 0.027
steady state REE (kcal/day) 1411.6±147.7 1822.7±156.4 <0.001
steady state REE (kcal/day/kgFFM) 29.9±3.5 26.5±2.0 0.025
Data are presented as mean ±SD. RQ: respiratory quotient; REE: resting energy expenditure; FFM: fat free mass;
NS-non significant difference (p>0.05)
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CHAPTER 10. THE EFFECT OF GENDER ON FREE FATTY 
ACID AND VLDL-TRIACYLGLYCEROL METABOLISM - 
DISCUSSION
In this study, postmenopausal obese women, compared with age- and BMI-matched men, had 
higher palmitate flux (Ra), MCR, non-oxidative disposal and TPFAO (relative to their FFM 
and REE), higher VLDLi- and VLDL^-triglyceride FCRs and circulating glycerol, FFA and 
leptin levels. They also tended to be more insulin sensitive (as estimated by a 
hyperinsulinaemic-euglycaemic clamp) and to have lower VLDLi- and VLDL^-triglyceride 
APRs, while the other variables, related to cardiometabolic risk (including fasting levels of 
plasma triglycerides, total cholesterol, HDL- and LDL-cholesterol, glucose, insulin, HOMA- 
model of insulin resistance and adiponectin), were not significantly different. This suggests 
that, compared with age- and BMI-matched men, obese postmenopausal women have an 
increased lipid turnover, which is not accompanied by an increased cardio-metabolic risk.
10.1. FFA kinetics
10.1.1. Plasma FFA flux
In the present study, women had higher rates of plasma FFA flux expressed per kg FFM or 
kcal REE (but lower if expressed per kg FM). The increased plasma FFA flux was mostly 
compensated by the increased non-oxidative FFA disposal, since plasma FFA oxidation was 
also increased, although in a lesser extent. This was associated with -26% higher levels of 
circulating plasma FFA in arterialised blood (and -110% higher glycerol levels in venous 
blood) in women.
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The results from the present study also indicate that in women adipose tissue is less 
lipolytically active per unit of adipose tissue, but the total amount of adipose tissue 
contributed to the higher whole body rate of lipolysis and the higher FFA supply in relation to 
their resting energy needs.
The findings from this study are in agreement with previous studies which compared FFA 
release in men and women [96] [97] [99] [100] [101] [102] [112] [113] [124].
Data from kinetic studies examining age- and BMI- or REE-matched men and premenopausal 
women (both obese and non-obese) also showed increased fatty acid flux per kg FFM or kcal 
REE, and lower lipolysis rates per kg fat tissue in women [96] [97] [99] [100] [101] [102]. In 
one study, after matching for % FM, women also had higher fatty acid release per kg FFM, 
although in that study men had higher BMI and total FM than the women [113]. To the best 
of the author's knowledge, only one study compared obese postmenopausal and 
premenopausal women and men matched for BMI (in that study BMI ranged 34-35 kg/m2) 
[97], but in that study subjects were not matched for age. The results from that study are also 
in agreement with the here presented results: premenopausal women and postmenopausal 
women had similar palmitate Ra per kg FFM, and in both female groups palmitate Ra per kg 
FFM was higher than in BMI-matched men. In another study which compared palmitate flux 
in older subjects (postmenopausal women and men, with a broader range of BMI than in this 
study), women and men did not have different palmitate Ra expressed in absolute terms 
(similar to the current study), but in that study female and male subjects were not matched for 
BMI and age (the men were older and BMI was not measured) [110].
Also, data form this study are in accordance with previous data in humans showing that obese 
women may have higher circulating plasma glycerol and FFA levels, compared with men, 
without having detrimental metabolic effects [112]. In this study, women had higher 
circulating plasma FFA levels in arterialised blood, compared with men. However, plasma 
FFA levels in the venous blood draining the forearm region were not significantly higher than
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in men (although they tended to be higher), suggesting a possible increased FFA uptake in the 
tissues of forearm region (including muscle and adipose tissue) in women, and/or a higher 
FFA release (from muscle and/or adipose tissue) in men. According to data from the literature 
[125] [126] [127] [128], the former explanation seems much more probable. However, in this 
study the findings using the stable isotopes (labelled palmitate), to examine the forearm FFA 
kinetics, did not confirm any of the proposed explanations, since the forearm FFA release and 
uptake rates (per ml of forearm tissue) were not significantly different between women and 
men (even they tended to be higher in women, in particular with respect to palmitate release). 
Nevertheless, in the present study the total forearm volume and the amount of muscle and 
adipose tissue in the forearm region were not measured, and it is possible that the net- 
differences in plasma FFA levels in arterialised and venous blood might be partly accounted 
for by the gender differences in forearm anthropometry [129] [130]. Additionally, the 
differences in local tissue blood flow (higher in men) could also contribute to the observed 
net-differences in FFA levels (lower in women). A higher blood flow in men may be also a 
consequence of increased catecholamine levels, and catecholamines, in turn, per se can 
increase FFA turnover [129].
Unfortunately, to the best of the author's knowledge, there are not published comparative 
studies examining the local forearm FFA kinetics between men and women. There is a study 
which compared the leg FFA kinetics between the genders [131], but a direct comparison with 
this study can not be done, because of different morphological and functional characteristics 
of the examined regions and different expression of the results (the whole leg palmitate 
release and uptake were expressed in absolute terms, per pmol/min). Nevertheless, also in that 
study no significant gender differences in the whole leg FFA kinetics were shown [131]. 
However, when the palmitate release rates were expressed relative to the leg FM, they were 
lower in women [131].
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10.1.1.1. The mechanisms underlying gender differences in plasma FFA 
fluxes in obesity
The differences in palmitate Ra could be mostly explained by a different body composition in 
men and women [25] [48] [102] [132] [133] [134] [135], since women not only have a higher 
% total FM, but also a higher % of the less lipolytically active SAT and a lower % of the 
more lipolytically active VAT [16] [33] [44] [48] [134] [133] [136]. Additionally, regarding 
SAT, women have also a lower % of more lipolytically active upper-body (abdominal) SAT 
and higher % of less lipolytically active lower-body (gluteo-femoral) SAT, compared with 
men [19] [22] [30] [31] [44] [109] [133] [137]. Those 3 adipose tissue depots display 
significant differences in adipocyte size and lipid content, vascularization and innervation, 
LPL activity, fatty acid uptake and entrapment (re-esterification), basal lipolysis and 
responsiveness to pro- and anti-lipolytic stimuli, including expression and sensitivity of pro­
lipolytic (beta-1, -2 and -3 adrenergic) receptors, and anti-lipolytic (alpha-2 adrenergic and 
insulin) receptors [19] [90] [109] [138] [139] [140] [141]. Both gender and obesity can 
independently influence these features.
The contribution of different adipose tissue depots to the whole body lipolysis has been 
examined by several kinetic studies, and the results show that in both men and women the 
upper-body SAT contributes the most (about 70-75%), independently of degree and type of 
obesity, both in the postprandial and postabsorptive state, while the contribution of lower- 
body SAT and VAT varies with phenotype and gender [109] [133] [142] [143] [144] [145].
In normal-weight women, during a 14h postabsorptive state, 70%, 21% and 9% of 126 g fat is 
estimated to be released from the upper-body SAT, lower-body SAT and VAT, respectively. 
In normal-weight men, those values are estimated to be 75%, 12% and 13% of 135 g of fat, 
respectively [109]. The higher contribution of VAT in men, which is even more evident in 
obesity, can be related to the increased hepatic FFA supply, susceptibility to hepatic insulin 
resistance, liver steatosis and increased VLDL-triglyceride secretion rates [102] [146] [147].
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It was estimated that in visceral obesity up to 30-50% of hepatic FFA supply can derive from 
VAT depots [102] [142] [143] [148]. Unfortunately, in this study splanchnic FFA kinetics 
was not measured, so a direct gender comparison cannot be done.
Comparing women and men, studies in vivo and in vitro showed that catecholamine 
stimulated lower-body (leg) FFA release per gram adipose tissue is lower in women than in 
men, while FFA release from the upper-body depots is comparable or higher in men, 
depending on the degree of obesity and obesity phenotypes [29] [102] [109] [149]. With 
respect to the obesity phenotypes, women with upper-body obesity, compared with women 
with lower-body obesity, have higher FFA release from upper-body SAT per kg FM in 
postabsorptive conditions [19] [150]. Also in postprandial conditions, women with upper- 
body obesity have increased FFA release in absolute terms and per kg FFM [142] [150].
The hormonal control of adipose tissue lipolysis in humans
In humans, inhibition of lipolysis is mainly under the control of insulin receptors [48] and 
alpha-2 adrenergic receptors [151] [152]. Adrenergic alpha-2 receptors are stimulated with 
low or very high catecholamine concentrations, as found in resting conditions or during high 
intensity exercise [151] [152]. In contrast, stimulation of lipolysis is mainly under the control 
of moderately increased catecholamine concentrations, as found during low intensity exercise, 
stress, prolonged fasting and hypoglycaemia, and occurs via activation of beta-1 and beta-2 
adrenergic receptors (mostly in SAT) and beta-3 adrenergic receptors (mostly in VAT) [48] 
[151] [152] [153] [154] [155]. Both insulin and catecholamine receptors influence the 
concentration of cAMP, which controls PKA activity and stimulation of HSL-dependent 
lipolysis, although through different pathways: insulin receptors through their action on 
phosphodiesterase type 3B (PDE-3B) [156], and catecholamine receptors through their action 
on adenylate cyclase [48] [141] [154]. Adrenergic beta receptors through their binding to 
stimulatory Gs-coupled proteins stimulate, and alpha receptors through their binding to
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inhibitory Gi-coupled proteins inhibit adenylate cyclase [48] [141] [154]. Apart from the 
influence of catecholamines and insulin, in humans, lipolysis is also under the control of other 
factors, including GH, glucagon, thyroid hormones, glucocorticoids, sex hormones, TNF- 
alpha, IL-6, natriuretic peptides, NPY and PYY, adenosine, eicosanoids (prostaglandins 
PGE2 and PGI2), nicotinic acid and others, which act through their specific pathways and 
receptors, possibly interfering with the adrenergic and insulin pathways [157] [158] [159] 
[160] [161] [162] [163] [164] [165] [166] [167] [168] [169].
The effects of obesity on adipose tissue lipolysis
Adipocyte hypertrophy is one of the major determinators of adrenergic and insulin receptors 
expression and lipolytic response [170] [171] [172] [173].
Referring to adrenergic receptors, adipocyte size is in a positive correlation with the number 
of alpha-2, and in a negative correlation with the number of beta-1 and beta-2 adrenergic 
receptors [170]. The higher the adipocyte size, the lower the adrenergic lipolytic 
responsiveness [170].
In obesity, there are depot-specific effects on adrenergic receptors. In SAT, there is an up- 
regulation of alpha-2 adrenergic receptors and increased sensitivity to anti-lipolytic adrenergic 
action, and a down-regulation of beta adrenergic receptors and decreased sensitivity to beta- 
agonists, as well some post-receptor defects [153] [169] [174] [175] [176]. On the contrary, in 
VAT, beta-3 adrenoreceptor sensitivity is increased, while alpha-2 adrenoreceptor sensitivity 
is decreased in obesity [140].
Additionally, in obesity, there is a decreased sensitivity to the anti-lipolytic actions of insulin 
[177], which contributes to the increased lipolysis in both the postabsorptive and postprandial 
states [22] [132], and this is more pronounced in men and women with the upper-body obesity 
phenotype [168] [178].
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Adipocytes with a higher volume are more lipolytically active in basal conditions and less 
sensitive to the insulin suppression of lipolysis [22] [171] [172] [173], thus people with more 
adipocyte hypertrophy are less insulin sensitive. Men have been shown to develop more 
adipocyte hypertrophy rather than increased adipocyte number, compared with women [171], 
which may contribute to the observed higher predisposition for insulin resistance in obesity in 
men [22].
Decreased sensitivity to the anti-lipolytic actions of insulin in obesity is present not only in 
VAT and the upper-body SAT, but also in the lower-body SAT [132] [138] [140] [168] [179] 
[180] [181] [182] [183] [184]. VAT seems to be the most important site of anti-lipolytic 
insulin resistance related to obesity [181].
Therefore, in obesity, with adipocyte enlargement, there is a lower lipolytic adrenergic and 
anti-lipolytic insulin responsiveness, which is a fat depot- and gender- specific.
Gender differences in adipose tissue lipolysis
Subtle gender differences in pro- and anti-lipolytic activity of each adipose tissue depot exist, 
both in normal-weight and obese subjects [21] [29] [31] [138] [153] [169] [180] [185] [186] 
[187] [188]. This could be related to different receptor density, affinity and sensitivity [19] 
[29] [31] [138] [139] [185] [187] [189].
In SAT, in normal-weight subjects, in both genders beta receptor sensitivity and density is 
higher in adipocytes isolated from abdominal vs. femoral fat depots [185]. On the other hand, 
in obesity, the differences in beta receptor density between abdominal and femoral adipocytes 
were not observed, indicating probably a downregulation of abdominal beta receptors [189].
In both SAT depots beta adrenergic density and sensitivity seems does not display gender 
diversity [113] [124] [151] [169] [185] [190], however there are considerable gender 
differences concerning alpha-2 adrenergic activity [113] [151] [169], related to the differences 
in receptor number, affinity and anti-lipolytic efficiency.
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Evidence exists that non-obese women, compared with non-obese men, may have higher 
density and sensitivity of alpha 2-receptors in adipocytes from gluteo-femoral SAT [151], and 
lower alpha 2-receptors sensitivity in adipocytes from abdominal SAT [169] [185]. In both 
non-obese and obese women, alpha-2 receptor sensitivity and affinity is lower in abdominal, 
compared with gluteo-femoral SAT adipocytes [169] [185]. In contrast, men have similar 
sensitivity and affinity of alpha-2 adrenergic receptors in abdominal and gluteo-femoral SAT 
depots [169] [185].
In obesity, the up-regulation of alpha-2 adrenergic activity is more noticeable in women with 
lower-body obesity phenotype, in both SAT depots [21] [152] [169], although it is more 
evident in the femoral SAT [30], while in men this only occurs in abdominal SAT [153]. 
Therefore, in obese women, alpha-2 receptor sensitivity in femoral adipocytes is much higher, 
than in obese men [21] [152] [169] [189]. On the other hand, in obese men, alpha-2 receptor 
sensitivity in subcutaneous abdominal adipocytes is higher than in obese women [152] [169]. 
Concerning VAT, in obesity, in men, VAT is more lipolytically active per gram tissue, than in 
women, because of more prominent increases in fat cell volume, increased sensitivity to beta- 
3 adrenergic stimulation and resistance to alpha-2 adrenergic inhibition, and increased ability 
of cAMP to activate HSL. The increased lipolytical activity of VAT (per gram tissue) in men 
can additionally contribute to the increased hepatic FFA supply, apart from the increased 
visceral fat depots [19] [187].
Regarding insulin receptors and their anti-lipolytic activity, affinity and number in different 
adipose tissue depots, the existing data in vitro failed to show significant gender specificities. 
However, there are only a few studies on that topic [187] [191]. The fat accumulation patterns 
and degree of obesity could also influence the results [192]. One study indicated higher 
insulin receptor number per fat cell in gluteal region of women, compared with men, but when 
the adipocyte size was taken into account (which was higher in females), insulin receptors 
number per cell surface was not different, nor was insulin anti-lipolytic action in vitro [191].
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Neither in VAT have gender differences in anti-lipolytic effect of insulin been observed 
[187].
Additionally, in vivo studies inconsistently reported significant gender differences in the 
effect of insulin on lipolysis suppression [101] [193] [194] [195], even though some of them 
suggested that women might have higher responsiveness [196]. However, also the opposite 
findings have been reported [197].
In both genders, data in vitro show the lowest responsiveness to anti-lipolytic effect of insulin 
in visceral fat, the highest in femoral, while subcutaneous abdominal fat is in the middle [138] 
[192] [198] [199]. This may be related to different expression, affinity or responsiveness 
(phosphorylation) of insulin receptors and their downstream signals, including IRS-1, PI3-K, 
PKB(Akt) and PDE-3B. However, some conflicting findings in vivo exist [156], and 
additional studies are needed to further explore this issue, both in vivo and in vitro.
Gender differences in the action of other factors which control lipolysis have been also under 
investigation [185] [199] [200] [201] [202] [203] [204], but limited data are available to make 
reliable conclusions.
In summary, there are evident gender differences in lipolytic activity of adipose tissue, which 
are depot-specific. They may include differences in number, affinity and/or activity of pro- 
and anti-lipolytic receptors and their downstream signalling molecules, as well as differences 
in concentrations of their ligands (e.g. catecholamines). However, particular mechanisms 
underlying those differences are not fully explored. Differences in alpha-2 adrenergic 
sensitivity to adrenergic stimulation seem to play a significant role in adipose tissue re­
distribution, which is gender specific. With obesity, gender differences in lipolytic activity of 
adipose tissue become even more apparent [205].
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The effect of local tissue blood flow on regional FFA kinetics
There are also regional differences to adipose tissue blood flow, which could contribute to the 
FFA acid fluxes from different fat tissue depots [190]. The highest blood flow is in visceral 
depot, while the lowest in subcutaneous femoral depot in both genders [190]. In this study, 
men had higher forearm blood flow in the forearm region, in agreement with the previously 
published data [125]. This could be related to the increased circulating catecholamine levels 
in men, compared with women, since beta adrenergic stimulation increases blood flow [48] 
[113] [206] [207] [208]. Additionally, in women there is a higher contribution of SAT in total 
forearm blood flow, and it is known that in obesity the adipose tissue blood flow (per ml 
adipose tissue) is decreased [206]. The increased capillary plasma flow decreases the local 
concentration of the released FFA in the interstitial space of adipose tissue, increasing the 
intracellular/extracellular FFA gradient (further stimulating FFA release), and decreasing FFA 
re-uptake and re-esterification in situ in forearm tissues (adipose tissue, muscle), before 
reaching the main vessels draining the forearm [190]. The increased blood and plasma flow 
contribute to the increased FFA uptake and release per kg forearm tissue in men, but this 
could be counteracted by the increased contribution of adipose tissue in the forearm region of 
women, therefore a net-result will be similar forearm palmitate kinetics in men and women.
10.1.1.2. The effects of sex hormones on adipose tissue lipolysis
Data in rodents show that oestrogen treatment alone (without progesterone) increases adipose 
tissue lipolysis [209] and FFA availability [210], while the addition of progesterone could 
abolish those effects. However, data in humans are conflicting and different from data in 
animals, and this may be explained by the fact that in rodents there are no alpha-2 adrenergic 
receptors [60].
According to several studies [106] [211], there was no difference in FFA kinetics between
menstrual cycle phases, indicating that changes in ovarian steroids during the menstrual cycle
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did not influence in a greater extent FFA metabolism. In amenorrhoeic women, oestradiol 
supplementation did not affect lipolysis [212]. In one study, oral contraceptives 
administration for 3 months in women had no effect on lipolysis at rest [213]. In another 
study, oral contraceptives (combination of oestrogens and progestins) given to premenopausal 
women for 6 months were shown to have no effect (only a marginal increase in lipolysis), but 
there was a more apparent increase in plasma FFA re-esterification and decrease in the 
percentage of plasma FFA released that was oxidised [214]. On the contrary, acute oral 
administration of oestrogens to postmenopausal women has been shown to decrease lipolysis, 
by increasing alpha-2 adrenergic activity in both abdominal and femoral SAT [215]. In 
another study, oral oestrogens in postmenopausal women (HRT with ethinyl oestradiol alone, 
in high doses to achieve a physiological range of concentrations), were shown to decrease 
noradrenaline-stimulated lipolysis in abdominal SAT, while addition of norethisterone acetate 
(NET, a progestin with pro-androgenic properties) did not influence that effect [216]. In that 
study, transdermal treatment of postmenopausal women with 17-beta-oestradiol alone or in 
combination with micronised progesterone was without effect on SAT metabolism [216]. 
Also in another study, oral HRT (oestradiol plus NET) in postmenopausal women was shown 
to decrease noradrenaline-stimulated lipolysis in adipocytes from abdominal SAT region, by 
lowering HSL activity and increasing mRNA of alpha-2 adrenergic receptors, while having no 
effect on beta-adrenergic receptors [217]. These results were confirmed by in vitro addition of 
oestradiol to isolated human adipocytes, which increased alpha-2 receptors mRNA and 
number in adipocytes isolated from SAT, but not in adipocytes isolated from VAT [217]. In 
another study in vivo, a 3-month oral oestrogen treatment in postmenopausal women had no 
effect of HSL expression in abdominal SAT adipocytes [218].
Long-term (1-year) oestradiol treatment (together with anti-androgens) in male-to-female 
transsexuals decreased basal lipolysis in abdominal and gluteal SAT adipocytes, which was
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accompanied by an increase in subcutaneous FM [219], but short-term supplementation with 
17-beta-oestradiol in men did not have any effects on lipolysis [220].
Similarly, 1-year testosterone treatment in female-to-male transsexuals increased basal 
lipolysis in abdominal SAT adipocytes, and decreased subcutaneous FM [219], and topical 
administration of androgens in postmenopausal women decreased both total and subcutaneous 
FM [86].
In men, short-term manipulation with testosterone did not have any effects on lipolysis [221]. 
However, testosterone given long-term to men significantly increased catecholamine lipolytic 
responsiveness in abdominal, but not femoral SAT, leading to decreased subcutaneous FM 
[222] [223] [224].
Contrary to the aforementioned studies, oral testosterone given for 3 months to 
postmenopausal women decreased basal lipolysis in abdominal SAT adipocytes, by 
decreasing expression of HSL and increasing expression of PDE-3B [218]. Women with 
polycystic ovarian syndrome (PCOS), who have the increased endogenous production of 
androgens, have reduced HSL protein expression and reduced expression and sensitivity of 
beta-2 adrenergic receptors [225]. In line with this, in vitro testosterone or dihydrotestosterone 
(DHT) addition to isolated human pre-adipocytes, derived from abdominal SAT and VAT, 
reduced the catecholamine-stimulated lipolysis, due to decreased expression of HSL and beta- 
2 adrenergic receptors, and these effects were observed only in pre-adipocytes from 
abdominal SAT, but not VAT [226]. Also in another study [227], DHT added to isolated 
abdominal SAT adipocytes inhibited HSL expression and basal lipolysis.
Data from experiments in rodents indicate that androgens increase lipolysis. In male mice, 
castration decreased lipolysis and beta adrenergic receptor number, while testosterone 
replacement reversed those affects [228]. The findings were confirmed by experiments with 
isolated rat preadipocytes in vitro [229].
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Therefore, androgens can have both stimulatory and inhibitory effect on lipolysis, particularly 
in abdominal SAT (gluteo-femoral SAT is less responsive to androgens [86]), and the effects 
depend on gender, type of androgens, duration of treatment, doses, route of administration and 
presence of other hormones. The effect of androgens on lipolysis in long-term experiments in 
vivo is confounded by the effects of androgens on adipocyte proliferation, differentiation, and 
lipid uptake and accumulation [230] [231]. Additionally, androgens can mediate some of their 
effects indirectly, through their conversion to oestrogens by adipose tissue aromatase activity 
[66] [67] [232], and there are gender and adipose tissue depot specificities in local androgen 
metabolism, which may additionally influence local adipose tissue androgen activity [84] 
[233].
In conclusion, the results from the studies both in vitro and in vivo on the effects of sex 
hormones on adipose tissue lipolysis suggest that female sex hormones (oestrogens and 
progesterone) may have a negative impact on adipose tissue lipolysis in humans, while 
testosterone may have the opposite effect. However, the published data are conflicting and 
indicate that other factors (including gender, concentrations of hormones, acute or chronic 
administration, specific depots characteristics, etc.) might have an additional influence and 
further studies are needed to clarify these effects.
10.1.2. Plasma FFA disposal: whole body uptake (Rd), MCR and non- 
oxidative disposal
The higher rates of FFA appearance expressed per kg FFM or kcal REE in women may be 
related to their increased: 1) storage (re-esterification in adipose tissue, muscle or liver); 2) 
secretion from liver (mostly incorporated in VLDL-triglycerides, but also in other lipoprotein 
fractions and lipids), and/or 3) oxidation (mostly in liver and muscle) [126] [234] [235].
In this study, postmenopausal obese women had higher rates of extracellular plasma fatty acid 
re-esterification (palmitate non-oxidative disposal). This is in agreement with previous studies
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in younger subjects, which either directly measured palmitate non-oxidative disposal [96], or 
estimated it indirectly, through normalization of palmitate Rd for REE [99]. Both obese and 
non-obese premenopausal women had increased non-oxidative disposal compared with BMI- 
matched men [96] [99], and the results from the present study expand those findings to obese 
post-menopausal women.
10.1.2.1. Gender differences in direct FFA uptake and FFA re-esterification
Increased plasma FFA supply stimulates FFA uptake in the cell proportionally with an 
increase in extracellular concentration [236], and this could explain the increased palmitate 
Rd and MCR in women in this study. Additionally, some gender differences in the rate of 
direct fatty acid uptake can contribute to the increased plasma FFA metabolic clearance in 
women [125] [126].
In vitro data showed that subcutaneous adipocytes from women took up and esterified twice 
as much FFA from the extracellular matrix, compared with adipocytes from men [127]. 
Efficacy of FFA storage in postabsorptive state was in a direct proportion with leg FM in 
premenopausal women [126].
With reference to SAT, in one study in vivo, in lean postabsorptive women and men, direct 
plasma FFA uptake (VLDL-independent) into femoral and abdominal SAT adipocytes 
(expressed per gram adipose tissue) was higher in women, compared with men [125]. In non- 
obese men, direct FFA uptake was 30% greater per gram fat tissue in abdominal SAT than in 
femoral SAT, while in non-obese women there was no difference between the two depots 
[125]. In that study, fat tissue biopsies were taken 40-45 minutes after bolus injection of a 
labelled FFA, when labelled fatty acids incorporated in VLDL-triglyceride were still 
negligible in the circulation.
However, in the same study [125], but this time in age- and BMI-matched obese subjects, the
rates of FFA uptake after 6h of continuous infusion (referring both to direct and VLDL-
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dependent fatty acid uptake) were significantly higher in femoral SAT in obese women, 
compared with obese men, while only tended to be higher in abdominal SAT. In obese men, 
the efficacy of FFA storage after 6h of continuous infusion tended to be greater in abdominal 
SAT, compared with femoral SAT. On the contrary, obese women had 40% higher FFA 
storage in femoral SAT [125].
Even though a direct comparison of those 2 studies [125] can not be done, since they 
examined different populations (obese and i  non-obese), and the effect of obesity can not be 
excluded, they showed that in women the rates of FFA uptake after bolus injection were 
similar between the two SAT depots, but were much higher in femoral SAT after 6h of 
continuous infusion. In contrast, in men the rates of FFA uptake after bolus injection were 
much higher in abdominal SAT, but only tended to be higher after 6h of continuous infusion. 
This suggests that femoral SAT in women has a much higher potential for direct fatty acid 
uptake, compared with men, while in men abdominal SAT takes plasma FFA more avidly 
compared with femoral SAT.
Additionally, this indicates a possible tracer recycling and re-distribution in postabsorptive 
states, both in men and women, in the form of FFA released from abdominal SAT, which then 
are taken up by femoral SAT, in the form of plasma FFA (directly), or in the form of 
lipoprotein-derived FFA (where FFA were previously incorporated into VLDL-triglycerides 
in liver and then released by femoral adipose tissue LPL) [125]. Indeed, a recent study in non- 
obese age- and BMI-matched men and women, confirmed that femoral SAT can contribute 
significantly to the fat re-distribution (recycled as FFA and VLDL-triglycerides), both in 
postabsorptive and in postprandial states [237].
As described above, after bolus injection FFA uptake in men was more pronounced in 
abdominal SAT, compared with femoral, and still tended to be higher after continuous 
infusion of a labelled FFA, which suggests that in men there is less fat redistribution during 
postabsorptive states towards femoral fat [125]. In postabsorptive women, in contrast, the
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higher redistribution of fat towards femoral fat was described, contributing to the typical 
gynoid body fat distribution [125].
In line with this findings, in men gene expression of fatty acid transporters FAT/CD36 and 
fatty acid transport protein (FATP)-4 in adipocytes from femoral SAT was lower, compared 
with women [125]. While in men the expression of FAT/CD36, FATP-1 and FATP-4 was 
higher in abdominal adipocytes, compared with femoral, in women there was no difference 
between the two depots [125].
With respect to VAT, in women, VAT contributes little in direct FFA uptake (only 8%), while 
the upper-body and lower-body SAT contribute with 53% and 39%, respectively [126]. 
However, in men, direct FFA uptake per gram adipose tissue is higher in VAT than in 
abdominal SAT, and the contribution of VAT to total fatty acid uptake is only 1.5 times lower 
than contribution of abdominal SAT [238].
As it was previously mentioned, women do not only have increased fatty acid uptake in 
adipocytes, but also have higher rates of their re-esterification and triglyceride synthesis 
[127]. Both insulin and acylation stimulating protein (ASP) favour that process, promoting 
fatty acid trapping [139] [177]. Additionally, both insulin and ASP are involved in higher 
adipocyte glucose uptake and conversion to fatty acids [139].
There is evidence that VAT, compared with abdominal SAT, has lower ASP receptor number 
and lower ASP and insulin receptor affinity and activation, and therefore lower capacity for 
re-esterification, both in women and men [139] [140] [239]. Studies show that women in 
general have a higher ASP-receptor density and affinity in VAT and abdominal SAT, 
compared with men [139]. Additionally, obese women, compared with non-obese women, 
have increased ASP-receptor affinity in abdominal SAT and decreased in VAT [139]. On the 
contrary, obese men have increased ASP-receptor affinity in VAT, but decreased in 
abdominal VAT, compared with non-obese men [139].
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Re-esterification and lipid storage in adipocytes are also under the control of enzymes 
PEPCK-1 [240], SCD-1 [241], adiponectin and PPAR-gamma [242]. SCD-1 stimulates 
storage and inhibits the oxidation of fatty acids [241] [243] [244]. In subcutaneous abdominal 
adipocytes of women mRNA content of PEPCK-1, SCD-1, adiponectin, PPAR-gamma and 
PPAR-alpha, is higher compared with men [184].
In summary, direct FFA uptake into adipocytes and efficacy of fat storage is higher in women, 
especially in SAT. This is may additionally contribute to the observed higher palmitate Rd, 
MCR and non-oxidative disposal in women in this study, apart from the effect of increased 
FFA supply. In women, SAT has higher efficacy of FFA uptake and storage, compared with 
VAT, particularly in femoral region. In men, VAT has higher efficacy of FFA uptake and 
storage, compared with SAT, and in men abdominal SAT has higher efficacy compared with 
femoral SAT. The gender differences in regional adipose tissue FFA uptake and re- 
esterification may make a contribution to the known gender differences in body fat 
distribution.
Higher lipolysis rate and FFA turnover in women does not have to be related only to adipose 
tissue.
A substantial fraction of whole body FFA turnover is related to skeletal muscle [245], in 
which an intensive triglyceride re-synthesis, deposition and lipolysis occurs [179] [246] [247]. 
In women this turnover seems to be increased [128]. In muscle, increased expression and 
protein content of fatty acid transporters, including FAT/CD36, FATP-1, FATP-4, plasma 
membrane and cytosolic FABP (FABPpm and FABPc) [248] [249], and enzymes involved in 
lipid storage, e.g. mtGPAT (mitochondrial glycerol-3-phosphate acyltransferase), have been 
described in women [250] [251].
Additionally, re-esterification in the liver can have an important contribution to the whole 
body non-oxidative disposal [234]. It was shown that only a small fraction (4-8%) of systemic 
FFA turnover appears in VLDL-triglycerides, yet the majority of FFA in VLDL are from
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systemic FFA [126]. Gender differences in liver fatty acid transporters (e.g. cytosolic hepatic 
hFABP), and enzymes involved in lipid storage (e.g. GPAT and ACSL), have been also 
described, showing higher mRNA and protein contents and/or activity in females [252] [253] 
[254] [255] [256] [257] [258]. Moreover, increased direct FFA (palmitate and oleate) uptake 
into hepatocytes isolated from females, compared with hepatocytes isolated from males, has 
been shown in humans [259] and rodents (rats) [260] [261].
In conclusion, women, compared with men, have higher potential for FFA uptake, re- 
esterification and non-oxidative disposal in adipose tissue, skeletal muscle and liver, related to 
the increased content and/or activity of fatty acid transporters, enzymes, receptors and 
transcription factors involved in those processes. Higher potential for direct FFA uptake and 
re-esterification, conduce to higher FFA metabolic clearance in women. The higher non- 
oxidative FFA disposal is also observed in obese postmenopausal women in this study, 
suggesting that the effect is independent from menopausal status, and accounted for the most 
of the observed higher FFA Rd and MCR in the female group.
10.1.3. Plasma FFA oxidation rates
The higher rates of FFA appearance expressed per kg FFM or kcal REE in women also
offered a possible explanation why women in this study tended to have higher plasma
palmitate and FFA oxidation rates compared with men, since increased FFA supply and
increased plasma FFA concentrations promote a preferential usage of plasma FFA as a fuel
for oxidative purposes, at the expense of other sources, e.g. carbohydrates (Randle’s theory
[262]) or non plasma- derived fatty acids, e.g. from VLDL-triglyceride lipolysis. Studies have
shown that high plasma FFA concentration can influence LPL activity by promoting the
release of LPL from the endothelial wall in capillary beds [263], consequently decreasing the
availability of competitive fatty acids derived from hydrolysis of plasma lipoproteins.
Whether increased plasma FFA supply to the tissues with a high fat oxidative capacity
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(including liver, myocardial and skeletal muscle) can preferentially increase their usage in 
competition with the usage of fatty acids from intracellular lipid stores (e.g. IMCL and IHCL) 
is less explored and clear. Probably, because of rapid cycles of re-esterification within a cell 
(as shown in hepatocytes [264] and myocytes [265] [266]), with a high turnover of the 
intracellular fatty acid pool, the usage of both plasma and stored intracellular fatty acids 
would be concomitantly increased.
Published data indicate that newly entered external fatty acids in skeletal muscle are guided 
towards oxidation and re-esterification in proportion 1:2, but some studies indicated that 
external fatty acids need firstly to enter the intracellular triglyceride pool before being 
oxidised in skeletal muscle [266] [267] [268]. In line with this, the studies exploring 
discrimination in the usage of fatty acids from different sources for oxidation in skeletal 
muscle, indicate equal or more preferential use of plasma FFA in resting conditions [247] 
[269]. They revealed that intracellular fatty acids and plasma FFA can contribute to fatty acid 
oxidation in ratio 1:1 up to 1:2 during rest, while during exercise the contribution of 
intercellular stored triglycerides increases, to make ratio of 1:1 in men [247] [270] [271] 
[272], while in women, in contrast, there is still higher contribution of plasma FFA (providing 
about 75% of total fatty acid oxidation) [113].
FFA oxidation in liver contributes in a great extent to whole body FFA oxidation. It was 
estimated that liver contributes equally as skeletal muscle (about 20%) in total energy 
expenditure in the Reference Man (70kg; skeletal muscle: 28kg, 13.1 kcal/day/kg tissue; liver: 
1.8kg, 200.6 kcal/day/kg tissue) [273]. Women have lower muscle mass, thus the contribution 
of visceral organs (which have higher energy expenditure rate per gram of tissue than 
muscle), including liver, to total body energy expenditure is even higher [273] [274] [275] 
[276] [277] [278] [279]. In liver, increased fatty acid supply stimulates not only intrahepatic 
lipid storage, assembly and secretion of VLDL-triglycerides, but also fatty acid beta-oxidation
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[280] [281] [282], and the ratio between those processes may vary, depending on numerous 
factors, including gender [283].
Therefore, there is evidence that increased plasma FFA supply to the tissues with high 
oxidative capacity stimulates their usage as a fuel for oxidation [176] [284], and this could 
offer an explanation why in this study obese postmenopausal women, who had higher plasma 
FFA levels and supply rates per kg FFM (metabolically active tissues), had also higher 
plasma FFA oxidation rates, than men. Indeed, the results from this study (data presented in 
Appendix, the section on correlations), and previous studies [113] [262] [285], showed that 
plasma palmitate oxidation rates were in a direct proportion with palmitate release and FFA 
concentrations.
Nevertheless, some more specific gender differences in preferences for fatty acid oxidation 
can also be included.
Most studies showed that women during endurance exercise of moderate intensity show 
increased fat oxidation compared with men [33] [113] [207] [250] [286] [287] [288] [289] 
[290] [291]. Therefore, during exercise, women rely more on fat as a fuel source, sparing 
glycogen, while men use more carbohydrates as a fuel source, and their glycogen reserves 
become more depleted [286] [288] [292]. The possible explanation for this is that women 
have higher IMCL lipid stores [289], and IMCL become increasingly used as a fuel during 
exercise [267] [293]. However, plasma FFA are also used more in exercising women, 
compared with men [113]. Therefore, women are more primed for increased fatty acid usage 
for oxidation during exercise, while men are more primed for glycogen usage. Since glycogen 
energy reserves are more limited in the body, women seem to be more capable of prolonged 
moderate intensity physical activity without exhaustion, compared with men [250] [294].
The analysis of skeletal muscles showed numerous gender differences in the morphology and 
function, which could offer an explanation for these findings. Women have more oxidative, 
slow twitch, type I fibres, which are rich with mitochondria and preferentially oxidise fatty
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acids, while men have more fast twitch, glycolytic, anaerobic, type II fibres, which 
preferentially oxidise glucose [289]. There is evidence that type I fibres have increased fatty 
acid turnover, and one study indicated 10 times more rapid turnover in the gastrocnemius 
muscle, which is rich in type I fibres, than in subcutaneous fat tissue, significantly increasing 
the contribution of skeletal muscle to whole body fatty acid turnover [247]. Some other 
factors also predispose women for higher usage (uptake, re-esterification, storage and 
oxidation) of fatty acids in skeletal muscle compared with men. FFA can enter skeletal muscle 
through processes of passive diffusion (depended on the concentration gradient, by the “flip- 
flop” mechanism), and through facilated protein-mediated transport [266] [295]. Women, 
compared with men, have increased mRNA and/or protein content of fatty acid transporters 
which are involved in myocellular fatty acid uptake, re-esterification and oxidation processes, 
including FAT/CD36, FATP-1 and FATP-4, FABPpm and FABPc [248] [249]. Additionally, 
women have higher mRNA level of LPL, SREBP-lc, mtGPAT, and higher mRNA and 
protein content of HSL, predisposing for higher fatty acid turnover (uptake, synthesis de novo, 
re-esterification, storage and lipolysis) in skeletal muscle [248] [249] [289]. Also, the mRNA 
content of proteins and enzymes involved in fatty acid oxidation is increased, including CPT- 
1, nuclear receptors (PPAR-alpha, PPAR-delta) and ACAA2 (acetyl-CoA acyltransferase 2), 
TFP-beta (trifiinctional protein-beta, known also as HADH-beta), SCHAD (short chain 
hydroxyacyl-CoA dehydrogenase), citrate synthase, catalase and UCP-2 [248] [249] [268]. 
The protein content of beta-oxidation enzymes in skeletal muscle, TFP-alpha (trifiinctional 
protein-alpha) and very long chain and medium chain acyl-CoA-dehydrogenase (VLCAD and 
MCAD), was also increased in women [251]. Women had also higher mRNA of myosin 
heavy chain I, insulin receptor, GLUT-4, glycogen synthetase and MAPK 6 and 8 [248] [249] 
[289] [296]. Thus, the existing data indicate that women, through the activity of their genes in 
skeletal muscle, are primed for increased FFA turnover and oxidation.
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There is no previous evidence in humans that women in resting conditions have increased 
plasma fatty acid oxidation rates per kg FFM or kcal REE compared with BMI matched men, 
as shown in this study. In most studies where premenopausal women were studied, the gender 
effect was not found in resting postabsorptive conditions [33] [113] [207] [250] [286] [287] 
[288] [289] [290] [291] [297] [298]. In many of these studies only fat oxidation rates 
estimated by indirect calorimetry were compared, without using tracer studies to estimate the 
effect on plasma FFA kinetics.
The effect of menopause on gender differences is even less studied. In one study, 
postmenopausal women had higher fat oxidation rates, estimated by indirect calorimetry, 
compared with premenopausal women [111]. Although in that study subjects did not differ 
significantly in BMI, the mean BMI in premenopausal vs. postmenopausal women was 22.2 
vs. 26.5 kg/m2, and postmenopausal women had higher %FM (almost doubled), as well 
plasma FFA concentrations, which probably explained the higher fat oxidation rates [111]. 
Very few studies have compared fat oxidation in postmenopausal women and men, and fat 
oxidation was estimated only by indirect calorimetry in those studies [110] [297] [299] [300]. 
In one study in age- and BMI-matched obese postmenopausal women and men [299], fat 
oxidation adjusted for FFM was higher during exercise in women than in men, and RQ was 
lower not only during exercise, but also in resting conditions, indicating preferential use of fat 
for oxidative purposes over carbohydrates. In that study, the level of oestradiol in women and 
men was not different, indicating that oestrogens per se do not explain the gender difference 
[299]. In another study by Toth et al. [110], where proper matching of subjects for BMI and 
age was not done, fat oxidation was increased (and RQ was lower) in men in resting 
conditions, and this remained significant after adjustment for differences in FFM. In the 
present study gender differences in RQ were not found. The possible explanation for the 
discrepancy between that study [110] and the present study is the diversity in BMI and age of 
the subjects studied by Toth et al., and it is known that both BMI and age per se significantly
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influence the oxidation rates [208]. In addition, the number of subjects in that study was 
limited (12 subjects in each group). In another study by Levadoux et al. [298], 
postmenopausal women also had lower resting (sleeping) fat oxidation rates, compared with 
age- and BMI-matched men, but the differences were fully accounted for by the differences in 
FFM and energy balance. Yet again, in that study as well the number of subjects was limited 
(10 subjects in each group) to make a more reliable conclusion. In contrast, there was a study 
including a higher number of subjects (427 men and 293 women), by Nagy et al. [300], where 
both age and body fatness varied in a broader range (e.g. in men and women, respectively, age 
varying from 17-90 years and 18-88 years, and %FM varying from 4.0-42.9% and 9.1- 
55.4%). In that study as well the fat oxidation rates were lower in women, and this remained 
significant after adjustment for FFM or REE. However, the high diversity in age and body 
fatness of the study subjects did not allow to examine the effects separately in obese and non- 
obese subgroups, and distinguish the findings in premenopausal and postmenopausal women, 
compared with the age-matched men. Therefore a direct comparison of those findings with 
the finding from the present study can not be done.
A caution in this study needs to be taken when interpreting data, since estimated TPFAO were 
significantly increased in women, while palmitate oxidation rates only tended to be increased, 
without reaching statistical significance. TPFAO were calculated from the palmitate oxidation 
rates and the contribution of palmitate in total plasma FFA. However, even though palmitate 
was found to be well representative for metabolism of total plasma fatty acids, the other 
plasma FFA have different properties and may not have the same potential for oxidation as 
palmitate, therefore making the conclusion on gender difference in TPFAO less reliable [301]. 
In summary, the increased palmitate oxidation rates in women in this study can be explained 
by the increased palmitate supply to the tissues with high oxidative capacity (including 
skeletal muscle and liver). However, some intrinsic characteristics of the oxidative tissues can 
additionally contribute to the increased potential for fatty acid oxidation in women.
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Nevertheless, previous data comparing both obese and non-obese premenopausal women and 
men did not show increased plasma FFA oxidation rates in women in resting postabsorptive 
conditions (even though they also showed increased FFA supply, but fully accounted for by 
increased non-oxidative disposal), and a possible effect of menopause cannot be excluded. 
Further research exploring the effect of menopause on plasma FFA oxidation is warranted.
10.1.3.1. The effects of sex hormones on fatty acid oxidation
Several studies examined the effect of sex hormones on fatty acid oxidation rates. The results 
revealed different effects, depending on species (animal or human studies).
In animals (rodents), oestrogens increase fatty acid oxidation, while addition of progesterone 
can abolish that effect [302]. Administration of oestrogens in male [210] and female [303] rats 
lowered the whole body RQ, carbohydrate and protein oxidation rates, and increased fat 
oxidation rates during exercise [304] [305] [306].
The effects of oestrogens on energy expenditure can be mediated through the central effects, 
stimulating SNS activity [82]. Also some direct effects on muscle and liver metabolism can 
be exerted [82]. In female ovariectomised rats supplemented with oestradiol, higher muscle 
CPT-1 and HADH-beta activities were observed, suggesting a higher potential for beta 
oxidation after oestrogen supplementation [306].
In agreement, ovariectomy in rodents leads to development of obesity and insulin resistance
[82] [307]. Ovariectomised rodents gain fat (especially visceral fat), have decreased energy
expenditure, SNS activity and spontaneous locomotor activity, while have only a transient
increase in appetite [307] [308]. Estrogen substitution reverses those effects [309] [310]
[311]. It was proposed that most of the oestrogen effects are mediated through ER alpha, since
selective ER alpha agonists reversed the effects of ovariectomy, while ER beta agonists did
not exert any effects [309]. In addition, ER alpha -/- animals with intact ovaries have the same
features as ovariectomised wild type animals [310] [312] [313] [314] [315]. Interestingly,
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ovariectomy in ER alpha -/- animals leads to improvement of the metabolic features (liver 
steatosis, dyslipidemia, visceral obesity and insulin resistance) [316], suggesting some contra- 
effects of ER beta or progesterone [316] [317] [318] [319] [320] [321] [322] [323]. 
Furthermore, aromatase deficient mice share the same phenotype as ER alpha deficient mice, 
and both oestrogen replacement and treatment with a selective ER alpha agonist reverses the 
metabolic features in those animals [324] [325] [326] [327] [328] [329]. Interestingly, ER 
beta deficient mice, contrary to aromatase and ER alpha deficient mice, are protected from 
obesity, insulin resistance and dyslipidemia when they are on a high-fat diet, suggesting that 
ER beta stimulation can exert a pro-obesogenic effect [313].
Regarding the effects of androgens, also AR deficient mice with advancing age progressively 
develop obesity, increased lipid accumulation in liver and muscle, reduced insulin sensitivity 
and increased leptin levels [330] [331]. The effects are more pronounced in male animals 
[331] [332]. This suggests that androgens as well have a stimulating effect on basal 
metabolism (and possibly fat oxidation).
However, the results from studies in rodents can not be directly referred to humans, since 
differences in sex-steroid actions have been described between species [60].
Indeed, studies in humans exploring the effect of sex hormones on fat oxidation have revealed 
conflicting findings.
In men, similarly as in animals, administration of oestrogens (oestradiol) also lowered the 
whole body RQ, carbohydrate and protein oxidation rates, and increased fat oxidation rates at 
rest and during exercise [304] [305] [306]. In agreement, in men administration of oestradiol 
increased the skeletal muscle protein content of mRNA of PPAR-alpha, PPAR-delta, CPT-1, 
TFP-alpha, PGC-1 alpha (PPAR-gamma co-activator-1 alpha), GLUT-4 and glycogen 
synthetase [306], and increased HADH-beta and MCHAD (medium chain hydroxyacyl-CoA 
dehydrogenase) [249] [306], indicating the increased potential for fatty acid oxidation in
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skeletal muscle, as well as glycogen storage. In vitro, oestradiol enhanced palmitate oxidation 
rates in human myotubes from male donors [333].
On the other hand, data on the effects of sex-hormones on fatty acid oxidation in women are 
more conflicting.
Some studies have not found the influence of menstrual cycle phase on fat oxidation [106] 
[214] [334] [335] [336] [337] [338], but some have shown that FFA oxidation during exercise 
(but not at rest) was increased in luteal phase, indicating the effect of oestrogens and/or 
progesterone [339] [340] [334]. Among oral contraceptive users, fat oxidation was increased 
during prolonged exercise in some studies [341], but not in others [342] [343]. In one study in 
amenorrhoeic women, ethinyl oestradiol supplementation did not affect fatty acid oxidation at 
rest or during exercise [212]. In contrast, in another study [344], ethinyl oestradiol 
administration in an amenorrhoeic woman decreased both the postabsorptive and postprandial 
resting fat oxidation in a dose dependent manner. Additionally, a single dose of oestradiol in 
16 postmenopausal women reduced basal lipid oxidation, and reduced lipolysis in adipose 
tissue [215]. On the other hand, in vitro, oestradiol did not influence palmitate oxidation rates 
in human myotubes from female donors [333]. Therefore, the effects of sex hormones on 
postabsorptive fatty acid oxidation in women have not been not uniformly confirmed [343], 
and additional studies are needed.
Even though gender differences in fat oxidation between men and premenopausal women 
have not been previously demonstrated in resting postabsorptive conditions, they have been 
demonstrated in postprandial states by some studies [345].
Women store fat more efficiently, because of reduced postprandial fat oxidation [345]. This 
goes along with the fact that men oxidize more dietary fat than women, and women store 
higher percentage of dietary fatty acids in fat tissue [294] [345]. In postprandial states (after 
mixed carbohydrate and fat meals) women use more carbohydrates for oxidative purposes, 
having increased “metabolic flexibility” (the ability to shift the substrate use), as a
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consequence of increased sensitivity to insulin mediated postprandial suppression of lipolysis 
[294]. This may be related to the effect of female sex hormones. Oral estrogens (because of 
higher doses), but not transdermal, decrease fat oxidation in postprandial states, which could 
be associated with decreased FFA flux [305] [346] [345] [347] [348]. Furthermore, “the first- 
pass effect” of oral oestrogens on fat oxidation in the liver could be included, since 
overstimulation of ER alpha in the liver could counteract some of the effects of PPAR-alpha 
on fatty acid oxidation, through the “nuclear receptors cross-talk” [310] [316] [317]. 
Nonetheless, there are also findings which have not confirmed that oral estrogens influence 
postprandial fat oxidation rates, both at rest and during exercise [214] [338] [342] [343], and 
therefore, additional studies are required.
The effects of androgens on fatty acid oxidation are even less studied. In male subjects, a 
gonadotropin-releasing hormone (GnRH) analogue androgen deprivation therapy was shown 
to decrease resting fat oxidation in both postabsorptive [349] and postprandial [350] states. 
However, the effect cannot be distinguished from the effect of oestrogen deprivation in these 
subjects, since GnRH analogues decrease both androgen and oestrogen production. In 
contrast, in another study in 8 young, healthy men, either testosterone deprivation (with a 
GnRH suppressant) or transdermal administration of testosterone did not influence 
significantly the rates of postabsorptive and postprandial fat oxidation at rest or during 
exercise [221]. In addition, a 2-year transdermal testosterone replacement in elderly androgen- 
deficient men had no effect on meal fat oxidation [351]. Quite the opposite, in a study in 13 
men with hypopituitarism, transdermal but not oral testosterone treatment increased 
postabsorptive fat oxidation at rest [352]. In a study with 8 healthy postmenopausal women, a 
2-week oral testosterone administration, in a dose to increase only portal concentrations of 
testosterone, without a systemic spill-over into the systemic circulation, did not change resting 
postabsorptive fat oxidation rates [353]. Finally, in vitro, testosterone treatment increased 
palmitate oxidation in myotubes from both male and female donors, and this effect was
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abolished at the presence of androgen receptor antagonist [333]. Therefore, the studies 
examining the effects of androgens on fatty acid oxidation rates in humans are limited and 
revealed conflicting findings, and thus more studies need to be performed to further assess 
this issue.
In conclusion, data in animals indicate that both oestrogens and (to a lesser extent) androgens 
can have a positive effect on fatty acid oxidation rates, in both genders, while in females 
progesterone can have the opposite effect. In contrast, data in humans are more conflicting, 
suggesting probably the gender-specific effects. Data indicate that oestrogens can promote 
fatty acid oxidation during exercise, while diminish it during non-exercising periods (the latter 
particularly in postprandial states). This may be related to more efficient fat storage in 
women, as a consequence of the effect of oestrogens on reduced FFA supply (lipolysis) and 
increased lipid accumulation in adipose tissue during non-exercising periods. Additionally, 
oestrogens, in higher doses, may adversely influence fatty acid oxidation in liver. Data on the 
effects of androgens are more limited and conflicting, indicating a probable positive influence 
on fat oxidation, although to a lesser extent compared with oestrogens. Therefore, the effects 
of sex hormones on fatty acid oxidation in humans are still sparsely explored, and further 
studies are desirable.
10.2. VLDL-kinetics
Several studies have compared VLDL-triglyceride kinetics between premenopausal women 
and men matched for BMI [98] [100] [103] [104] [105], but only one study examined directly 
the gender differences in VLDL-triglyceride kinetics between postmenopausal women and 
men [97]. However, in that study subjects were matched for BMI, but not for age (men were 
younger), and it is known that age per se can influence VLDL-triglyceride kinetics [354]. 
Additionally, FCRs of VLDL %- and VLDL^-triglyeeride subfractions were not explored in that 
study.
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In the present study, men tended to have increased VLDLi-triglyceride APRs (expressed in 
absolute terms and per kg BW, and to a lesser extent per kg FFM and kcal/min REE), while in 
women VLDLz-triglyceride APRs tended to be higher. VLDLi- and VLDLi-triglyceride 
plasma secretion rates (in pmol/min per ml plasma) were not different. When total body fat 
amount was taken into consideration, VLDLi-triglyceride production (per kg FM) was almost 
doubled in men. This means that although men have lower total body adipose tissue (which 
provides the main source of fatty acids for VLDL-triglyceride synthesis), their VLDLi- 
triglyceride production is higher. In this study visceral FM in men was significantly higher 
than in women (-1.5 times, and the contribution of visceral fat to total fat was almost 
doubled61), and it is known that visceral fat could contribute to increased hepatic FFA supply. 
This could be related also to increased IHCL and the development of fatty liver [355], and 
increased production of large, triglyceride rich VLDLi-particles, which present the 
characteristic of insulin resistance and metabolic syndrome [356].62
Furthermore, as previously mentioned, some evidence exists that in obese men lipolytic 
activity of visceral fat per gram tissue is higher than in women, which can additionally 
increase hepatic FFA supply. Even in lean subjects, in men visceral fat contributes more to 
total fatty acid turnover than in women (13% vs. 9%), and in obesity the difference is higher, 
because of further increased lipolysis, related to a larger fat-cell volume, increased sensitivity 
of beta-3 adrenoreceptors, decreased sensitivity to alpha-2 adrenergic receptors, and increased 
ability of cAMP to activate HSL [143].
Apart from the influence of visceral FFA supply (and probably some of the adipokines and 
cytokines, secreted from VAT [90] [136] [147] [357]), some specific differences in hepatic 
metabolism and VLDL-particle assembly and secretion could also exist. Expression of
61 This part o f  the study belongs to the Katherine Backhouse’s PhD thesis work. VAT(kg): 4 .1± 1.4kg vs. 
6.0±1.1 kg (p=0.007) and VAT (as % o f  total fat): 9.9±3.4% vs. 17.5±3.5% (p<0.001), female vs. male, 
respectively [714].
62 In this study, in men IHCL was 30% higher, although this was not statistically significant: IHCL (expressed 
as a ratio to liver water content): 14.0±20.6% vs. 18.3±14.0% (p=0.137), female vs. male, respectively).This 
part o f  the study also belongs to the Katherine Backhouse’s PhD thesis work [714].
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numerous factors involved in liver lipid metabolism has shown gender diversity [235] [358]. 
For example, microsomal triglyceride transfer protein (MTP) is important for VLDL-particle 
assembly (transfer of triglycerides to apoB and addition of triglycerides to primordial VLDL- 
particles). Studies in animals have shown that MTP mRNA and protein expression is higher 
in female rats than in male rats [359] [360]. Also apoE could be involved in the gender 
difference in VLDL-triglyceride production and clearance, since some gender differences in 
apoE metabolism have been described in humans [359]. The rate of cholesterol synthesis and 
metabolism also has been shown to be influenced by gender [312] [361].
In the study of Gormsen et al., men also tended to have increased VLDL-triglyceride 
production rates (expressed in pmol/min), compared with premenopausal women, while 
VLDL-triglyceride secretion rates into plasma (expressed in pmol/min/ml plasma) were not 
different. Nevertheless, in that study subjects were younger and leaner than in the current 
study [100].
Other studies have shown that lean premenopausal women, compared with lean men, could 
have similar VLDL-triglyceride APR (expressed in pmol/min), but higher VLDL-triglyceride 
plasma secretion rates (expressed in pmol/min/ml plasma), because women generally have 
lower plasma volume compared with men [103] [105]. On the other hand, both VLDL-apoB 
production and secretion rates were lower in lean women in these studies [103] [105]. 
Therefore, lean premenopausal women secrete VLDL-particles which are richer in 
triglycerides, and data show that those particles are more readily cleared from plasma [103]. 
In contrast, men not only produce more apoB particles [103], they also have lower VLDL- 
apoB clearance. In obesity, production of VLDL-triglycerides and apoB is increased in obese 
men, both in fasting conditions and during hyperinsulinaemic-euglycaemic clamp [105] [362], 
while plasma clearance (in ml plasma/min) is not different in fasting conditions and is 
decreased only during hyperinsulinaemic-euglycaemic clamp [105] [362]. In contrast, in 
women in obesity there is a more significantly reduced plasma clearance of VLDL-
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triglycerides in fasting conditions [105]. Obese women, after menopause, have further 
increased rates of VLDL-triglyceride secretion, compared with BMI-matched premenopausal 
women, while VLDL-apoB secretion is not different; therefore, their VLDL-triglyceride/apoB 
ratio was further increased.
Comparing pre- and postmenopausal women, in a study by Magkos et al. [97], both hepatic 
VLDL-triglyceride secretion and plasma VLDL-triglyceride clearance were higher in obese 
postmenopausal, compared with BMI-matched obese premenopausal women, while plasma 
triglyceride and VLDL- triglyceride concentrations were similar, suggesting that the increased 
VLDL-triglyceride production in obese postmenopausal women was compensated by the 
increased VLDL-triglyceride clearance. That was in agreement with some studies in which 
postmenopausal women, compared with premenopausal women, after well controlling for 
age, BMI, and/or body fat, had similar fasting plasma triglyceride and VLDL-triglyceride 
concentrations [16] [97].
Comparing postmenopausal women and men, VLDL-triglyceride secretion (in pmol/min/ml 
plasma) was similar between obese postmenopausal women and BMI-matched men in the 
study of Magkos et al. [97]. The results from the present study are in accord with those 
findings.
In the present study, women were shown to have increased VLDLi- and VLDL^-triglyeeride 
FCRs expressed in absolute terms (pools/day), and the difference remained significant even 
after adjustment for the diversity in BW, FFM and REE, and was lost only after adjustment 
for total body adiposity. This indicates that in women higher VLDL-triglyceride FCR could 
be related to increased total FM, with probably increased VLDL-triglyceride LPL hydrolysis, 
fatty acid uptake and re-esterification in adipose tissue. It is known that total FM is 
proportional to plasma post-heparin LPL concentration [363], and this could provide an 
additional mechanism to explain relation between total adipose tissue mass, LPL activity and 
gender differences in VLDL-triglyceride clearance.
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The results from this study are in agreement with previous results which have examined the 
gender differences in VLDL-triglyceride clearance [48] [97] [98] [100] [103] [104] [105] 
[364], where both premenopausal and postmenopausal lean women were shown to have 
increased VLDL-triglyceride plasma clearance (per ml plasma/min) or FCR (pools/day). Only 
in one study the effect of gender on VLDL-triglyceride clearance was not shown, but in that 
study the BMI of subjects varied in a broad range [100]. In obese subjects, the gender 
difference diminished, because VLDL-triglyceride plasma clearance per ml plasma decreased 
in women, but remained unchanged in men [105], and obese men could have lower plasma 
clearance (per ml plasma) than age- and BMI-matched premenopausal women [105]. That 
effect could be partially explained by the difference in plasma volume between lean and obese 
subjects, since differences in body mass and body surface area contribute to the differences in 
calculated plasma clearance (per ml plasma).
Women have been generally shown to have increased both VLDL-triglyceride and apoB 
clearance (higher FCR and lower MRT), compared with men, but the difference in VLDL- 
triglyceride clearance was more pronounced than the difference in VLDL-apoB clearance, 
probably because of the effect of LPL, which contributes more to lipolysis of VLDL- 
triglycerides, and less to the whole VLDL-particle uptake [16] [363]. In one study, even 
though lean premenopausal women had increased VLDL-triglyceride plasma clearance 
compared with men, their VLDL-apoB plasma clearance was not different [103]. When 
VLDL apoB and triglyceride MRT was compared, both VLDL apoB and triglyceride MRT 
were lower in females [103].
In the present study, in both genders, FCRs for VLDLi- and VLDL^-triglyeerides were 
similar. This indicates that there was no difference in VLDL-triglyceride clearance between 
VLDLi and VLDL] subtractions. Some previous studies indicated that larger, triglycerides- 
rich VLDL-particles (e.g. as are VLDLi compared with VLDLi), are more easily cleared from 
plasma, since LPL has higher preference for larger particles [16] [48]. However, this can be
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related also to specific composition of apoCII, apoCIII and apoE of such particles, which can 
vary within subjects [358]. Triglycerides in VLDLi subfractions can derive both from direct 
secretion from liver and from hydrolysis of triglycerides in VLDLi, and probably in 
individual subjects the composition of apoCII, apoCIII and apoE is similar in both fractions. It 
is estimated that about half of apoB in VLDLi subfractions is directly cleared from 
circulation, without appearing in denser fractions, probably through the LRP (LDL-receptor 
related protein) and the VLDL-reeeptor, and LPL stimulates the process of whole VLDL- 
particle uptake in the cells [358]. VLDLi particles are more readily cleared directly by the 
LDL-receptor [358]. In agreement with the present study, the rates of hydrolysis of 
triglycerides in VLDLi and VLDLi were similar in study of Adiels et al. [365], in normal- 
weight and overweight normolipidaemic subjects, but the gender characteristics of the 
subjects were not presented [365].
10.2.1. The mechanisms underlying the gender differences in VLDL- 
triglyceride metabolism
Both the effects of sex hormones and some intrinsic factors which express gender dimorphism
could be involved in the identified gender differences in VLDL-triglyceride metabolism.
In general, administration of exogenous oestrogens in women has been shown do decrease fat
oxidation and increase VLDL-triglyceride secretion. However, this effect was observed only
with orally given oestrogens [70] [76] [366]. Oral oestrogens in postmenopausal women were
found to stimulate VLDLI-triglyceride (and apoB) production, with no effect on VLDLi
production. Transdermally administered oestrogens did not alter VLDL-triglyceride
production [70] [76], therefore the effect of orally administrated oestrogens could be
explained by the “first-pass-effecf ’ in the liver. Because more than 90% of the oestrogen dose
in HRT formulation is reduced by direct catabolism in the liver during first pass, and only a
small proportion reaches circulation, the dose of oestrogens in oral HRT formulations must be
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increased [367]. The effect on VLDL-triglyceride and apoB secretion could be explained 
through a direct effect of oestrogens (or their metabolites) on liver enzymes, nuclear receptors 
and other proteins involved in fatty acid and lipoprotein metabolism, or by indirect effects of 
oestrogens on metabolism in other tissues, e.g. through the effects of oestrogens in CNS, 
SNS, growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis, muscle, pancreas and 
adipose tissue, affecting the kinetics of FFA, glucose, insulin, and production of adipokines, 
myokines and chemokines, which can influence VLDL-triglyceride metabolism (e.g. leptin 
and adiponectin decrease VLDL-triglyceride secretion and increase VLDL-triglyceride 
clearance) [133] [136] [308] [366] [368] [369] [370].
Increased triglyceride secretion can be explained by the inhibition of hepatic beta-oxidation, 
by interfering adversely with PPAR-alpha signalling pathway directly (“the first pass effect” 
in the liver, through ER alpha), therefore guiding fatty acids more towards secretion [317], or 
indirectly, by interfering adversely with PPAR-gamma in adipocytes (only when present in 
high doses, through ER beta), thus decreasing FFA “trapping” in adipose tissue and inhibiting 
adiponectin secretion (while adiponectin in turn activates AMPK and PPAR-alpha in the 
liver) [318].
Oral oestrogens not only increase both VLDL-apoB and triglyceride secretion, but also 
increase the cascade of VLDL—>IDL—»LDL transformation and increase LDL apoB direct 
catabolism, by inducing the LDL/apoB 100-receptor [371] [372] [373] [374] [375]. Formation 
of small dense LDL and catabolism of HDL-cholesterol was also decreased, because of 
reduced activity of HL [376] [377] [378]. Oral oestrogens did not influence CETP activity 
[372] [379], while have different effects on adipose tissue LPL activity (the conflicting 
findings have been reported) [215]. Additionally, some changes in apoE and apoCIII content, 
influencing catabolism of apoB containing particles, have been described after oral oestrogen 
use [380] [381].
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In contrast to the effects of oral oestrogens on VLDL-triglyceride and VLDL-apoB secretion, 
VLDL-triglyceride and VLDL-apoB clearance rates were not affected by oral estrogens [16] 
[366] [375] [382] [383] [384]. Transdermal administration of oestrogens, in contrast to oral 
administration, did not influence plasma VLDL-triglyceride and apoB concentrations and 
kinetics (production and clearance) [375]. Additionally, there was no effect of menstrual cycle 
phase on VLDL-triglyceride and VLDL-apoB kinetics [16].
Progestins have been shown to have a hypotriglyceridaemic effect, irrespective of the route of 
administration, since they increase both VLDL-triglyceride and apoBlOO clearance, through 
their effects on LPL activity [382] [385].
Data on the effects of androgens on VLDL-triglyceride and apoB concentrations and kinetics, 
are still scarce. In healthy young and elderly men, as well in hypogonadal men, androgens 
have not shown a significant effect, regardless of the route of administration and potential for 
aromatisation [16] [386]. In women, only orally given and aromatisable androgens (similarly 
as the orally given oestrogens), increased triglyceride concentrations due to a prominent 
increase in hepatic triglyceride secretion (followed by a rather small increase in plasma 
triglyceride clearance), suggesting that aromatisation in the liver and adipose tissue into 
oestrogens may be responsible for the observed effects of oral androgens [16] [387] [388] 
[389].
10.2.2. The effects of gender on LPL mass and activity
The increased VLDL-triglyceride FCRs in women could be explained by the effect of gender
on LPL mass and activity. LPL is not only involved in hydrolysis of triglycerides in
lipoproteins, but is also involved in the whole VLDL-particle cellular uptake, therefore can
influence both VLDL-triglyceride and apoBlOO clearance. Compared with men,
premenopausal women have higher fasting post-heparin plasma LPL mass (but not activity
[15] [378]), most probably because they have increased total fat and subcutaneous FM [363].
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The gender difference in plasma LPL mass between men and women was lost when the 
subjects were matched on %FM [363]. Most post-heparin plasma LPL mass derives from 
adipose tissue, and LPL mass was shown to correlate positively with %FM and total 
abdominal fat (in cm2) [4]. In obesity there is an increase in plasma LPL mass [363], while 
data on post-heparin LPL activity in plasma are conflicting, with most data reporting no 
change LPL activity in fasting conditions [363] [378] [390]. From the other hand, in obesity 
there is a decrease in skeletal muscle LPL activity in insulin resistant states (with no change in 
a simple obesity without insulin resistance) [390], while there is an increase in adipose tissue 
LPL activity per cell number (since larger adipocytes secrete more LPL) [363] [391] [392], 
but no change if LPL activity is expressed per gram tissue [390]. However, there are also 
findings which indicate a decreased adipose tissue LPL activity in obesity, especially in 
insulin resistant states [393].
Even though fasting plasma postheparin LPL activities showed no significant gender 
dimorphism in lean premenopausal women compared with lean men [15], studies have shown 
that fasting abdominal and femoral adipose tissue LPL mRNA and activities were 
significantly higher in women than in men, regardless if expressed per gram adipose tissue, 
per cell number or per cell size [15] [394]. Most of the studies which included more men than 
women, showed higher LPL activity in VAT, compared with SAT [395]. On the contrary, 
most of the studies which included more women than men, showed higher LPL activity in 
SAT, compared with VAT [395]. Indeed, in men LPL activity in VAT is higher than in SAT, 
while in women it the opposite was shown [395] [396] [397] [398]. In women, higher LPL 
mRNA, mass and activity in SAT, together with the increased SAT amount, contribute to the 
gender difference in the VLDL-triglyceride clearance [399] [400] [401]. In addition, some 
data indicate that in fasting conditions, most fasting post-heparin plasma LPL activity derives 
from skeletal muscle [15] [402], and women are shown to have higher skeletal muscle LPL 
mRNA and activity [217].
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In men, studies have shown or no difference between gluteo-femoral and abdominal SAT in 
LPL activity [15] [222] [391] [394], or increased activity in the abdominal subcutaneous 
depot, compared with gluteo-femoral fat [394], especially in obesity [391]. In contrast, in 
premenopausal women, gluteo-femoral adipose tissue LPL activity has been shown to be 
higher, compared with abdominal SAT LPL activity [15] [394]. Therefore, in premenopausal 
women, gluteo-femoral tissue LPL activity has been shown to be higher, compared with i 
gluteo-femoral tissue LPL activity in men [15] [109] [403] [404]. This contributes to the 
increased fasting and postprandial storage of fat in this region, compared with men. However, 
according to some data, but not all [405], in postmenopausal women, LPL activity was equal 
in both SAT depots, indicating the effect of the loss of ovarian steroids on LPL activity in 
femoral adipose tissue [406]. With respect to the effects of menopause, the higher adipose 
tissue LPL activity has been reported after ovariectomy in rats [407] [408], and in obese 
postmenopausal, compared with BMI-matched perimenopausal women [405], in both gluteal 
and abdominal SAT [405]. On the contrary, data from another study comparing BMI-matched 
non-obese premenopausal and postmenopausal women, did not show the difference in the 
abdominal SAT size and LPL activity, but the VAT size and the VAT/abdominal SAT LPL 
activity ratio were higher in postmenopausal women, along with higher adipocytes size in 
VAT region [409]. In line with this, measured post-heparin plasma LPL activity was higher in 
postmenopausal and surgically menopausal women, compared with premenopausal women in 
some studies [71] [410] [411], but not all [412], suggesting that ovarian steroids probably 
control the adherence of LPL activity to the adipose tissue [402], and directing the FFA 
storage towards peripheral adipose tissue depots [71]. There is evidence that in non-pregnant 
premenopausal women and particularly during the first and the second trimester of pregnancy 
(when oestrogens and progesterone start to increase), LPL activity is increased in femoral 
SAT, and then, during the last trimester of pregnancy (a very high oestrogen and progesterone 
state, but some other hormone levels are as well altered [413] [414]), LPL activity diminishes
in femoral adipose tissue and augments in placenta, mammary gland and the liver, increasing 
the local lipid accumulation in those tissues, the hepatic VLDL-triglyceride secretion and 
supply of FFA to the foetal tissues [415]. In menopause, with loss of ovarian function, an 
increased efflux of adipose tissue LPL activity into circulation could occur, which could be 
followed by the increased influx of LPL activity in the liver, pancreas and the muscle. This, in 
turn could contribute to the increased lipid accumulation in those organs, as already described 
in postmenopausal women [41] [42] [43] [44]. However, during menstrual cycle, with small 
physiological fluctuations in ovarian hormones, no significant changes in plasma LPL 
concentration have been observed [98].
Therefore, women have higher adipose tissue LPL activity in SAT (in particular in femoral 
depot), compared with men, which, together with the higher total SAT amount, contribute to 
the increased VLDL-triglyceride clearance in women. In women, LPL activity in SAT is 
higher than in VAT. Men, in turn, have higher LPL activity in VAT. Women also may have 
higher LPL activity in skeletal muscle, compared with men. Some gender differences in LPL 
activity may be attributed to the effects of sex hormones on LPL gene expression and post- 
transcriptional and post-translational regulation [416].
10.2.3. The effects of sex hormones on LPL mass and activity
The effects of sex steroids on LPL activity have been studied in animals (rodents) and
humans. Studies in rodents indicate that oestrogens and androgens are potent blockers of LPL
activity, both in intact and in gonadectomised animals, while progesterone has a stimulatory
effect, counteracting the effect of oestrogens but only in females [60] [416]. However, data in
humans have shown that sex hormones (oestrogens, androgens and progesterone) can have
different effects, depending on gender, concentration, and specific tissues and sites [60] [90]
[416]. Oestrogens stimulate LPL activity and expression in skeletal muscle [217], and can
have both stimulatory and inhibitory effect on LPL activity in adipose tissue, stimulating with
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lower doses and inhibiting with higher doses [90] [417], while have an inhibitory effect on 
total post-heparin plasma LPL activity [217]. The exact mechanism by which oestrogens 
influence LPL expression and activity is still unknown. Because no classical oestrogen 
responsive elements (ERE) have been detected in the promoter region of LPL gene, and there 
is another transcription factor (activator protein 1, AP-l)-like sequence in the promoter region 
of LPL, it was proposed that ER could control the expression of LPL indirectly, by its 
interaction with AP-1, via protein-protein interaction and interaction with the recruitment of 
co-activators and co-repressors [90] [217] [418]. Additionally, oestrogens have been shown to 
increase (through its central effects) the secretion of GH, which stimulates lipolysis and 
inhibits LPL activity in adipose tissue [416]. On the other hand, progesterone was shown to 
have stimulatory effect on LPL expression and activity in SAT, especially in gluteo-femoral 
SAT [222] [406] [419] [420]. The effect of progesterone was demonstrated only in women, 
probably because in female adipose tissue progesterone receptors (PR) have been detected, 
while data on the presence of progesterone in male adipose tissue are still conflicting [421] 
[422] [423]. The effects of testosterone and DHT on LPL expression and activity differed 
depending on gender [90] [218] [227] [416]. In men, acute and chronic testosterone 
administration decreased the abdominal SAT LPL activity, with no effect on the femoral SAT 
LPL activity [223]. On the contrary, in premenopausal and postmenopausal women, 
testosterone administration increased the abdominal SAT LPL activity, both in vitro and in 
vivo [218] [227]. Some effects of testosterone on LPL expression and activity are mediated 
through its direct effects on AR in adipose tissue [227] [424], and some through its 
conversion to oestradiol and stimulation of oestrogen receptors (preferentially ER alpha) [60] 
[90] [416]. Additionally, it is possible that androgens could influence LPL activity through 
their local effects on metabolism of oestrogens (increasing inactivation) and glucocorticoids 
(increasing activation) in adipose tissue [425] [426]. On the other hand, female sex steroids
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could have inhibitory effect on AR or glucocorticoids activation in adipose tissue [427], and it 
is known that glucocorticoids stimulate LPL activity, preferentially in VAT [84] [416].
In conclusion, the effects of sex hormones on LPL mRNA and activity involve complex 
pathways. Studies examining the effect of sex hormones on LPL mRNA and activity revealed 
conflicting findings, and results varied depending on species, gender, specific tissues and 
depots, conditions of subjects, and concentration and type of sex hormones used. In general, 
they have suggested that androgens can have an inhibitory effect on adipose tissue LPL 
activity, progesterone can have a stimulatory effect, while oestrogens can have a “biphasic 
effect”: stimulating with lower doses and inhibiting with higher doses. Oestrogens can 
increase LPL activity in skeletal muscle. Additional studies are warranted to further explore 
the mechanisms by which sex hormones influence LPL mass and activity.
10.3. Plasma cholesterol levels
In the present study, statistically significant differences between the two genders in plasma 
total cholesterol, LDL-cholesterol and HDL-cholesterol were not observed. This could be 
attributed to the effect of menopause. Decreased oestrogens levels after menopause are 
associated with decreased hepatic LDL/apoB 100-receptor synthesis, leading to decreased 
LDL-cholesterol clearance and increased LDL-cholesterol levels [16] [73] [79] [416]. 
Additionally, decreased oestrogens levels after menopause are associated with decreased 
HDL-cholesterol levels, due to decreased synthesis of apoAI (leading to decreased production 
of HDL-particles) and increased synthesis and activity of HL (leading to increased catabolism 
of HDL-particles) [16] [366] [377] [378] [379] [428] [429] [430]. Oestrogens also stimulate 
intrahepatic enzymes involved in cholesterol metabolism (transformation to bile acids) and 
enzymes and proteins involved in cholesterol excretion from hepatocytes into bile vessels [16] 
[312]. Contrary to the effects of oestrogens, progesterone decreases HDL-cholesterol levels,
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because of decreased synthesis of apoAI [16], but does not influence LDL-cholesterol levels, 
because it increases both production and clearance of LDL-apoB100 [16].
On the other hand, androgens are shown to increase HL activity, and also play a significant 
role in gender sex dimorphism in HDL- and LDL-subfraction profiles [15] [16] [378] [431] 
[432] [433] [434]. Hepatic lipase activity is generally higher in males, and correlates directly 
with degree of insulin resistance and obesity, especially of the centripetal type [435]. 
Androgens also decrease synthesis of apoAI [16] [436]. Therefore, androgens both decrease 
production and increase catabolism of HDL- particles, leading to decreased HDL-cholesterol 
levels [16] [436].
Related to LDL- and HDL-particle catabolism, a positive association between plasma CETP 
concentrations and concentrations of small VLDL-, LDL-, and HDL-particles was described 
[363]. Interestingly, plasma concentrations of CETP are lower in postmenopausal women, 
compared with premenopausal woman, and show a positive correlation with serum oestradiol 
levels [363]. In contrast, plasma lecithin-cholesterol acyltransferase (LCAT) activity, which is 
involved in formation of cholesterol esters transferred from LDL- and HDL-particles to 
VLDL-particles, was higher in postmenopausal and surgically menopausal women, compared 
with premenopausal women [71], which could contribute additionally to the increased 
formation of small dense LDL-particles and increased catabolism of HDL-particles in 
postmenopausal women.
In conclusion, there are gender differences in HDL-cholesterol and LDL-cholesterol 
metabolism, connected with differences in production and/or activities of functional proteins 
(including apoA, LDL/apoB 100-receptor, HL, CETP and LCAT). Those differences are under 
influence of sex hormones, both androgens and oestrogens. In women, after menopause, the 
decreased oestrogen levels cause a decrease in HDL-cholesterol and an increase in LDL- 
cholesterol levels, diminishing on that account the gender differences observed during 
reproductive age [378] [437].
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10.4. Insulin sensitivity
Many studies have compared insulin sensitivity in premenopausal women and men, and 
premenopausal and postmenopausal women. Most of them have shown that women tend to be 
more insulin sensitive compared with men with the same degree of obesity, and that 
premenopausal women are more insulin sensitive than postmenopausal women [13]. The 
effect of menopause however in some studies could not be distinguished from the effect of 
age on metabolism and body composition [40] [41] [42] [44] [47] [438]. Nevertheless, most 
studies confirm that menopause per se brings increased risk for worsening insulin sensitivity 
[13] [17] [439].
Since skeletal muscles account for 75% of glucose disposal during a hyperinsulinaemic- 
euglycaemic clamp [267], insulin sensitivity indices derived from hyperinsulinaemie- 
euglycaemic clamp mostly refer to skeletal muscle insulin sensitivity.
Most studies showed that increased fatty acid supply and oxidation in untrained skeletal 
muscle can be related to disturbed insulin signalling and insulin resistance in the muscle, but 
the exact mechanism is still unknown [171] [172] [173] [440]. Indeed, palmitate oxidation 
rates in this study were in negative correlation with insulin sensitivity estimated by the 
hyperinsulinaemie-euglyeaemie clamp (data presented in Appendix, the section on 
correlations).
On the other hand, in this study, women tended to have increased insulin sensitivity
(estimated by the hyperinsulinaemie-euglyeaemie clamp), despite the fact that they had
increased FFA turnover and increased FFA supply to all organs, including muscles. There is
evidence that in women intralipid-infusion reduces insulin sensitivity (skeletal muscle glucose
disposal) much less than in men [441] [442] [443]. This indicates that there are compensatory
mechanisms in the human female body, protecting skeletal muscles from “lipotoxicity” [441]
[442] [444] [445]. Indeed, women can handle increased IMCL, and at the same time be more
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insulin sensitive (similar to endurance trained athletes [446]). Many of these effects are 
related to gender differences in morphology and function of human skeletal muscle mentioned 
above. Both increased leptin (as shown in other gender studies, and also in this study) and 
adiponectin (shown in other gender studies, but not in this study) in women can lead to 
improved insulin sensitivity in women [136].
Although in this study women had increased supply of systemic FFA to the liver, they did not 
have higher liver insulin resistance, as reflected by HOMA model (related to hepatic glucose 
output [442]) or VLDLi-trglyceride secretion [282]. However, we could not estimate the 
contribution of the portal FFA supply, which was most probably greater in men, because of 
higher (in this study 50% higher) visceral fat reserves, and previously described increased 
visceral lipolysis per unit of visceral fat tissue. Moreover, it is known that VAT produces 
some inflammatory adipokines and cytokines, which can contribute to decreased hepatic and 
peripheral insulin sensitivity in men [90] [133] [136] [295] [357].
Data from this study indicate that also after menopause obese women are protected from 
hepatic and skeletal muscle insulin resistance caused by increased systemic FFA supply. This 
could be related to increased peripheral subcutaneous FM, which can serve as a metabolic 
sink for the excess of FFA (and glucose) [172] [442] [447]. Many studies have shown that 
peripheral fat depots are beneficially related to metabolic profile and are protective of insulin 
resistance [448], and that disturbed fatty acid re-esterification in SAT could be related to 
increased visceral fat depot lipid accumulation and decreased insulin sensitivity [447].
Women have higher “metabolic-flexibility”- with a carbohydrate supply, they shift their 
oxidation processes more towards use of carbohydrates, because they more efficiently inhibit 
adipose tissue lipolysis by insulin, compared with men [184]. Consequently, their glucose 
uptake and oxidation are higher, since there is little competitiveness with plasma FFA [184] 
[236].
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10.4.1. The effects of sex hormones on insulin sensitivity
After menopause, insulin sensitivity diminishes, while oestrogen replacement can protect 
from these changes. The changes in insulin sensitivity can be related in part to re-distribution 
of fat tissue, with decreased femoral subcutaneous depots and increased visceral fat depots. 
The role of steroid hormones in those processes have already been described, with net effect 
of oestrogens and progesterone in promoting subcutaneous fat accrual, preferentially in the 
lower-body, and androgens in women promoting accrual of fat in the upper-body, increasing 
visceral and decreasing subcutaneous fat accumulation.
Apart from this effect on regional fat metabolism, there can be other, more direct effects of 
steroid hormones on insulin stimulated glucose disposal. This can be related to the direct 
effect of oestrogens, progesterone and androgens (by activating ERs, PRs and AR) in insulin- 
responsive tissues (liver, muscle and adipose tissue) [232] [424] [449] [450].
The effect of sex hormones can be mediated directly, e.g. by their action on human skeletal 
muscle insulin receptor cascade and translocation of GLUT-4 transporter, the activity of 
glycogen synthetase or other enzymes involved in glucose metabolism [294] [319]. The local 
direct effects of sex hormones on skeletal muscles in experiments in vitro varied depending 
on gender, dose and type of sex hormone used, indicating that there are some intrinsic gender 
dimorphic traits in skeletal muscle related to carbohydrate metabolism [9] [85].
Oestrogens have been shown to promote insulin sensitivity, by activating ER alpha in skeletal 
muscle, adipose tissue and liver, while activation of ER beta decreased insulin sensitivity 
[307] [310] [319] [320] [321] [322] [451] [452] [453] [454]. In humans ER beta is present 
mostly in adipose tissue, while in the liver and skeletal muscle it is present only in small 
amounts [320] [363]. In one study, expression of ER alpha in human skeletal muscle was 
shown to be 180 times higher than ER beta [455]. The expression of ER beta in adipose tissue 
is higher in humans than in animals, and is higher in subcutaneous than in visceral fat depots. 
The ratio between ER alpha and beta differs with gender, adipose tissue depots and degree of
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obesity [322] [450] [456]. Although oestrogens can downregulate the expression of their 
receptors (ER alpha), to avoid an overstimulation [457], the effect of menopausal status on 
expression of different ER subtypes was not shown to be significant in women [456].
In physiological doses oestrogens improve insulin sensitivity both in men and women (mostly 
by acting through ER alpha), but higher doses or concentrations of oestrogens (e.g. when 
using oral contraceptives or in pregnancy, which is a hyperoestrogenic state) can worsen 
insulin sensitivity (possibly through activation of ER beta) [307] [321] [322] [452] [453] 
[454].
The impact of HRT on insulin sensitivity in postmenopausal women may be different, with 
data showing both increased, decreased or unchanged insulin sensitivity after oral oestrogen 
treatment [72] [458]. The effect mostly varied depending on the dosage, and the higher doses 
and use of more potent oestrogens deteriorated insulin sensitivity [74] [439]. Transdermal 
oestrogens, most probably because of much lower doses, did not show significant effects on 
insulin sensitivity [458].
Progesterone is also related to decreased insulin sensitivity (e.g. high progesterone states as 
luteal phase of menstrual cycle or pregnancy), and use of progestins with more androgenic 
properties in HRT can have more detrimental effect and can abolish the beneficial effects of 
oestrogens on insulin sensitivity, compared with progestins with less androgenic properties or 
anti-androgenic properties [459].
The effects of androgens on insulin sensitivity have been also explored.
Some of the effects of androgens on insulin sensitivity are mediated through their direct 
action on AR and androgen responsive elements (ARE) in the DNA sequence [460], but many 
of them are mediated through their conversion to oestrogens. On the other hand, in male 
animals [66] [323] [324] [325] [326] [327] [461] [462] [463] [464] and humans [66] [67] 
[465] [466] [467] that lack aromatase activity, insulin resistance and metabolic syndrome 
develops, which indicates that androgen actions in prevention of metabolic syndrome are
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possibly mediated by activation of ER (most probably ER alpha [325]). Additionally, men 
who have mutation of aromatase or mutation of ER alpha share the same phenotype, which 
includes insulin resistance, visceral obesity, diabetes development and elevated plasma 
triglyceride levels [66] [67] [68] [465] [466] [467] [468]. In subjects with aromatase 
deficiency the levels of oestradiol are low, while the levels of testosterone are increased or 
normal [66] [68] [465] [466] [467]. Administration of testosterone is related to the 
deterioration, while administration of oestrogens is related to the improvements of clinical 
features of these subjects [466] [467] [469]. Also animal models of genetic ablation of 
aromatase and ER alpha are characterised with visceral obesity, insulin resistance and features 
of metabolic syndrome [323] [324] [325] [326] [327] [461] [462] [463] [464]. In line with 
this, orchiectomised rodents remain lean if they are treated with oestradiol or testosterone, but 
if they are treated with DHT (a non-aromatised androgen) they develop obesity [60]. 
Interestingly, in men with complete androgen insensitivity syndrome, the female habitus 
develops, with typical gynoid body fat distribution and without presence of insulin resistance 
[60]. In contrast, in men with partial androgen insensitivity syndrome, insulin resistance and 
metabolic syndrome are present, with increased levels of testosterone in circulation [60]. On 
the other hand, the use of anti-androgen in prostate action treatment, which blocks AR 
activity, also leads to development of metabolic syndrome.
Insulin sensitivity increased after substitution of androgens in younger hypogonadal men to 
achieve physiological range, while decreased if androgens were given in supraphysiological 
doses to eugonadal men [51] [52] [59] [67] [470] [471] [472] [473] [474] [475] [476]. In 
contrast, in one study in older men, long-term testosterone HRT did not have any effect on 
insulin sensitivity [477].
In women treated with androgens both acutely and chronically or in women with increased 
endogenous androgen production (PCOS, virilising diseases), insulin sensitivity is also 
decreased [478] [479] [480]. From another side, obesity, insulin resistance and consecutive
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hyperinsulinaemia and increased FFA levels may per se lead to increased ovarian and adrenal 
androgen production in women [481] [482] [483] [484]. Additionally, hyperinsulinaemia 
decreases the sex hormone-binding globulin (SHBG) production in the liver [485]. The 
decreased SHBG levels, in return, increase the availability of free (active) androgens to 
tissues, causing a relative hyperandrogénie state, which pre se decreases insulin sensitivity, 
making a vicious cycle [24] [35] [63] [480] [486] [487] [488] [489] [490] [491].
Interestingly, cross-sectional studies have shown that in postmenopausal women higher 
endogenous oestrogen levels can be related to increased insulin resistance, risk for diabetes 
and cardiometabolic risk, and this was independent of obesity [448] [490] [492] [493] [494] 
[495]. However, causality from cross sectional studies can not be estimated, since increased 
oestrogen in postmenopausal women could be related to both obesity and increased 
production of adrenal androgens, which are subsequently in adipose tissue metabolised to 
oestrogens, making a vicious cycle [177] [494]. It was shown that insulin stimulates 
aromatase activity in adipose tissues, therefore increasing local oestrogen production [177] 
[488] [494] [496]. Also, since hyperinsulinaemia decreases the hepatic SHBG production (the 
decreased SHBG production is causally related to insulin resistance) [485], this additionally 
increases the free (active) oestradiol fraction, leading to a functional hyperoestrogenic state 
[487].
In conclusion, the effects of sex hormones on insulin sensitivity are complex, still unclear and 
include multiple pathways. Studies show the effects may differ depending on the gender and 
characteristics of subjects, as well as characteristics, concentrations and routes of sex steroids 
administration. Additional studies are needed to explain the mechanisms by which sex 
hormones influence insulin sensitivity.
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10.5. Leptin
In the present study, postmenopausal women had higher serum leptin levels compared with 
men, and this remained higher also when corrected for the total FM. This is in agreement with 
the previous findings, where both premenopausal and postmenopausal women have been 
shown to have higher circulating leptin levels for any amount of FM, compared with age- 
matched men [60] [114] [115] [116] [117]. Total FM and subcutaneous FM are the major 
predictors of leptin levels [39] [497] [498] [499] [500]. More leptin is secreted from 
subcutaneous adipocytes than from visceral (2-3 times more) [501] [502], and women not 
only have more total FM, but also have more subcutaneous FM, which can influence the 
difference. In addition, more leptin is secreted from larger adipocytes [499], and there is 
evidence that women have larger adipocytes in the femoral depot, compared with men [60]. 
Furthermore, women have been shown to have increased stimulated leptin secretion from 
omental adipocytes [502].
Even though differences in body fat distribution contribute in significantly to the sexual 
dimorphism in leptin levels, a direct action of sex hormones and influence of some sex- 
chromosomes related genetic factors on leptin production, secretion and action, can not be 
excluded [503] [504] [505] [506].
10.5.1. The effects of sex hormones on leptin levels
Most of the data in animals and humans, in vitro and in vivo, have shown that oestrogens 
stimulate, and androgens inhibit leptin production and secretion, although there are some 
conflicting findings [60].
In vitro, the addition of testosterone or DHT to human adipocytes has been shown to decrease
leptin production and secretion, while the opposite effect has been noted with the addition of
oestradiol [60] [500] [507]. Progesterone has been shown in some studies not to have a direct
effect on leptin secretion [60] [507]. Oestrogens have been shown to increase the central
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sensitivity to leptin [508], and women are more sensitive to centrally administrated leptin than 
men [33]. A considerable amount of data indicates that the effects of sex steroids on leptin 
production in adipocytes could be gender specific [60] [500] [502] [505] [507]. The effects on 
leptin mRNA expression are most probably mediated through direct ER and AR activation. In 
the DNA sequence, ERE has been detected in the promoter region of the leptin gene, and the 
evidence exists that stimulation of ER alpha increased leptin expression, while stimulation of 
ER beta did not have any effects [60]. Male mice with selective adipose tissue AR deficiency 
have increased leptin levels, without development of obesity [330]. Interestingly, in non- 
obese mice, orchiectomy increased adiposity and increased leptin levels, while in obese male 
mice orchiectomy decreased and testosterone replacement increased leptin levels [60]. 
Aromatase inhibitor did not show the influence on leptin levels in young men, indicating the 
direct effects through AR [60]. In line with this, AR blockade increased leptin level in man, 
even before significant loss of FM [60].
In female animals, some findings indicate that ovariectomy decreases circulating leptin levels, 
as well as leptin expression in adipocytes [505], but there are also some conflicting reports 
[60]. The explanation for these discrepancies could be the fact that leptin decreased initially, 
but later, as animals started to increase weight and develop obesity (because of hyperphagia, 
decreased ambulatory activity and decreased REE, as consequences of loss of oestrogens), 
their leptin levels increased [60].
Both in young and older man, leptin levels correlate inversely with total testosterone, free 
testosterone, SHBG, and directly with oestradiol [509] [510]. There is also an inverse 
relationship of leptin with the ratio of DHT/oestradiol [114]. However, the relation between 
testosterone and leptin levels could be bidirectional, since in obesity the lower conversion 
rates of testosterone precursors to testosterone in testes have been described, which could be 
mediated by the direct effects of leptin on steroidogenesis [114]. In men, the negative 
correlation of leptin with total testosterone and SHBG can also be related to increased visceral
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adiposity [486] [509] [511]. However, in hypogonadal men, leptin levels are three times 
higher than in eugonadal, but FM is not increased in the same proportion [60] [509]. 
Testosterone supplementation in hypogonadal men, as well anabolic androgen use in body 
builders, decreased leptin levels [60] [509] [512], while a single dose of a gonadal suppressant 
in healthy males increased leptin levels [512].
Treatment of female-to-male transsexuals with testosterone administration has been shown to 
decrease leptin levels, while treatment of male-to-female transsexuals with oestradiol and 
antiandrogens has been shown to exert the opposite effect [60] [513].
Many studies have shown a positive correlation of leptin with oestradiol levels [60] [514]. In 
women, the inverse relationship between leptin and testosterone may not exist, but there is 
still an inverse relationship with SHBG, and a positive relationship with total oestradiol and 
free oestradiol [60] [509]. In postmenopausal women, compared with premenopausal, lower 
leptin circulating levels have been described in some (but not all) studies, after adjusting for 
total FM [8] [114] [515]. This can be related to the differences in sex hormone levels, body fat 
distribution and ageing process [515]. Leptin levels decrease with age in both sexes, but in 
women a more sharp drop related to menopause has been observed [114]. HRT with 
oestrogen increased leptin levels [60] [516]. In postmenopausal women without HRT, 
bioavailable oestrogen has been shown to correlate directly with circulating leptin levels 
[114].
There is evidence that differences in circulating leptin levels between genders are present 
even before birth, in utero [33] [499] [507] [517] [518]. In prepubertal boys and girls, leptin 
levels are not very different [519] [520], but with the activation of gonads, in boys leptin 
levels start to decrease, while in girls they increase, in parallel with changes in body fatness 
and body fat distribution [39] [508] [521] [522]. Women and men have similar leptin 
secretion in terms of leptin pulse organization or oscillation frequency, but pulse amplitude 
(the amount of total leptin released per unit time) is higher in women [523].
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The kinetics of leptin removal from plasma is still unexplored issue, and there are no studies 
comparing gender influences [523].
Therefore, most of the published data suggest that oestrogens have a positive and androgens 
have a negative effect on leptin production and secretion.
10.5.2. The effects of leptin on lipid metabolism and insulin sensitivity
Since there are significant gender differences in leptin levels (and sensitivity to leptin), it is 
open to discussion if these differences could be related to some of the here presented gender 
differences in lipid kinetics, insulin sensitivity and metabolic risk [524]. Leptin has been 
shown to influence metabolism through both central and peripheral mechanisms [308] [525] 
[526]. Through the central activation of leptin ObRb receptors, leptin increases basal 
metabolism through the effects on melanocortin and SNS [526] [527] [528] [529] [530] [531] 
[532], thyroid axis [533] [534] [535], thermogenesis [536], gonadal axis [508] (the 
stimulating effects) and HPA axis (the inhibiting effects) [308]. At the periphery, ObRb leptin 
receptors have been found in metabolically active tissues, e.g. muscle, liver, adipose tissue 
and pancreas [537].
In muscle, leptin increases insulin mediated glucose uptake (by increasing GLUT-4), and 
increase fatty acid metabolism. Leptin increases fatty acid oxidation in skeletal muscle 
probably through activation of AMPK. AMPK phosphorylates and inhibits ACC, leading to 
the reduced formation of malonyl-CoA, the inhibitor of the activity of carnitine CPT-1. 
Through activation of AMPK, leptin increases not only fatty acid beta oxidation, but also 
insulin sensitivity and glucose disposal in skeletal muscle [532].
Leptin activates AMPK via two distinct mechanisms. One is rapid and occurs directly through
activation of ObRb leptin receptors in skeletal muscle, increasing intracellular AMP content
and activating AMPK. The other is slower, via actions in the CNS, leading to stimulation of
the SNS and activation of G-coupled alpha adrenergic receptors expressed in skeletal muscle
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[538]. Through the central effects, leptin also increases the expression of UCP-2 and UCP-3 
in skeletal muscle [539].
In the liver, in postabsorptive conditions leptin increases gluconeogenesis and hepatic glucose 
output (probably through the effects of sympathetic stimulation of noradrenergic receptors 
located on hepatocytes [540]), but during hyperglycaemic conditions leptin decreases hepatic 
glucose output and increases glycogen synthesis (again via its central actions) [541] [542]. It 
also increases fatty acid oxidation, decreases de novo fatty acid synthesis, lipid accumulation 
and triglyceride secretion. VLDL-triglyceride production is negatively influenced by leptin 
[244]. The effects in the liver on fatty acid metabolism are mediated through activation of 
AMPK and PPAR-alpha, and inhibition of SCD-1 [243] [244] [543].
In WAT adipocytes, leptin stimulates lipolysis, decreases glucose uptake (through decreased 
GLUT-4 mRNA and protein levels and decreased insulin-stimulated GLUT-4 translocation to 
the plasma membrane), and decreases fatty acid synthesis and lipid accumulation, having an 
antiadipogenic effect [542]. In rodents, leptin stimulates lipolysis in WAT through both 
indirect (central) and direct (peripheral) activation of leptin ObRb receptors expressed in 
hypothalamus, brain stem and adipocytes, while in humans no direct leptin effects on basal 
and stimulated lipolysis were shown in isolated human preadipocytes and adipocytes, 
indicating possible species differences [544] [545]. Denervation of WAT adipocytes 
abolished the inhibitory effect of central leptin on glucose transport, indicating that the effects 
on glucose metabolism are mediated through central leptin effects [546]. Even though central 
leptin has been shown to improve the overall insulin sensitivity, it has been shown in vivo to 
decrease insulin action in WAT (including diminished insulin receptor autophosphorylation, 
insulin receptor substrate-1 tyrosine-phosphorylation, and PKB(Akt) activation, as well 
down-regulation of insulin receptor substrate-1 mRNA and protein levels [546]. Consistent 
with this, leptin antagonises the effects of insulin to inhibit lipolysis [546]. The effects of 
leptin on LPL in humans are still unexplored, but data in rodents indicate that leptin
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stimulates LPL activity in skeletal muscle [547] [548] [549] and cardiac muscle [550], and 
has no effect [551] or inhibits LPL activity in WAT and BAT [549] [552] [553], while 
increases LPL mRNA in skeletal muscle, cardiac muscle and BAT, and decreases in WAT 
[548] [554] [555] [556] [557]. However, conflicting data are reported, depending on the 
duration of treatment, pre-treatment conditions of animals, and whether direct or indirect 
(central) effects of leptin were examined [553] [551].
In BAT adipocytes leptin stimulates lipolysis, lipid oxidation, thermogenesis and glucose 
uptake [558] [559] [560]. The effect on brown fat thermogenesis is mediated through 
stimulation of both hypothalamic-pituitary-thyroid axis and beta-3 adrenergic activity [536].
In the pancreas leptin decreases insulin secretion [308], exerting an inhibitory feedback on 
pancreatic insulin secretion within the so-called “adipoinsular axis” [561], in order to decrease 
lipogenesis. Insulin, in turn, stimulates leptin production and secretion in the adipose tissue 
[562].
Therefore, considering the above discussed effects of leptin, the higher leptin levels in women 
in this study could be related to the observed increased lipolysis rates, plasma FFA oxidation 
rates (both in muscle and the liver), decreased VLDL-triglyceride production rates, and 
increased insulin sensitivity and peripheral glucose disposal (in skeletal muscle).
10.6. Adiponectin
Some studies have found that both premenopausal and postmenopausal women have greater 
concentrations of adiponectin, particularly the HMW form (which is the most metabolically 
active form of adiponectin [118] [119] [563] [564]), compared with age- and BMI-matched 
males [120] [121] [565] [566]. It was proposed that this effect could be possibly attributed to 
an inhibitory effect of androgens and/or a stimulatory effect of oestrogens and progesterone 
on adipocyte adiponectin secretion, predominantly affecting the HMW form. To confirm this,
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different studies exploring the effect of sex hormones on adiponectin secretion have been 
conducted. Unexpectedly, they revealed contradictory findings.
10.6.1. The effects of sex hormones on adiponectin levels
The negative effect of androgens on adiponectin secretion was confirmed, both in vitro and in
vivo. Testosterone most probably influences adiponectin secretion at the level of
posttranscriptional and posttranslational modulation, since it was not shown to influence the
adiponectin mRNA expression [565] [567] [568]. The effect of testosterone on adiponectin
secretion is presumably mediated through AR activation, since in the AR deficient mice
adiponectin levels are increased and administration of a selective AR-agonist to castrated or
intact rats decreases adiponectin levels in a dose-dependent manner [429] [569] [570]. There
is in vivo and in vitro evidence that testosterone selectively inhibits the secretion of HMW
adiponectin [565]. In line with this, in premenopausal women, the ratio of HMW adiponectin
to total adiponectin was negatively associated with testosterone, free testosterone and
androstendione, both before and after adjustment for BMI and age (since both those factors
significantly influence adiponectin secretion) [509] [571]. In women with hyperandrogenism
(PCOS), the HMW adiponectin is selectively reduced [568] [572], independently of BMI and
degree of insulin resistance [568], and therapy with antiandrogen-contraceptives causes an
increase in adiponectin levels. In prepubertal boys and girls there is no difference in serum
adiponectin levels [121]. While in girls there is no change during pubertal transition, in boys
adiponectin levels start to decrease, becoming at mid puberty significantly lower than in girls
[121]. In hypogonadal men, higher concentrations of adiponectin have been described, and
the testosterone administration to hypogonadal and eugonadal men decreases adiponectin
levels by selectively decreasing the HMW form [565] [573]. The same was confirmed in
rodents, where total and the HMW form adiponectin were higher and the medium- and low-
molecular weight (MMW and LMW) forms were lower in female compared with age- and
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body weight-matched male mice [565]. Castration of male mice was related to an increase in 
total adiponectin, due to selective elevation of the HMW form, while the administration of 
testosterone to both castrated and sham-operated animals caused the opposite effects [565]
[574].
Even though there is a sufficient amount of evidence that testosterone negatively influences 
adiponectin secretion, there are also data in older women and men, where total adiponectin 
levels were in positive correlation with total testosterone levels in both genders [120].
The effects of oestrogens and progesterone on adiponectin secretion are less clear, since the 
conflicting data have been reported [565] [574] [575]. In contrast to the hypothesised, in vitro 
studies have found either no effect of oestrogen on adiponectin secretion [565], or that 
oestrogen decreases adiponectin production [575]. Similarly with testosterone, the oestrogen 
inhibition of adiponectin production was predominantly at the level of posttranslational 
modification and secretion, while the transcription and mRNA levels of adiponectin were less 
affected [575], although there are also findings indicating that oestrogen could increase 
adiponectin mRNA levels [574]. Similarly, the conflicting results have been reported on 
correlation of serum adiponectin with female sex hormones. While in some studies there was 
no association of the levels of total adiponectin with the levels of sex hormones [571], in 
some studies a negative correlation of adiponectin with total and free oestradiol and 
progesterone levels have been found in both genders [119] [120] [122] [509]. In some studies, 
in postmenopausal or ovariectomised women the increased levels of both total and HMW 
adiponectin have been described (after adjustment for age, FM and fat distribution) [119]
[575], while some other studies reported no difference comparing with premenopausal women 
[123] [567], or even a decrease in adiponectin levels [448] [576]. In the studies where higher 
adiponectin levels were shown in postmenopausal women, both total and HMW adiponectin 
were in an inverse correlation with oestradiol and progesterone levels [119]. In line with the 
conflicting results on the effect of loss of ovarian steroids on adiponectin levels, HRT in
postmenopausal and ovariectomised women was related to a decrease [122] [516] [577], no 
change [123] [578], or an increase [516] in adiponectin levels, most probably depending on 
the type, dose and route of HRT administration (e.g. the transdermal oestrogens led to an 
increase in adiponectin levels, while oral oestrogens led to a decrease) [516]. In some studies 
in ovariectomised mice, adiponectin was increased and the oestrogen substitution reversed 
that effect [120] [575], while in some other studies adiponectin levels were not different in 
ovariectomised mice [567], and addition of oestrogen to ovariectomised or non- 
ovariectomised mice did not affect significantly adiponectin levels [311] [574]. In men, the 
administration of aromatase inhibitor did not influence adiponectin levels, despite significant 
reductions in oestradiol levels [579] [580].
In conclusion, the androgens seem to influence negatively the adiponectin secretion, 
specifically of the HMW form, while the effect of oestrogens and progesterone is less clear.
In addition to the effects of sex steroids, a positive correlation of adiponectin with SHBG 
have been found in both genders [120] [123] [509]. Decreased SHBG levels are related to 
insulin resistance (hyperinsulinaemia decreases the liver SHBG secretion and low SHBG can 
be considered as a marker of insulin resistance [49] [488] [511] [581]), and therefore in 
insulin resistant states the increased bioactive (free) fractions of sex hormones could 
additionally negatively influence the adiponectin secretion [485]. From the other hand, 
adiponectin can directly stimulate SHBG secretion from the liver, and the relation 
adiponectin-SHBG can be bidirectional [123] [485] [509].
10.6.2. The effects of obesity and insulin resistance on adiponectin levels
Data show that adiponectin levels have a strong genetic component, with heritability
estimated between 30 and 50% in both genders [582], while the non-hereditary external
factors (including BMI, age, diet composition and physical activity) additionally modulate the
adiponectin levels. Adiponectin increases with age, probably because of decreased
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adiponectin clearance [509]. The degree of obesity is negatively related with the circulation 
levels of adiponectin and its HMW form, and weight reduction can increase the levels of 
adiponectin, but only after more significant weight loss [583]. Subjects with more visceral fat 
accumulation in obesity have lower levels of adiponectin, compared with subjects with the 
same FM but who have more subcutaneous fat distribution [584] [585].
The insulin resistant states (including diabetes type 2, glucose intolerance, obesity, 
lipodystrophy and visceral fat accumulation) are related not only with lower adiponectin 
production and secretion (particularly of its HMW form) [582] [584] [586] [587] [588] [589] 
[590] [591], but also with lower adiponectin action, manifested by lower density and affinity 
of adiponectin receptors [592].
The mechanisms by which insulin resistance and visceral obesity decrease adiponectin levels 
and adiponectin signalling include the increased production of TNF-alpha and IT-6, and the 
increased local adipose tissue activation of glucocorticoids, which all negatively influence 
adiponectin secretion, possibly through the inhibition of PPAR-gamma signalling [593] [594] 
[595] [596] [597] [598] [599] [600] [601] [602] [603] [604]. Oestrogens have been shown to 
increase inactivation of glucocorticoids in adipose tissue, while androgens have the opposite 
effect [426] [427]. Additionally, in contrast to leptin, which is more secreted by SAT and by 
enlarged adipocytes, adiponectin is more secreted by VAT and smaller adipocytes [605] 
[606]. Increased adipocytes volume and mechanical “stretching” decreases adiponectin 
secretion through the mechanisms of mechanical stress and hypoxia, the consecutive low- 
grade inflammation and production of pro-inflammatory cytokines (TNF-alpha and IT-6), 
leading to downregulation of PPAR-gamma (PPAR-gamma are potent stimulators of 
adiponectin secretion, particularly of the HMW form) [590] [607] [608] [609] [610] [611] 
[612]. In obesity, men have more hypertrophy than hyperplasia of adipocytes, compared with 
women, therefore the lower adiponectin levels in men can be also a consequence of increased 
adipocyte cell size, particularly in VAT [590] [609].
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Nevertheless, contrary to the expected higher levels of adiponectin in the female group, in the 
present study serum adiponectin levels were not different between the two genders, even 
though the female subjects tended to be more insulin sensitive and had less VAT. The 
possible explanation why in this study the gender difference in adiponectin levels was not 
found is the high inter-subject variability in adiponectin levels and small number of the 
participants involved (particularly in the male group). When the male group in this study was 
extended by additional inclusion of BMI- and age-matched subjects (to achieve a total number 
of 13 men in the male group), the statistical significance of the gender difference increased, 
and men tended to have lower levels of total adiponectin compared with women (p=0.060, 
data not shown). Moreover, since adiponectin levels are determined also by body fat 
distribution and obesity phenotype [8] [575] [584] [585] [613] [614], and in the present study 
the female group was heterogeneous regarding the obesity phenotype (both upper-body and 
lower-body obese women were included), this could contribute to the higher inter-subject 
variability in the female group, influencing the statistical power to detect the differences. 
Besides, there was no measurement of different molecular weight adiponectin forms, 
including the HMW form (which was shown by previous studies to be selectively higher in 
women) [120] [121] [566] [565]. The HMW form is the most active form related to the 
insulin sensitising, hypolipidaemic, anti-inflammatory and antifibrinogenic properties of 
adiponectin, and the more recent studies suggest that the low HMW adiponectin and the low 
ratio of HMW to total adiponectin rather than low total adiponectin are associated with insulin 
resistance, dyslipidaemia, diabetes, hypertension, and increased risk for cardiovascular events, 
both in men and women [563]. Therefore, the possibility cannot be excluded that in the 
present study the HMW adiponectin levels were higher in the female group and contributed to 
the observed gender differences in insulin sensitivity and FFA and VLDL-triglyceride 
kinetics.
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10.6.3. The effects of adiponectin on lipid metabolism and insulin 
sensitivity
Adiponectin correlates inversely with the degree of insulin resistance and plasma triglyceride 
levels and positively with HDL-cholesterol levels [8] [118] [120] [123] [509] [606]. Also in 
the present study, adiponectin levels correlated inversely with components of metabolic 
syndrome (data presented in Appendix, the section on correlations). In the female group, 
adiponectin correlated inversely with %FM, FM, waist circumference, VLDLi-triglyceride 
and VLDLi-cholesterol, while correlated directly with HDL-cholesterol and steady state GIR 
and glucose MCR during the hyperinsulinaemie-euglyeaemie clamp (data presented in 
Appendix, the section on correlations).
Adiponectin acts mainly by activation of its targets AMPK and PPAR-alpha in the liver and 
skeletal muscle, and PPAR-gamma in adipocytes [615] [616]. It also stimulates a stress kinase 
p38 MAPK, and it has been shown that p38 MAPK phosphorylates and activates PPARs and 
their co-activator PGC-1 alpha [615] [617] [618] [619] [620] [621].
Improved insulin sensitivity in women can be related to the higher adiponectin levels in 
women (particularly of the HMW form) [136].
Adiponectin reduces plasma glucose by reducing hepatic glucose production, by increasing 
adipose tissue and skeletal muscle glucose uptake, by increasing skeletal muscle glucose 
oxidation and by increasing de novo fatty acid synthesis in adipocytes [592] [622] [623] 
[624] [625] [626] [627]. Studies have confirmed the involvement of adiponectin in the 
control of insulin stimulated glucose disposal in myocytes and adipocytes, by increasing 
GLUT-4 expression and translocation to the plasma membrane [618] [628]. Adiponectin also 
decreases hepatic glucose output by decreasing both gluconeogenesis and glycogenolysis 
[629] [630] [631]. In pancreas, adiponectin increases glucose stimulated and basal insulin 
secretion in mouse pancreatic cells in high glucose environment, and decreases insulin 
secretion in low glucose settings, but this effect is not confirmed in humans [592] [632] [633].
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Adiponectin reduces plasma FFA by decreasing lipolysis and by increasing FFA uptake and 
“trapping” (re-esterification) in adipose tissue, by increasing FFA uptake and oxidation in 
skeletal muscle, and by increasing FFA oxidation in the liver [628] [630] [634]. It affects the 
FFA uptake in the cells (stimulating in myocytes and adipocytes and inhibiting in 
hepatocytes), probably through its effects on cellular fatty acid transporters, including 
FAT/CD36 and FATP-1 [615] [635]. Re-esterification and lipid storage in adipocytes are also 
under control of adiponectin [242] [628] [634]. Through activation of C/EBP-alpha 
(CCAAT/enhancer-binding protein-alpha), PPAR-gamma and SREBP-lc in adipocytes, it 
increases proliferation, differentiation and lipid accumulation in SAT [242] [616] [626] [627] 
[628] [634], therefore indirectly influencing VAT lipid accumulation and preventing 
development of insulin resistance.
In women, higher adiponectin levels could contribute to the higher liver and skeletal muscle 
fatty acid oxidation rates [244] [295] [623] [630] [636] [637]. Through the activation of 
AMPK and PPAR-alpha, adiponectin increases beta oxidation of fatty acids in skeletal 
muscle, hepatocytes and BAT adipocytes [244] [295] [623] [630] [636] [637]. In muscle and 
BAT, adiponectin increases expression and activity of PGC-1 alpha, and increases 
mitochondrial number [615]. In BAT, WAT and skeletal muscle adiponectin increases energy 
dissipation (thermogenesis and heat production) by inducing expression of UCP-1, UCP-2 
and UCP-3, and by stimulating sympathetic nerve activity in BAT [638].
In women, higher adiponectin levels could contribute to the decreased VLDL-triglyceride 
secretion and increased VLDL-triglyceride clearance [244] [295] [370] [623] [630] [636] 
[637]. Adiponectin reduces plasma triglycerides, VLDL-triglycerides and VLDL-apoB by 
stimulating VLDL-particle catabolism and by decreasing VLDL-triglyceride and VLDL-apoB 
secretion [369] [639]. Adiponectin reduces VLDL-triglyceride secretion by decreasing 
hepatic FFA supply and uptake, by increasing hepatic FFA oxidation, by decreasing de novo 
fatty acids synthesis and lipid accumulation in the liver, and by increasing hepatic insulin
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sensitivity [628] [634]. It increases catabolism of VLDL-triglycerides and VLDL-apoB by 
increasing the expression and activity of adipose tissue and muscular LPL [369]. Adiponectin 
promotes HDL formation and reduces HDL catabolism [606].
Therefore, considering the above discussed effects of adiponectin, it is possible that in women 
the higher HMW rather than total adiponectin levels could contribute to the increased plasma 
FFA oxidation rates (both in muscle and the liver), increased VLDL-triglyceride clearance 
and decreased VLDL-triglyceride production rates, and increased insulin sensitivity and 
peripheral glucose disposal (in skeletal muscle).
10.7. The underlying mechanisms covering gender differences
A large body of research confirms that both female and male sex hormones are involved in 
the control of metabolism and energy homeostasis. They can act through both central and 
peripheral mechanisms, since their receptors are present both in central nervous system areas 
involved in the regulation of metabolism and energy balance (hypothalamus) and peripheral 
metabolically active tissues. In the central nervous system they can interact with other 
signalling neuropeptides involved in energy balance, including leptin, POMC, CRH, alpha- 
MSH and melanocortin system, CART, NPY, AgRP, ghrelin, and through their influence on 
the SNS and GH secretion, can indirectly influence metabolism [308] [368] [452]. ERs, PRs 
and AR are also distributed in peripheral metabolically active tissues (e.g. liver, various 
adipose tissue depots, skeletal muscle, pancreas) in different proportions (depending also on 
gender) [313] [450] [640], and many of the actions of sex hormones are mediated locally, 
through their genomic and non-genomic nuclear receptor actions [232] [332] [367] [449] 
[460]. Additionally, they can interact with other nuclear receptors (“nuclear receptors cross­
talk”), by interacting and competing with them for requirement of co-activators (e.g. steroid 
receptor co-activator-1 (SRC-1), PGC-1 alpha, CREB-binding protein (CREB-BP)) and co­
repressors (e.g. SMRT (silencing mediator of retinoic acid and thyroid hormone receptor), N-
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CoR (nuclear receptor co-repressor) (e.g. interaction of ERs with PPAR-gamma in the process 
of adipocyte differentiation), or by interacting with other nuclear receptor responsive elements 
sequences because of homology (e.g. ER and PPAR-alpha share the same nucleotide repeats 
sequences in their responsive elements) [318] [317]. Interestingly, ARE can be also 
recognised by glucocorticoid and progesterone receptors, suggesting that there could be 
interactions between different receptors [424].
Most of the gender differences in metabolism have been tried to be explained by direct effects 
of sex hormones in certain tissues, through their both genomic and non-genomic actions [232] 
[332] [367] [460] [641]. In line with this are the data indicating that gender differences in 
metabolism and health risks (e.g. in insulin resistance, levels of triglyceride and HDL, 
centripetal- “android” type of fat accumulation) become the most apparent in the time of 
puberty, when gonads become active, and are kept during the reproductive age, but with the 
onset of menopause and relatively abrupt cessation of ovarian function and hormonal 
secretion, the differences become the less apparent.
In effort to explain the gender differences by the effects of sex hormones, the effects of 
gonadal steroids were examined in various tissues and metabolic processes. The tests were 
performed in vitro and in vivo, in humans, animals and different embryonic cell lines. 
However, the results varied depending on species tested (mice, rats, non-human primates, 
humans), the developmental states, and, most importantly - on gender, indicating that many of 
the hormonal effects were biased by genetic, especially sex-chromosome linked factors. 
Different genetically manipulated cell lines and animals were generated, in order to clarify the 
metabolic effects of gonadal steroids, including general and tissue specific (e.g. adipose 
tissue, liver or skeletal muscle) knockout mice (e.g. oestrogen receptor alpha (aERKO) [310] 
[314] [315] [316] [319], beta (PERKO) [314] [318] [319] [322], or both alpha and beta 
(aPERKO) deficient mice [642]; progesterone receptor deficient (PRKO) [643]; androgen 
receptor deficient (ARKO) [644] [645]; and aromatase deficient (ArKO) [66] [319] [324]
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[325] [328] [463] [646] mice), or mice which overexpressed steroid receptors or genes 
involved in metabolism of steroids [313] [329] [425] [646] [647] [648] [649]. Again, the 
findings varied according to the gender of animals. Data in humans on the effects of hormone 
administration or blockade also differed according to the gender of subjects involved. This 
suggests that some intrinsic, pre-determined, gender related factors exist in humans and 
animals, and additional efforts were made to discover those mechanisms.
As previously mentioned, the gender differences in metabolism become the most apparent 
during pubertal transition. Puberty is a period in intensive growth and development, and some 
irreversible changes in body composition and function from that period are maintained 
through the rest of life [650]. The levels of sex hormones surge in prepubertal period and it is 
possible that some permanent changes (“programming”) in cells and tissues occur in that 
period [651] [652]. However, some data show that it is more probable that gender differences 
in metabolism are much earlier “imprinted” in the cells and tissues [653] [654].
During foetal and early postnatal development, rapidly proliferating and differentiating cells 
are increasingly sensitive for epigenetic manipulation, and can permanently “imprint” and 
memorise the local environmental settings, as are the local levels of metabolites and 
hormones. This could permanently change their function in the later life. Therefore the 
exposure of the developmental cells to the specific conditions can be associated with the 
presence of the certain traits later in the adulthood (according to “The foetal-origin 
hypothesis”, originally developed by Dr. David Barker and later termed “The developmental 
origin of health and disease” [655]).
The sexually dimorphic development of female and male embryos begins about 7-8 weeks 
after gestation. It is determined by the presence of genes on the Y chromosome which encode 
testis development (e.g. the sex determining region Y (SRY) gene). Because of early 
development and the beginning of testicular function, the testosterone levels in male foetuses 
and newborns are much higher than in female foetuses and newborns [656] [657] [658] [659]
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[660] [661]. These higher levels of testosterone influence the “masculinisation” of the male 
brain (and possibly other tissues), making the permanent gender “programming” of the cells 
[653] [654] [657] [662]. For example, with the exposure to high testosterone levels, the 
hypothalamus of the male brain become “masculinised” [657]. The “masculinised 
hypothalamus” starts to secrete growth hormone-releasing hormone (GH-RH) in a gender 
specific mode, which further induces the male (pulsatile) pattern GH secretion from pituitary. 
By distinction, in females the pattern of GH secretion is more constant. It was shown that 
pattern of GH secretion could further influence the metabolism in peripheral tissues (e.g. the 
liver, skeletal muscle or adipose tissue), by changing the activity of many nuclear steroid 
receptors and enzymes included in the metabolic control and local metabolism of steroid 
hormones, including sex hormones [653] [662]. Therefore, early intrauterine and perinatal 
events can permanently influence and program cells to show sexual dimorphism in expression 
of genes [653] [654] [657] [662] [663] [664] [665] [666].
In support to this early developmental hypothesis, the data from studies in humans, non­
human primates, sheep and rodents, have shown that in females exposed to high 
concentrations of androgens during foetal and early postnatal life, the permanent changes in 
metabolism could be attained, influencing the increased risk for the development of metabolic 
syndrome, insulin resistance and dyslipidaemia later in life [479] [663] [664] [665] [667] 
[668] [669] [670] [671] [672] [673] [674] [675] [676] [677].
On the other hand, it was shown that foetal male and female brain cells differ in the 
morphology, function and gene expression even before the foetal gonadal development and 
secretion of testosterone. This suggests that some intracellular intrinsic, probably X and Y 
chromosome dependent differences could be present earlier in the intrauterine life [657] [666] 
[678] [679] [680].
Some of the genes included in the metabolic control are located on sex chromosomes, 
particularly X chromosome [657] [666] [681] [682]. In women, the second X chromosome is
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inactivated very early in developmental life [678] [679] [680]. Nevertheless, it has been 
estimated that about 15% of the second X-chromosome genes escapes the inactivation and 
remains active [681], thus in female tissues up to two fold higher expression of those genes 
could be expected compared with males [666] [681] [682]. On the other hand, in males, 22% 
of the genes on Y chromosome have their analogues on the female X chromosomes [657] 
[666], and in males both alleles can be active, thus the expression of those genes can be up to 
2 fold increased in males [666]. Therefore, some of the gender differences in metabolism, 
health risks and longevity could be a direct consequence of different sets of genes present and 
activated on X and Y chromosomes in males and females in different tissues [678] [683] 
[684].
Through evolution, in women and men different sets of genes were selected and optimized, 
which are related to their different sexual roles in reproduction, mostly to the specific 
functions which in women are related to pregnancy, lactation and child bearing [33] [111] 
[345]. In the past, the food scarcity and predator pressures, competition between and within 
species, were the main problem for survival and reproduction. Increased energy demands and 
at the same time reduced mobility during pregnancy, lactation and children raising, required 
women to have an increased ability for energy conservation and to have higher energy 
reserves stored in the body [33] [128] [294] [345] [685]. These reserves, in the form of 
adipose tissue with lower lipolytic activity, are distributed in specific regions in human 
females (in the lower-body area: gluteo-femoral region, around knees, subcutaneous 
abdominal depot under umbilicus and at lower back; also breasts and posterior-medial part of 
the upper arm), allowing proper centre of gravity and balance, and not compromising mobility 
(not interfering with the biomechanics of bipedal locomotion), and allowing proper 
thermoregulation [33] [686] [687]. Therefore, women developed specific metabolic 
adaptations to conserve energy and to use it at a time when food availability was limited [33] 
[99] [128] [294] [345] [685] [688]. Female fertility is dependent on the levels of body fat
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stored, and in the time of food scarcity and depleted body energy reserves (e.g. when %FM is 
less than 17%), anovulation occurs by mechanisms which involve the effect of leptin in the 
stimulation of the HPG axis [33] [357] [689] [690] [691]. In contrast, functions involved in 
fighting enemies and hunting, influenced men to store energy in the depots where it can be 
promptly mobilised for muscle activity (e.g. visceral depot).
I
Although the gender differences I in body morphology and function are the most pronounced
i
during the reproductive period, | they are also present before, from the early intrauterine 
development and are still maintained in the later life, in the post reproductive age.
10.8. The limitations of the study
The main weakness of this study is a limited number of the study participations involved, 
especially in the male group. As previously stated, some data indicate that the minimal 
number of study participants in a cross-sectional study design should be 1 2 - 2 0  subjects per 
group to have sufficient statistical power for postabsorptive plasma FFA and VLDL- 
triglycerides kinetics [692], and for VLDL-triglyceride subtractions, the number can be even 
higher, because of the increased intra-individual inter-day variability (particularly for VLDL2 
kinetics) [693]. However, with careful study protocol preparation and the sample processing, 
a lower variability can be achieved [694], thus the required number can be reduced to 6-10 
subjects per group [98] [695] [696]. In this study, the original number of participants was 
planned to be 16 males and 16 females, to achieve a reliable statistical power, but the time 
limitations for study to be completed (including subject recruitment, tests performed and all 
data laboratory analysed) did not allow the higher number in the male group to be included. 
Therefore, further studies, involving more participants would be advisable to confirm these 
findings.
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10.9. Conclusion
In conclusion, the results from this study indicate that postmenopausal obese women, 
compared with men matched for age and degree of obesity, defined by BMI, have increased 
whole body plasma FFA turnover, including the FFA release, uptake, re-esterification and 
oxidation rates expressed per kg FFM and per kcal REE, and VLDLi and VLDLz-triglyceride 
clearance. Despite increased whole body plasma FFA supply, postmenopausal obese women 
tended to be more insulin sensitive, having increased insulin stimulated glucose disposal 
during hyperinsulinaemic-euglycaemic clamp, and did not show increased cardio-metabolic 
risk, estimated by other parameters, including plasma lipid concentrations, HOMA model of 
insulin resistance assessment, and serum adiponectin levels. This suggests that women, 
compared with men, are intrinsically “primed” for increased lipid turnover, without a 
significant deterioration of cardio-metabolic risk, and this female “advantage” is independent 
of menopausal status and obesity.
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CHAPTER 11. APPENDIX
11.1. THE STUDY METHODOLOGY VALIDATION
Most of the methods and clinical and laboratory procedures used in this study were 
previously validated and used as standardised clinical and laboratory procedures and methods 
at the Postgraduate Medical School of University of Surrey. However, some methods were 
developed for the study and required validation. Therefore several pilot studies were 
performed.
11.1.1. A pilot study to assess the methodology for measuring FFA 
kinetics and FFA forearm muscle uptake by AV-difference
To explore the feasibility and validity of the method for measuring FFA kinetics and forearm 
muscle FFA uptake by A-V difference, a pilot study was performed (Pilot 1) with 2 study 
days. The study was performed on one subject (Subject 1: female, BW: 54kg; BMI=20.8; 
%FM= 26.1%, FM= 14 kg; FFM=40kg), who came on 2 separate occasions (2 months apart) 
at the CEDAR clinical research unit. There was no body weight change between studies.
The first study day (Pilot 1.1) included a 2-hour constant infusion of [1,2-13C] sodium acetate 
(infusion rate= 0.08umol/kg/min), and the second study day (Pilot 1.2) included a 2-hour 
constant infusion of [U-13C] sodium palmitate in 5% albumin (infusion rate= 0.01 
pmol/kg/min). Both infusions were primed with [13C] sodium bicarbonate (0.085 mg/kg), to 
equilibrate the bicarbonate pool. Blood and breath samples were taken at 0, 30, 60 90, 100, 
110 and 120min to measure plasma palmitate and breath CO2 enrichment, along with plasma 
concentration AV difference for FFA, palmitate, glycerol, total triglycerides and cholesterol 
(breath samples were taken on both study days, while blood samples were taken only during 
the second study day). The studies were performed in resting, postabsorptive (fasting) 
conditions.
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11.1.1.1. A-V difference method for forearm lipids kinetics assessment
In Table A .l are shown the data on forearm blood and plasma flow from the Pilot 1.2 study. 
Table A .I. Forearm blood and plasma flow in the Pilot 1.2 study_________________________________________
M easurem ent unit value
forearm blood flow ml/100m l tissue/m in 2.52
haem atocrit 0.33
forearm plasm a flow ml/100ml tissue/m in 1.69
The mean 0-110 minutes blood oxygen saturation was 93.6±2.1% (CV=2.2%) for arterialised 
and 65.3±2.3% (CV=3.6%) for (deep) venous blood samples. This was constant during the 
study. The values for arterialised venous blood were in the recommended range (90-95%), 
but venous blood oxygen saturation was above the recommended values (60%). This could be 
explained by an inadequate position of the cannula, resulting in the contribution of superficial 
venous blood draining the subcutaneous fat tissue (Figure A .l).
120.0
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Figure A .l. Arterialised and deep venous blood oxygen saturation (% OHb)
In the Table A.2 and Figure A.2 are shown the results for the A-V difference and net forearm 
flux values (V-A difference multiplied by forearm plasma flow) for plasma FFA, glycerol, 
triglycerides and cholesterol levels in the blood samples taken between 0 and 120 minutes.
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Table A.2. Forearm plasm a concentration A-V difference in Pilot 1.2 and net flux for FFA, 
palmitate, glycerol, triglycerides and cholesterol (mean±SD, N=7) _________________________________________
arterialised
(mmol/1)
venous
(mmol/1)
A-V
difference
(mmol/1)
V-A
difference%
N et flux (V-A difference) 
(pmol/lOOml tissue/min)
plasma FFA 0.266 0.400 -0.134 Î50.4% 0.226
±0.021 ±0.038 ±0.023 release release
plasm a palmitate 66.3 91.5 -25.3 T38.1% 0.043
±5.0 ±8.3 ±4.5 release release
plasma 0.030 0.066 -0.036 T121.3% 0.061
glycerol ±0.002 ±0.007 ±0.005 release release
plasma 0.453 0.455 -0.002 T0.4% 0.003
triglycerides ±0.027 ±0.034 ±0.021 negligible negligible
plasma 4.499 4.524 -0.025 T0.5% 0.042
cholesterol ±0.134 ±0.120 ±0.136 negligible negligible
Venous blood values for plasma FFA and glycerol concentrations were 50% and 121% 
respectively higher than in arterialised blood, showing a release from the local forearm 
tissues (muscle and fat). There was no significant difference for plasma triglycerides and 
cholesterol, which could be foreseen (the more significant difference was expected in the 
postabsorptive state, but not in fasting state, since there is no insulin to increase LPL 
activity). These results are in accordance with the published data [236] [697] [698] [699] 
[700] [701].
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Figure A.2. Plasm a concentration A-V difference for: FFA (a), glycerol (b), 
triglycerides (c) and cholesterol (d)
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Plasma palmitate concentration was 35% higher in venons blood (Table A.2, Figure A.3), and 
in the steady state (90-120 min) palmitate enrichment in arterialised blood was almost 2 times 
higher than in venous, showing dilution (release) from the local tissues (Figure A.3, Table 
A.3). Calculated values for the palmitate forearm uptake and release show that at least part of 
the blood was also draining fat tissue, not only muscle, since the local uptake rate was 2.5 
times lower than the release rate (Table A.3). The results are in accordance with the 
published data [697] [700] [702] [703] [704] [705].
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Figure A.3. Plasma palmitate A-V difference for concentration (a) and enrichm ent (b)
Table A.3. Forearm palmitate uptake and release rate
Param eter unit value
forearm  plasm a flow m l/100m l tissue/m in 1.69
net flux  (V -A  difference) (m ean 9 0 -1 10min) nm ol/100m l tissue/m in 52.6
positive=  release, 
negative^  uptake
release
% FE (fractional extraction) (A V -difference) positive^  uptake, 0.274
negative=  release uptake
palm itate forearm  uptake rate nm ol/100m l tissue/m in 31.87
palm itate forearm  release rate nm ol/100m l tissue/m in 84.49
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11.1.1.2. Acetate recovery factor
Calculated ARF from the study Pilotl.l was 22.2%, which is similar to previously reported 
values (23.3%, according to Schrauwen et al. [706]) (Table A.4).
Table A.4. Acetate recovery factor (study Pilot 1.1)
Measurement: Value:
acetate infusion rate F (irnnol/min/kg) 0.08
VC02 production (gmol/min) 5523.4
TTR C02 (mean 90-120min) 3.48 xlO'4
V13C02 production (jamol/min) 1.92
Acetate recovery factor 0.222
11.1.1.3. FFA systemic rate of appearance, disappearance and oxidation
In Table A.5 are presented measurements needed for the calculation of palmitate systemic 
rate of appearance (lipolysis), disappearance (systemic uptake) and palmitate and total plasma 
FFA oxidation rates. These results are in accordance with the published data [697] [700] 
[702] [703] [706].
Table A.5. Systemic palmitate and rate o f  appearance and oxidation (study Pilot 1.2)
Measurement: Value:
plasma palmitate TTR- (mean 90-120 min) 0.0107
Palmitate Ra ( gmol/kg/ min) 0.949
Palmitate Ra (gmol/kgFFM/min) 1.282
C02 production rate (pmol/min) 5345.2
C02 TTR (mean 90-120 min) 1.16 xlO"4
13C02 production rate (gmol/min) 0.619
acetate recovery factor 0.222
Fraction of infused tracer oxidised 0.316
Palmitate oxidation rate (gmol/min/kgBW) 0.300
Palmitate oxidation rate (mol/min/kgFFM) 0.406
FFA concentration (mean 90-120min) (jnmol/1) 266
palmitate concentration (mean 90-120min) (pmol/1) 67.1
[palmitate/total plasma FFA ] ratio 0.25
Total plasma FFA oxidation rate ( pmol/kgBW/min) 1.201
Total plasma FFA oxidation rate (pmol/kgFFM/min) 1.623
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11.1.1.4. Validation of the implementation of acetate recovery factor for the 
total plasma FFA oxidation assessment
This study was performed in order to confirm the rationale for use of [1,2-I3C] ARF for the 
correction of [U-13C] palmitate oxidation rates in humans [269] [707] [706]. The ARF was 
proposed to be used since the metabolic studies on substrate oxidation showed that the 
appearance of 13C0 2  in breath samples, coming from the oxidation of infused tracers 
(including labelled palmitate), is very low in the first hours of infusion, especially under 
resting conditions. This means that part of the label is temporarily fixed in some metabolic 
pools in the body. Sidossis et al. [269] [707] showed that a part of the palmitate tracer is 
accumulated in products of the tricarboxylic acid (TCA) cycle (glucose, glutamate and 
glutamine, pyruvate, lactate, aspartate). It was claimed that the fixation of the tracer in these 
products, together with the fixation in the bicarbonate pool, was the main reason for the 
delayed and incomplete appearance of 13C0 2  in the breath, which could lead to the 
underestimation of the palmitate oxidation rate. They suggested that the amount of the 
palmitate label fixation can be determined by measuring 13C0 2  production during infusion of 
13C-labelled acetate, because acetate, like palmitate, is firstly converted to acetyl-CoA, which 
enters the TCA cycle before 13C02 is produced. It was thus recommended that the ARF was 
used to correct calculated palmitate oxidation rates for the proportion of label incorporated in 
the metabolic pools.
In the same pilot study (Pilot 1), the appearance of labelled 13C 02 was measured in breath 
after a 2h constant infusion of both labelled acetate and palmitate, and the rates of FFA 
oxidation were calculated with or without using the ARF.
Calculated breath samples 13CC>2/12C02 TTRs, fractional recovery of 13CC>2 in breath and 
calculated 13C0 2  production rates in acetate and palmitate infusion studies, without and with 
the use of ARF are presented in the Table A.6. and Figure A.4. Calculated palmitate and FFA
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oxidation rates in the palmitate infusion study without and with the use of ARF are presented 
in the Figure A.5.
Table A.6. 13C 0 2/ 12C02 TTRs and the fractional recovery o f 13C 0 2 in the breath samples taken every 10min 
between 90-120min o f  [1,2-13C] sodium acetate and U -ljC sodium palmitate infusion, and calculated UC 02 
production rates, w ithout and with the use o f  ARF_______________________________
tim e-
m in
C 0 2 T T R
Fractional
la
recovery o f  
Del
13C 0 2 production rate 
(pm ol/m in)
acetate palm itate acetate palm itate acetate palm itate
palm itate
A R F
corrected
0 0 0.000000 0.00 0.00 0.00 0.00 0.00
90 0.000305 0.000102 0.19 0.06 1.68 0.55 2.56
100 0.000332 0.00011 0.21 0.07 1.83 0.59 2.52
110 0.000362 0.000121 0.23 0.07 2.00 0.65 2.55
120 0.000394 0.000129 0.25 0.08 2.18 0.69 2.50
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Figure A.4. 13C 0 2 production rate after acetate infusion and after palmitate infusion-with 
and without using the ARF correction (Pilot 1)
without ARF
Figure A.5. Total plasma FFA oxidation rate with and without using the ARF (Pilot 1)
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These results confirmed that the appearance of labelled 13CC>2 in breath samples during the 2 
hour constant infusion of labelled palmitate does not reach steady state. This can be really 
explained by the partial incorporation of CO2 produced during FFA oxidation into metabolic 
pools in the body [269] [706] [707], since the ARF completely accounts for such delayed 
appearance of labelled 13C02 in breath. After the correction for CO2 incorporation in 
metabolic pools (ARF), CO2 production after palmitate infusion plateaued. Delayed 
appearance of labelled 13C02 in breath could lead to an almost 4.5 times lower estimation of 
FFA oxidation rates (0.36 vs. 1.62 pmol/kgFFM/min), if the ARF is not applied.
11.1.2. Reproducibility of the C 0 2 production measurement
To examine the reproducibility of the CO2 production measurement, a pilot study (Pilot 2) 
was performed. We measured on the same subject (Subject 2) CO2 production on 4 
consecutive days. The subject was fasted overnight and came to the research unit at 9 a.m... 
The day before the study days, the subject was asked not to drink alcohol and to have the 
same dinner at the same time (8 p.m.). On the study day subject rested on the bed for Ih, then 
the measurements of CO2 production were taken for 20 minutes, 2-4 times, with in-between 
intervals of 20 minutes which included recalibration of the instrument. In total 11 
measurements were taken. Results are shown on Table A.7. Within a day-variability 
(expressed as CV%) was varying between 1.9%- 5.5% (p=0.000- 0.017, ANOVA). Between 
all measurements variability (expressed as CV%) was 5.1% (p=0.000, ANOVA).
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Table A.7. Between measurements and between days variability for breath C02 production measurements 
(Pilot 2) ____________________________________________________________________
C 0 2 production (ml/min)
Measurement: Mean Std. Dev min max cv% P(ANOVA)
Day 1 - first 166.1 7.2 151.0 177.0 4.3
Day 1 - second 167.5 8.9 154.0 183.0 5.3
Day 1 - third 153.8 5.0 145.0 164.0 3.2
Day 1 - fourth 149.9 6.5 141.0 163.0 4.3
Day-1 inter­
measurements variability 159.3 8.8 149.9 167.5
5.5 0.000
Day 2 - first 162.1 5.8 154.0 178.0 3.6
Day 2 - second 171.0 11.2 156.0 195.0 6.6
Day-2 inter­
measurements variability 166.5 6.3 162.1 171.0
3.8 0.003
Day 3 - first 177.0 7.7 162.0 188.0 4.4
Day 3 - second 167.6 4.6 156.0 176.0 2.8
Day-3 inter­
measurements variability 172.3 6.6 167.6 177.0
3.9 0.000
Day 4 - first 157.1 5.6 143.0 165.0 3.5
Day 4 - second 160.2 6.6 147.0 171.0 4.1
Day 4 - third 154.3 6.6 140.0 168.0 4.3
Day-4 inter­
measurements variability 157.2 2.9 154.3
160.2 1.9 0.017
TOTAL
MEASUREMENTS: N = ll 162.4 8.3 149.9 177.0 5.1 0.000
11.1.3. Reproducibility of the breath samples (13C02/12C02) TTR 
measurements between samples variability and between 
measurements variability
To examine the reproducibility of the CO2 TTR measurement, in the pilot palmitate infusion 
study (Pilot 1.2) 3 breath samples were taken for each time point. All the samples were run 
on CF/IRMS on the same day. Between measurement variability (expressed as CV%) varied 
from 0.6% to 1.9%. This was considered to be an acceptable CV (Table A.8).
Table A.8. Between samples variability for breath 13C02 enrichment after palmitate infusion
APE
time N Mean Std. Dev CV%
0 3 0.000 0.000 0.0
30 3 0.0070 0.0001 1.1
60 3 0.008 0.0002 1.9
90 3 0.010 0.0001 0.7
100 3 0.011 0.0001 1.0
110 3 0.012 0.0002 1.3
120 3 0.013 0.0001 0.6
309
This was repeated in the pilot acetate infusion study (Pilot 1.1). The samples were run on 3 
different days, to confirm CF/IRMS reproducibility. The mean CV between all samples was 
again 1.1% (Table A.9).
Table A.9. Inter-measurement variability for breath 13C 0 2 enrichment after acetate infusion study 
__________(Pilot 1.1) (measurements performed on different days)__________
AP]E
time N Mean
Std.
Dev CV%
0 3 0.000 0.000 0.0
90 3 0.033 0.0003 0.9
100 3 0.035 0.0007 2.1
110 3 0.038 0.0002 0.6
120 3 0.041 0.0003 0.6
To confirm time stability of breath samples storage and to test inter-measurements variability, 
duplicates of 30 breath samples were analysed twice: the first measurement after the samples 
were collected and the second measurement after 6 months of storage. Results before and 
after 6 months of storage showed statistically significant correlation (Pearson’s coefficient of 
correlation 0.999, p=0.000), the average CV was =1.4% (Figure A.6). Even though there was 
a statistically significant difference between measurements (paired T-test, /?=0.003) with a 
slight tendency to measure lower values after 6 months in some samples (which could be 
related to both sample storage or to differences in mass-spectrophotometer measurements). 
However, those differences were still negligible and were considered to be acceptable.
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Figure A.6. Between-measurements reproducibility of CF/IRMS breath samples L'C 0 2 enrichment 
measurements -  long term stability of stored samples - Pearson’s coefficient o f correlation (between 
measurements repeated after 6 months on the stored duplicate of the samples)
11.1.4. Mass spectrometry- measurement of plasma palmitic acid 
enrichment and concentration by GC/C/IRMS
In the original article by Schrauwen et al. [706], GC/C/IRMS technique was used to measure 
plasma palmitate isotopic enrichment. We wanted to explore if the results would be different 
if the measurements are done by GC/MS or GC/C/IRMS techniques.
Therefore, the isotopic enrichment and concentration of the plasma palmitic acid methyl ester 
was measured both by GC/MS (5975 inert XL MSD coupled with the 6890 series GC, 
Agilent Technologies, U.K.), as described in the methodology chapter, and by gas- 
chromatography combustion isotope ratio mass spectrometry GC/C/IRMS (on the DeltaPlus 
XP with GC combustion III inlet systems, Thermo Electron, Bremen, Germany), and the
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results were compared. The latter instrument was equipped with a CTC A200S autosampler, 
and coupled to the MS via a Finnigan MAT GCCIII interface (Thermo Electron, Bremen, 
Germany). The samples (Ipl) were injected via autosampler injector in the splitless mode. 
The flow rate of helium was kept at 1 ml/min, constant flow. The initial temperature of the 
injector was set at 250 °C. The oven initial temperature was set at 150 °C for 3 minutes, then 
increased with a ramp of 4°C/min to 195°C. After passing through an SGE BP1 capillary 
column (100% dimethylpolysiloxane, length 30 m x internal diameter 0.25 mm x film 
thickness 0.25 pm), the separated fractions of palmitic acid and heptadecanoic acid methyl 
esters reached the combustion reactor (an alumina tube containing Cu, Ni and Pt wires 
maintained at 940 °C), where they were combusted (thermally oxygenised) into CO2 
molecules (17 CO2 molecules derived from each palmitic acid methyl ester molecule and 18 
CO2 molecules derived from each heptadecanoic acid methyl ester molecule). After passing a 
reduction reactor (an alumina tube containing three Cu wires maintained at 600 °C) to reduce 
any nitrogen oxides to nitrogen and a water separator (a tube constructed from a water 
permeable nafion) to remove water, the sample was introduced into the ion source of the MS 
by an open split interface. The MS operated in El mode. Ions at m/z 44 and m/z 45 
corresponding to 12C160 160  isotopomer of CO2 (derived from unlabelled plasma palmitic 
acid- tracee, heptadecanoic acid- internal standard and methyl-ester group from derivative 
agent) and 13C160 160  isotopomer of CO2 (derived from uniformly labelled palmitic acid- 
tracer), respectively, were selectively measured.
The equations [1] and [12] (in the analytical methodology chapter) were used to calculate 
TTR of plasma palmitate, which was additionally corrected by a factor 17/16 to account for 
the extra methyl group of the methyl palmitate derivative. Measurement of the plasma 
palmitate concentration was carried out by measuring the ratio between the area of the CO2 
curve originating from the combustion of palmitate and that generated by the combustion of 
the internal standard heptadecanoic acid.
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There was no statistical difference in the results obtained from GC/MS or GC/C/IRMS, both 
for plasma palmitate enrichment and concentration measurements (Table A. 10), and there 
was a significant correlation between data obtained from GC/MS and GC/C/IRMS (Figure 
A.7). This indicates that both techniques could be used equally.
Table A.10. Plasma palmitate concentration and enrichment measurement: GC/MS vs. GC/C/IRMS
GC/MS IRMS GC/MSvs.GC/C/IRMS
p1N mean SD CV% mean SD CV%
Concentration (pmol/l)
10 84.5 2.8 3.4 88.2 3.4 3.8 0.069
Enrichment (TTR )
10 0.00605 0.0002 2.7 0.00633 0.0001 1.9 0.0521
1 student T test for two paired samples; statistical significance at p<0.05
0.012 i y = 1.044x + 2E-05 
R2 = 0 .9 9 9 8 /
■g 0.008 -
ra 0.006 -
<0 0.004 ■
3  0.002  -
0.0120.010.006 0.0080.0040.002
I RMS measured TTR
Pearson’ coefficient o f  correlation^ 0.9998, p<0.000
Figure A.7. Correlation between GC/C/IRMS and GC/MS measurements for palmitate standards TTR
11.1.5. Reproducibility of the GC/MS and GC/C/IRMS plasma palmitate 
concentration and enrichment measurements: intra and inter-assay 
variation, limits of detection
To test the reproducibility of the method for measuring plasma palmitate concentration and 
enrichment, 10 measurements of the same plasma sample were performed to test the intra­
assay variability. Each set of 10 samples was run 3 times on the MS, to test the GC/MS and
GC/C/IRMS reproducibility. To test the inter-assay variability of plasma palmitate
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concentration, 3 different assays (plasma palmitate isolation and derivatisation) of the same 
plasma sample were performed on the 3 different days, using 3 separately prepared standards 
of heptadecanoic acid (concentration^ 13.64 pmol/1).
For the plasma palmitate concentration, intra-assay CV was 6.9% (Table A.ll) ,  while inter­
assay CV was 6.0% (Table A. 12). For the plasma palmitate enrichment measurement, intra­
assay CV was 1.8% (Table A. 13) !
Table A . l l .  Plasma palmitate concentration (GC/MS) measurement: intra-assay variability
Concentration (pmol/1)
Assay N run mean SD min max CV% p1
1 10
I 78.8 1.4 77.3 81.1 1.8
0.001II 81.9 6.3 75.1 87.9 7.7III 89.0 1.9 85.2 90.5 2.2
total 83.2 5.7 75.1 90.5 6.9
ANOVA; statistical significance at p<0.05
Table A.12. Plasma palmitate concentration (GC/MS measurement): inter-assay variability
Concentration (pmol/l)
Assay N run mean SD min max CV% P1
1 10 I 78.8 1.4 77.3 81.1 1.8 0.001
2 10 I 89.2 1.0 87.7 90.3 1.1
0.0003 10 I 84.1 4.1 80.8 89.7 4.8
Total 30 84.0 5.0 77.3 90.3 6.0
ANOVA; statistical significance at p<0.05
Table A.13. Plasma palmitate enrichment (GC/C/IRMS) measurement: intra-assay variability
Enrichment (Tr/Te )
Assay N run mean SD min max CV% p-
1 10
I 0.0219 0.0002 0.0218 0.0221 0.7
0.756II 0.0217 0.0006 0.0213 0.0223 2.6III 0.0219 0.0005 0.0216 0.0225 2.2
total 0.0218 0.0004 0.0213 0.0225 1.8
ANOVA; statistical significance at p<0.05
Figures A.8 and A.9 show typical standard curves for measurement of the expected range of 
palmitate concentration and enrichment, which showed a good correlation between 
theoretical and observed ratios. The minimum sample concentration for accurate detection
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and measurement of plasma palmitate concentration by GC/MS was 0.13 pmol/1. With 
concentrations lower than 1 pmol/1 a high influence of background contamination was noted. 
Maximal concentration tested was 10 mg/ml (data not shown).
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Figure A.8. Standard curve for GC/M S m easurem ent o f plasma palmitate concentration using 
internal standard o f heptadecanoic acid (HAstd= 113.64 pmol/1, PAstd= 136.87 pmol/1)
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Figure A.9. Standard curve for GC/C/IRM S measurem ent o f  plasma palmitate enrichm ent 
(U -ljC N aPA std=2.76 pmol/l, PAstd= 136.87 pmol/1)
To test the specificity of the method for plasma free-palmitate isolation and measurement, a
test using a mixture heptadecanoic acid and tripalmitoyl-glycerol standards (in heptane) was
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performed. Fatty acids were extracted and derivatised by the method of Patterson et al. [708]. 
The test confirmed that the method is specific only for non-esterified fatty acids, since no 
peaks for methyl-palmitate occurred on GC/MS (data not shown).
These results confirmed that the method for plasma non-esterified palmitate isolation, 
derivatisation and measurements was specific and accurate enough for the expected range of 
plasma palmitate concentration (110-200 pmol/1) and enrichment (TTR: 0.005-0.01). Also, 
the results suggested that all samples (before and after treatment) should be analysed in one 
assay, using the same internal standard.
11.1.6. Reproducibility of the method for blood flow measurement: 
inter-subject and intra-subject variation
To test the within-subject variability in measuring blood flow with the Hokanson C6 strain 
gauge plethysmography, 3x10 measurements on each subject (N=3) were repeatedly 
performed the same day, and than were repeated on 3 different days to test between-day 
variability.
Mean inter-measurement variability was CV=27.7%, while the inter-day measurement 
variability was CV=35.9% (Table A. 14). There was statistically significant difference in both 
within-day (between 3 different measurements) and between- day variability (p=0.000). 
These results are in accordance with the published data (between measurements variability 
CV=10-30% [709] [710] [711]), and show the inaccuracy of the method that has to be taken 
into account.
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Table A. 14. Blood flow measurement with Hokanson C6 strain gauge plethysmography: 
within subject intra-day and inter-day variability_______________________________________________________
Subject
No N day
Blood flow Between
measurementsmean SD CV
ml/lOOml tissue/min % P1
1
3x10 I 2.75 0.77 28.07 0.008
3x10 II 3.09 0.56 18.05 0.012
3x10 III 3.58 0.93 26.06 0.005
total 30 3.74 1.20 36.31 0.000
2
3x10 I 3.67 1.08 29.43 0.003
3x10 II 2.73 0.65 23.81 0.000
3x10 III 2.76 0.81 29.35 0.009
total 30 3.05 1.01 39.30 0.000
3
3x10 I 3.88 1.59 40.98 0.000
3x10 II 2.87 0.64 22.3 0.023
3x10 III 2.73 0.85 30.97 0.004
30 3.16 1.14 37.96 0.000
1 ANOVA; statistical significance at p<0.05
11.1.7. Between-subjects variation of the acetate recovery factor
In one pilot subject (Pilot 3) acetate was infused for 3 hours, to see if steady state was 
achieved after 3 hours. After 15 minutes of infusion, a linear slope of label appearance in 
breath was noted. Steady state wasn’t achieved even after 3 hours. In total, in 4 pilot subjects 
(Pilot 1, 2, 3, 4) morning breath samples were taken on 5 consecutive days after the infusion, 
to determine when breath enrichment returned to baseline levels (to establish how many days 
are necessary between acetate and palmitate study). By the next morning, the breath 13C02 
enrichment had decreased to the baseline levels.
Results for the first 4 Rimonabant study subjects and 4 pilot subjects are shown on Figure 
A.10.
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Figure A.10. 1jC 0 2/12C02 TTR in breath samples after ljC acetate infusion for 8 female 
subjects (4 from the Rimonabant study and 4 pilot subjects)
Recovery of label after acetate infusion was significantly correlated with the body weight of 
subjects (Pearson coefficient of correlation^ 0.811, p=0.015) (Figure A .ll) . Schrauwen and 
colleagues [706] found that the main determinants of the ARF are the basal metabolic rate 
(even after adjustment for FFM), RQ (both in a positive correlation), and %FM (in a negative 
correlation). Obese subjects compared with non-obese have a higher basal metabolic rate 
(higher FFM and FM) and therefore a higher basal C 0 2 production [712], which could 
explain the shown positive correlation between recovery of acetate and body weight.
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Figure A .l l .  Correlation between body weight and breath samples 1jC 0 2/12C02 TTR
after the 13C acetate infusion
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Figure A.12 shows ^COz/^CO] TTR in breath samples during the acetate and palmitate 
infusions in 5 subjects. The figure shows that steady state of ^COi/^CO] in breath samples is 
not achieved during last 30 minutes of the 2-hour acetate and palmitate infusion period. 
However, if ACR is applied for each sample time point, the steady state in 13C02 is achieved 
during last 30 minutes of infusion (Figure A.13.)
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11.2. CORRELATIONS IN THE FEMALE GROUP: Correlations between 
VLDL-triglyceride kinetics, plasma palmitate kinetics and other 
measured variables in the female group
In 15 female subjects linear correlation between VLDL-triglyceride kinetics, plasma 
palmitate kinetics and other measured metabolic variables was examined using Pearson 
correlation coefficient. Only correlations which achieved statistical significance are presented 
here.
11.2.1. VLDL-triglyceride kinetics
VLDLi- triglyceride APR (Table A. 15) correlated positively with fasting plasma 
triglyceride, VLDLi- and VLDL^-triglyceride, VLDLi- and VLDL^-cholesterol 
concentrations. VLDLi-triglyceride APR correlated inversely with VLDL^-triglyceride FOR. 
Statistically significant positive linear correlations were found with palmitate oxidation rate 
expressed in absolute terms, per kg FFM and per kcal/min REE. Additionally, there was a 
positive correlation with arterialised plasma steady state FFA (no correlations with FFA 
concentrations in venous plasma), fasting glycerol and insulin concentrations), a product of 
palmitate Ra and fasting insulin concentrations (an indicator of resistance to the anti-lipolytic 
action of insulin [713]), HOMA2-R, HOMA2-%B, and negative with HOMA2-%S and ISI- 
HOMA. Positive correlations were also found with body weight, FM and waist 
circumference.
VLDL2-  triglyceride APR (Table A. 15) correlated directly with fasting plasma triglyceride, 
VLDLi- and VLDL^-triglyceride, VLDLi- and VLDL^-cholesterol concentrations. VLDL2- 
triglyceride APR correlated inversely with VLDLi-triglyceride FCR. Additionally, there was 
a positive correlation with fasting insulin, HOMA2-R, and a negative with HDL 
concentrations.
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Statistically significant negative linear correlations were found between VLDLi- 
triglyceride FCR (Table A. 16) and fasting plasma triglyceride, VLDLi- and VLDL2- 
triglyceride, VLDLi- and VLDL^-cbolesterol, total cholesterol and LDL-cholesterol 
concentrations. Significant negative linear correlations were found between VLDLi- 
triglyceride FCR and palmitate Ra expressed per kg FM and palmitate oxidation rate 
expressed per kg BW, while the negative correlations with palmitate oxidation rate expressed 
in absolute terms, per kg FFM and kcal/min REE approached statistical significance.
VLDL2-  triglyceride FCR (Table A. 16) significantly inversely correlated only with VLDLi- 
triglyceride APR and plasma glycerol concentrations.
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Table A.15. Correlations between VLDLi and VLDL2 -triglyceride APR and 
other metabolic variables   ,
VLDLrTG APR 
(mg/kg/d)
VLDL2-TG APR 
(mg/kg/d)
Correlation
coefficient
p-value
Correlation
coefficient
p-value
Triglycerides mmol/1) 0.718 0.002 0.521 0.039
VLDLi-triglyceride (mmol/1) 0.718 0.002 0.537 0.032
VLDLa-triglyceride (mmol/1) 0.601 0.014 0.853 <0.001
VLDLi-cholesterol (mmol/1) 0.690 0.003 0.528 0.036
VLDL2-cholesterol (mmol/1) 0.667 0.005 0.591 0.016
HDL-cholesterol
(mmol/1)
-0.560 0.024
VLDLi-TG FCR 
(pools/d)
-0.590 0.016
VLDL2-TG FCR 
(pools/d)
-0.531 0.034
arterialised plasma FFA (pmol/1) 0.613 0.015
glycerol (pmol/1) 0.608 0.012
fasting insulin (pU/ml) 0.719 0.002 0.524 0.037
HOMA2-IR 0.732 0.002 0.509 0.044
HOMA2- %S -0.576 0.020
HOMA2- %B 0.545 0.029
ISI-HOMA -0.596 0.015
fasting insulin x  palmitate Ra 
(pU/ml) (pmol/min)
0.731 0.002
palmitate oxidation rate 
(pmol/min)
0.633 0.011
palmitate oxidation rate 
( pmol/kgFFM/min)
0.601 0.018
palmitate oxidation rate 
(pmol/kcal/min)
0.621 0.013
BW  (kg) 0.614 0.011
FM (kg) 0.674 0.004
Waist (cm) 0.520 0.039
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Table A.16. Correlations between VLDLi and VLDL2 -triglyceride FCR 
and other metabolic variables____________________________________
VLDLi-TG FCR 
(pools/d)
VLDL2-TG FCR 
(pools/d)
Correlation
coefficient
p-value
Correlation
coefficient
p-value
Triglycerides mmol/1) -0.643 0.007
VLDLi -triglyceride (mmol/1) -0.595 0.015
VLDL2-triglyceride (mmol/1) -0.554 0.026
VLDLi-cholesterol (mmol/1) -0.587 0.018
VLDL2-cholesterol (mmol/1) -0.574 0.020
Cholesterol (mmol/1) -0.564 0.023
LDL-cholesterol
(mmol/1)
-0.625 0.006
VLDLi-TGAPR
(mg/kg/d)
-0.531 0.034
VLDL2-TG APR  
(mg/kg/d)
0.531 0.034
glycerol (pmol/1) -0.501 0.048
palmitate Ra 
(pmol/kgFM/min)
-0.518 0.048
palmitate oxidation rate 
(pmol/kgBW/min)
-0.572 0.026
palmitate oxidation rate 
(pmol/min)
-0.482 0.069
palmitate oxidation rate 
(pmol/kgFFM/min)
-0.493 0.062
palmitate oxidation rate 
(pmol/kcal/min)
-0.495 0.060
11.2.2. Plasma palmitate and total plasma FFA kinetics
Because of simplicity, only statistically significant linear correlations of palmitate and total 
plasma FFA kinetic parameters expressed in absolute terms are presented here, while all 
others modes of expression (per kg FM, kg FFM or kcal/min REE) mostly followed the here 
presented correlation coefficients and statistical significance (data not shown). All examined
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palmitate kinetics parameters (including palmitate Ra, MCR, non-oxidative disposal, 
oxidation rate, and TPFAO) expressed in absolute terms significantly correlated positively in- 
between (data not shown).
Statistically significant positive linear correlations were found between palmitate Ra 
(expressed in absolute terms) (Table A. 17) and venous plasma FF A concentrations (while the 
correlation with FFA concentrations in arterialised plasma only approached significance), 
fasting glycerol, the product of palmitate Ra and fasting insulin concentrations, fasting 
plasma triglyceride, VLDLi-triglyceride, VLDLi-cholesterol and LDL-cholesterol 
concentrations. Positive correlations were also found with the steady state measured O2 
consumption and REE. No significant correlations were found with anthropometric indices 
(data not shown).
Statistically significant positive linear correlations were found between palmitate oxidation 
rate (expressed in absolute terms) (Table A. 17) and VLDLi-triglyceride APR, fasting plasma 
triglyceride, VLDLi-triglyceride, VLDLi-cholesterol, VLDL2-cholesterol and LDL- 
cholesterol concentrations (while with HDL-cholesterol an inverse correlation approached 
statistical significance). Additionally, positive linear correlations were found with venous 
FFA concentrations (no significant correlation with FFA concentrations in arterialised 
plasma), fasting glycerol, insulin, the product of palmitate Ra (pmol/min) and fasting insulin 
concentrations (pU/ml), HOMA2-R and HOMA2-%B. Significant positive correlations were 
found with the steady state measured 0 2 consumption), C 02 production, REE and forearm 
blood flow. No significant correlations were found with anthropometric indices (data not 
shown).
Palmitate MCR (expressed in absolute terms) correlated positively only with venous plasma 
FFA concentration (p=0.535, p=0.049).
Palmitate non-oxidative disposal rate (expressed in absolute terms) correlated positively 
with venous plasma FFA (p=0.709, p=0.005) and fasting glycerol concentration (p=0.581,
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p=0.023), with the product of palmitate Ra and fasting insulin concentrations (p=0.550, 
p=0.033), and the steady state measured O2 consumption (p=0.646, p=0.009) and REE 
(p=0.594, p=0.020).
Table A. 17. Correlations between palmitate Ra and palmitate oxidation rate
and other metabolic variables _________________________________________________________________ ________ _
palmitate Ra 
(pmol/min)
palmitate oxidation rate 
(pmol/min)
Correlation
coefficient
p-value
Correlation
coefficient
p-value
Triglycerides mmol/1) 0.608 0.016 0.794 p<0.001
VLDLi-triglyceride (mmol/1) 0.523 0.046 0.730 0.002
VLDLi-cholesterol (mmol/1) 0.520 0.047 0.718 0.003
VLDL2-cholesterol (mmol/1) 0.695 0.004
LDL-cholesterol
(mmol/1)
0.690 0.003 0.530 0.042
HDL-cholesterol
(mmol/1)
-0.483 0.068
VLDLi-TG APR 
(mg/kg/d)
0.633 0.011
arterialised plasma FFA (pmol/l) 0.493 0.062
venous plasma FFA (pmol/l) 0.772 0.001 0.774 0.001
glycerol (pmol/l) 0.619 0.014 0.594 0.020
fasting insulin (pU/ml) 0.662 0.007
HOMA2-IR 0.668 0.006
HOMA2- %B 0.566 0.028
fasting insulin x  palmitate Ra 
(pU/ml) (pmol/min)
0.666 0.007 0.831 p<0.001
0 2 consumption (ml/min) 0.699 0.004 0.696 0.004
C 0 2 production (ml/min) 0.566 0.028
steady state REE (kcal/day) 0.659 0.008 0.694 0.004
forearm plasma flow  
(ml/min/100 ml forearm tissue)
0.610 0.027
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The product of palmitate Ra (pmol/min) and fasting insulin concentrations (pU/ml)
(Table A. 18) correlated positively with VLDLi- triglyceride APR, fasting plasma 
triglyceride, VLDLi- and VLDL^-triglyceride, VLDLi- and VLDL^-cholesterol 
concentrations. Significant positive correlations were found with palmitate oxidation rate 
expressed in absolute terms, per kg FFM and per kcal/min REE. Additionally, there were 
positive linear correlations with venous plasma steady state FFA (no correlations with FFA 
concentrations in arterialised plasma), fasting glycerol and insulin, HOMA2-R, HOMA2-%B, 
and negative with HOMA2-%S, ISI-HOMA and ISI-clamp. A positive correlation was also 
found with WHR. No other significant correlations, including correlations with VLDLi and 
VLDLi-triglyceride FCR, were found.
The insulin sensitivity index HOMA2-R (Table A. 18) correlated positively with VLDLi- and 
VLDLi-triglyceride APR, fasting plasma triglyceride, VLDLi- and VLDL^-triglyceride, 
VLDLi- and VLDL^-cholesterol concentrations. Statistically significant positive linear 
correlations were found with the palmitate oxidation rates expressed in absolute terms, per kg 
FFM and per kcal/min REE, and with the product of palmitate Ra and fasting insulin 
concentrations. Additionally, there was a positive correlation with fasting insulin, HOMA2- 
%B, and negative with HOMA2-%S, ISI-HOMA, ISI-clamp, glucose MCR and glucose 
steady state GIR. Positive correlations were also found with BMI, FM, waist circumference, 
and WHR. No other significant correlations, including correlations with VLDLi- and 
VLDLz-triglyceride FCRs, were found.
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Table A. 18. Correlations between the product (fasting insulin x palmitate Ra) and HOMA2-IR and other 
metabolic variables _________
fasting insulin (pU/ml) x 
palmitate Ra (pmol/min)
HOMA2-IR
Correlation
coefficient p-value
Correlation
coefficient
p-value
VLDLi-TG APR  
(mg/kg/d)
0.731 0.002 0.723 0.002
v l d l 2-t g a p r
(mg/kg/d)
0.509 0.044
Triglycerides mmol/1) 0.930 p<0.001 0.831 pO.OOl
VLDLi -triglyceride (mmol/1) 0.917 p<0.001 0.840 pO.001
VLDL2-triglyceride (mmol/1) 0.745 0.001 0.758 0.001
VLDLi-cholesterol (mmol/1) 0.916 p<0.001 0.827 pO.OOl
VLDL2-cholesterol (mmol/1) 0.865 p<0.001 0.839 p<0.001
venous FFA (pmol/1) 0.613 0.015
glycerol (pmol/l) 0.622 0.013
fasting insulin (pU/ml) 0.934 p<0.001 0.998 p<0.001
HOMA2-IR 0.935 p<0.001
HOMA2- %S -0.568 0.027 -0.761 0.001
HOMA2- %B 0.716 0.003 0.807 p<0.001
ISI-HOMA -0.581 0.023 -0.778 p<0.001
Steady state GIR (mg/kg/min) -0.511 0.043
Glucose MCR 
(ml/kg/min)
-0.521 0.038
ISIrec (ml//kg/min) (pU/ml)"1 0.596 0.019 -0.702 0.002
fasting insulin x  palmitate Ra 
(pU/ml) (pmol/min)
0.935 pO.OOl
palmitate oxidation rate 
(pmol/min)
0.831 p<0.001 0.668 0.006
palmitate oxidation rate 
(pmol/kgFFM/min)
0.844 p<0.001 0.688 0.005
palmitate oxidation rate 
(pmol/kcal/min)
0.723 0.002 0.613 0.015
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Table A.18. Correlations between the product (fasting insulin x palmitate Ra) and HOMA2-IR and other
metabolic variables (continued)
fasting insulin (pU/ml) x  
palmitate Ra (pmol/min)
HOMA2-IR
Correlation
coefficient
p-value
Correlation
coefficient
p-value
BMI (kg/m2) 0.636 0.008
FM (kg) 0.502 0.047
Waist (cm) 0.603 0.013
WHR 0.598 0.019 0.586 0.017
11.2.3. Leptin and adiponectin
Leptin correlated significantly with %FM (p=0.588, p=0.017) (with FM it approached 
significance, p=0.487, p=0.055) and venous palmitate concentration (p=0.546, p=0.035), 
while adiponectin correlated significantly with %FM (p=-0.625, p=0.010), FM (p=-0.502, 
p=0.048), the steady state GIR (mg/kg/min) (p=0.534, p=0.038) and plasma HDL 
concentrations (p=0.504, p=0.047). Correlations with glucose MCR (p=0.495, p=0.051), 
VLDLi-triglyceride (p=-0.465, p=0.069) and VLDLi-cholesterol (p=-0.449, p=0.081) 
concentrations, and waist circumference (p=-0.440, p=0.088) tended to be significant. The 
ratio adiponectin to leptin was in a significant correlation with the steady state GIR (p=0.667, 
p=0.005), glucose MCR (p=0.615, p=0.011), and HOMA2-%B (p=-0.513, p=0.042). The 
correlations with the other examined metabolic parameters were not significant, including 
correlation with FFA and VLDL-triglyceride kinetics.
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THE THESIS DERIVED PUBLICATIONS
Two publications were published from the research in this PhD thesis:
1. Backhouse K, Sarac I, Shojaee-Moradie F, Stolinski M, Robertson MD, Frost GS, Bell 
JD, Thomas EL, Wright J, Russell-Jones D, Umpleby AM. Fatty acid flux and 
oxidation are increased by rimonabant in obese women. Metabolism. 2012 
Sep;61(9): 1220-3.
2. Sarac I, Backhouse K, Shojaee-Moradie F, Stolinski M, Robertson MD, Bell JD, 
Thomas EL, Hovorka R, Wright J, Umpleby AM. Gender differences in VLDL1 and 
VLDL2 triglyceride kinetics and fatty acid kinetics in obese postmenopausal women 
and obese men. J Clin Endocrinol Metab. 2012 Jul;97(7):2475-81.
These publications were a joint work of the listed authors. The first two authors made an 
equal contribution to the both manuscripts.
There are some differences between the data presented in the thesis and the published articles:
1. In the first article, data on REE and intrahepatocellular lipid (IHCL) and 
intramyocellular lipid (IMCL) content and diet composition were obtained and 
analysed by Dr Katherine Backhouse for her PhD thesis. In the published article, data 
on REE were derived from Testl, while the data presented in this thesis were derived 
from Test 2, when subjects were fasting and resting for 3 hours longer. In the article 
REE was calculated using the data on nitrogen excretion. This was not available for
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test 2. In the published article, palmitate enrichment in venous blood was used for the 
analysis of palmitate kinetics, while in the thesis palmitate enrichment in arterialised 
blood was used. Data on adiponectin levels were erroneous in the published article, 
and were corrected after publication.
2. In the second article, the study participants were different from those presented in this 
thesis. In the published article 8 obese men (60=1=3 yr, BMI=32±1 kg/m2) (mean±SEM) 
and 10 postmenopausal obese women (58±2 yr, BMI =33±1 kg/m2) matched for 
fasting plasma triglyceride levels were included in the study. This included 4 subjects 
recruited after the author had completed her research in the UK. In this thesis, only 
subjects that the author studied were included. In the published article, palmitate 
enrichment in venous blood was used for the analysis of palmitate kinetics, while in 
the thesis palmitate enrichment in arterialised blood was used. Additionally in the 
published article, data on body composition (adipose tissue content), IHCL, IMCL and 
REE were obtained and analysed by Dr Katherine Backhouse.
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SUMMARY OF THE WORK
THE EFFECT OF RIMONABANT AND GENDER ON LIPID KINETICS IN 
OBESITY
In this thesis the effects of rimonabant, the CB1 endocannabinoid receptor antagonist, and gender 
on free fatty acid (FFA) and very-low-density lipoprotein (VLDL)-triacylglycerol kinetics, insulin 
sensitivity and circulating adipokines was examined in obese postmenopausal women and age- and 
body mass index (BMI)- matched men.
In the first study, the effect of rimonabant (20 mg/day for 12 weeks, with energy intake matched for 
energy requirements) was compared with the effect of a hypocaloric diet (to achieve the same 
weight loss as on the rimonabant treatment, for 12 weeks). Fourteen obese (BMI=33.0±0.5 kg/m2), 
postmenopausal, aged 57.8±4.7 years Caucasian women were randomised to the 2 treatments and 
the following was measured at the baseline and after 12 weeks: FFA kinetics, VLDL-triglyceride 
kinetics; insulin sensitivity; circulating fasting glucose, FFA, glycerol, triglycerides, VLDLi and 
VLDLz-triglycerides, total cholesterol, high-density lipoprotein (HDL)-cholesterol, low-density 
lipoprotein (LDL)-cholesterol, leptin, adiponectin and insulin. In the second study, the same 
variables were compared between 16 obese postmenopausal Caucasian women (57.9±5.4 years, 
BMI=32.8±1.8 kg/m2) and 7 age- and BMI- matched men (60.6=1=6.6 years, BMI=31.5±1.4 kg/m2). 
Results: Weight loss was not different between 2 treatment groups in the first study (2.6±1.4 kg in 
the rimonabant group vs. 3.1=t=2.8 kg in the diet group, p>0.05). Rimonabant treatment increased 
palmitate rates of appearance (Ra), metabolic clearance rates (MCR) and oxidation rates, while 
dietary treatment did not influence these variables. The effect of rimonabant on palmitate oxidation 
rates was significantly different from the effect of the hypocaloric diet, as well as the effect on
VLDLi and VLDLi-triglyceride absolute production rates (APR), circulating fasting triglycerides, 
VLDLi- and VLDL^-triglycerides, glucose, insulin and homeostasis model assessment (HOMA)- 
estimates of insulin sensitivity. Both treatments similarly increased adiponectin and decreased 
leptin. Neither treatment significantly changed insulin sensitivity estimated by hyperinsulinaemic- 
euglycaemic clamp. In the second study, women had higher palmitate Ra, MCR, non-oxidative 
disposal and total plasma fatty acid oxidation (TPFAO) rates, VLDLi and VLDL^-triglyceride 
fractional clearance rates (FCR), circulating leptin, glycerol and FFA. The other variables were not 
significantly different.
In conclusion, the increase in fatty acid turnover and oxidation may be the mechanism by which the 
weight loss was achieved by rimonabant treatment, without caloric restriction. The effects of 
rimonabant on FFA and VLDL-kinetics, insulin sensitivity and metabolic parameters, were the 
opposite from the effects of the hypocaloric diet, although the weight loss was similar. 
Postmenopausal obese women, compared with age- and BMI-matched men, have higher rates of 
fatty acid turnover, accounted by both increased metabolic clearance, non-oxidative disposal and 
increased fatty acid oxidation. However, their metabolic profile was not different from the men. 
This suggests that women are intrinsically “primed” for increased lipid turnover, without a 
significant deterioration of metabolic risk.
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